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Abstract	  
	  Cushing’s	   syndrome	   is	   characterised	   by	   changes	   in	   body	   composition	   and	  cardiovascular	  disease	  risk	  profiles	  that	  have	  similarities	  to	  the	  aged	  phenotype.	  11β-­‐hydroxysteroid	   dehydrogenase	   type	   1	   (11β-­‐HSD1)	   converts	   inactive	  glucocorticoids	   (GCs)	   to	   their	   active	   form	   (cortisone	   to	   cortisol	   in	   humans).	  There	  is	  growing	  evidence	  that	  11β-­‐HSD1	  expression/activity	  increases	  with	  age	  in	   key	   target	   tissues	   including	   adipose	   tissue,	   bone,	   and	   skin.	   This	   thesis	  encompasses	  a	  series	  of	  novel	  studies	  investigating	  the	  role	  of	  GCs	  and	  their	  pre-­‐receptor	  metabolism	  in	  determining	  the	  ageing	  phenotype,	  with	  a	  central	   focus	  on	  skeletal	  muscle.	  	  	  We	  show	  that	  although	  cure	  of	  Cushing’s	  disease	  results	  in	  rapid	  improvements	  in	  clinical	  parameters,	  excess	  mortality	  may	  persist.	  We	  show	  in-­‐vitro	  evidence	  of	   regulation	   of	   proteolytic	   genes	   by	   11β-­‐HSD1.	   We	   show	   that	   11β-­‐HSD1	  knockout	  mice	  are	  protected	  from	  muscle	  weakness	  due	  to	  GCs	  and	  ageing.	  	  	  We	   recruited	   healthy	   subjects	   (n=135,	   aged	   20-­‐80	   years)	   who	   underwent	   in-­‐depth	   phenotyping,	   along	   with	   muscle	   biopsies	   (analysed	   by	   gene	   expression	  array)	   and	   urine	   steroid	   metabolite	   analysis.	   Skeletal	   muscle	   11β-­‐HSD1	  expression	  increased	  with	  age	  in	  women	  and	  this	  change	  may	  be	  driven	  by	  the	  menopause.	   The	   therapeutic	   potential	   of	   selective	   inhibitors	   of	   11β-­‐HSD1	   in	  ameliorating	   the	   adverse	   metabolic	   and	   body	   composition	   profile	   associated	  with	   ageing	   and	   the	   menopause	   remains	   to	   be	   determined.	   Furthermore	   we	  highlight	   future	  directions	   in	   investigating	  potential	   therapeutic	   targets	   related	  to	  GC-­‐signalling	  in	  muscle	  atrophy	  due	  to	  sarcopenia	  and	  other	  aetiologies	  such	  as	  critical	  illness.	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  2	  	  LDL-­‐C	   	   	   Low	  density	  lipoprotein	  cholesterol	  LFTs	   	   	   Liver	  Function	  Tests	  LH	   	   	   Luteinising	  Hormone	  LJ2	   	   	   Selective	  11β-­‐HSD1	  inhibitor	  (Pfizer,	  CA,	  USA)	  LPL	   	   	   Lipoprotein	  Lipase	  LVH	   	   	   Left	  Ventricular	  Hypertrophy	   	  	  MAFbx/Atrogin1	   Muscle	  Atrophy	  F-­‐box	  Protein	  (F-­‐Box	  Protein	  32)	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MAPK	   	   	   Mitogen-­‐Activated	  Protein	  Kinase	  MHC	   	   	   Myosin	  Heavy	  Chain	  miRNA	   	   Micro-­‐RNA	  MIPEP	  	   	   Mitochondrial	  Intermediate	  Peptidase	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  Mass	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  MR	   	   	   Mineralocorticoid	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  Acid	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  Protein	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  Myelocytomatosis	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  Carcinoma	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  MYH1	   	   	   Myosin	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  MYH2	   	   	   Myosin	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  Cell	  Adhesion	  Molecule	  NF-­‐κB	   	   	   Nuclear	  Factor	  Kappa	  B	  NHS	   	   	   National	  Health	  Service	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P300	   	   	   E1A	  Binding	  Protein	  	  PCR	   	   	   Polymerase	  Chain	  Reaction	  PDK4	   	   	   Pyruvate	  Dehydrogenase	  Kinase	  Isozyme	  4	  PER2	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  Circadian	  Clock	  2	  PI3K	   	   	   Phosphoinositide-­‐3-­‐Kinase	  PKB	   	   	   Protein	  Kinase	  B	  (AKT)	  Pmax	   	   	   Maximum	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  POMC	   	   	   Pro-­‐opiomelanocortin	  PPAR	   	   	   Peroxisome	  Proliferator-­‐Activated	  Receptor	  PPIB	   	   	   Peptidylpropyl	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  B	  (cyclophilin	  B)	  PPP3R2	   	   Protein	  Phosphatase	  3,	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  Subunit	  B	  	  PRT	   	   	   Progressive	  Resistance	  Training	  PSMA	   	   	   Proteasome	  Subunit	  Alpha	  PSMC	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  26S	  Subunit	  ATPase	  PSMD	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  26S	  Subunit	  non-­‐ATPase	  PVDF	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  Diflorise	  	  QUAD	   	   	   Quadriceps	  Muscle	  qPCR	   	   	   Quantitative	  Polymerase	  Chain	  Reaction	  	  REDD1	   	   Regulated	  in	  DNA	  Damage	  and	  Development	  RelA	   	   	   V-­‐Rel	  Reticuloendotheliosis	  Viral	  Oncogene	  Homolog	  A	  	  RNA	   	   	   Ribonucleic	  Acid	  RT	   	   	   Reverse	  Transcriptase	  RTPCR	  	   	   Reverse	  Transcriptase	  Polymerase	  Chain	  Reaction	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RU486	  	   	   Roussel-­‐Uclaf	  38486th	  compound	  (Mifeprisone)	  RXRB	   	   	   Retinoid	  X	  Receptor-­‐beta	  	  	  S2LJ	   	   	   Standing-­‐2-­‐Legged-­‐Jump	  S6K1	   	   	   Ribosomal	  Protein	  S6	  Kinase	  1	  SBP	   	   	   Systolic	  Blood	  Pressure	  SDS-­‐PAGE	   Sodium	  Dodecyl	  Sulphate	  Polyacrylamide	  Gel	  Electrophoresis	  	  SHBG	   	   	   Sex	  Hormone	  Binding	  Globulin	  SIRT	   	   	   Sirtuin	  SLC2A4	   	   Solute	  Carrier	  Family	  2,	  Member	  4	  (GLUT4)	  SMI	   	   	   Skeletal	  Mass	  Index	  SMR	   	   	   Standardized	  Mortality	  Ratio	  	  SOD1	   	   	   Superoxide	  Dismutase	  1	  SREBF1	   	   Sterol	  Regulatory	  Element	  Binding	  Transcription	  Factor	  1	  StAR	   	   	   Steroidogenic	  Acute	  Regulatory	  Protein	  TGFB1	  	   	   Transforming	  Growth	  Factor,	  Beta	  1	  THA	   	   	   Tetrahydrodehydocorticosterone	  THB	   	   	   Tetrahydrocorticosterone	  THE	   	   	   Tetrahydrocortisone	  THF	   	   	   Tetrahydrocortisol	  TNF-­‐α	  	   	   Tumour	  Necrosis	  Factor-­‐Alpha	  TRIM54	   	   Tripartite	  Motif	  Containing	  54	  (MURF3)	  TRIM63	   	   Tripartite	  Motif	  Containing	  54	  (MURF1)	  TSA	   	   	   Trichostatin	  A	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TSH	   	   	   Thyroid	  Stimulating	  Hormone	  	  U+Es	   	   	   Urea	  and	  Electrolytes	  UFC	   	   	   Urinary	  Free	  Cortisol	  UPS	   	   	   Ubiquitin-­‐Proteasome	  System	  USP19	  	   	   Ubiquitin	  Specific	  Peptidase	  19	  	  VEGF	   	   	   Vascular	  Endothelial	  Growth	  Factor	  VEH	   	   	   Vehicle	  Vmax	   	   	   Maximum	  Velocity	  	  WT	   	   	   Wildtype	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1.1	  Corticosteroid	  Secretion	  and	  Action	  
1.1.1.	  Adrenal	  Glands	  Bartholomeo	  Eustachius	  was	  the	   first	   to	  characterise	  adrenal	  gland	  anatomy	  in	  1563.	   However	   it	   was	   almost	   300	   years	   before	   a	   Thomas	   Addison,	   at	   Guy’s	  Hospital,	   ascribed	   them	   a	   pathological	   role	   in	   the	   disease	   that	  was	   to	   take	   his	  name.	   He	   detailed	   a	   syndrome	   of	   “anaemia,	   general	   languor	   and	   debility,	  remarkable	   feebleness	   of	   the	   heart’s	   action,	   irritability	   of	   the	   stomach	   and	   a	  peculiar	  change	  in	  colour	  of	  the	  skin”	  in	  patients	  with	  disease	  of	  the	  “supra-­‐renal	  capsules”	   (Addison,	   1855,	   Pearce,	   2004).	   Outlook	   for	   these	   patients	  was	   grim,	  with	   survival	   of	   most	   patients	   measured	   in	   months.	   Addison’s	   contemporary	  Brown-­‐Sequard,	   confirmed	   that	   functioning	   adrenals	  were	   essential	   for	   life,	   by	  performing	   bilateral	   adrenalectomies	   in	   a	   range	   of	   species.	   Osler	   tried	  unsuccessfully	   to	   treat	   a	   young	   patient	   with	   adrenal	   insufficiency	   with	   orally	  administered	   adrenal	   extract	   (DeGroot	   and	   Jameson,	   2006).	   In	   the	   late	   1940s,	  whilst	   working	   at	   the	   Mayo	   Clinic,	   Kendall	   and	   Hench	   obtained	   a	   supply	   of	  	  “compound	   E”	   (cortisone)	   and	   found	   it	   to	   be	   an	   effective	   treatment	   for	  rheumatoid	  arthritis	  and	  other	  inflammatory	  arthritides	  (Hench,	  1949,	  Kater	  et	  al.,	  2007).	   	  At	  Harvard,	  Thorn	  and	  Forsham	  were	  pioneers	  in	  using	  cortisone	  to	  treat	  Adrenal	   Insufficiency	  reporting	  dramatic	   improvements	   in	  mortality	   from	  80%	  at	  2	  years	  to	  50%	  at	  7	  years	  in	  their	  initial	  cohort	  (Thorn	  et	  al.,	  1949).	  Since	  Addison’s	   original	   description,	   the	   physiological	   roles	   of	   individual	   adrenal	  hormones	   in	   the	   stress	   response,	   carbohydrate	   metabolism,	   water	   and	  electrolyte	  balance	  have	  been	  elucidated	  along	  with	  their	  pathological	  effects	  in	  excess	   (Gathercole	   et	   al.,	   2013).	   Anatomically	   the	   two	   adrenals	   are	   pyramidal	  structures	  with	  dimensions	  of	  up	  to	  3.0	  x	  6.0	  x	  1.0cm,	  each	  is	  surrounded	  by	  an	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outer	  capsule,	  and	  is	  located	  superiorly	  to	  the	  kidney.	  They	  are	  divided	  into	  the	  functionally	   distinct	   outer	   cortex,	   which	   produces	   corticosteroids	   and	   a	  sympathetically	   innervated	   inner	   medulla,	   which	   produces	   catecholamines	  (Wilson	   and	   Williams,	   1998).	   The	   cortex	   is	   derived	   from	   the	   coelomic	   (body	  cavity)	   epithelium	   and	   begins	   to	   develop	   from	   the	   6	   week	   of	   gestation.	   The	  medulla	  is	  ectodermal	  in	  origin,	  with	  neural	  crest	  cells	  migrating	  to	  the	  centre	  of	  this	  coelomic	  tissue.	  During	  gestation,	  the	  cortex	  develops	  into	  2	  layers,	  the	  outer	  zona	   glomerulosa	   and	   the	   inner	   zona	   fasiculata,	  with	   a	   deeper	   third	   layer,	   the	  zona	  reticularis	  not	  appearing	  until	  the	  third	  year	  of	  life	  (Hubbard	  et	  al.,	  2009).	  In	   the	   mature	   adrenal	   these	   zones	   have	   distinct	   functional	   roles,	   the	   zona	  glomerulosa,	   fasiculata,	   and	   reticularis	   producing	   mineralocorticoids,	  glucocorticoids	  and	  androgens	  respectively	  (Arlt	  and	  Stewart,	  2005).	  According	  to	  Wilson	  and	  Williams	  (1998),	  arterial	  blood	  supply	  is	  obtained	  from	  branches	  of	  the	  aorta,	  inferior	  phrenic,	  renal	  and	  occasionally	  intercostal	  arteries,	  and	  left	  internal	   spermatic	   or	   ovarian	   arteries.	   Venous	   return	   from	   the	   right	   and	   left	  adrenal	   veins	   usually	   flows	   to	   the	   inferior	   vena	   cava	   and	   left	   renal	   vein,	  respectively.	  	  
1.1.2.	  Steroidogenesis	  	  Cholesterol	   is	   the	   common	   precursor	   for	   all	   adrenal	   steroids,	   which	   have	   the	  cyclopentanoperhydrophenthanthrene	   structure	   (3	   cyclohexane	   rings;	   1	  cyclopentane	  ring)	  (Arlt	  and	  Stewart,	  2005).	  Diversity	  of	  function	  is	  obtained	  by	  chemical	  modifications	   to	   this	   common	   structure	  with	   attachment	  of	   hydroxyl,	  ketone	   or	   other	   groups.	   Cholesterol	   is	   derived	   from	   circulating	   low-­‐density	  lipoprotein	   cholesterol	   (LDL-­‐C)	   by	   a	   receptor-­‐mediated	  pathway	   (DeGroot	   and	  Jameson,	  2006).	  Hydrolysis	  of	  intracytoplasmic	  vesicles	  containing	  LDL-­‐C	  occurs	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leading	  to	  release	  of	  cholesterol.	  Steroidogenesis	  has	  been	  reviewed	  in	  depth	  by	  Arlt	  and	  Stewart	  (2005)	  and	  the	  main	  pathways	  are	  outlined	   in	   figure	  1-­‐1.	  The	  rate-­‐limiting	   step	   of	   steroid	   biosynthesis	   takes	   place	   in	   all	   adrenal	   zones	   and	  involves	   transport	   of	   cholesterol	   to	   the	   internal	   mitochondrial	   membrane	   by	  steroidogenic	  acute	  regulatory	  protein	  (StAR).	  
	  
Figure	  1-­‐1:	  Major	  Pathways	  of	  Steroidogenesis	  in	  Humans.	  Steroids	  are	  listed	  in	  boxes;	  enzyme	  
activities	   are	   outside	   boxes.	   Cholesterol	   is	   the	   common	   precursor	   for	   all	   downstream	   steroids	  
including	   progestogens,	   mineralocorticoids,	   glucocorticoids,	   androgens	   and	   oestrogens.	   StAR	  
initiates	   the	   rate-­‐limiting	   step	  of	   corticosteroid	  biosynthesis.	   Figure	   represents	  pathways	  outlined	  
by	  Arlt	  and	  Stewart	  (2005).	  	  Cytochrome	   P450scc	   is	   responsible	   for	   cleavage	   of	   cholesterol	   to	   generate	  pregnenolone	  (Arlt	  and	  Stewart,	  2005).	  Zonal	  enzyme	  expression	  confers	  ability	  to	   generate	   steroid	   type,	   with	   P450c18	   exclusively	   expressed	   in	   the	   zona	  glomerulosa,	   P450c17	   17α-­‐hydroxylase	   activity	   predominating	   in	   the	   zona	  fasiculata	  and	  17,20-­‐lyase	  in	  the	  zona	  reticularis,	  determined	  by	  concentration	  of	  cytochrome	   b5	   (Arlt	   and	   Stewart,	   2005),	   resulting	   in	   generation	   of	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mineralocorticoids,	   glucocorticoids	   and	   adrenal	   androgens	   respectively.	  Pathway	   flux	   is	   regulated	   by	   the	   effects	   of	   hormones	   on	   the	   adrenal	   cortex,	  primarily	   angiotensin	   II,	   which	   stimulates	   aldosterone	   production	   and	   ACTH,	  which	   results	   in	   cortisol	   secretion.	   DHEA	   production	   is	   stimulated	   by	   ACTH,	  however	  there	  is	  also	  input	  from	  a	  range	  of	  other	  factors	  including	  prolactin,	  sex	  steroids,	   and	   cytokines	   (Glasow	   et	   al.,	   1996,	   Herrman	   et	   al.,	   2002,	   Lobo	   et	   al.,	  1982).	  	  	  	  	  
1.1.3.	  The	  Hypothalamic	  Pituitary	  Adrenal	  (HPA)	  Axis	  In	   humans	   cortisol	   is	   the	   principal	   GC.	   Its	   biosynthesis	   and	   secretion	   are	  regulated	   by	   the	   HPA-­‐axis	   (as	   shown	   in	   Figure	   1-­‐2).	   The	   system	   is	   modified	  centrally	  by	  stress	  factors	  including	  trauma,	  hypoglycaemia,	  hypoxia	  and	  painful	  stimuli	  (DeGroot	  and	  Jameson,	  2006).	  Activity	  is	  pulsatile	  and	  follows	  a	  circadian	  rhythm	  with	  early	  morning	  peaks	  and	  nocturnal	  nadirs,	  set	  by	  the	  hypothalamus.	  	  Corticotropin-­‐releasing	   hormone	   (CRH)	   and	   arginine	   vasopressin	   (AVP)	   are	  secreted	   by	   the	   paraventricular	   nucleus	   into	   hypophyseal	   portal	   veins	   to	  stimulate	   adrenocorticotrophic	   hormone	   (ACTH)	   release	   by	   anterior	   pituitary	  corticotrophs.	   CRH	   acts	   via	   membrane	   bound	   receptors	   coupled	   to	   adenylate	  cyclase,	  whilst	  AVP	  is	  thought	  to	  exert	  its	  action	  via	  phosphoinositide-­‐pathway-­‐mediated	  increases	  in	  sensitivity	  to	  CRH	  (DeGroot	  and	  Jameson,	  2006).	  ACTH	  is	  produced	   in	   the	   anterior	   pituitary	   by	   post-­‐translational	   processing	   of	   Pro-­‐opiomelanocortin	   (POMC),	   which	   is	   also	   the	   precursor	   of	   peptides	   including	  melanocyte-­‐stimulating	   hormones	   and	   β-­‐endorphin	   (Wilson	   and	   Williams,	  1998).	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Figure	   1-­‐2:	   The	   hypothalamic	   pituitary	   adrenal	   (HPA)	   axis.	  CRH	   =	   corticotropin	   releasing	  hormone,	  ACTH	  =	  adrenocorticotrophic	  hormone.	  	  	  ACTH	  promotes	  adrenal	  steroidogenesis,	  acting	  via	  the	  melanocortin-­‐2	  receptor	  activation	   of	   adenylate	   cyclase,	   with	   downstream	   effects	   on	   cholesterol	  conversion	   to	   pregnenolone	   and	   up-­‐regulation	   of	   adrenal	   steroidogenic	  enzymes.	   Cortisol	   regulates	   its	   own	   secretion	   via	   negative	   feedback	   by	   acting	  through	   pituitary	   and	   hypothalamic	   GR	   receptors.	   MR	   is	   co-­‐expressed	   in	   the	  hippocampus	  with	  GR	  and	  may	  also	  modulate	  this	  process	  (Jacobson,	  2005).	  Pro-­‐inflammatory	   cytokines	   have	   direct	   stimulatory	   effects	   on	   HPA-­‐axis	   function	  providing	  a	   link	  between	   inflammation	  and	  modulation	  of	   the	  endocrine	  stress	  response	  (DeGroot	  and	  Jameson,	  2006).	  They	  stimulate	  CRH	  secretion	  from	  the	  hypothalamus,	   and	   have	   also	   been	   shown	   to	   have	   effects	   at	   the	   pituitary	   and	  adrenal	  (Spangelo	  et	  al.,	  1989,	  Salas	  et	  al.,	  1990).	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1.1.4.	  Glucocorticoid	  Receptor	  (GR)	  The	  GR	  is	  a	  nuclear	  receptor,	  which	  is	  associated	  with	  two	  heat-­‐shock-­‐protein-­‐90	  (HSP90)	  molecules	   in	   the	   absence	   of	  GCs	   (Mendel	   et	   al,	   1986).	   Ligand	  binding	  triggers	   a	   series	   of	   events	   including	   GR	   phosphorylation,	   release	   from	   bound	  proteins,	  translocation	  to	  the	  nucleus,	  with	  trans-­‐activation	  and	  trans-­‐repression	  of	  target	  genes	  via	  glucocorticoid	  responsive	  elements	  (GREs),	  as	  represented	  in	  figure	  1-­‐3	  (DeGroot	  and	  Jameson,	  2006).	  	  	  	  
Figure	  1-­‐3:	  Activation	  of	  GR	  by	  Glucocorticoids	  (GCs).	  1.	   In	  the	  absence	  of	  GC	   ligand,	  GR	  forms	  
part	  of	  a	  multi-­‐unit	  complex	  with	  2	  molecules	  of	  heat	  shock	  protein	  90	  (HSP90)	  and	  other	  proteins.	  
2.	   After	   binding	   GC	   this	   complex	   dissociates	   and	   GR	   is	   phosphorylated.	   3.	   Nuclear	   translocation	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1.1.5.	  Effects	  of	  Glucocorticoids	  (GCs)	  GCs	  are	   essential	   for	   life	   and	  have	  a	  multitude	  of	   effects	   in	   a	   variety	  of	   tissues	  (see	  table	  1-­‐1).	  	  
Tissue	   Effect	  
Liver	   éGluconeogenesis	  
êGlycogenolysis	  
éDe	  novo	  lipogenesis	  
Muscle	   êGlucose	  Uptake	  
éProtein	  catabolism	  
êProtein	  Synthesis	  
Adipose	   Lipolysis	  (é	  with	  fasting)	  Lipogenesis	  (ê	  with	  fasting,	  é	  in	  fed	  state)	  Lipid	  uptake	  (é	  in	  fed	  state)	  Dyslipidaemia	  &	  Central	  Fat	  Distribution	  Chronically	  
Bone	   Inhibition	  of	  Osteoblasts	  
êIntestinal	  Calcium	  absorption	  
éRenal	  Calcium	  loss	  
Skin	   Dermal	  thinning	  Disorganisation	  of	  collagen	  deposition	  
Brain	   Hippocampal	  atrophy	  
Pancreas	   ê Insulin	  production	  
Renal/Cardiovascular	  system	   éEndothelial	  Permeability	  Activation	  of	  MR	  
éFree	  water	  clearance	  
éVascular	  reactivity	  to	  pressors	  
Eyes	   é Intraocular	  pressure	  
Immune	  System	   Anti-­‐inflammatory	  and	  immunosuppressive	  effects:	  Repression	  of	  NF-­‐κB,	  AP-­‐1	  signalling	  Suppression	  of	  Pro-­‐inflammatory	  T-­‐cells	  Stimulation	  of	  Regulatory	  T-­‐cells	  Inhibition	  of	  monocyte	  proliferation	  &	  differentiation	  
éLymphocyte	  Apoptosis,	  êNeutrophil	  Apoptosis	  	  
Table	  1-­‐1:	  Some	  of	  the	  Diverse	  Actions	  of	  Glucocorticoids	  on	  Numerous	  Organs	  and	  Systems	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1.1.6.	  The	  Renin-­‐Angiotensin-­‐Aldosterone	  Axis	  Aldosterone	  is	  the	  body’s	  principal	  mineralocorticoid,	  acting	  to	  regulate	  sodium,	  potassium	  and	  water	  balance.	  It	  acts	  via	  the	  mineralocorticoid	  receptor,	  which	  is	  widely	  expressed,	  but	  has	  major	  effects	  in	  the	  kidney	  related	  to	  reabsorption	  of	  sodium	  via	  the	  epithelial	  sodium	  channel	  (ENaC)	  and	  other	  regulatory	  proteins	  (Funder,	  2005).	  Aldosterone	  is	  produced	  in	  the	  adrenal	  zona	  glomerulosa	  under	  renin-­‐angiotensin	   system	   regulation	   (shown	   in	   Figure	   1-­‐4),	   with	   further	  modulation	  by	   factors	  such	  as	  ACTH,	  catecholamines	  and	  somatostatin	  (Wilson	  and	  Williams,	  1998).	  	  In	  summary,	  the	  juxtaglomerular	  apparatus,	  in	  response	  to	  reduced	   renal	   perfusion	   pressure,	   produces	   renin.	   Angiotensinogen	   is	  synthesized	  in	  the	  liver	  and	  subsequently	  cleaved	  by	  renin,	  yielding	  angiotensin	  I.	   This	   in	   turn	   is	   cleaved	   by	   Angiotensin	   Converting	   Enzyme	   (ACE)	   and	  angiotensin	   II	   is	   formed,	   with	   the	   pulmonary	   vasculature	   the	   major	   site	   of	  conversion.	   Angiotensin	   II	   stimulates	   aldosterone	   synthesis,	   vasoconstriction,	  and	  arginine	  vasopressin	  (AVP)	  release	  from	  the	  posterior	  pituitary.	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Figure	  1-­‐4:	  The	  Renin-­‐Angiotensin	  Axis	  and	  the	  Regulation	  of	  Adrenal	  Aldosterone	  Secretion	  
	  
	  	  Aldosterone	   promotes	   sodium	   reabsorption	   by	   the	   distal	   nephron,	   via	  mineralocorticoid	   receptor	   mediated	   effects	   (Wilson	   and	   Williams,	   1998).	  Aldosterone	  mediated	   increases	   in	   plasma	   volume	   are	   a	   determinant	   of	  mean	  arterial	  blood	  pressure	  (BP),	  with	  dysregulation	  of	  this	  system	  implicated	  in	  the	  pathogenesis	  of	  hypertension.	  	  	  
	  
1.2.	  Regulation	  of	  Glucocorticoid	  Action	  In	   addition	   to	   the	   HPA-­‐axis,	   GC-­‐action	   is	   regulated	   at	   the	   circulatory	   and	  peripheral	   tissue	   levels	   by	   protein	   binding	   and	   pre-­‐receptor	   glucocorticoid	  metabolism.	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1.2.1.	  Corticosteroid	  Binding	  Globulin	  This	   area	   has	   been	   extensively	   reviewed	   previously,	   and	   a	   brief	   overview	   is	  presented	  here	  (Wilson	  and	  Williams,	  1998).	  Cortisol	  in	  the	  circulation	  is	  mainly	  protein	  bound	  (<95%),	  predominantly	   to	  corticosteroid	  binding	  globulin	  (CBG)	  (≈90%),	   and	   the	   remainder	   to	   albumin	   (≈7%)	  or	   other	  proteins.	   CBG	  has	  high	  affinity	  for	  cortisol,	  but	  a	  low	  capacity,	  with	  a	  binding	  capacity	  of	  approximately	  690	  nmol/L.	  An	  important	  clinical	  consideration	  is	  that	  CBG	  levels	  are	  increased	  by	  factors	  such	  as	  old	  age,	  pregnancy	  and	  oestrogen	  administration,	  and	  reduced	  by	   liver	   disease,	   polycystic	   ovary	   syndrome,	   critical	   illness	   and	   protein	   losing	  enteropathies	   (Wilson	   and	   Williams,	   1998).	   In	   these	   states,	   there	   may	   be	   a	  discrepancy	  between	  the	  total	  measured	  cortisol	  and	  the	  biologically	  active	  free	  levels	  (Dhillo	  et	  al.,	  2002).	  	  	  
1.2.2.	  Glucocorticoid	  Metabolism	  Below	   is	   a	   summary	   of	   the	   process	   of	   cortisol	   metabolism	   and	   clearance	   as	  reviewed	  by	  Tomlinson	  et	  al	  (2004).	  Approximately	  15mg	  of	  cortisol	  is	  produced	  per	   day,	   with	   a	   circulating	   half-­‐life	   of	   between	   70-­‐120	   minutes.	   Cortisol	   is	  metabolised	  hepatically	  with	  cortisone	  following	  a	  similar	  pathway	  (Figure	  1-­‐5).	  The	   C-­‐4	   double	   bond	   is	   reduced	   to	   yield	   dihydrocortisol	   or	   dihydrocortisone	  metabolites,	   this	   is	   followed	   by	   3α-­‐hydroxysteroid	   dehydrogenase	   (3α-­‐HSD)	  activity,	   which	   yields	   tetrahydrocortisol	   (THF)	   or	   tetrahydrocortisone	   (THE)	  metabolites.	   20α-­‐	   or	   20β-­‐HSD	   mediated	   reduction	   of	   cortisol	   and	   cortisone	  metabolites	  result	  in	  formation	  of	  α-­‐	  or	  β-­‐	  cortols	  and	  cortolones	  respectively.	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Figure	  1-­‐5:	  Metabolism	  of	  Cortisol.	  Cortisone	  and	  cortisol	  are	  interconverted	  by	  11β-­‐HSD1	  and	  2.	  	  
Subsequent	  metabolism	  is	  similar	  for	  both	  steroids.	  	  	  	  	  	  
1.3.	  Cushing’s	  Syndrome	  	  Cushing’s	   syndrome	   encompasses	   biochemical	   hypercortisolaemia	   and	   the	  clinical	  features	  that	  develop	  with	  longer-­‐term	  exposure.	  Exogenous	  Cushing’s	  is	  the	   commonest	   cause	   and	   develops	   as	   a	   result	   of	   administration	   of	  supraphysiological	  doses	  of	  GCs.	  Endogenous	  Cushing’s	  is	  a	  rare	  condition,	  with	  the	  incidence	  estimated	  to	  be	  between	  0.7	  to	  2.4	  per	  million/year	  (Newell-­‐Price	  et	   al.,	   2006).	   Clinical	   phenotype	   varies	   in	   severity,	   but	   classically	  may	   involve	  central	   obesity,	   proximal	   myopathy,	   osteoporosis,	   skin	   changes	   (thin	   skin,	  bruising,	   striae),	   depression,	  menstrual	   irregularities,	   hypertension	   and	   insulin	  resistance	   (See	   Table	   1-­‐2).	   Diagnostic	   challenges	   include	   confirmation	   of	  hypercortisolaemia,	   exclusion	   of	   so-­‐called	   pseudo-­‐Cushing’s	   states	   and	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confirmation	   of	   underlying	   aetiology.	   Diagnosis	   is	   often	   challenging	   and	   is	  limited	  by	  performance	  of	  tests	  currently	  available.	  First-­‐line	  tests	  as	  listed	  in	  the	  Endocrine	   Society’s	   Clinical	   Practice	   Guidelines	   include	   urinary	   free	   cortisol	  (UFC),	   late	   night	   salivary	   cortisol,	   and	   1mg	   dexamethasone	   suppression	   test	  (DST)(Nieman	  et	  al.,	  2008).	  Once	  hypercortisolaemia	  is	  confirmed,	  serum	  levels	  are	  used	  to	  discriminate	  whether	  the	  condition	  is	  ACTH	  dependent.	  Radiological	  imaging	   including	   CT	   of	   the	   adrenal	   glands	   is	   the	   mainstay	   for	   further	  investigation	   of	   ACTH	   independent	   disease.	   ACTH	   dependent	   disease	   usually	  involves	   further	   biochemical	   tests	   and	   MRI	   pituitary	   imaging	   to	   distinguish	  whether	   the	  source	  of	  secretion	   is	  pituitary	  (known	  as	  Cushing’s	  Disease	  (CD))	  or	   ectopic	   (Nieman	  et	   al.,	   2008).	  Median	   survival	  of	  untreated	  Cushing’s	   in	   the	  original	   series	   was	   4.6-­‐years	   illustrating	   that	   early	   diagnosis	   and	   effective	  treatment	   is	   essential	   (Cushing,	   1932).	   Previous	   series	   of	   CD	   patients	   post-­‐transsphenoidal	   surgery	   suggest	   that	   excess	   mortality	   risk	   normalizes	   with	  biochemical	   ‘cure’,	   however	   these	   studies	   may	   be	   under-­‐powered	   or	   of	  insufficient	   duration	   of	   follow	   up	   to	   identify	   persisting	   risk	   (Sherlock	   et	   al.,	  2010).	   Indeed,	   studies	   assessing	   resolution	   of	   clinical	   features	   have	   shown	  reductions	  in	  adipose	  tissue	  mass,	  and	  BMI	  post-­‐cure	  but	  no	  increase	  in	  absolute	  muscle	   mass	   (Lonn	   et	   al.,	   1994,	   Geer	   et	   al.,	   2012).	   Furthemore,	   osteoporosis	  usually	   requires	   long-­‐term	   use	   of	   bisphosphonates,	   and	   there	   is	   evidence	   for	  persisting	   cardiovascular	   risk,	   and	   impaired	   quality	   of	   life	   (Colao	   et	   al.,	   1999,	  Pivonello	  et	  al.,	  2007).	  Optimal	  treatment	  should	  involve	  life-­‐long	  follow	  up	  and	  normalization	  of	  cardiovascular	  disease	  risk,	  other	  morbidities	  and	  prevention	  of	  treatment	   induced	   adverse	   events,	   in	   addition	   to	   achieving	   biochemical	   ‘cure’.	  Treatment	   options	   depend	   upon	   the	   aetiology	   and	   include	   transsphenoidal	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hypophysectomy	   for	   pituitary	   disease,	   with	   second	   line	   options	   including	  medical	   therapies,	   radiotherapy	   and	   adrenalectomy.	   Medical	   therapies	   are	  generally	  adjunctive	  in	  nature,	  and	  are	  used	  in	  situations	  including	  stabilization	  of	  hypercortisolaemic	  patients	  prior	  to	  definitive	  treatment,	  during	  acute	  illness,	  or	  whilst	  awaiting	  the	  effects	  of	  radiotherapy	  (Tritos	  and	  Biller,	  2012).	  Currently	  available	  medical	   therapies	   include	   inhibitors	   of	   steroidogenesis,	   GR	   inhibitors	  and	   centrally	   acting	   agents,	   unfortunately	   although	   they	   provide	   additional	  treatment	  options	  they	  are	  limited	  by	  side	  effect	  profiles	  and	  efficacy	  (Tritos	  and	  Biller,	  2012).	  	  
Clinical	  Features	   Proportion	  
Facial	  Plethora	   95%	  
Rounded	  Face	   90%	  
Decreased	  Libido	   90%	  
Skin	  Thinning	   85%	  
Decreased	  Linear	  Growth	   70-­‐80%	  
Menstrual	  Irregularity	   80%	  
Hypertension	   75%	  
Hirsuitism	   75%	  
Depression/emotional	  lability	   70%	  
Easy	  Bruising	   65%	  
Glucose	  Intolerance	   60%	  
Weakness	   60%	  
Osteopenia	  or	  fracture	   50%	  
Nephrolithiasis	   50%	  	  
Table	  1-­‐2:	  Clinical	  Features	  of	  Cushing’s	   syndrome	   (Data	   reproduced	   from	  Newell-­‐Price	   et	  al,	  
2006)	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An	  important	  aside	  is	  the	  case	  of	  a	  20-­‐year-­‐old	  woman	  with	  a	  clear	  biochemical	  diagnosis	  of	  CD	  and	  evidence	  of	  a	  defect	   in	  11β-­‐HSD1	  activity.	  The	  patient	  had	  repeatedly	  elevated	  UFCs,	   failure	  of	   low-­‐dose	  dexamethasone	  suppression,	   loss	  of	  circadian	  cortisol	  secretion,	  suppression	  with	  high	  dose	  dexamethasone,	  and	  a	  marked	   ACTH	   response	   to	   CRH),	   in	   the	   absence	   of	   a	   cushingoid	   phenotype.	  Surgery	   revealed	   a	   corticotroph	   adenoma,	   and	   post-­‐operative	   cortisol	   was	  undetectable.	  On	  starting	   replacement	  cortisone	  acetate	   it	  became	  evident	   that	  reduction	   to	   cortisol	   was	   impaired,	   whilst	   cortisol	   clearance	   was	   elevated	  (Tomlinson	   et	   al.,	   2002).	   New	   medical	   therapies	   for	   Cushing’s	   are	   drastically	  needed,	   and	   the	   scope	   for	   use	   of	   selective	   11β-­‐HSD	   inhibitors	   should	   be	  explored.	  	  	  	  
1.4.	  Pre-­‐Receptor	  Glucocorticoid	  Metabolism	  
	  
1.4.1.	  11	  Beta-­‐Hydroxysteroid	  Dehydrogenase:	  Types	  1	  and	  2	  There	   are	   2	   isozymes	   of	   11beta-­‐hydroxysteroid	   dehydrogenase	   (11β-­‐HSD),	  which	  regulate	  GC	  action	  at	  a	  local	  tissue	  level	  by	  inter-­‐converting	  GCs	  between	  their	   active	   and	   inactive	   forms	   (Tomlinson	   et	   al.,	   2004).	   The	   enzymes	   have	  distinct	  tissue	  specific	  expressions,	  co-­‐factor	  requirements	  and	  enzyme	  kinetics	  that	  confer	   their	  different	  biological	   functions.	  The	   type	  1	   isozyme	  (11β-­‐HSD1)	  amplifies	   local	   tissue	  GC	  by	  replacing	  the	  C11-­‐keto	  group	  of	  cortisone	  (in	  mice,	  11-­‐dehydrocorticosterone)	  with	  a	  C11-­‐hydroxyl	  group	  to	  form	  cortisol	  (in	  mice,	  corticosterone)(Tomlinson	   et	   al.,	   2004).	   The	   type	   2	   isozyme	   (11β-­‐HSD2)	  protects	   the	  MR	   from	   activation	   by	   cortisol	   (Draper	   and	   Stewart,	   2005).	   11β-­‐HSD1	   is	  widely	   expressed	   in	   liver,	   fat,	   brain,	   skeletal	  muscle,	   bone,	   heart,	   eye,	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skin,	  gonad,	  placenta	  and	   lymphoid	  tissue	  (Tomlinson	  et	  al.,	  2004).	   It	   functions	  primarily	   as	   an	   oxo-­‐reductase	   in	   intact	   tissues,	   however	   this	   activity	   is	   lost	   in	  favour	  of	  dehydrogenase	  activity	  when	  disruption	  of	  cells	  occurs.	  This	  is	  thought	  to	  reflect	  the	  critical	  importance	  of	  presence	  of	  NADPH	  as	  co-­‐factor,	  generated	  by	  H6PDH	   using	   NADP	   and	   G-­‐6-­‐P	   as	   substrate,	   in	   the	   lumen	   of	   the	   endoplasmic	  reticulum	  (See	  Figure	  1-­‐6)	  (Draper	  et	  al.,	  2003).	  	  
Figure	   1-­‐6:	   Schematic	   diagram	   demonstrating	   Pre-­‐receptor	   Glucocorticoid	   Regulation	   by	  
11β-­‐HSD1:	  11β-­‐HSD1	  catalyses	  the	  reduction	  of	  cortisone	  to	  cortisol	  in	  the	  Endoplasmic	  Reticulum	  
(ER)	   in	   the	   presence	   of	   co-­‐factor,	   NADPH	   generated	   by	   H6PDH.	   Glucose-­‐6-­‐phosphate	   (G6P)	   is	  
transferred	   from	   the	   cytosol	   for	   oxidation	   to	   6-­‐phosphogluconate	   (6PG)	   (Redrawn	   and	   adapted	  
from	  Gathercole	  et	  al,	  2013).	  	  The	   affinity	   of	   11β-­‐HSD1	   for	   cortisone	   is	   higher	   (Km=0.3μM)	   than	   for	   cortisol	  (Km=2.1μM)	   (Stewart	   and	   Whorwood,	   1994).	   Monder	   and	   White’s	   research	  groups	   cloned	   the	   gene	   encoding	   11β-­‐HSD1	   in	   the	   late	   1980s	   (Agarwal	   et	   al.,	  1989).	   It	   has	   been	   designated	   HSD11B1	   and	   is	   located	   on	   chromosome	   1,	  consisting	   of	   6	   exons	   and	   5	   introns,	   covering	   30kb	   (Draper	   et	   al.,	   2002,	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Tomlinson	   et	   al.,	   2004).	   Pre-­‐receptor	   GC	   dysregulation	   has	   been	   implicated	   in	  the	   pathogenesis	   of	   a	   range	   of	   disease	   states	   including	   obesity,	   non-­‐alcoholic	  fatty	   liver	   disease,	   insulin	   resistance,	   osteoporosis,	   inflammatory	   arthritis,	  dementia	  and	  idiopathic	  intracranial	  hypertension	  (Gathercole	  et	  al.,	  2013).	  11β-­‐HSD2	  was	   identified	   as	   a	   distinct	   isoform	  when	   it	   emerged	   that	   the	  HSD11B1	  gene	  was	   normal	   in	   patients	  with	   “Apparent	  Mineralocorticoid	   Excess”	   (AME),	  and	  furthermore	  that	  it	  was	  absent	  from	  the	  kidney.	  A	  series	  of	  studies	  identified	  that	  the	  kidney	  expressed	  a	  high	  affinity	  NAD	  dependent	  isoform	  and	  its	  function	  in	   to	  protecting	   the	  MR	   from	  activation	  by	  GCs	  and	   role	   in	  AME	  was	  proposed	  (Stewart	   et	   al.,	   1994).	   	   A	   human	   in-­‐vivo	   study	   showed	   that	   liquorice	   inhibits	  cortisol-­‐cortisone	  11β-­‐HSD	  activity	  in	  the	  kidney	  providing	  an	  explanation	  for	  its	  mineralocorticoid	   action	   (Stewart	   et	   al.,	   1987).	   	   Cortisol	   and	   aldosterone	   bind	  the	  MR	  with	  similar	  affinities	  in	  vitro.	  11β-­‐HSD2	  is	  attached	  to	  the	  ER,	  with	  the	  catalytic	  domain	  residing	   in	   the	  cytosol.	   It	   inactivates	  cortisol	  by	  conversion	   to	  cortisone,	  thus	  allowing	  aldosterone	  to	  act	  as	  the	  primary	  ligand	  (Edwards	  et	  al.,	  1988).	  This	  results	  in	  activation	  of	  the	  epithelial	  sodium	  channel	  and	  the	  sodium	  chloride	  co-­‐transporter,	   and	   increased	  sodium	  reabsorption	  via	   the	  basolateral	  Na+/K+	   ATPase.	   11β-­‐HSD2	   is	   also	   present	   in	   other	   tissues	  with	   abundant	  MR	  expression	  such	  as	   the	   large	   intestine,	  and	  salivary	  glands.	  Placental	  11β-­‐HSD2	  acts	  to	  protect	  the	  foetus	  from	  GC	  exposure	  in	  normal	  pregnancies,	  whilst	  there	  is	   evidence	   that	   reduced	   expression	   may	   be	   involved	   in	   the	   pathogenesis	   of	  intrauterine	  growth	  retardation,	  and	   foetal	  programming	   for	  metabolic	  disease	  (McTernan	  et	  al.,	  2001,	  Asztalos,	  2012).	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1.4.2.	  Regulation	  of	  11β-­‐HSD1	  by	  GH-­‐IGF-­‐I	  	  A	   number	   of	   in-­‐vitro	   and	   in-­‐vivo	   studies	   have	   been	   carried	   out	   to	   investigate	  regulation	  of	  11β-­‐HSD1,	  and	  some	  of	  the	  identified	  regulatory	  factors	  change	  in	  their	   abundance	   across	   the	   lifespan	   in	   humans.	   Endocrine	   regulation	   features	  prominently,	  in	  cell	  culture	  studies	  with	  increased	  expression	  in	  response	  to	  GCs	  and	  downregulation	   in	   response	   to	   IGF-­‐I	   (Gathercole	   et	   al.,	   2013).	  Moore	   et	   al	  (1999)	   showed	   that	   GH/IGF-­‐I	   status	   correlated	   with	   markers	   of	   11β-­‐HSD1	  activity	  in	  studies	  of	  acromegalic	  patients	  pre-­‐	  and	  post-­‐	  transsphenoidal	  surgery	  and	   post-­‐	   withdrawal	   of	   medical	   therapy	   (Sandostatin-­‐LAR).	   Urine	   steroid	  profiles	  showed	  an	  inverse	  relationship	  between	  GH,	  IGF-­‐I	  and	  THF+5αTHF/THE	  ratios.	  Subsequently	  IGF-­‐I	  was	  shown	  to	  be	  responsible	   in	  studies	  of	  11β-­‐HSD1	  expression/activity	   in	   cell	   culture	  and	   transgenic	  mice	   (Tomlinson	  et	   al.,	   2004,	  Huang	  et	  al.,	  2010).	  This	  relationship	  was	  also	  seen	   in	  a	  study	  of	  hypopituitary	  patients	   on	   stable	   doses	   of	   hydrocortisone,	  who	  were	   administered	   increasing	  doses	  of	  GH	  replacement	  (Toogood	  et	  al.,	  2000a).	  These	  findings	  were	  confirmed	  in	   clinical	   studies	   of	   hypopituitary	  patients	   and	  obese	   subjects	   (Beentjes	   et	   al.,	  2001,	   Tomlinson	   et	   al.,	   2003,	   Swords	   et	   al.,	   2003,	   Paulsen	   et	   al.,	   2006).	   These	  data	   have	   important	   clinical	   ramifications	   including	   the	   theoretical	   risk	   of	  precipitation	  of	  adrenal	  crises	   in	  partially	  ACTH	  deficient	  patients	  commencing	  GH.	  Additionally	  the	  phenotypic	  features	  of	  hypopituitarism	  may	  be	  secondary	  to	  increased	   11β-­‐HSD1	   activity,	   and	   that	   beneficial	   effects	   of	   GH-­‐IGF-­‐I	   in	  hypopituitarism	  may	   be	   partly	   mediated	   via	   modulation	   of	   11β-­‐HSD1.	   Finally	  GH-­‐IGF-­‐I	   secretion	   falls	  with	   age	   and	  we	  may	   hypothesise	   that	   this	  may	   drive	  increases	   in	   11β-­‐HSD1	   expression	   and	   activity	   contributing	   to	   adverse	   body	  composition	  and	  metabolic	  profiles	  (Stewart	  et	  al.,	  2001).	  	  
	   20	  
1.4.3.	  Regulation	  of	  11β-­‐HSD1	  by	  Pro-­‐Inflammatory	  Cytokines	  The	  HPA-­‐axis	  is	  activated	  during	  inflammation	  and	  in	  recent	  years	  evidence	  has	  grown	   that	   GC	   action	   may	   also	   be	   amplified	   under	   these	   conditions	   via	  upregulation	   of	   11β-­‐HSD1	   expression/activity,	   with	   potential	   implications	   for	  ageing.	   Treatment	   of	   pre-­‐adipocytes,	   adipocytes,	   osteoblasts,	   aortic	   and	  bronchial	   smooth	  muscle	   cells,	  myoblasts	   and	   fibroblasts	  with	   TNF-­‐α	   or	   IL-­‐1β	  result	   in	   increased	  11β-­‐HSD1	  expression	  (Tomlinson	  et	  al.,	  2001,	  Tomlinson	  et	  al.,	  2004).	  Co-­‐treatment	  of	   stromal	  cells	  with	  TNF-­‐α/IL-­‐1β	  and	  GCs	  results	   in	  a	  synergistic	   increase	   in	   11β-­‐HSD1	   expression	   (Kaur	   et	   al.,	   2010).	   A	   subsequent	  study	   found	   that	   TNF-­‐α/IL-­‐1β	   induction	   of	   11β-­‐HSD1	   occurred	   via	   a	   NF-­‐κB	  dependent	  mechanism	  (Ahasan	  et	  al.,	  2012).	  In	  vivo	  studies	  have	  confirmed	  that	  11β-­‐HSD1	   expression	   is	   increased	   in	   inflammatory	   diseases	   such	   as	   ulcerative	  colitis	   and	   rheumatoid	   arthritis	   (Zbankova	   et	   al.,	   2007,	   Hardy	   et	   al.,	   2008).	  Interestingly	   salicylates,	  which	   are	  well	   known	   for	   anti-­‐inflammatory	   use,	   also	  have	  insulin	  sensitising	  effects,	  and	  down-­‐regulate	  adipose	  11β-­‐HSD1	  expression	  in	   mice	   and	   humans	   (Nixon	   et	   al.,	   2012).	   In	   summary	   pre-­‐receptor	   GC	  metabolism	  appears	  to	  play	  a	  prominent	  role	  in	  inflammation	  and	  this	  may	  be	  a	  compensatory	  mechanism,	  which	  results	  in	  adverse	  long-­‐term	  outcomes	  (Cooper	  and	  Stewart,	  2009).	  	  
	  
1.4.4.	  11β-­‐HSD1	  Expression	  and	  Activity	  in	  Skeletal	  Muscle	  Elucidating	   the	   11β-­‐HSD1’s	   role	   in	   ageing	   muscle	   is	   central	   to	   this	   thesis.	  Whorwood	  et	  al	  (2001)	  were	  the	  first	  to	  characterise	  expression	  of	  11β-­‐HSD1	  in	  human	   skeletal	   myoblasts,	   observing	   regulation	   of	   enzyme	   activity	   by	   GCs.	  Subsequently	  Jang	  et	  al	  (2006)	  showed	  that	  11β-­‐HSD1	  was	  expressed	  in	  vastus	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lateralis	   biopsy	   samples	   from	  11	  non-­‐diabetic	   community	   dwelling	   volunteers.	  Expression	   was	   similar	   between	   different	   muscle	   fibre	   types.	   In	   this	   study,	  muscle	   mRNA	   expression	   was	   100-­‐fold	   lower	   than	   in	   liver	   specimens,	   whilst	  mean	   conversion	   of	   cortisone	   to	   cortisol	   was	   17.7%/200mg	   tissue/24	   hours.	  Liver	   mRNA	   expression	   of	   11β-­‐HSD1	   is	   65-­‐fold	   greater	   than	   that	   of	   mouse	  quadriceps	   (18.4	   AU	   in	   liver,	   0.29	   AU	   quadriceps),	   although	   oxo-­‐reductase	  activity	  was	  only	  2.5-­‐fold	  greater,	  comparable	  to	  adipose	  tissue	  (≈250pmol/g/hr	  in	  liver,	  120pmol/g/hr	  in	  quadriceps)(Morgan	  et	  al.,	  2009).	  This	  compares	  to	  5-­‐10	  fmol/mg/hr	  seen	  in	  human	  skin	  (Tiganescu	  et	  al.,	  2011).	  	  In	  view	  of	  the	  role	  of	  GCs	  in	  inducing	  insulin	  resistance	  and	  the	  primacy	  of	  skeletal	  muscle	  as	  a	  site	  of	   glucose	   disposal,	   there	   has	   been	   much	   interest	   in	   the	   contribution	   of	   local	  muscle	   GC	   generation	   to	   the	   pathogenesis	   of	   type	   II	   diabetes.	   11β-­‐HSD1	  expression	  was	  increased	  in	  muscle	  from	  a	  rodent	  diabetes	  model	  (Zhang	  et	  al.,	  2009)	  and	  in	  primary	  human	  myotubes	  from	  obese	  type	  II	  diabetics	  (Abdallah	  et	  al.,	   2005).	   Furthermore,	   there	   have	   been	   reports	   of	   positive	   associations	  between	  myoblast	  11β-­‐HSD1	  expression	  and	   insulin	   resistance,	  BMI	  and	  blood	  pressure	   (Whorwood	   et	   al.,	   2002).	   One	   study	   found	   that	   although	   muscle	  expression	   of	   11β-­‐HSD	   types	   -­‐1,	   -­‐2	   and	  H6PDH	  were	   similar	   between	  patients	  with	  diabetes	  and	  controls,	  explants	  from	  diabetics	  had	  lower	  oxo-­‐reductase	  and	  higher	  dehydrogenase	  activities	  (Jang	  et	  al.,	  2007).	  Conversely,	  Inder	  et	  al	  (2011)	  found	  that	  11β-­‐HSD1	  oxo-­‐reductase	  activity	  was	  not	  correlated	  with	  markers	  of	  obesity	  or	  insulin	  resistance	  in	  a	  study	  of	  20	  non-­‐diabetic	  subjects.	  Inhibition	  of	  11β-­‐HSD1	   results	   in	   attenuation	   of	   cortisone-­‐induced	   reductions	   in	   glucose	  uptake	   in	   human	   myotubes	   (Abdallah	   et	   al.,	   2005,	   Salehzadeh	   et	   al.,	   2009).	  Selective	  11β-­‐HSD1	  inhibition	  has	  insulin	  sensitizing	  effects	  via	  decreased	  IRS-­‐1	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serine	   307	   phosphorylation,	   and	   increased	   Akt/PKB	   Threonine	   308	  phosphorylation	   in	   skeletal	   muscle	   (Morgan	   et	   al.,	   2009).	   The	   effects	   of	   pre-­‐receptor	   GC	   metabolism	   in	   skeletal	   muscle	   in	   other	   physiological	   and	  pathological	   states	   have	   received	   less	   attention.	   However,	   studies	   have	   shown	  that	  11β-­‐HSD1	  plays	  a	  dynamic	  role	  in	  response	  to	  stress,	  with	  increased	  muscle	  expression	  in	  post-­‐surgery	  and	  increased	  global	  activity	  following	  acute	  exercise,	  it	  has	  been	  suggested	  that	  this	  is	  driven	  by	  stimulation	  by	  myokines	  (Jang	  et	  al.,	  2009,	  Dovio	  et	  al.,	  2010).	  Recently,	  11β-­‐HSD1	  was	  shown	  to	  regulate	  GC-­‐driven	  protein	  degradation	  and	  associated	  changes	  in	  E3	  ubiquitin	  ligase	  expression	  in	  human	  primary	  myoblasts	  and	  the	  C2C12	  murine	  myotube	  cell	  line	  (Biedasek	  et	  al.,	   2011),	   leading	   to	   suggestions	   that	   selective	  11β-­‐HSD1	   inhibitors	  may	  be	  of	  therapetic	  use	  in	  muscle	  wasting.	  	  	  
	  
1.4.5.	  Transgenic	  Models	  used	  to	  investigate	  11β-­‐HSD1	  Function	  Since	  the	  end	  of	  the	  last	  century,	  our	  knowledge	  of	  the	  metabolic	  consequences	  of	  pre-­‐receptor	  glucocorticoid	  regulation	  has	  increased	  exponentially	  through	  a	  series	  of	   studies	   in	   transgenic	  mice.	  This	   started	  with	  Kotelevtsev	   et	   al	   (1997)	  who	   generated	   a	   transgenic	   11β-­‐HSD1	   knockout	   mouse,	   and	   observed	   a	  beneficial	   metabolic	   phenotype	   with	   resistance	   to	   stress	   and	   obesity	   induced	  hyperglycaemia,	  an	  inability	  to	  generate	  CORT	  from	  11-­‐DHC	  and	  compensatory	  adrenal	   hyperplasia.	   These	   mice	   have	   resistance	   to	   obesity,	   a	   favourable	   fat	  distribution	  with	  accumulation	   in	  epididymal	   rather	   than	  visceral	   fat	  depots	   in	  spite	  of	   increased	  caloric	   intake,	   improved	   lipid,	  hepatic	   insulin	  sensitivity,	  and	  glucose	   tolerance	  profiles	   (Morton	  et	   al.,	   2001,	  Morton	  et	   al.,	   2004).	  Mice	  with	  liver-­‐specific	  disruption	  of	  11β-­‐HSD1	  on	  the	  other	  hand,	  did	  not	  have	  significant	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improvements	   in	   fat	  mass,	  body	  weight,	  or	   lipid	  profiles,	  were	  able	  to	  generate	  cortisol	   to	   40%	  of	   control,	   and	  had	   increased	   adrenal	  weights	   in	   keeping	  with	  HPA-­‐axis	   activation.	   Both	   extra-­‐hepatic	   11β-­‐HSD1	   and	  HPA-­‐axis	   compensation	  appear	   to	  make	   important	  contributions	   to	  metabolic	  phenotype	  (Lavery	  et	  al.,	  2012).	   Mice	   with	   adipose	   specific	   enzyme	   overexpression	   (aP2-­‐HSD1	   mice)	  develop	   visceral	   fat	   accumulation	   associated	   with	   hyperphagia,	   dyslipidaemia	  characterised	  by	  raised	  free	  fatty	  acids	  and	  triglycerides,	  fatty	  liver,	   insulin	  and	  leptin	   resistance	   (Masuzaki	   et	   al.,	   2001).	   In	   follow	   up	   experiments	   these	  mice	  were	  shown	  to	  have	  arterial	  hypertension,	  in	  association	  with	  renin-­‐angiotensin-­‐aldosterone	   system	  activation	  and	   salt-­‐sensitivity	   (Masuzaki	   et	   al.,	   2003).	  Mice	  with	   hepatic	   overexpression	   of	   11β-­‐HSD1	   (apoE-­‐HSD1)	   (x2-­‐5-­‐fold	   increased	  activity)	  have	  mild	  insulin	  resistance,	  fatty	  liver	  and	  dyslipidaemia	  (Paterson	  et	  al.,	  2004).	  Some	  of	  these	  models	  have	  been	  utilized	  to	  ascertain	  the	  contribution	  of	   pre-­‐receptor	   GC-­‐regulation	   in	   a	   range	   of	   areas	   including	   inflammation,	  immunity,	  angiogenesis,	  bone	  turnover	  and	  cerebral	  function	  (McSweeney	  et	  al.,	  2010,	  Coutinho	  et	  al.,	  2012,	  Gathercole	  et	  al.,	  2013).	  	  Research	  into	  other	  aspects	  of	  ageing	  including	  sarcopenia	  is	  awaited.	  	  
	  
1.4.6.	  Human	  Genetic	  Mutations	  in	  11β-­‐HSD1	  and	  2	  	  
1.4.6.1	   HSD11B1:	  Cortisone	  Reductase	  Deficiency	  (CRD)	  and	  H6PDH:	  
Apparent	  Cortisone	  Reductase	  Deficiency	  (ACRD)	  	  CRD	   and	   ACRD	   are	   caused	   by	   mutations	   in	   the	   HSD11B1	   and	   H6PDH	   genes	  respectively	  (see	  figure	  1-­‐7)	  (Draper	  et	  al.,	  2003,	  Lawson	  et	  al.,	  2011).	  11	  cases	  have	  been	  described	  in	  the	  literature,	  with	  patients	  presenting	  with	  symptoms	  of	  hyperandrogenism,	   and	   investigations	   revealing	   urinary	   steroid	   metabolite	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ratios	   consistent	   with	   low	   11β-­‐HSD1	   oxo-­‐reductase	   activity	   (low	   THF+5α-­‐THF/THE	   ratios),	   failure	   of	   cortisol	   generation	   on	   cortisone	   challenge	   and	  evidence	   of	   HPA-­‐axis	   activation	   with	   adrenal	   hyperplasia,	   elevated	   plasma	  cortisone	  levels,	  and	  increased	  cortisol	  clearance	  (Phillipov	  et	  al.,	  1996,	  Jamieson	  et	  al.,	  1999,	  Biason-­‐Lauber	  et	  al.,	  2000,	  Lavery	  et	  al.,	  2008,	  Lawson	  et	  al.,	  2011).	  The	  HPA-­‐axis	  is	  activated	  to	  compensate	  for	  impaired	  active	  GC	  generation	  and	  reduced	   GR	   activation.	   ACTH	   secretion	   drives	   excess	   adrenal	   androgen	  production,	   and	   adrenal	   hyperplasia.	   These	   conditions	   highlight	  hyperandrogenism	   as	   a	   theoretical	   pitfall	   of	   selective	   11β-­‐HSD1	   inhibition,	  furthermore	   the	   muscle	   and	   broader	   ageing	   phenotypes	   would	   be	   of	   great	  interest,	  to	  delineate	  the	  contribution	  of	  11β-­‐HSD1	  across	  the	  human	  lifespan.	  	  	  
	  
Figure	  1-­‐7:	  Representations	  of	  HSD11B1	  and	  H6PDH	  genes	  with	  mutations	  identified	  to	  date,	  
associated	   with	   Cortisone	   Reductase	   Deficiency	   (CRD)	   and	   Apparent	   Cortisone	   Reductase	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1.4.6.2.	   HSD11B2:	  Apparent	  Mineralocorticoid	  Excess	  (AME)	  AME	   arises	   because	   of	   mutations	   in	   the	   HSD11B2	   gene	   leading	   to	   enzyme	  deficiency	   (Stewart	   et	   al.,	   1996).	   Over	   100	   cases	   have	   been	   reported	   in	   the	  literature,	   with	   the	   condition	   typically	   characterised	   by	   presentation	   in	   early	  childhood	  in	  association	  with	  hypertension,	  hypokalaemic	  alkalosis,	  suppression	  of	   renin	   activity,	   aldosterone	   and	   deoxycorticosterone	   (Hassan-­‐Smith	   and	  Stewart,	   2011).	   The	   condition	   may	   be	   complicated	   by	   failure	   to	   thrive,	  rhabdomyolysis,	  kidney	  and	  cardiovascular	  disease.	  If	  untreated,	  the	  prognosis	  is	  poor	   and	   is	   associated	   with	   increased	   mortality.	   Urinary	   steroid	   metabolite	  ratios	   are	   characterised	   by	   high	   THF+5α-­‐THF/THE	   ratios.	   Over	   40	   different	  mutations	  have	  been	  reported	  to	  date	  in	  kindreds	  in	  Europe,	  America,	  Asia	  and	  the	  Middle	  East	  (Ulick	  et	  al.,	  1979,	  New,	  1994,	  Wilson	  et	  al.,	  1995,	  Ferrari	  et	  al.,	  1996,	  Kitanaka	  et	  al.,	  1996,	  Kitanaka	  et	  al.,	  1997,	  Li	  et	  al.,	  1997,	  Dave-­‐Sharma	  et	  al.,	  1998,	  Lavery	  et	  al.,	  2003,	  Carvajal	  et	  al.,	  2003,	  Morineau	  et	  al.,	  2006,	  Coeli	  et	  al.,	  2008,	  Al-­‐Harbi	  and	  Al-­‐Shaikh,	  2012,	  Parvez	  and	  Sayed,	  2013)(See	  figure	  1-­‐8).	  	  Treatment	   involves	   correction	   of	   hypokalaemia	   and	   hypertension	   as	   an	   initial	  aim,	   with	   suppression	   of	   endogenous	   cortisol	   secretion	   by	   dexamethasone	  suppression	   in	   the	   long-­‐term	   (Hassan-­‐Smith	   and	   Stewart,	   2011).	   There	   is	   a	  paucity	  of	  data	  on	  body	  composition,	  metabolic	  syndrome	  phenotype	  and	  long-­‐term	  outcomes	  in	  AME.	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HSD11B2
Figure	  1-­‐8:	   Summary	  of	  published	  mutations	   in	  HSD11B2.	  Over	  40	  HSD11B2	  gene	  mutations	  
have	  been	   reported	   in	  association	  with	  Apparent	  Mineralocorticoid	  Excess.	  Located	  at	  16q22,	   the	  
gene	   is	   6.2kb	   long	   and	   spans	   5	   exons.	   Diagram	   is	   not	   to	   scale	   Adapted	   from	  Hassan-­‐Smith	   et	   al,	  
2011.	   
	  
1.4.7.	  Selective	  11β-­‐HSD1	  Inhibitors	  Naturally	   occurring	   inhibitors	   of	   11β-­‐HSD	  enzymes	  have	   long	  been	   recognized	  including	   glycyrrhetinic	   acid,	   which	   is	   derived	   from	   liquorice,	   flavanone,	   bile	  acids	   and	   progesterone	  metabolites	   (Gathercole	   et	   al.,	   2013).	   Proof-­‐of-­‐concept	  studies	   have	   highlighted	   a	   potential	   role	   of	   modulation	   of	   pre-­‐receptor	  glucocorticoid	   metabolism	   in	   metabolic	   disease	   states.	   The	   non-­‐selective	   11β-­‐HSD-­‐inhibitor	   carbenoxolone	  was	   shown	   to	   reduce	   serum	   cholesterol,	   glucose	  production	   rates	   and	   to	   limit	   the	   availability	   of	   active	  GCs	   to	   adipose	   tissue	   in	  healthy	  volunteers	  (Andrews	  et	  al.,	  2003).	  Pharmaceutical	  companies	  sought	  to	  develop	   compounds	   targeted	   to	   the	   type	   1	   isoform	   due	   to	   the	   limitations	   of	  hypertension	   seen	   in	   non-­‐selective	   agents.	   These	   compounds	   were	   shown	   to	  have	   lipid	   and	   glucose	   lowering	   actions	   in	   animal	   studies	   (Gathercole	   et	   al.,	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2013).	   Initial	   human	   studies	   have	   demonstrated	   safety,	   efficacy	   and	   isoform	  selectivity	  of	  compounds	  developed	  by	  Pfizer	  (PF-­‐00915275),	  Merck	  (MK-­‐0736	  -­‐0916)	   and	   Incyte	   (INCB13739)	   (Courtney	   et	   al.,	   2008,	   Rosenstock	   et	   al.,	   2010,	  Shah	   et	   al.,	   2011,	   Feig	   et	   al.,	   2011).	   However,	   effects	   on	   metabolic	   syndrome	  parameters	  are	  modest	  at	  best	  (HbA1c	  reductions	  0.3-­‐0.6%,	  fasting	  glucose	  up	  to	  24mg/dL,	   HOMA-­‐IR	   up	   to	   24%	   and	   LDL-­‐cholesterol	   6.3-­‐10.4%).	   HPA-­‐axis	  activation	  at	   the	  doses	  used	  appears	   to	  be	  mild	  with	   increases	   in	   serum	  ACTH	  and	   adrenal	   androgen	   levels	   within	   the	   normal	   reference	   ranges	   (Feig	   et	   al.,	  2011,	  Rosenstock	  et	  al.,	  2010).	  The	  strength	  of	   the	  case	   for	   the	  use	  of	  selective	  11β-­‐HSD1	   inhibitors	   in	   the	   metabolic	   syndrome	   remains	   to	   be	   seen,	   and	  exploitation	   of	   these	   agents	   in	   alternative	   clinical	   scenarios	   should	   also	   be	  assessed.	   In	   particular,	   studies	   of	   effects	   on	   muscle	   turnover,	   strength,	  metabolism	  and	  other	  aspects	  of	  ageing	  would	  be	  of	  great	  interest.	  	  	  
1.5.	  Skeletal	  Muscle	  
1.5.1.	  Skeletal	  Muscle	  Physiology	  and	  Structure	  On	  average	  40%	  of	   the	  human	  body	   is	  composed	  of	  skeletal	  muscle,	  which	  has	  both	  contractile	  and	  metabolic	  functions.	  Muscles	  are	  composed	  of	  thousands	  of	  fibres,	  which	   range	   from	  10-­‐100μm	   in	  diameter	  and	   from	  a	   few	  millimetres	   to	  several	  centimetres	  in	  length	  (See	  Figure	  1-­‐9)(Ropper	  et	  al.,	  2005).	  Muscle	  fibres	  are	  multinucleated	  and	  are	  surrounded	  by	  an	   inner	  membrane	  or	  sarcolemma,	  and	  an	  outer	  basement	  membrane.	  Muscle	  fibres	  contain	  many	  myofibrils,	  which	  are	   composed	   of	   myofilaments,	   and	   proteins	   including	   actin,	   myosin,	  tropomyosin,	  troponin,	  titin	  and	  nebulin.	  Branches	  of	  motorneurones	  originating	  from	  anterior	  horn	  cells	  or	   cranial	  nerve	  nuclei	   innervate	  muscle	   fibres,	  which	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themselves	  receive	  projections	  from	  upper	  motorneurones	  under	  control	  of	  the	  motor	  cortex.	  Acetylcholine	  (ACh)	  is	  released	  by	  motorneurones	  at	  the	  synaptic	  cleft	  where	  it	  diffuses	  to	  bind	  sarcolemmal	  receptors.	  	  
	  
Figure	   1-­‐9:	   Skeletal	   Muscle	   Structure:	   At	   the	   ultrastructural	   level	   myofibrils	   are	   made	   up	   of	  
sarcomeres	  arranged	  in	  series,	  which	  themselves	  are	  composed	  of	  actin	  and	  myosin	  filaments.	  The	  Z	  
disc	  forms	  the	  limit	  of	  each	  sarcomere.	  The	  I	  band	  flanks	  the	  Z	  disc	  where	  actin	  is	  present.	  Overlap	  of	  
actin	  and	  myosin	   filaments	  occurs	   in	   the	  A	  band.	  ATP	  dependent	  overlapping	  of	  actin	  and	  myosin	  
drives	  muscle	  contraction	  (Squire,	  1997).	  	  	  Action	   potentials	   are	   generated	   down	   T	   tubules	   liberating	   Ca2+	   from	   the	  sarcoplasmic	   reticulum.	   Ca2+	   associates	   with	   troponin	   and	   induces	   a	  conformational	   change,	   removing	   the	   inhibitory	   action	   of	   tropomyosin	   and	  revealing	   active	   sites	   of	   actin.	   Myosin	   cross-­‐bridges	   are	   made	   with	   actin	   at	   a	  different	  location	  on	  the	  filament	  allowing	  shortening	  of	  the	  filament	  via	  an	  ATP	  dependent	   process	   (Ropper	   et	   al.,	   2005).	   	   Skeletal	   muscle	   demonstrates	  plasticity	   in	   its	   properties	   according	   to	   its	   environment.	   Factors	   including	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Contraction	  Time	   Slow	   Moderately	  fast	   Fast	   Very	  Fast	  
Motor	  Unit	  Size	   Small	   Medium	   Large	   Very	  Large	  
Fatigue	  Resistance	   High	   Moderate	   Moderate	   Low	  
Duration	  of	  Use	   Hours	   <30	  min	   <5	  min	   <1	  min	  
Power	  Produced	   Low	   Medium	   High	   Very	  High	  
Mitochondrial	  Density	   High	   High	   Medium	   Low	  
Capillary	  Density	   High	   Intermediate	   Low	   Low	  
Oxidative	  Capacity	   High	   High	   Intermediate	   Low	  
Glycolytic	  Capacity	   Low	   High	   High	   High	  
Primary	  Energy	  Source	   Triglyceride	   Creatine	  Phosphate,	  glycogen	  
Creatine	  Phosphate,	  glycogen	  
Creatine	  Phosphate,	  glycogen	  
Myosin	  Heavy	  Chain	   MYH7	   MYH2	   MYH1	   MYH4	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1.5.2.	  Glucocorticoid-­‐Induced	  Myopathy	  Harvey	   Cushing	   described	   muscle	   weakness	   as	   a	   feature	   in	   his	   seminal	   case	  series.	   In	  cases	  of	  Cushing’s	   syndrome	  weakness	  has	  a	  prevalence	  of	  60%,	  and	  proximal	   myopathy	   specifically	   is	   a	   key	   discriminatory	   diagnostic	   feature	  (Newell-­‐Price	   et	   al.,	   2006).	   Data	   from	   large	   community	   cohorts	   estimate	   that	  between	  0.5-­‐0.9%	  of	   the	  UK	  population	  use	  oral	  GCs,	  with	   this	   figure	   rising	   to	  2.5%	  between	  the	  ages	  of	  70-­‐79	  years	  (Walsh	  et	  al.,	  1996,	  van	  Staa	  et	  al.,	  2000).	  GC-­‐induced	  myopathy	   is	  associated	  with	  atrophy,	   reduced	  strength	  and	   insulin	  resistance.	   	   GCs	   also	   mediate	   muscle	   atrophy	   under	   conditions	   of	   starvation	  (Wing	   and	   Goldberg,	   1993),	   sepsis	   (Tiao	   et	   al.,	   1996,	   Smith	   et	   al.,	   2010)	   and	  metabolic	  acidosis	   (May	  et	  al.,	  1986).	  These	  studies	  used	  either	  adrenalectomy	  or	   GR	   antagonists	   to	   demonstrate	   that	   GCs	   are	   required	   for	   development	   of	  skeletal	   muscle	   atrophy.	   Atrophy	   may	   impact	   upon	   existing	   disease	   specific	  functional	   limitations	  as	   in	  cases	  of	   respiratory	  muscle	  weakness	   in	  asthmatics	  (Akkoca	   et	   al.,	   1999),	   and	   in	   reduced	   muscle	   power	   in	   inflammatory	  rheumatological	   disease	   (Rothstein	   et	   al.,	   1983).	   Reduced	   muscle	   bulk	   is	  associated	  with	  reduced	  survival	  in	  conditions	  including	  renal	  failure	  and	  COPD	  (Swallow	   et	   al.,	   2007,	   Kalantar-­‐Zadeh	   et	   al.,	   2010).	   To	   summarise,	   in-­‐vitro	   cell	  culture	   systems,	   transgenic	   mouse	   models,	   and	   experimental	   medical	  approaches	  in	  human	  subjects	  have	  been	  utilized	  to	  advance	  our	  understanding	  of	   mechanisms	   involved	   in	   GC-­‐induced	   myopathy.	   GCs	   appear	   to	   shift	   the	  equilibrium	   of	   protein	   turnover	   away	   from	   protein	   synthesis	   and	   towards	  breakdown	  (See	  Figure	  1-­‐10).	  It	  is	  clear	  that	  this	  is	  an	  active	  process	  associated	  with	   a	   complex	   interplay	   of	   anabolic	   and	   catabolic	   mediators,	   regulated	   by	  growth	  regulators	  (myostatin	  and	  IGF-­‐I),	  transcription	  factors	  (FOXO	  and	  GSK3-­‐	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Figure	  1-­‐10:	  Integrated	  pathway	  of	  Glucocorticoid	  Induced	  Myopathy:	  1.	  GCs	  promote	  muscle	  
atrophy	   and	   impair	   protein	   synthesis	   by	   via	   GR	   effects	   on	   gene	   transcription,	   and	   directly.	   GCs	  
stimulate	  atrophy	  pathways	  leading	  to	  ubiquitin	  proteasome	  system	  activation	  and	  antagonize	  IGF-­‐
I/PI3K/Akt	  signaling,	  mTOR	  and	  amino	  acid	  transport.	  Symbols:	  +	  indicates	  stimulation,	  -­‐	  indicates	  
inhibition.	   Red	   boxes	   indicate	   proteolytic	   mediators.	   IGF-­‐I	   =	   insulin-­‐like	   growth	   factor	   1,	   PI3K	   =	  
phosphatidylinositol-­‐3-­‐kinase,	   Akt	   =	   protein	   kinase	   B,	   GSK3β	   =	   glycogen	   synthase	   kinase	   3	   beta,	  
FOXOs	  =	  forkhead	  transcription	  factors,	  MAFbx	  A.K.A	  F-­‐box	  protein	  32	  or	  atrogin-­‐1,	  UPS	  =	  ubiquitin	  
proteosomal	  system,	  mTOR	  =	  mammalian	  target	  of	  rapamycin,	  ER	  =	  endoplasmic	  reticulum,	  GR	  =	  
glucocorticoid	  receptor.	  	  	  	  β).	   A	   central	   pathway	   appears	   to	   involve	   upregulation	   of	   E3-­‐ubiquitin	   ligases	  with	   resulting	   increases	   in	   ubiquitination	   and	   proteasomal	   activity.	   The	  contribution	   of	   alternative	   proteolytic	   systems	   (lysosomal	   and	   calcium-­‐dependent)	  has	  yet	  to	  be	  fully	  characterized.	  Protein	  synthesis	  is	  also	  reduced	  by	  inhibition	   of	   IGF-­‐I	   and	   downstream	   signaling	   and	   at	   the	   level	   of	   mRNA	  translation	   via	   inhibition	   of	   translational	   initiation	   factors,	   and	   ribosomal	  function.	  New	  perspectives	   are	   emerging	  with	   research	   focusing	  on	   the	   role	  of	  insulin	  resistance	  and	  post-­‐translational	  regulation.	  Delineation	  of	  the	  pathways	  involved	   is	   vital	   in	   order	   to	   develop	   rational	   therapies.	   To	   date	   there	   are	   no	  licensed	  pharmacological	  treatments	  for	  muscle	  atrophy	  due	  to	  GC	  excess,	  or	  for	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muscle	  atrophy	  conditions	  where	  GC-­‐signaling	  is	  required.	  Pre-­‐clinical	  and	  early	  phase	   human	   studies	   have	   investigated	   interventions	   including	   exercise,	  anabolic	  hormone	  treatment,	  and	  nutritional	  supplementation.	  	  
	  
1.5.2.1.	   Clinical	  Features	  of	  GC-­‐Induced	  Myopathy	  GC	  myopathy	  presents	  with	  proximal	  muscle	  weakness	  that	  is	  pronounced	  in	  the	  legs	   vs.	   arms	   co-­‐existing	   with	   endogenous	   disease	   or	   exogenous	   steroid	  treatment.	  Other	  systemic	  features	  of	  GC	  excess	  are	  likely	  to	  be	  present.	  All	  GCs	  can	   induce	   muscle	   atrophy,	   however	   historically	   it	   was	   noted	   to	   be	   a	   more	  prominent	   feature	   of	   fluorinated	   steroids,	   such	   as	   dexamethasone	   and	  triamcinolone	   (Askari	   et	   al.,	   1976).	   Muscle	   weakness	   usually	   takes	   weeks	   to	  develop,	   although	   acute	   presentations	   have	   been	   reported	   (Rothstein	   et	   al.,	  1983).	  Body	  composition	  changes,	  characterized	  by	  declines	  in	  muscle	  and	  bone,	  and	  expansion	  of	   fat	  mass,	  are	  seen	  by	  2	  months	  treatment	  duration	  (Natsui	  et	  al.,	   2006).	   Respiratory	   muscle	   weakness	   has	   been	   reported	   as	   the	   primary	  feature	   in	   a	   case	   of	   endogenous	   Cushing’s	   (Blanco	   et	   al.,	   2001).	   Cranial	   nerve	  innervated	  muscles	  are	  spared.	  Paradoxically	  in	  the	  early	  stages	  of	  GC	  treatment,	  there	   may	   be	   an	   increase	   in	   force	   generation	   secondary	   to	   actions	   on	  corticospinal	  excitability	  (Minetto	  et	  al.,	  2010).	  	  	  GCs	   play	   a	   role	   in	   the	   pathogenesis	   of	   critical	   illness	   myopathy	   along	   with	  neuromuscular	  blocking	  agents,	  and	  pro-­‐inflammatory	  cytokines.	  Dose	  response	  relationships	   between	   total	   GC,	   neuromuscular	   blocking	   agents	   and	   onset	   of	  myopathy	  have	  been	  observed	  (Shee,	  1990).	  	  Critical	  care	  myopathy	  manifests	  as	  a	   spectrum	   from	   prolonged	   ventilatory	   weaning	   through	   to	   generalized	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weakness	   (Lacomis	   et	   al.,	   1996).	   Long-­‐term	   prognosis	   is	   variable	   with	   the	  majority	   of	   cases	   achieving	   full	   recovery,	   and	   almost	   one	   third	   being	   left	  with	  disability	   (Latronico	   et	   al.,	   2005).	   GCs	   also	   have	   profound	   effects	   on	   cardiac	  muscle,	   characterized	   by	   fibrosis	   and	   structural	   damage,	   with	   Cushing’s	  associated	   with	   a	   reversible	   cardiomyopathy	   (Yiu	   et	   al.,	   2012).	   	   Furthermore,	  GCs	   affect	   gene	   expression	   in	   smooth	   muscle,	   which	   may	   contribute	   to	  improvements	  in	  airway	  responsiveness	  observed	  when	  used	  in	  asthma	  (Yick	  et	  al.,	  2013).	  	  	  
	  
1.5.2.2.	   Investigations	  for	  GC-­‐Induced	  Myopathy	  	  Serum	   CK,	   and	  myoglobulin	   are	   frequently	   reduced	   or	   normal	   (Khaleeli	   et	   al.,	  1983a,	  Minetto	  et	  al.,	  2010).	  Although	  in	  the	  critical	  care	  setting	  increases	  have	  been	   reported,	   which	   may	   be	   due	   to	   factors	   such	   as	   mechanical	   ventilation,	  immobility	   or	   trauma	   (Douglass	   et	   al.,	   1992).	   Human	   histological	   findings	   are	  characterized	  by	  reduced	  myofibre	  cross-­‐sectional	  area	  and	  preferential	   loss	  of	  type	   II	   fibres,	   myofilament	   fragmentation,	   darkly	   stained	   nuclei,	   enlarged	  mitochondria,	  and	  a	  reduction	  in	  glycogen	  content	  (Golding	  et	  al.,	  1961,	  Pleasure	  et	   al.,	   1970,	   Khaleeli	   et	   al.,	   1983b,	   Danon	   and	   Schliselfeld,	   2007).	   Histological	  features	  reported	  in	  rodent,	  dog	  and	  equine	  models	  include	  preferential	  type	  IIB	  fibre	   atrophy,	   necrosis	   and	   heterogenous	   sizes	   of	   fibres,	   aggregation	   of	  mitochondria,	   and	   intramuscular	   fat	   accumulation	   (Braund	   et	   al.,	   1980,	  Dekhuijzen	   et	   al.,	   1995,	   Aleman	   et	   al.,	   2006).	   Conventional	   Needle	  Electromyelography	   (EMG)	   reveals	   a	   so-­‐called	   myopathic	   pattern	   as	  characterized	  by	  reduced	  mean	  potential	  amplitude	  and	  duration	   (Yates,	  1963,	  Khaleeli	   et	   al.,	   1983b,	   Golding	   et	   al.,	   1961).	   Needle	   EMG	  may	   be	   normal	   as	   it	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preferentially	   studies	   type	   I	   fibres	   (Minetto	   et	   al.,	   2010).	   Surface	   EMG	   is	  more	  sensitive	  and	  cases	  show	  reduced	  muscle	  fibre	  conduction	  velocity,	  a	  marker	  of	  sarcolemmal	  excitability,	  and	  myoelectric	  manifestations	  of	  fatigue	  seen	  in	  cases	  (Minetto	  et	  al.,	  2011).	   	  EMG	  is	  useful	   in	  excluding	  alternative	  diagnoses	  such	  as	  inflammatory	  myopathy,	  which	  may	  be	  associated	  with	  fibrillation	  potentials.	  	  	  
1.5.2.3.	   Molecular	  Mechanisms	  of	  GC-­‐Induced	  Myopathy	  Stable	   isotope	   studies	   in	   humans	   have	   shown	   that	   GC	  myopathy	   is	   associated	  with	  reduced	  global	  and	  “fractional	  mixed	  muscle	  protein	  synthesis”	  rates	  (Pacy	  and	   Halliday,	   1989).	   Animal	   studies	   have	   confirmed	   both	   reduced	   MHC	  synthesis,	  along	  with	  elevated	  myofibrillar	  degradation,	  with	  MHC	  IIB	  markedly	  affected	   by	   dexamethasone	   treatment	   (Seene	   et	   al.,	   2003).	   GCs	   act	   via	   the	   GR,	  which	   is	   complexed	   to	   heat	   shock	   proteins	   (HSP)	   in	   the	   basal	   state	   but	   in	   the	  presence	  of	  hormone,	  translocates	  to	  the	  nucleus	  to	  alter	  gene	  transcription	  by	  binding	   to	   Glucocorticoid	   Response	   Elements	   (GREs).	   Overexpression	   of	   heat	  shock	  proteins,	  have	  been	  shown	  to	  protect	  against	  muscle	  atrophy	  (Senf	  et	  al.,	  2008).	   Presence	   of	   GR	   is	   a	   requirement	   for	   GC	   induced	   inhibition	   of	   Akt	   via	  dephosphorylation	  (Zhao	  et	  al.,	  2009).	  	  
1.5.2.4.	   GC-­‐Induced	   Myopathy	   and	   the	   Ubiquitin-­‐Proteasome-­‐System	  
(UPS)	  
	  A	  number	  of	   studies	  have	   illustrated	   that	   the	  UPS	   is	   central	   to	  muscle	  atrophy	  signaling	   (Lecker	   et	   al.,	   2004,	   Schakman	   et	   al.,	   2008).	   It	   involves	   a	   series	   of	   3	  enzyme	  groups,	  E1	   ligases,	   that	  activate	  ubiquitin,	  E2	   ligases	  that	  act	  as	  carrier	  proteins	  and	  E3	  ligases,	  that	  include	  MAFbx/Atrogin1	  and	  MuRF1,	  which	  target	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specific	  proteins	  for	  ubiquitination,	  including	  components	  of	  the	  sarcomere	  and	  proteins	   involved	   in	   apoptosis	   (Rajan	   and	   Mitch,	   2008).	   MAFbx/Atrogin1	   and	  MuRF1	  are	  increased	  in	  muscle	  atrophy	  of	  different	  aetiologies	  including	  cancer	  cachexia,	   diabetes	   mellitus	   and	   renal	   failure,	   making	   up	   a	   “universal	   atrophy	  pathway”	   (Bodine	   et	   al.,	   2001,	   Lecker	   et	   al.,	   2004).	   Furthermore,	   mice	   with	  targeted	   deletion	   of	   these	   genes	   were	   protected	   from	   muscle	   atrophy	   due	   to	  denervation	  and	  disuse	  (Labeit	  et	  al.,	  2010).	  Dexamethasone	  treatment	  results	  in	  atrophy	  of	  murine	  myotubes	  and	  upregulation	  of	  MAFbx/Atrogin-­‐1	  and	  MuRF1	  (Stitt	  et	  al.,	  2004).	  Both	  E3-­‐ubiquitin	  ligases	  physically	  interact	  with	  myofibrillar	  proteins	  prior	  to	  degradation	  (Clarke	  et	  al.,	  2007,	  Lokireddy	  et	  al.,	  2012).	  MuRF1	  directly	  interacts	  with	  myosin	  heavy	  chains	  prior	  to	  degradation,	  and	  absence	  of	  this	   gene	   protects	   mice	   against	   GC	   induced	   atrophy	   (Clarke	   et	   al.,	   2007).	  Interestingly	   MAFbx/Atrogin1	   and	   MuRF1	   do	   not	   function	   similarly	   in	   all	  models,	  as	  mice	  with	  deletion	  of	  the	  latter	  are	  protected	  against	  atrophy	  during	  14	   days	   dexamethasone	   treatment,	   whereas	   MAFbx/Atrogin1	   knock	   out	   mice	  are	   not	   (Baehr	   et	   al.,	   2011).	   Amino	   acids	   and	   their	   metabolites	   such	   as	   beta-­‐hydroxy	   beta	   methylbutyric	   acid	   negatively	   regulate	   the	   UPS	   in	   a	   dose-­‐dependent	   manner	   and	   attenuate	   its	   activation	   by	   GCs	   and	   resulting	   muscle	  atrophy	   (Sadiq	   et	   al.,	   2007,	   Yamamoto	   et	   al.,	   2010,	   Aversa	   et	   al.,	   2012).	  Ubiquitinated	   myofibrillar	   proteins	   are	   cleaved	   by	   caspase-­‐3	   prior	   to	   20S	  proteasomal	  processing	   (Du	  et	  al.,	  2004,	  Dirks-­‐Naylor	  and	  Griffiths,	  2009).	  GCs	  have	   been	   shown	   to	   have	   effects	   at	   all	   levels	   of	   this	   system	   (Combaret	   et	   al.,	  2004).	   Alternative	   proteolytic	   systems	   (autophagic/lysosomal	   (cathepsin),	   and	  calcium	   dependent	   (calpain))	   may	   also	   be	   involved	   in	   GC-­‐mediated	  myopathy	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although	   full	   characterization	   is	   awaited	   (Komamura	   et	   al.,	   2003,	   Hong	   and	  Forsberg,	  1995,	  Dardevet	  et	  al.,	  1995).	  	  	  
1.5.2.5.	   GC-­‐Induced	   Myopathy	   and	   Forkhead	   Box	   Transcription	  
Factors	  (FOXOs)	  
	  GCs	   activate	   FOXOs	   by	   dephosphorylation,	   with	   downstream	   upregulation	   of	  atrogenes	  by	  promoter	  binding	  events.	  A	   recent	   study	   identified	  3	  GREs	   in	   the	  FOXO3a	  promoter	  and	  demonstrated	  GCs	  regulation	  at	  the	  mRNA	  transcriptional	  level	   (Lutzner	   et	   al.,	   2012).	   In	   vitro	   and	   in	   vivo	  models	   show	   that	   GC	   induced	  muscle	   atrophy	   is	   attenuated	   when	   FOXO	   is	   inhibited	   by	   dominant	   negative	  constructs	   and	   siRNAs	   (Sandri	   et	   al.,	   2004).	   Progressive	   increases	   in	   muscle	  mRNA	  expression	  of	  FOXO1	  and	  FOXO3a,	  but	  not	  FOXO4,	  were	  observed	  over	  1	  week	   in	   rodent	   GC	   time-­‐course	   experiments.	   FOXOs	   regulate	  MAFbx/Atrogin1	  and	   MuRF1	   expression	   by	   binding	   their	   promoters.	   In	   addition	   a	   highly	  conserved	  GRE	  is	  located	  200bp	  upstream	  from	  the	  transcription	  initiation	  point	  of	   the	  MuRF1	  gene	  allowing	  GR	  and	  FOXO1	  act	   synergistically	   to	  activate	  gene	  expression	  (Waddell	  et	  al.,	  2008).	  A	  GRE	  for	  MAFbx	  has	  not	  been	  identified,	  with	  GC	   action	   thought	   to	   occur	   principally	   via	   FOXO.	   In	   low	   energy	   states	   AMP-­‐activated	  protein	  kinase	  (AMPK)	  acts	  synergistically	  with	  GCs	  to	  induce	  FOXO3a	  expression	  (Lutzner	  et	  al.,	  2012).	  Separate	  studies	  showed	  that	  AMPK	  activation	  upregulates	  ubiquitin	  ligase	  expression	  in	  murine	  cell	  culture	  and	  animal	  models	  (Krawiec	   et	   al.,	   2007,	   Lim	   et	   al.,	   2010).	   Peroxisome	   proliferator-­‐activated	  receptor	   β/δ	   (PPARβ/δ)	   inhibition	   results	   in	   attenuation	   of	   dexamethasone	  induced	  FOXO-­‐1	   activation,	  MuRF1	   expression,	   and	   atrophy	   in	   cell	   culture	   and	  animal	  models	   leading	   to	   this	   being	   suggested	   as	   a	   putative	   therapeutic	   target	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(Castillero	   et	   al.,	   2013).	   In	   vitro	   and	   in	   vivo	   data	   show	   that	   testosterone	  treatment	   attenuates	   dexamethasone	   induced	  muscle	   atrophy,	   proteolysis	   and	  increased	   MAFbx	   expression	   (Zhao	   et	   al.,	   2008).	   This	   is	   likely	   to	   occur	   via	   a	  FOXO/Akt	  dependent	  mechanism	  (Jones	  et	  al.,	  2010).	  	  
1.5.2.6.	   GC-­‐Induced	  Myopathy	  and	  IGF-­‐I/PI3K/Akt	  Signaling	  IGF-­‐I	   is	   an	  anabolic	  hormone,	  which	  has	  an	  antagonistic	   relationship	  with	  GCs.	  GCs	   reduce	   total	   IGF-­‐I	   levels	   in	   serum,	   and	   gene	   expression	   levels	   in	   liver	   and	  muscle	  (Gayan-­‐Ramirez	  et	  al.,	  1999).	  Treatment	  of	  murine	  myotubes	  with	  IGF-­‐I	  induces	   hypertrophy,	   and	   dominantly	   inhibits	   dexamethasone	   induced	  proteolysis	   and	   MuRF1	   and	   MAFbx	   up-­‐regulation,	   via	   a	   PI3K-­‐dependent	  mechanism	   (Stitt	   et	   al.,	   2004).	   IGF-­‐1	   receptor	   binding,	   results	   in	   IRS-­‐1	  phosphorylation	   with	   downstream	   activation	   of	   signalling	   pathways	   including	  PI3K/Akt.	   In-­‐vivo	   rat	   experiments	   confirm	   that	   IGF-­‐I	   prevents	   GC-­‐induced	  muscle	   atrophy,	   partly	   via	   suppression	   of	   mRNA	   expression	   of	   ubiquitin,	  ubiquitin	   conjugating	   enzymes	   and	   proteasome	   subunits	   (Kanda	   et	   al.,	   1999,	  Chrysis	  and	  Underwood,	  1999,	  Chrysis	  et	  al.,	  2002).	  Over-­‐expression	  of	  IGF-­‐I	  in	  muscle	  by	  electroporation	  in	  rats	   is	  also	  associated	  with	  protection	  against	  GC-­‐mediated	   muscle	   wasting	   (Schakman	   et	   al.,	   2005).	   Akt	   inhibits	   FOXO	  transcription	   factors	   by	   both	   phosphorylation	   and	   by	   suppressing	   mRNA	  expression	   (Sandri	   et	   al.,	   2004).	   Experiments	  with	   constitutively	   active	   FOXO1	  and	   FOXO3a	   demonstrate	   that	   inactivation	   of	   FOXOs	   are	   required	   for	   IGF-­‐I	   to	  have	  its	  anti-­‐catabolic	  effects	  (Stitt	  et	  al.,	  2004,	  Sandri	  et	  al.,	  2004).	  IGF-­‐I	  rapidly	  inhibits	  MAFbx/atrogin-­‐1,	  whereas	  effects	  on	  MuRF1	  are	  slower	  (Sacheck	  et	  al.,	  2004).	  GCs	   increase	   free	  ubiquitin	  expression	   (UbC)	   in	  muscle	   cells	   and	   tissue,	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via	  transcriptional	  regulation	  of	  Sp1	  and	  effects	  on	  MEK	  signalling	  (Marinovic	  et	  al.,	  2002).	  	  	  
1.5.2.7.	   GC-­‐Induced	  Myopathy	  and	  Insulin	  Signalling	  Disease	  states	  such	  as	  critical	  illness	  (Dhar	  and	  Castillo,	  2011),	  trauma	  (Bonizzoli	  et	  al.,	  2012),	  chronic	  kidney	  disease	  (Bailey,	  2013)	  and	  type	  2	  diabetes	  mellitus	  (Andersen,	  2012)	  are	  characterized	  by	  atrophy	  and	  insulin	  resistance	  of	  skeletal	  muscle.	  GCs	   interfere	  with	   insulin	  signalling	  at	  many	   levels	  of	   the	  pathway,	  via	  direct	   effects	   and	   via	   altered	   protein	   and	   lipid	  metabolism.	   Insulin	   acts	   via	   its	  receptor,	   resulting	   in	   activation	   of	   IRS-­‐1	   and	   downstream	   signalling	   pathways	  including	   PI3K/Akt.	  Whether	   insulin	   resistance	   contributes	   to	  muscle	   atrophy	  observed	  in	  presence	  of	  GCs	  is	  of	  great	  interest.	  Animal	  and	  human	  studies	  have	  revealed	   that	   reduced	   insulin	   levels	   are	   associated	   with	   UPS	   activation	   and	  increased	   muscle	   proteolysis	   (Price	   et	   al.,	   1996).	   GCs	   were	   shown	   to	   induce	  resistance	   to	   the	   anti-­‐proteolytic	   effects	   of	   insulin	   in	   a	   human	   study	   utilizing	  leucine	   stable	   isotope	   and	   insulin	   clamp	   techniques	   (Zimmerman	   et	   al.,	   1989).	  Db/db	   mice	   had	   muscle	   atrophy	   and	   increased	   Caspase-­‐3	   expression	   and	  proteasomal	  activity.	  IRS-­‐1	  was	  phosphorylated	  at	  serine	  307,	  with	  resulting	  low	  levels	  of	  PI3K	  activity	  and	  Akt	  phosphorylation.	  In	  the	  basal	  state	  these	  mice	  are	  known	   to	   have	   increased	   circulating	   GC	   levels.	   Treatment	   with	   rosiglitazone	  attenuated	   all	   of	   the	   above	   effects	   (Wang	   et	   al.,	   2006).	   In	   the	   same	   series	   of	  experiments,	   using	   muscle	   specific	   GR	   and	   insulin	   receptor	   KO	   mice,	   it	   was	  demonstrated	  that	  both	  reduced	  insulin	  signaling	  and	  GR	  activation	  are	  required	  for	  muscle	   proteolysis	   to	   occur	   (Hu	   et	   al.,	   2009).	   A	   study	   utilizing	  microarray	  analysis	   and	   chromatin	   immunoprecipitation	   sequencing	   in	   a	  murine	  myotube	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cell	  line,	  identified	  173	  GR	  regulated	  genes,	  8	  of	  which	  are	  known	  to	  be	  involved	  in	  IGF-­‐1	  or	  insulin	  signaling	  pathways.	  One	  of	  these	  genes,	  the	  regulatory	  subunit	  of	  PI3K,	  p85α,	  was	  shown	  to	  regulate	  muscle	  atrophy	  and	  its	  absence	  reduced	  GC	  induced	  inhibition	  of	  Akt	  and	  p70	  S6K,	  and	  serine	  307	  phosphorylation	  of	  IRS-­‐1	  (Kuo	  et	  al.,	  2012).	  	  
	  
1.5.2.8.	   GC-­‐Induced	   Myopathy	   and	  Mammalian	   Target	   of	   Rapamycin	  
(mTOR)	  	  mTOR	  promotes	  protein	  synthesis	  and	  inhibits	  GR-­‐mediated	  atrophy.	  It	  activates	  eukaryotic	   translation	   initiation	   factor	   4E	   binding	   protein	   1	   (4E-­‐BP1),	   and	  ribosomal	   protein	   p70	   S6	   kinase	   1	   by	   phosphorylation	   (Shah	   et	   al.,	   2000,	  Schakman	   et	   al.,	   2008,	   Shimizu	   et	   al.,	   2011).	   Conversely	   GR	   binds	   the	   gene	  promoter	  of	  muscle	  ‘Regulated	  in	  DNA	  damage	  and	  development’	  gene	  (REDD1),	  which	   increases	   its	  expression	  and	  results	   in	   inhibition	  and	  dephosphorylation	  of	  mTOR	  (Kumari	  et	  al.,	  2011).	  	  
1.5.2.9.	   GC-­‐Induced	   Myopathy	   and	   Glycogen	   Synthase	   Kinase	   Beta	  
(GSK-­‐3β)	  
	  Akt	  inactivates	  GSK-­‐3β	  by	  phosphorylating	  serine	  9,	  which	  attenuates	  inhibition	  of	   eukaryotic	   inhibitory	   initiation	   factor	   2B	   and	   promotes	   protein	   synthesis	  (Welsh	  et	  al.,	  1998,	  Verhees	  et	  al.,	  2011).	  Experiments	  in	  rodent	  myotubes	  show	  that	  IGF-­‐I	  acts	  partly	  via	  inhibition	  of	  GSK-­‐3β	  (Vyas	  et	  al.,	  2002,	  Li	  et	  al.,	  2005).	  Inhibition	  of	  GSK-­‐3β	  in	  vitro	  attenuates	  GC	  induced	  MAFbx/Atrogin1	  and	  MuRF1	  expression	   and	   proteolysis,	   with	   sparing	   of	   myosin	   heavy	   and	   light	   chains	  (Evenson	  et	  al.,	  2005,	  Schakman	  et	  al.,	  2008,	  Verhees	  et	  al.,	  2011).	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1.5.2.10.	   GC-­‐Induced	   Myopathy,	   P300	   and	   CCAAT/Enhancer	   Binding	  
Factor	  (C/EBP)	  
	  GCs	  increase	  muscle	  mRNA	  and	  protein	  expression	  of	  the	  nuclear	  co-­‐factor,	  p300	  (Yang	   et	   al.,	   2005).	   Treatment	   of	   rat	   myotubes	   with	   GCs	   induces	   the	   acetyl	  transferase	   activity	   of	   p300	   and	   reduces	   expression	   of	   histone	   deacetylases	   3	  and	  6	  (HDAC3,	  HDAC6),	  conditions	  that	  promote	  hyperacetylation.	  Inhibition	  of	  histone	   deacetylases	   with	   trichostatin	   A	   (TSA)	   results	   in	   protein	   degradation.	  These	   findings	   suggest	   that	   GC	   induced	   proteolysis	   is	   partly	   regulated	   by	  acetylation	  (Yang	  et	  al.,	  2007).	  Recent	  work	  has	  identified	  other	  p300	  acetylation	  targets	  that	  have	  important	  roles	  in	  muscle	  atrophy	  including	  its	  homologue	  the	  histone	   acetyl	   transferase	   CREB-­‐binding	   protein	   (C/EBP),	   as	   well	   as	   FOXO1,	  FOXO3a	  and	  components	  of	  NF-­‐kappa	  B	  (Perrot	  and	  Rechler,	  2005,	  Chamberlain	  et	   al.,	   2012).	  Deacetylation	   of	   FOXO1	  by	   SIRT1	   is	   associated	  with	   inhibition	   of	  activity	   (Motta	   et	   al.,	   2004).	   C/EBPβ	   inhibition	   attenuates	   dexamethasone	  induced	   protein	   degradation	   and	   associated	   increases	   in	  MAFbx/Atrogin1	   and	  MuRF1	  in	  rat	  myoblasts	  (Gonnella	  et	  al.,	  2011).	  Similarly,	  inhibition	  of	  p300	  and	  C/EBP	  in	  murine	  myotubes	  by	  Cited2	  resulted	  in	  attenuation	  of	  dexamethasone	  induced	   muscle	   atrophy	   and	   ubiquitin	   ligase	   up	   regulation	   (Tobimatsu	   et	   al.,	  2009).	  Recently	  a	  series	  of	  in	  vivo	  rat	  experiments	  confirmed	  these	  findings,	  with	  dexamethasone	   treatment	   resulting	   in	   increased	   expression	   of	   p300,	  MAFbx/Atrogin1	  whilst	  downregulating	  HDAC3	  and	  HDAC6.	  Interestingly	  sepsis	  produced	  a	  similar	  pattern,	  and	  use	  of	  the	  GR	  antagonist	  RU486	  attenuated	  these	  effects	   indicative	  of	  a	  GC-­‐dependent	  pathway	  (Alamdari	  et	  al.,	  2010).	   Inhibition	  of	   the	   histone	   deacetylase	   SIRT1,	   by	   the	   polyphenol	   resveratrol,	   resulted	   in	  attenuation	   of	   FOXO1	   acetylation,	   ubiquitin	   ligase	   expression	   and	   proteolysis	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(Alamdari	   et	   al.,	   2012).	   The	   translational	   potential	   of	   modulation	   of	   atrophy	  associated	  protein	  acetylases	  remains	  to	  be	  determined.	  	  	  
1.5.2.11.	   GC-­‐Induced	  Myopathy	  and	  Myostatin	  Myostatin	   (growth	   and	   differentiation	   factor	   8)	   is	   a	   muscle-­‐specific	   negative	  growth	   regulator.	   It	   has	   a	   highly	   conserved	   gene	   sequence	   across	   species,	  inactivating	   mutations	   result	   in	   marked	   muscle	   hypertrophy/hyperplasia	   as	  exemplified	  by	  “Belgian	  Blue”,	  “Piedmontese”	  and	  “Marchigiana”	  cows,	  the	  “Bully	  Whippet”	  and	  transgenic	  mouse	  models	  (McPherron	  et	  al.,	  1997,	  McPherron	  and	  Lee,	  1997,	  Kambadur	  et	   al.,	   1997,	  Marchitelli	   et	   al.,	   2003,	  Mosher	  et	   al.,	   2007).	  Furthermore	   Schuelke	   et	   al	   (2004)	   reported	   a	   fascinating	   case	   of	   a	   child	  with	  evidence	  of	  an	  inactivating	  mutation,	  with	  a	  muscular	  appearance	  who	  was	  “able	  to	   hold	   two	   3kg	   dumbbells	   in	   horizontal	   suspension”.	   Conversely	   systemic	  overexpression	   causes	   marked	   muscle	   atrophy	   (Zimmers	   et	   al.,	   2002).	   An	   in	  depth	  review	  of	  myostatin	  signaling	  in	  muscle	  atrophy	  is	  provided	  by	  Elkina	  et	  al	  (2011),	   in	   summary	   it	   acts	   via	   the	   Activin	   Receptor	   Type	   IIB/ALK4/5	  heterodimer	  resulting	  in	  phosphorylation	  of	  SMAD2	  and	  SMAD3	  with	  effects	  on	  gene	   transcription.	   Downstream	   targets	   of	   SMAD	   signalling	   under	   inhibitory	  control	  include	  MyoD	  and	  myogenin	  (Langley	  et	  al.,	  2002),	  which	  are	  involved	  in	  myogenesis.	   GCs	   also	   suppress	   satellite	   cell	   regeneration	   by	   a	   myostatin	  dependent	  pathway	  (Dong	  et	  al.,	  2013).	  Myostatin	  acts	  to	  antagonize	  IGF-­‐I	  effects	  by	   inhibition	   of	   Akt	   phosphorylation	   associated	   with	   activation	   of	   the	   UPS	  (Elkina	   et	   al.,	   2011).	   MAPK	   activation	   and	   downstream	   effects	   may	   also	   be	  involved.	   In	  a	  recent	  study,	  MAFbx/Atrogin1	  accounted	  for	  80%	  of	  myofibrillar	  protein	  loss	  with	  the	  remainder	  due	  to	  MuRF1	  (Lokireddy	  et	  al.,	  2011).	  Absence	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of	   atrogin1	   in	   primary	   muscle	   cultures	   attenuated	   the	   atrophic	   effects	   of	  myostatin	  treatment.	  Myostatin	  treatment	  increased	  the	  number	  of	  interactions	  between	  MAFbx/Atrogin1	  and	  sarcomeric	  proteins	  (Lokireddy	  et	  al.,	  2012).	  	  	  Myostatin	  gene	  KO	  mice	  had	  preservation	  of	  body	  weight	  during	  dexamethasone	  treatment	  (1mg/kg/day)	  over	  10	  days.	  They	  were	  spared	  from	  muscle	  atrophy,	  with	   preserved	   tibialis	   anterior,	   and	   gastrocnemius	   tissue	   weights	   at	   both	  1mg/kg/day	   for	   10	   days	   and	   5mg/kg/day	   for	   4	   days.	   Reductions	   in	   soleus	  muscle	   weight	   in	   dexamethasone	   treated	   wildtype	   mice	   failed	   to	   reach	  significance.	  Reductions	  in	  muscle	  fibre	  cross	  sectional	  area	  were	  also	  attenuated	  in	   KO	   animals.	   Myofibrillar	   protein	   contents	   were	   greater	   in	   KO	   animals.	  	  Absence	   of	   myostatin	   was	   associated	   with	   attenuation	   of	   proteolytic	   gene	  induction	   (FOXO3a,	   MAFbx/Atrogin1,	   MuRF-­‐I	   and	   cathepsin-­‐L)	   and	   reduced	  proteasomal	   activity.	  Absence	  of	  myostatin	  did	  not	   affect	   the	  decrease	   in	   IGF-­‐I	  expression	   seen	   with	   dexamethasone	   treatment.	   However	   both	   saline	   and	  dexamethasone	  treated	  KOs	  had	  increased	  IGF-­‐II	  expression	  (Gilson	  et	  al.,	  2007).	  	  	  	  
1.5.2.12.	   GC-­‐Induced	  Myopathy	  and	  Apoptosis	  Pathways	  of	  GC-­‐induced	  apoptosis	  have	  been	  elucidated	  using	  studies	  of	  immune	  cells,	   with	   a	   paucity	   of	   studies	   in	   skeletal	   muscle.	   	   GC-­‐induced	   mitochondrial	  dysfunction,	   reactive	   oxygen	   species	   (ROS)	   generation	   and	   apoptosis	   were	  demonstrated	  in	  a	  human	  sarcoma	  cell	   line	  (Oshima	  et	  al.,	  2004).	  Fas-­‐mediated	  signaling,	  ceramides	  and	  proteolytic	  systems	  are	  currently	  being	  investigated	  as	  alternative	   mediators	   of	   GC-­‐induced	   apoptosis	   (Dirks-­‐Naylor	   and	   Griffiths,	  2009).	  In	  cell	  cultures	  experiments	  using	  L6	  myotubes,	  IGF-­‐I/PI3K/Akt	  signaling	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protected	   against	   stress-­‐induced	   apoptosis,	   while	   dexamethasone	   treatment	  inhibited	  this,	  resulting	  in	  increased	  caspase-­‐3	  activity	  and	  reduced	  cell	  viability	  (Singleton	   et	   al.,	   2000).	   An	   in-­‐vivo	   study	   identified	   myofibre	   necrosis	   in	   the	  presence	  of	  proteins	  involved	  in	  apoptosis	  such	  as	  p53,	  Fas	  antigen,	  and	  caspase-­‐8	  in	  the	  muscles	  of	  rats	  treated	  with	  GCs	  in	  contrast	  to	  controls	  (Lee	  et	  al.,	  2001,	  Lee	  et	  al.,	  2005).	  	  	  	  
1.5.2.13.	   GC-­‐Induced	  Myopathy	  and	  MicroRNAs	  MicroRNAs	  appear	  to	  be	  involved	  in	  the	  regulation	  of	  skeletal	  muscle	  growth	  and	  development	   (Chen	   et	   al.,	   2006).	   They	   regulate	   gene	   transcription	   by	   binding	  untranslated	   regions	   on	   mRNA	   to	   reduce	   translation	   or	   by	   reducing	   mRNA	  stability.	  MicroRNAs	  miR-­‐1,	  miR-­‐133,	  miR-­‐206,	  and	  miR-­‐125	  act	  to	  suppress	  IGF-­‐I/PI3K/Akt	  signaling	  in	  muscle,	  whereas	  miR-­‐23a	  and	  miR-­‐486	  increase	  activity	  of	   this	   pathway	   (Wang,	   2013).	   MiR-­‐1	   is	   increased	   during	   dexamethasone	  induced	   skeletal	   muscle	   atrophy	   via	   a	   myostatin	   dependent	   mechanism.	  Furthermore	   transgenic	   mice	   with	   myostatin	   deletion	   also	   had	   attenuation	   of	  dexamethasone	   induced	   miR-­‐1	   expression	   (Wang,	   2013).	   Furthermore	  myostatin	  appeared	  to	  increase	  GR	  nuclear	  translocation	  thus	  facilitating	  binding	  to	  a	  GRE	  in	  the	  miR1	  promoter	  (Wang,	  2013).	  Use	  of	  a	  miR-­‐1	  inhibitor	  resulted	  in	  hypertrophy	   of	   myotubes,	   and	   attenuation	   of	   GC	   induced	   E3-­‐ubiquitin	   ligase	  expression	   and	   atrophy.	   HSP70	   was	   identified	   as	   a	   target	   of	   miR-­‐1,	   with	  inhibition	   associated	   with	   muscle	   atrophy	   with	   expected	   changes	   in	   gene	  expression	   and	   protein	   phosphorylation	   (Kukreti	   et	   al.,	   2013).	   Another	   study	  suggested	   that	   GC	   induced	  myostatin	   expression	  was	   regulated	   by	  miR-­‐27	   via	  binding	   to	   elements	   in	   its	   3’-­‐untranslated	   region.	   miR-­‐27	   was	   more	   highly	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expressed	  in	  fast	  twitch	  muscle	  fibres,	  in	  a	  manner	  similar	  to	  myostatin.	  miR-­‐27	  was	   found	   to	   have	   effects	   on	  mRNA	   stability	   of	   the	  myostatin	   gene	   (Allen	   and	  Loh,	  2011).	  The	  effects	  of	  GCs	  on	  targets	  involved	  in	  muscle	  atrophy	  are	  outlined	  in	  table	  1-­‐4.	  	  	  
Target	  	   Effect	  of	  GCs	   Reference	  
Ubiquitin	  Proteasomal	  System	  Components	  MAFbx/Atrogin1	   é	   Stitt	  et	  al	  (2004)	  	  Clarke	  et	  al	  (2007)	  MuRF1	   é	  
Alternative	  Proteasomal	  Systems	  Cathepsins	   é	   Komamura	  et	  al	  (2003)	  Hong	  et	  al	  (1995)	  Dardevet	  et	  al	  (1995)	  Fareed	  et	  al	  (2006)	  Calpains	   é	  
Transcription	  Factors	  FOXOs	   é	   Lutzner	  et	  al	  (2012)	  Sandri	  et	  al	  (2004)	  
Growth	  Regulators	  IGF-­‐I	   ê	   Gayan-­‐Ramirez	   et	   al	  (1999)	  Myostatin	   é	   Dong	  et	  al	  (2013)	  Ma	  et	  al	  (2001)	  Ma	  et	  al	  (2003)	  Gilson	  et	  al	  (2007)	  
Nuclear	  Co-­‐factors	  P300	   é	   Alamdari	  et	  al	  (2010)	  Yang	  et	  al	  (2005)	  
Histone	  Deacetylases	  HDAC3	   ê	   Yang	  et	  al	  (2005,	  2007)	  HDAC6	   ê	  
Cell	  growth	  regulators	  mTOR	   Inhibited	  via	  REDD1	  dependent	  dephosphorylation	   Kumari	  et	  al	  (2011)	  
MicroRNAs	  mi-­‐27	  mi-­‐R1	   é é	   Allen	  and	  Loh	  (2011)	  Kukreti	  et	  al	  (2013)	  	  
Table	  1-­‐4:	  Summary	  of	  the	  Effects	  of	  Glucocorticoids	  on	  Targets	   involved	  in	  Muscle	  Atrophy	  (é	  =	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1.5.2.14.	   Potential	  Therapies	  for	  GC-­‐Induced	  Myopathy	  	  In	  myopathy	   secondary	   to	   exogenous	   GCs,	   the	   primary	   approach	   should	   be	   to	  reduce	   exposure	   to	   the	   minimum	   effective	   dose	   where	   possible.	   Where	  appropriate	   switching	   to	   a	   non-­‐fluorinated	   GC	   may	   be	   useful	   (Robinson	   and	  Robinson,	  1959).	  The	  development	  of	  dissociated	  glucocorticoids,	  with	   the	  aim	  of	  maintaining	  trans-­‐repressive	  effects	  on	  inflammatory	  pathways	  from	  adverse	  effects	   from	   trans-­‐activation	   has	   been	   the	   focus	   of	  much	   research,	   however	   to	  date	  this	  class	  has	  not	  made	  it	  to	  market	  (Catley,	  2007).	  In	  endogenous	  Cushing’s	  long-­‐term	   cure	   characterized	   by	   normalization	   of	   glucocorticoid	   levels,	   is	   the	  primary	  aim	  of	  therapy.	  Khaleeli	  et	  al	  (1983a)	  found	  that	  overall	  and	  type	  II	  fibre	  area	   and	   force	   per	   unit	   increased	   in	   CD	   patients	   following	   successful	   pituitary	  surgery,	  however	  a	  more	  recent	  study	  found	  that	  although	  there	  were	  reductions	  in	  body	  fat	  mass	  at	  6	  months	  post-­‐op,	  no	  increase	  in	  muscle	  mass	  was	  observed	  (Pirlich	   et	   al.,	   2002).	   From	   the	   discussion	   of	   pathways	   involved	   in	   GC	   induced	  myopathy	  and	  related	  muscle	  atrophy	  states	  outlined	  above,	  putative	  targets	  for	  the	  development	  of	  new	  treatments	  include	  myostatin,	  p300,	  SIRT1	  and	  GSK-­‐3β	  inhibitors,	   insulin	   sensitizers,	   modulators	   of	   IGF-­‐I/PI3K/Akt	   signaling	   and	  nutritional	  supplements.	  	  	  
Exercise	   in	   GC-­‐Induced	   Myopathy:	   At	   present	   exercise	   is	   the	   most	   promising	  therapy	  to	  prevent	  muscle	  atrophy	  in	  GC	  treated	  patients.	  An	  early	  in	  vivo	  study	  showed	   that	   exercise	   prevented	   25-­‐50%	   of	   weight	   loss	   induced	   by	   cortisone	  acetate	   (Hickson	   and	   Davis,	   1981).	   Rats	   undergoing	   a	   four	   sessions	   per	   week	  resistance	   exercise	   programme	   for	   6	   weeks	   were	   protected	   against	  triamcinolone	   acetonide	   induced	   atrophy	   and	   loss	   of	   power	   measured	   at	   the	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gastrocnemius	   muscle,	   and	   loss	   of	   fast-­‐twitch	   muscle	   fibres	   (Gardiner	   et	   al.,	  1980).	   Muscle	   atrophy	   was	   associated	   with	   the	   degree	   of	   muscle	   recruitment	  with	   greater	   muscle	   atrophy	   and	   lower	   rates	   of	   increase	   in	   the	   recruitment	  marker	  citrate	  synthase	  in	  the	  gastrocnemius	  compared	  to	  the	  plantaris	  muscle	  (Czerwinski	   et	   al.,	   1987).	   Mild	   exercise	   was	   shown	   to	   have	   an	   effect	   in	  preventing	   hydrocortisone	   (10mg/kg/day)	   induced	   muscle	   atrophy	   in	   Wistar	  rats,	  as	  measured	  by	  type	  I	  fibre	  cross-­‐sectional	  area	  in	  soleus,	  and	  type	  IIa	  fibres	  in	   extensor	   digotorum	   longus	  muscles	   (Nakago	   et	   al.,	   1999).	   Recent	   studies	   of	  exercise	  interventions	  during	  GC-­‐treatment	  have	  shown	  improvements	  in	  insulin	  sensitivity	  along	  with	  prevention	  of	  muscle	  atrophy	  (Barel	  et	  al.,	  2010,	  Nicastro	  et	   al.,	   2012).	   Similar	   effects	   are	   seen	   in	   humans	   with	   50	   days	   of	   isokinetic	  training	   improving	   mid-­‐thigh	   muscle	   areas,	   mid	   thigh	   fat/muscle	   ratios	   and	  mean	   peak	   torque	   and	   total	   work	   output	   in	   patients	   treated	   with	   prednisone	  (Horber	   et	   al.,	   1985).	   Another	   study	   assigned	   14	   male	   post	   heart	   transplant	  patients	  with	  GC-­‐induced	  myopathy	  to	  an	  exercise	  training	  or	  control	  group	  for	  6	  months.	  At	  follow	  up,	  mean	  lean	  mass	  was	  reduced	  below	  pre-­‐transplant	  levels	  in	  the	  control	  group	  (-­‐7.0%),	  while	  it	  was	  increased	  in	  the	  exercise-­‐trained	  group	  (+3.9%)	  and	  muscle	  strength	  was	  x4-­‐6-­‐fold	  greater	  in	  the	  exercise-­‐trained	  group	  vs.	  controls	  (Braith	  et	  al.,	  1998).	  
	  
Anabolic	  Hormone	  Administration	   in	  GC-­‐Induced	  Myopathy:	  Further	   to	   the	  work	  on	  prevention	  of	  muscle	  atrophy	  by	  anabolic	  hormone	  administration	  or	  over-­‐expression	   outlined	   in	   the	   sections	   above,	   several	   human	   studies	   have	  investigated	   the	  effects	  GH,	   IGF-­‐I	   and	  androgens	  administration	  on	  GC-­‐induced	  myopathy	  by	  utilizing	  stable	  isotope	  and	  nitrogen	  balance	  techniques	  to	  estimate	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protein	  turnover,	  body	  composition	  and	  muscle	  strength	  measures.	  GH	  and	  IGF-­‐I	  have	   been	   found	   to	   induce	   a	   positive	   protein	   balance	   in	   healthy	   volunteers	  treated	   with	   oral	   prednisolone	   (Horber	   and	   Haymond,	   1990,	   Mauras	   and	  Beaufrere,	  1995).	  Clinical	  studies	  have	  assessed	  the	  benefits	  of	  therapy	  with	  GH	  alone	  or	  in	  combination	  with	  androgens.	  Ragnarsson	  et	  al	  (2013)	  studied	  12	  men	  (mean	  age	  74	  years,	   range	  64-­‐85)	  on	   long-­‐term	  prednisolone	   treatment	   (mean	  9.3	   years,	   range	   1.5-­‐20)	   for	   polymyalgia	   rheumatica.	   	   GH,	   testosterone	   or	  combination	   treatments	  were	  administered	   for	  2-­‐weeks,	  with	  2	  week	  washout,	  in	  a	  cross-­‐over	  design.	  Lean	  mass	  increased	  with	  GH	  and	  combination	  treatment,	  but	   not	  with	   testosterone	   alone.	   Appendicular	   skeletal	  muscle	  mass	   increased	  following	   all	   3	   treatment	   periods,	  with	   the	   greatest	   increase	  with	   combination	  therapy.	   Extracellular	   water	   also	   increased	   with	   combination	   therapy.	   Fasting	  glucose	   increased	   in	   the	   combination	   group,	   but	   did	   not	   breach	   thresholds	   for	  diagnosis	   of	   impaired	   fasting	   glucose.	   	   The	   study	   was	   limited	   by	   the	   short	  treatment	  period,	  the	  lack	  of	  a	  placebo	  group	  and	  absence	  of	  strength	  test	  data.	  Burt	  et	  al	  (Burt	  et	  al.,	  2008)	  studied	  6	  elderly	  patients	  on	  long-­‐term	  GC	  therapy	  (mean	  prednisone	  dose	  8.3mg/day).	  In	  a	  dose	  optimization	  study	  GH	  treatment	  was	   administered	   for	   2	   weeks	   at	   0.8mg/day	   increasing	   to	   1.6mg/day	   for	   2	  weeks.	   GH	   treatment	   at	   both	   doses	   was	   associated	   with	   protein	   anabolism,	  however	  the	  higher	  dose	  was	  associated	  with	  fasting	  hyperglycaemia	  in	  a	  third	  of	   subjects.	   In	   a	   follow	  on	   study	  of	   10	   elderly	  women	   (mean	   age	  71	   years)	   on	  long-­‐term	  GCs	  (mean	  dose	  5.4mg/day)	  addition	  of	  DHEA	  (50mg/day)	  to	  GH	  had	  no	  additional	  effects	  on	  protein	  turnover.	  A	  randomized	  placebo	  control	  study	  of	  testosterone	   20mmg	   and	   nandrolone	   decanoate	   200mg	  was	   carried	   out	   in	   51	  men	   aged	   over	   20	   years	   (mean	   60.3)	   given	   GCs	   for	   1-­‐year.	   Both	   treatments	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resulted	   in	   increased	   lean	   mass	   and	   muscle	   strength	   and	   reduced	   fat	   mass	  although	   the	   greatest	   changes	   were	   seen	   with	   nandrolone	   (Crawford	   et	   al.,	  2003).	  However	  long-­‐term	  safety	  concerns	  remain	  a	  major	  hurdle.	  	  	  
1.6.	  Ageing	  –	  General	  Concepts	  
1.6.1.	  The	  Ageing	  Population	  The	  population	  of	  industrialized	  nations	  is	  ageing.	  According	  to	  a	  Government’s	  Actuary	  Department	  Report	  for	  Parliament	  (2010)	  “a	  boy	  born	  in	  the	  UK	  in	  1981	  could	  expect	  to	  live	  to	  84	  years,	  while	  a	  child	  born	  today	  has	  a	  life	  expectancy	  of	  89	  years”.	  Furthermore	  the	  median	  age	  of	  the	  UK	  population	  increased	  from	  35.4	  	  to	  39.7	  years	  over	  the	  period	  from	  1985	  to	  2010	  and	  is	  projected	  to	  rise	  further	  to	  42.2	  years	  by	  2035	  (Office	  for	  National	  Statistics,	  Report	  (2012)).	  The	  largest	  increases	  have	  been	  in	  those	  aged	  over	  85,	  rising	  from	  0.7	  million	  in	  1985	  to	  1.4	  million	  in	  2010,	  expected	  to	  reach	  3.5	  million	  by	  2035.	  In	  the	  US	  there	  were	  37.3	  million	   people	   aged	   over	   65	   in	   2006,	   and	   the	   figure	   is	   expected	   to	   double	   by	  2050	  (FORUM	  Report	  (2008,	  Manini	  and	  Clark,	  2012).	  In	  the	  EU,	  over	  65s	  made	  up	  17.1	  million	  of	  the	  population	  in	  1998,	  with	  a	  projected	  rise	  to	  25.4	  million	  in	  2035	   and	   30	  million	   in	   2060	   (Sakuma	   and	   Yamaguchi,	   2013,	   Eurostat,	   2008).	  Healthy	  life	  expectancy	  has	  lagged	  behind	  increases	  in	  longevity	  however,	  with	  a	  gap	   between	   overall	   life	   expectancy	   and	   disability	   free	   life	   expectancy	   of	   9.2	  years	   for	  women	   aged	   65	   and	   7.4	   years	   for	  men	   (Office	   for	  National	   Statistics	  Report	   (2012)).	   	   Changing	   birth	   rate	   patterns	   also	   play	   a	   role	   in	   population	  ageing,	  with	  the	  post-­‐war	  baby	  boomer	  generation	  now	  between	  middle	  age	  and	  retirement,	  and	  fertility	  rates	  remaining	  under	  replacement	  levels	  for	  the	  past	  3	  decades	   (Office	   for	   National	   Statistics	   Report	   (2012)).	   This	   has	   economic	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implications	  for	  society,	  with	  the	  Department	  of	  Work	  and	  Pensions	  stating	  that	  those	  over	  working	  age	  consume	  65%	  (£100	  billion)	  of	  benefit	  expenditure,	  and	  the	  Department	   of	  Health	   stating	   that	   this	   group	   accounts	   for	   double	   the	  NHS	  costs	  of	  non-­‐retired	  households	   (Government’s	  Actuary	  Department	  Report	   for	  UK	   Parliament,	   2010).	   There	   is	   a	   need	   for	   interventions	   to	   increase	   healthy	  lifespan	   and	   on	   this	   background,	   ageing	   has	   been	   identified	   as	   a	   key	   research	  challenge	  by	   funding	  agencies	   in	   the	  UK,	  with	   ‘Living	  a	   long	  and	  healthy	   life’	   a	  central	   theme	   of	   the	   Medical	   Research	   Council’s	   strategic	   plan	   (2009),	   and	  ‘Investigating	   development,	   ageing	   and	   chronic	   disease’	   stated	   as	   one	   of	   the	  Wellcome	   Trust’s	   5	   major	   research	   challenges	   (2010).	   Population	   ageing	  represents	  a	  profound	  challenge	  and	  opportunity	  for	  translational	  medicine.	  	  
	  
1.6.2.	  Theories	  of	  Ageing	  The	   process	   of	   ageing	   has	   become	   synonymous	   with	   decline,	   in	   physiological	  function	   and	   in	   development	   of	   chronic	   disease.	   Many	   theories	   have	   been	  proposed	  over	  the	  years,	  which	  can	  be	  broadly	  divided	  into	  those	  that	  state	  that	  it	  is	  an	  innate	  programmed	  process,	  or	  those	  that	  state	  that	  it	  is	  the	  consequence	  of	  the	  accumulation	  of	  molecular,	  cell	  and	  tissue	  damage	  over	  time	  (Jin,	  2010).	  In	  evolutionary	   terms,	   ageing	   has	   been	   seen	   as	   the	   consequence	   of	   selection	   of	  traits	   that	   provided	   an	   advantage	   in	   reaching	   reproductive	   age,	   which	   have	  adverse	  effects	  in	  later	  life.	  Studies	  in	  small	  short-­‐lived	  organisms	  such	  as	  yeast,	  worms	   and	   flies	   have	   identified	   pathways,	   which	   if	   altered	   result	   in	   dramatic	  alterations	   in	   longevity	   (Heemels,	   2010).	   These	   pathways	   involve	   stress	   and	  nutrient	   response	   genes	   including	   mTOR,	   AMPK,	   sirtuins,	   IGF-­‐I	   and	   FOXOs.	  Mouse	  models	   of	   human	   longevity	   involving	   GH-­‐IGF-­‐I	   signalling	   are	   discussed	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elsewhere	   in	   this	   thesis.	   Other	   prominent	   targets	   in	   ageing	   include	   chronic	  inflammation,	   increased	   oxidative	   stress,	   mitochondrial	   dysfunction,	   telomere	  shortening	   and	   subsequent	   macromolecular	   damage	   (Kenyon,	   2010).	   Rare	  syndromes	   of	   accelerated	   ageing	   have	   been	   studied	   to	   provide	   insights	   into	  normal	  ageing.	  Werner	  and	  Hutchinson-­‐Gilford	  progeroid	  syndromes	  are	  due	  to	  single	   gene	   mutations,	   which	   result	   in	   altered	   DNA	   metabolism	   and	   nuclear	  function	   (Cox	   and	   Faragher,	   2007).	   Other	   studies	   have	   taken	   a	   cross-­‐sectional	  approach	   with	   comparisons	   between	   individuals	   of	   different	   age	   groups.	  Centenarians	   have	   been	   used	   to	   identify	   factors	   that	   may	   predispose	   to	  successful	  ageing.	  Many	  questions	  remain	  unanswered	  however,	  and	  the	  search	  for	  the	  nature	  of	  the	  initiating	  event,	  viable	  therapeutic	  targets	  in	  humans,	  and	  a	  unifying	  theory	  of	  ageing	  is	  ongoing.	  	  
1.6.3.	  The	  Ageing	  Phenotype	  Ageing	  is	  characterized	  by	  declining	  physiological	  functions	  in	  multiple	  systems,	  and	  tissues.	  There	  is	  a	  marked	  inter-­‐individual	  variation	  in	  phenotype	  with	  age	  with	  regards	  to	  co-­‐morbidities	  and	  physical	   functioning.	  Frailty	   is	  defined	  as	  “a	  clinical	   syndrome	   of	   adverse	   ageing”,	   which	   is	   defined	   by	   the	   decreased	  physiological	   reserve	   and	   diminished	   resistance	   to	   stress	   (Clegg	   et	   al.,	   2013).	  Fried	   et	   al	   (2004)	   used	   “unintentional	   weight	   loss,	   self-­‐reported	   exhaustion,	  reduced	  grip	  strength,	  walking	  speed	  and	  physical	  activity”	  as	  diagnostic	  criteria	  for	  frailty	  and	  found	  that	  it	  was	  an	  independent	  predictor	  of	  a	  variety	  of	  adverse	  outcomes	   including	   falls,	   functional	   decline,	   hospital	   admission	   and	   death.	   A	  recent	   systematic	   review	   reported	  weighted	   average	   prevalence	   rates	   of	   9.9%	  for	   frailty	   and	   44.2%	   for	   pre-­‐frailty,	   taking	   into	   account	   21	   community-­‐based	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studies	   (n=61500)(Clegg	   et	   al.,	   2013).	   Adverse	   ageing	   is	   underpinned	   by	  dysfunction	   of	   the	   immune,	   endocrine,	   central	   nervous,	   and	   musculoskeletal	  systems.	  Important	  age-­‐related	  clinical	  presentations	  such	  as	  falls,	  incontinence,	  dementia	   and	   delirium,	   are	   clinical	   syndromes	   of	   multi-­‐factorial	   aetiology.	  Increased	   visceral	   fat,	   reduced	   lean	   mass,	   and	   bone	   mineral	   density	   and	  development	   of	   alochronic	   conditions	   (hypertension,	   type	   2	   diabetes	   and	  cardiovascular	  disease)	  are	  central	  to	  the	  ageing	  phenotype.	  	  
	  
1.7.	  Ageing	  and	  the	  Endocrine	  System	  Across	  human	  ageing	   there	   are	  marked	   changes	   in	   regulation	   and	   secretion	  of	  hormones	   including	   oestrogen	   (menopause),	   testosterone	   (andropause),	  GH/IGF-­‐I	   (somatopause),	   thyroid	   hormone,	   cortisol,	   and	   DHEA	   (adrenopause)	  (Chahal	   and	   Drake,	   2007).	   Whether	   modulation	   of	   these	   changes	   could	   be	   of	  therapeutic	  benefit	  has	  been	  the	  focus	  of	  much	  research	  interest.	  	  
	  
1.7.1.	  Ageing	  and	  the	  GH-­‐IGF-­‐I	  Axis	  	  GH	   levels	   are	   low	   during	   childhood,	   and	   increase	   up	   to	   3-­‐fold	   during	   puberty,	  associated	   with	   marked	   increases	   in	   somatic	   growth,	   coinciding	   with	   the	  attainment	  of	  reproductive	  maturity	  (Sherlock	  and	  Toogood,	  2007).	  A	  plateau	  is	  reached	  in	  early	  adulthood,	  and	  levels	  decline	  in	  middle	  and	  old	  age	  by	  14%	  per	  decade,	  a	  phenomenon	  that	  has	  been	  labelled	  the	  ‘somatopause’	  (Rudman	  et	  al.,	  1981,	  Shibasaki	  et	  al.,	  1984,	  Ho	  et	  al.,	  1987,	  Iranmanesh	  et	  al.,	  1991).	  IGF-­‐I	  levels	  in	  the	  elderly	  are	  50%	  of	  those	  seen	  in	  young	  adulthood	  (Veldhuis	  et	  al.,	  2005).	  GHRH	  and	  arginine	  stimulation	  studies	  suggest	  that	  GH	  reserve	  is	  retained	  with	  ageing	  and	  that	  regulation	  of	  release,	  possibly	  via	  sensitivity	   to	  somatostatin	   is	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partly	   responsible	   for	   changes	  observed	   (Sherlock	  and	  Toogood,	  2007,	  Lang	  et	  al.,	  1987,	  Ghigo	  et	  al.,	  1990).	  BMI	  is	  inversely	  correlated	  with	  GH,	  and	  weight	  loss	  in	  obese	  individuals	  attenuates	  these	  effects	  (Rudman	  et	  al.,	  1981,	  Rasmussen	  et	  al.,	   1995,	   Fowke	   et	   al.,	   2010).	   Exercise	   has	   been	   shown	   to	   induce	   GH	   release	  (Libardi	   et	   al.,	   2013).	   Sleep	   studies	   have	   revealed	   that	   patients	   with	   GH	  deficiency	  have	   abnormalities	   in	   sleep	   architecture	   including	   increases	   in	   slow	  wave	  sleep,	  and	  that	  GH	  administration	  in	  GHD	  reverses	  these	  abnormalities	  and	  increases	  REM	  sleep	  (Morselli	  et	  al.,	  2013,	  Van	  Cauter	  et	  al.,	  1998).	  Furthermore	  lean	   mass	   and	   IGF-­‐I	   are	   increased	   in	   response	   to	   continuous	   positive	   airway	  pressure	   (CPAP)	   in	   men	   with	   obstructive	   sleep	   apnoea	   (Munzer	   et	   al.,	   2010).	  Dietary	  factors	  may	  play	  a	  role,	  as	  ageing	  may	  be	  associated	  with	  reduced	  energy	  intake,	   and	   evidence	   that	   fasting	   reduces	   IGF-­‐I	   levels	   (Clemmons	   and	  Underwood,	  1991).	  	  	  
1.7.1.1.	   GH	  Treatment	  in	  Elderly	  Subjects	  without	  Pituitary	  Disease	  	  Growth	  Hormone	  Deficiency	  is	  characterized	  by	  increased	  fat	  mass,	  reduced	  lean	  and	  bone	  mass,	  with	  adverse	  effects	  on	  quality	  of	  life	  measures	  (Bengtsson	  et	  al.,	  1993).	  GH-­‐replacement	  in	  elderly	  subjects	  has	  been	  investigated	  in	  a	  number	  of	  studies.	  Rudman	  et	  al	  (1990)	  carried	  out	  the	  first	  such	  study	  in	  21	  healthy	  men	  (aged	  61-­‐81	  years).	  Increases	  in	  lean	  mass	  (+8.8%),	  and	  mean	  lumbar	  vertebral	  bone	  mineral	  density	  (+1.6%),	  and	  skin	  thickness	  (+7.1%)	  were	  observed	  in	  the	  treatment	  group	  at	  6	  months.	  A	  reduction	  in	  fat	  mass	  (-­‐8.8%)	  was	  also	  observed.	  Similar	  results	  were	  found	  in	  post-­‐menopausal	  women	  (n=13	  cases),	  along	  with	  reported	   increases	   in	   bone	  markers	   (Holloway	   et	   al.,	   1994).	   This	   study	   shares	  limitations	  with	  many	   subsequent	   studies	  with	   limited	   follow	   up	   of	   6	  months	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duration	   and	   an	   absence	  of	  muscle	   strength	  measures.	  Where	  muscle	   strength	  has	  been	  measured	  improvements	  have	  been	  mild	  at	  best	  with	  Welle	  et	  al	  (1996)	  reporting	   a	   14	   (+/-­‐5%)	   increase	   at	   3	   months,	   and	   Hennessey	   et	   al	   (2001)	  reporting	   an	   additional	   absolute	   increase	   of	   7.8%	   over	   exercise	   alone	   over	   6	  months.	  There	  are	  concerns	  that	  observed	  increases	  in	  lean	  mass	  may	  be	  partly	  attributed	  to	  GH	  induced	  sodium	  and	  water	  retention.	  Cohn	  et	  al	  (1993)	  noted	  a	  high	   incidence	   of	   adverse	   events	   including	   carpal	   tunnel	   syndrome	   (16%,	  10/62),	   gynaecomastia	   (6%,	   4/62)	   and	   hyperglycaemia	   (5%,	   3/62)	   in	   GH	  treated	  patients.	  A	  recent	  large	  study	  (n=131)	  showed	  increases	  in	  measures	  of	  insulin	   resistance,	   with	   an	   improved	   plasma	   lipid	   profile	   in	   healthy	   elderly	  patients	  on	  GH	  (Munzer	  et	  al.,	  2009).	  Overall	  occurrence	  of	  adverse	  effects	  was	  between	   38-­‐80%	   in	   subsequent	   studies	   (Sherlock	   and	   Toogood,	   2007).	   In	  summary	  the	  studies	  showed	  only	  mild	  or	  modest	  effects	  on	  body	  composition	  and	  are	  limited	  by	  side	  effect	  profiles	  (including	  carpal	  tunnel	  syndrome,	  insulin	  resistance).	   Furthermore	  many	   of	   the	   earlier	   studies	   used	   higher	   doses	   of	   GH,	  which	   may	   explain	   their	   effects	   and	   the	   short	   duration	   of	   follow	   up	   of	   most	  studies	   (<1	   year)	   means	   that	   long-­‐term	   safety	   concerns	   have	   not	   been	  addressed.	  	  	  
1.7.1.2.	   The	  Paradox	  of	  GH-­‐IGF-­‐I	  and	  Ageing	  The	   observation	   that	   caloric	   restriction	   resulted	   in	   increased	   longevity	   of	  rodents	   was	   made	   80	   years	   ago	   (McCay	   and	   Crowell,	   1934).	   Furthermore,	  hypophysectomised	   rats	   were	   found	   to	   have	   a	   reduction	   in	   age-­‐associated	  collagen	   changes	   in	   tail	   tendons	   (Olsen	   and	   Everitt,	   1965).	   There	   is	   now	  overwhelming	   evidence	   from	   studies	   in	   yeast,	  worms,	   flies,	   and	  mammals	   that	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impairment	  of	   insulin	   and	   IGF-­‐I	   signaling	   results	   in	   reduced	   features	  of	   ageing	  and	   increased	   lifespan.	   Transgenic	   mice	   with	   impaired	   GH-­‐IGF-­‐I	   signaling	  include	  Ames	  (prop-­‐1	  mutant),	  which	  have	  impaired	  differentiation	  of	  pituitary	  gland	  cell	  subtypes	  and	  reduced	  body	  size,	  Snell	  (pit-­‐1	  mutant)	  where	  the	  defect	  is	   downstream	  of	   prop-­‐1	   and	  mice	   are	   phenotypically	   similar,	   Laron	   (GHR/BP	  knock-­‐out),	   IGF-­‐1R	   heterozygote	   knock-­‐out,	   and	   Little	   (GHRH-­‐R	   mutant).	   All	  have	  prolonged	   lifespans	   (extensions	  21-­‐68%)	  and	   reduced	  body	   size	   (Brown-­‐Borg,	   2009).	   Proposed	   mechanisms	   of	   protection	   include,	   resistance	   to	   cell	  stress,	   attenuation	   of	   pro-­‐neoplastic	   anti-­‐apoptotic	   proliferative	   pathways,	   and	  improved	  insulin	  sensitivity	  (Bartke,	  2011).	  The	  picture	  in	  humans	  is	  less	  clear-­‐cut,	  with	  both	  GH	  excess	   in	  acromegaly,	  and	  GH	  deficiency	   in	  pituitary	  disease,	  associated	   with	   excess	   mortality	   (Holdaway	   et	   al.,	   2008,	   Besson	   et	   al.,	   2003).	  Laron	   syndrome	   (GH	   resistance)	   is	   characterized	   by	   short-­‐stature,	   obesity,	  increased	   lipids,	  and	   insulin	   resistance.	  Data	   from	  135	  Laron	  Dwarves	   from	  an	  Ecuadorian	  cohort	  and	  65	  from	  an	  Israeli	  cohort	  have	  been	  reported.	  22	  deaths	  in	   childhood	   were	   reported	   in	   the	   Ecuadorian	   cohort,	   whilst	   only	   one	   was	  reported	  in	  the	  Israeli	  cohort,	  with	  the	  oldest	  known	  individuals	  reaching	  their	  late	   70s.	   Although	   full-­‐standardized	   mortality	   ratio	   data	   are	   not	   available	   a	  survival	  advantage	  seems	  unlikely	  (Laron,	  2008).	  The	  reason	  for	  the	  discrepancy	  between	  GH-­‐IGF-­‐I	  effects	  on	   longevity	  between	  mice	  and	  humans	  has	  not	  been	  confirmed.	  However	   a	   recent	   review	   on	   the	   subject	   (Bartke,	   2011),	   speculates	  that	   it	   may	   be	   that	   most	   laboratory	   mice	   die	   from	   cancer,	   from	   which	   IGF-­‐I	  suppression	   provides	   protection,	   an	   effect	   diminished	   in	   humans	  where	   other	  causes	   of	   death	   are	   also	   prevalent.	   Alternatively	   it	   could	   be	   explained	   by	   the	  pleiotrophic	  gene	   theory	  whereby	   increased	   IGF-­‐I	  signaling	  provides	  a	  survival	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advantage	  in	  mice	  in	  early	  life	  by	  promoting	  promoting	  growth,	  and	  achievement	  of	  reproductive	  potential,	  at	  the	  expense	  of	  susceptibility	  to	  ageing	  and	  cancer	  in	  later	   life.	   This	   is	   less	   prominent	   in	   humans	   who	   have	   a	   longer	   lifespan	   and	   a	  prolonged	   dependency	   during	   childhood	   to	   allow	   development	   of	   higher	  functions.	  	  	  
1.7.2.	  Ageing	  and	  the	  Hypothalamic	  Pituitary	  Adrenal	  (HPA)	  Axis	  	  Many	  studies	  have	  assessed	  age-­‐related	  changes	  in	  the	  HPA-­‐axis	  with	  variability	  in	  results,	  however	  in	  recent	  years	  some	  broad	  themes	  have	  emerged	  which	  are	  summarized	  below	  (See	  Table	  1-­‐5).	  	  
Biochemical	  Parameter	   Change	  with	  Age	   References	  
	  
Mean	   24	   hr	   Cortisol	  
(urine)	  
é	   Dodt	  et	  al	  1994,	  	  Van	  Cauter	  et	  al	  1996	  
Serum	  Morning	  Cortisol	   _ 
 
é 	  
Giordano	  et	  al	  2001,	  	  Belanger	  et	  al	  1994,	  	  Barrett-­‐Connor	  et	  al	  2000,	  	  Ferrari	  et	  al	  2001	  Zhao	  et	  al	  2003	  
Diurnal	  Variation	  (serum)	   Earlier	  Acrophase	  
êAmplitude	   Sherman	  et	  al	  1985,	  Van	  Coevordan	  et	  al	  1991	  
ACTH	   é	   Magri	  et	  al	  1997	  
CBG	   _	   Bergendahl	  et	  al	  2000	  




êresponse	   Wilkinson	   et	   al	   1997,	  Wilkinson	   et	   al	  2001,	  Magri	  et	  al	  1997	  
Short	  Synacthen	  Test	   épeak	  
êresponse	  (low	  dose)	   Parker	  et	  al	  2000	  Giordano	  et	  al	  2001	  
Stress	  Response	   Prolonged	  time	  to	  normalisation	   Transtadottir	  et	  al	  2004	  
	  
Table	  1-­‐5:	  Summary	  of	  Changes	  in	  Measured	  Parameters	  of	  the	  HPA-­‐axis.	  (-­‐	  =	  No	  change)	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1.7.2.1.	   Age-­‐Related	  Changes	   in	  Mean	  24-­‐hour	  Cortisol	  Secretion	  and	  
Diurnal	  Variation	  
	  Some	   studies	   carried	   out	   in	   the	   1980s	   and	   1990s	   did	   not	   show	   differences	   in	  mean	  cortisol	   levels	  with	  age,	  but	  did	  identify	  a	  characteristic	  diurnal	  profile	  of	  cortisol	   secretion.	   Sherman	  et	   al	   (1985)	  had	  negative	   results	   for	  differences	   in	  mean	  24	  hour	  cortisol	   levels	   in	  34	  healthy	  subjects	  (aged	  18-­‐75	  years),	  but	  did	  demonstrate	  earlier	   timing	  of	  cortisol	  acrophase	  (time	  point	  of	  peak	  amplitude	  of	  rhythm),	  peak	  and	  nadir	  were	  seen	  with	  age,	  although	  this	  may	  be	  related	  to	  the	   earlier	   time	   of	   usual	   bedtime	   reported	   by	   this	   age	   group.	   Similarly	   Van	  Coevorden	  et	   al	   (1991)	   found	   that	   although	  mean	   cortisol	   levels	   in	   the	   elderly	  were	  normal,	  the	  amplitude	  of	  the	  diurnal	  variation	  was	  decreased	  in	  a	  study	  of	  8	  young	  (20-­‐27	  years)	  and	  8	  elderly	  (67-­‐84	  years)	  healthy	  men.	  	  In	  contrast	  Dodt	  et	  al	  (1994)	  observed	  HPA-­‐axis	  activation	  with	  age	  (increased	  mean	  cortisol	  and	  ACTH	   levels	   between	   2300-­‐0300h).	   Furthermore	   there	   was	   an	   association	  between	   these	   changes	   and	   reduced	   periods	   of	   slow	   wave	   and	   rapid	   eye	  movement	  sleep.	  Van	  Cauter	  et	  al	  (1996)	  corroborated	  the	  main	  findings	  here	  in	  a	   re-­‐analysis	   of	   177	   plasma	   cortisol	   profiles	   from	   90	   healthy	   subjects	   aged	  between	  18-­‐83	  years.	  Mean	  cortisol	   levels	  were	   increased	  by	  20-­‐50%	  from	  the	  age	  of	  20	   to	  80	  years.	   	  There	  was	  a	  blunting	  of	   the	  normal	  diurnal	  variation	  of	  cortisol	   secretion	   with	   age	   and	   overnight	   cortisol	   levels	   gradually	   increased.	  There	  were	  also	  gender	  specific	  differences,	  with	  pre-­‐menopausal	  women	  having	  slightly	   lower	   mean	   cortisol	   levels	   than	   age	   matched	   men	   and	   older	   women	  exhibiting	  an	  increase	  in	  morning	  acrophase	  that	  was	  absent	  in	  men.	  A	  follow	  up	  prospective	  study	  of	  24-­‐hour	  serum	  profiles	  in	  healthy	  men	  (n=149,	  aged	  16-­‐83	  years)	   revealed	   that	   the	   increase	   mean	   cortisol	   levels	   at	   3nmol/L/decade,	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(p<0.001)	   over	   the	   age	   of	   50.	   The	   authors	   speculated	   that	   this	  may	   be	   due	   to	  reduced	   REM	   sleep,	   however	   this	   did	   not	   reach	   statistical	   significance	   as	   an	  independent	  variable	  (Van	  Cauter	  et	  al.,	  2000).	  Deuschle	  et	  al	  (1997)	  found	  that	  mean	  plasma	  cortisol	   levels	  were	   increased	  across	  age	   in	  a	  study	  of	  33	  healthy	  subjects.	  	  	  
1.7.2.2.	   Age-­‐Related	  Changes	  in	  Morning	  Cortisol	  Levels	  There	  is	  a	  similar	  variability	  in	  data	  on	  morning	  cortisol	  levels,	  with	  some	  groups	  finding	  no	  differences	  with	  age	  (Giordano	  et	  al.,	  2001,	  Ferrari	  et	  al.,	  2001a),	  and	  others	   demonstrating	   increases	   of	   between	   20-­‐30%	   from	   middle	   to	   old	   age	  (Belanger	  et	  al.,	  1994,	  Laughlin	  and	  Barrett-­‐Connor,	  2000).	  Zhao	  et	  al	  (Zhao	  et	  al.,	  2003)	  showed	  that	  morning	  cortisol	  levels	  increased	  with	  age	  across	  a	  group	  of	  male	  and	   female	  subjects	   (n=145	  aged	  31-­‐110)	  (p<0.0001).	  Furthermore	   those	  age	  over	  80	  had	  increased	  cortisol	  levels	  vs.	  those	  in	  their	  60s	  or	  70s.	  	  	  
1.7.2.3.	   Age-­‐Related	  Changes	  in	  ACTH	  Magri	  et	  al	   (1997)	   found	   increased	  ACTH	   levels	  with	  age,	  but	  no	  differences	   in	  ACTH	   diurnal	   profile	   between	   healthy	   young	   (n=22),	   healthy	   old	   (n=52)	   and	  elderly	  patients	  diagnosed	  with	  dementia	  (n=35).	  ACTH	  spikiness,	  a	  measure	  of	  pulsatility	  of	  secretion,	  increases	  with	  age,	  particularly	  in	  women	  (p=0.046).	  The	  proportion	   of	   pulsatile	   ACTH	   secretion	   correlated	  with	   24-­‐hour	  mean	   cortisol	  concentrations	   (p=0.009),	   and	   irregularity	   of	   cortisol	   increased	   with	   age	  (Veldhuis	  et	  al.,	  2009).	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1.7.2.4.	   Age-­‐Related	  Changes	  in	  Cortisol	  Binding	  Globulin	  (CBG)	  CBG	   levels	   appear	   to	   change	   across	   the	   lifespan,	  with	   low	   levels	   during	   foetal	  gestation,	  and	   increases	   in	  the	  pre-­‐pubertal	  phase	  and	  reductions	  with	  old	  age.	  Furthermore,	   dramatic	   reductions	   have	   been	   reported	   in	   elderly	   subjects	  with	  Alzheimer’s	  disease	  (Ferrari	  et	  al.,	  2001b,	  Meaney	  et	  al.,	  1995).	  	  
	  
1.7.2.5.	   Age-­‐Related	  Changes	  in	  Dynamic	  Tests	  of	  the	  HPA-­‐Axis	  Dynamic	   testing	   reveals	   evidence	   of	   altered	   neuroendocrine	   functioning	   with	  ageing,	  with	   regards	   sensitivity	   of	   the	   hypothalamus	   and	  pituitary	   to	   feedback	  from	  circulating	  GCs,	  and	  sensitivity	  of	  the	  pituitary	  to	  stimulation	  by	  CRH.	  	  
Ageing	  and	  the	  CRH-­‐test:	  Several	  studies	  have	  found	  no	  differences	  in	  responses	  to	  ovine	  CRH	  testing	  with	  increasing	  age	  in	  men	  (Pavlov	  et	  al.,	  1986,	  Greenspan	  et	   al.,	   1993,	  Waltman	  et	   al.,	   1991).	   	  However	  Greenspan	  et	   al	   (1993)	  observed	  increases	   in	   basal,	   peak,	   and	   5-­‐hour	   nadir	   cortisols	   following	   ovine	   CRH	  administration	  in	  women.	  	  
Ageing	  and	  Suppression	  of	  the	  HPA-­‐Axis	  by	  Exogenous	  GCs:	  Sensitivity	  of	  both	  the	  ACTH	   and	   cortisol	   suppressive	   response	   to	   exogenous	   GCs	   is	   delayed	   and	  reduced	  in	  elderly	  subjects,	  irrespective	  of	  the	  time	  of	  sampling	  (Wilkinson	  et	  al.,	  1997,	  Wilkinson	  et	  al.,	  2001,	  Magri	  et	  al.,	  1997).	  Furthermore	  the	  effect	  was	  most	  marked	  in	  dementia	  patients	  (Magri	  et	  al.,	  1997).	  This	   is	   indicative	  of	   impaired	  negative	  feedback	  with	  ageing	  and	  dementia.	  	  
Ageing	  and	  HPA-­‐Axis	  Stress	  Response:	  High	  intensity	  exercise	  is	  a	  model	  of	  stress	  resulting	   in	   ACTH	   release.	   A	   study	   of	   31	   women	   found	   that	   normalization	   of	  serum	  ACTH	  following	  exercise	  was	  delayed	  in	  older	  women,	  and	  aerobic	  fitness	  attenuated	   this	   effect.	   These	   subjects	   also	   had	   higher	   cortisol	   levels	   during	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recovery	   suggestive	   of	   enhanced	   adrenal	   sensitivity.	   This	   study	   indicates	   an	  important	  role	  of	  physical	  fitness	  in	  preventing	  age-­‐associated	  alterations	  in	  the	  HPA-­‐axis	   such	   as	   blunted	   negative	   feedback	   and	   reduced	   adrenal	   sensitivity	  (Traustadottir	  et	  al.,	  2004).	  Conversely,	  Kudielka	  et	  al	  (2004)	  examined	  the	  HPA-­‐axis	  response	  to	  the	  “Trier	  social	  stress”	  test	  in	  31	  children,	  41	  young	  adults	  and	  30	   elderly	   adults.	   The	   test	   elicited	   increases	   in	   ACTH	   and	   cortisol	   levels	   in	   all	  groups.	  Ageing	  was	   associated	  with	   a	   reduction	   in	  ACTH	   response	   in	  men,	   but	  not	  women,	  and	  increased	  cortisol	  levels	  in	  both	  genders.	  	  
Ageing	  and	   the	   Short	   Synacthen	  Test:	  Evidence	   from	  most	   studies	   investigating	  adrenal	   cortisol	   reserve	   suggests	   that	   it	   is	   preserved	   with	   age	   (Ferrari	   et	   al.,	  2001b).	  An	  increased	  cortisol	  response	  to	  standard	  synacthen	  test	  was	  observed	  in	  one	  study	  (Parker	  et	  al.,	  2000)	  and	  conversely	  adrenal	  sensitivity	  to	  very	  low	  dose	   (0.06μg)	   ACTH	   stimulation	   was	   reduced	   in	   healthy	   elderly	   (n=8,	   63-­‐75	  years)	   compared	   to	   young	   subjects	   (n=12,	   22-­‐34	   years)	   in	   another	   study	  (Giordano	  et	  al.,	  2001).	  	  	  
1.7.2.6.	   Heritability	  of	  Age-­‐Related	  HPA	  changes	  	  If	   HPA-­‐axis	   dysfunction	   contributes	   to	   chronic	   disease	   states	   associated	   with	  ageing,	   there	   is	   a	   question	   as	   to	   whether	   certain	   individuals	   are	   protected	  against	   this	   phenotype	   by	   virtue	   of	   a	   beneficial	   pattern	   of	   cortisol	   secretion.	  Noordam	   et	   al	   (2012)	   tried	   to	   address	   this	   by	   studying	   the	   offspring	   of	  nonagenarians.	   They	   found	   that	   cases	   (n=149)	   had	   reduced	   HPA-­‐axis	   activity	  (diurnal	   salivary	   cortisol),	   but	   no	   change	   in	   response	   to	   dexamethasone	  suppression	  compared	  to	  controls	  (n=154).	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1.7.2.7.	   Sexual	  Dimorphism	  in	  Age-­‐Related	  HPA-­‐Axis	  Changes	  There	   is	   evidence	   of	   sexual	   dimorphism	   in	   HPA-­‐axis	   functioning,	   with	   some	  reports	   of	   higher	   cortisol	   levels	   in	   elderly	   women	   vs.	   men	   (Greenspan	   et	   al.,	  1993,	  Seeman	  et	  al.,	  2001,	  Keenan	  et	  al.,	  2009).	  Differential	  efficacy	  and	  potency	  of	  ACTH,	  between	  women	  and	  men,	  has	  been	  proposed	  as	  a	  potential	  underlying	  mechanism	   (Keenan	   et	   al.,	   2009).	   	   Animal	   studies	   have	   demonstrated	   that	  oestrogens	   increase	   whilst	   testosterone	   decreases	   cortisol	   secretion	   (Viau,	  2002).	   Levels	   of	   sex	   steroids	   including	   oestrogens	   were	   positively	   correlated	  with	  cortisol	   levels	   in	  a	  sub-­‐set	  analysis	  of	   the	  “Seattle	  Midlife	  Women’s	  Health	  Study”	   (n=132)(Woods	   et	   al.,	   2009).	   In	   addition,	   short-­‐term	   testosterone	  administration	  attenuated	  CRH-­‐stimulated	  cortisol	   levels	   in	  healthy	  young	  men	  with	  experimentally	  induced	  hypogonadism	  in	  one	  study	  (Rubinow	  et	  al.,	  2005).	  	  
1.7.2.8.	   Relationship	   between	   Cortisol	   Concentration/Secretion	   and	  
Age-­‐Associated	  Chronic	  Disease	  
	  A	  series	  of	  epidemiological	  and	  observational	  cohort	  studies	  have	  demonstrated	  a	   link	   between	   elevations	   in	   circulating	   cortisol	   levels	   and	   adverse	   body	  composition	  changes,	  and	  chronic	  disease	  states	  that	  are	  themselves	  associated	  with	  ageing.	  These	  conditions	  include	  dementia,	  osteoporosis	  and	  aspects	  of	  the	  metabolic	  syndrome.	  Subsequently	  there	  has	  been	  interest	  in	  whether	  aspects	  of	  the	  HPA-­‐axis	  may	  be	  used	  as	  a	  biomarker	  for	  disease,	  or	  whether	  its	  modulation	  may	   have	   translational	   potential.	   A	   summary	   of	   the	   data	   from	   these	   studies	   is	  outlined	  below,	   followed	  by	  a	  discussion	  of	   the	  studies	  that	  have	  assessed	  how	  different	  measurements	  of	  HPA-­‐axis	  function	  alter	  with	  increasing	  age.	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1.7.2.9.	   Circulating	  Cortisol,	  Cognitive	  Decline	  and	  Dementia	  Cognitive	  decline	  is	  seen	  as	  a	  key	  feature	  of	  the	  ageing	  process	  that	  may	  result	  in	  increased	  dependency	  with	  inherent	  social	  care	  and	  health	  service	  costs.	  There	  has	   been	   much	   focus	   on	   the	   contribution	   of	   HPA-­‐axis	   dysfunction	   to	   the	  spectrum	  of	   cognitive	   decline	   leading	   to	   dementia	   (Yau	   and	   Seckl,	   2012).	   This	  reasoning	   is	   supported	   by	   observations	   from	   animal	   and	   human	  neuropathological	  studies	  that	  hippocampal	  atrophy	  is	  both	  a	  prominent	  feature	  of	  dementia	  and	  may	  be	  induced	  by	  GC	  excess	  and	  chronic	  stress	  (Yau	  and	  Seckl,	  2012,	  Landfield	  et	  al.,	   1978,	  Sousa	  et	  al.,	   1998,	  Magarinos	  and	  McEwen,	  1995).	  Furthermore	   the	   hippocampus	   is	   involved	   in	   modulation	   of	   the	   HPA-­‐axis	   via	  inhibitory	  control	  with	  high	  expression	  of	  GR	  (Ferrari	  et	  al.,	  2001b).	  Lupien	  et	  al	  (1994)	  found	  that	  the	  slope	  of	  increase	  in	  cortisol	  levels	  over	  4	  years	  follow	  up	  in	  19	   healthy	   elderly	   volunteers,	   was	   associated	   with	   development	   of	   cognitive	  deficits	   in	   memory	   and	   selective	   attention,	   parameters	   that	   involve	   the	  hippocampal	   and	   limbic	   system.	   A	   recent	   study	   appeared	   to	   support	   this	  association,	   and	   highlighted	   a	   possible	   area	   of	   sexual	   dimorphism	   in	   the	  interplay	   between	   the	   HPA-­‐axis	   and	   cognition	   with	   the	   observations	   that	  increased	  morning	  cortisol	  was	  associated	  with	  reduced	  cognitive	  performance,	  (visuo-­‐spatial	  performance	   in	  men	  and	  verbal	   fluency	   in	  women)	   in	   a	   study	  of	  197	  elderly	  subjects	   living	   in	  the	  community.	  Data	   from	  Greendale	  et	  al	  (2000)	  supported	   these	   findings	   in	   136	   post-­‐menopausal	   women	   living	   in	   Southern	  California	  over	  2	  years	  follow	  up.	  Mean	  and	  nadir	  cortisol	  levels	  were	  associated	  negatively	  with	  the	  mini-­‐mental	  state	  examination	  in	  a	  study	  of	  22	  healthy	  young	  subject	  and	  52	  healthy	  old	  and	  35	  elderly	  patients	  with	  dementia	   (Magri	  et	  al.,	  1997).	  An	  analysis	  of	  189	  subjects	  enrolled	  in	  the	  Rotterdam	  Study	  (mean	  follow	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up	  1.9	  years),	   found	   that	   impaired	   cortisol	   suppression	   to	  dexamethasone	  was	  associated	  with	  cognitive	  decline	  (Kalmijn	  et	  al.,	  1998).	  Strawski	  RS	  et	  al	  (2011)	  found	   that	   higher	   cognitive	   function	   scores	   were	   associated	   with	   a	   ‘healthier’	  overall	   cortisol	   diurnal	   profile,	   characterized	   by	   a	   steep	   increase	   and	   high	  morning	  peak	  and	  lower	  evening	  and	  nocturnal	  nadir,	  in	  a	  study	  of	  1500	  subjects	  (aged	  33-­‐84	  years).	  In	  summary	  although	  increases	  in	  morning	  cortisol,	  reduced	  sensitivity	   to	   GC	   negative	   feedback	   and	   altered	   diurnal	   rhythms	   have	   been	  associated	  with	  cognitive	  decline,	  an	  overarching	  temporal	  relationship	  has	  not	  yet	  been	  established.	  	  	  
1.7.2.10.	   Circulating	  Cortisol	  and	  Osteoporosis	  	  Osteoporosis	   is	   a	   highly	   prevalent	   condition	   in	   later	   life	   resulting	   in	   fractures,	  reduced	  mobility	  and	  associated	  morbidities.	  It	  is	  also	  a	  key	  feature	  of	  Cushing’s	  syndrome,	   and	   osteoporosis	   from	   exogenous	   GC	   treatment,	   is	   the	   commonest	  iatrogenic	  cause	  and	  is	  a	  particular	  risk	  to	  the	  elderly	  population	  (Vestergaard	  et	  al.,	  2002,	  Newell-­‐Price	  et	  al.,	  2006).	   	   Increased	  11β-­‐HSD1	  activity	  with	  age	  was	  proposed	  as	  a	  mechanism	  of	   increased	   sensitivity	   to	  GCs	   (Cooper	  et	   al.,	   2002).	  	  Interestingly,	  bone	  loss	  is	  greater	  in	  adrenal	  vs.	  pituitary	  Cushing’s	  and	  this	  may	  be	  due	  to	  higher	  adrenal	  androgens	  in	  the	  latter	  (Minetto	  et	  al.,	  2004).	  	  However	  inhibition	  of	  osteoblast	  function	  and	  reduced	  bone	  formation	  is	  thought	  to	  be	  the	  main	   mechanism	   underlying	   GC-­‐induced	   osteoporosis,	   with	   secondary	   effects	  from	   stimulation	   of	   parathyroid	   hormone,	   and	   reduced	   gut	   absorption,	   and	  increased	   renal	   excretion	   of	   calcium	   (Wilson	   and	  Williams,	   1998).	   The	   role	   of	  physiological	  changes	  in	  the	  HPA-­‐axis	  in	  humans	  and	  effects	  on	  bone	  density	  has	  been	  investigated	  by	  a	  few	  studies.	  Serum	  cortisol	   is	  negatively	  correlated	  with	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proximal	  and	  lumbar	  bone	  mineral	  density	  (Dennison	  et	  al.,	  1999).	  Greendale	  et	  al	  (1999)	  found	  that	  increased	  urinary	  free	  cortisol	  levels	  were	  associated	  with	  incident	   fractures	   in	  a	   cohort	   study	  of	  684	  elderly	   subjects	   (aged	  70-­‐70	  years)	  over	  follow	  up	  from	  1988	  to	  1995.	  	  	  
1.7.2.11.	   Circulating	  Cortisol	  and	  the	  Metabolic	  Syndrome	  There	  is	  an	  increased	  prevalence	  of	  components	  of	  the	  metabolic	  syndrome	  with	  age.	   Phillips	   et	   al	   (1998)	  observed	   correlations	  between	  measures	  of	   impaired	  glucose	   tolerance/insulin	   resistance	   and	   plasma	   cortisol	   in	   a	   UK-­‐study	   of	   370	  men	  elderly	  men.	  	  A	  Korean	  study	  reported	  that	  late	  night	  salivary	  cortisol	  levels	  were	  increased	  in	  association	  with	  the	  metabolic	  syndrome,	  and	  that	  levels	  were	  positively	   associated	   with	   insulin	   resistance,	   fasting	   blood	   glucose,	   and	   waist	  circumference	   (Jang	   et	   al.,	   2012).	   Another	   study	   demonstrated	   a	   positive	  association	   between	   24-­‐hour	   cortisol	   production	   rate	   and	   percentage	   body	   at	  and	   BMI,	   but	   showed	   no	   change	   in	   circulating	   free	   levels	   due	   to	   increases	   in	  clearance	   (Purnell	   et	   al.,	   2004).	   However	   no	   significant	   correlations	   were	  observed	  in	  a	  larger	  study	  (n=726	  age	  48-­‐89	  years)	  (DeSantis	  et	  al.,	  2011).	  	  	  
1.7.2.12.	   Ageing	  and	  DHEA	  The	   adrenal	   zona	   reticularis	   atrophies	   from	   young	   adulthood	   onwards	   in	  association	  with	  a	   reduction	   in	   the	  biosynthesis	  and	  secretion	  of	  DHEA	  and	   its	  sulphated	   form	   DHEAS	   at	   a	   rate	   of	   “1-­‐2%	   per	   year”	   (Ferrari	   et	   al.,	   2001b).	  Adrenal	  androgens	  appear	  to	  counteract	  many	  of	  the	  adverse	  effects	  of	  chronic	  cortisol	   exposure,	   and	   have	   pleiotropic	   effects	   on	   muscle	   growth,	   insulin	  resistance,	   central	   nervous	   and	   immune	   systems	   (Chahal	   and	   Drake,	   2007,	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Valenti,	   2004).	   The	   past	   2	   decades	   have	   seen	  much	   research	   interest	   in	   using	  DHEA	  as	  an	  anti-­‐ageing	  therapy,	  and	  this	  is	  discussed	  elsewhere	  in	  this	  thesis.	  A	  number	  of	  studies	  have	  identified	  increases	  in	  the	  cortisol:DHEAS	  ratio	  with	  age,	  and	   it	   is	   now	   established	   as	   a	   research	   tool	   to	   characterize	   adrenal	   ageing	  (Laughlin	  and	  Barrett-­‐Connor,	  2000,	  Ferrari	  et	  al.,	  2001a,	  Giordano	  et	  al.,	  2001,	  Chehab	   et	   al.,	   2007).	   Increased	   cortisol:DHEAS	   ratios	   are	   seen	   in	   dementia	  patients	  (Ferrari	  et	  al.,	  2001a).	  Carvalhaes-­‐Neto	  et	  al	  (2003)	  compared	  markers	  of	   HPA-­‐axis	   function,	   between	   an	   independent	   community	   dwelling	   elderly	  cohort	  and	  a	  frail	  institutionalized	  elderly	  cohort.	  Diurnal	  levels	  of	  serum	  cortisol	  and	   DHEAS	   were	   similar	   through	   the	   day	   between	   the	   two	   cohorts,	   as	   were	  cortisol	   levels	   following	   ACTH	   stimulation.	   However	   the	   frail	   group	   had	  increased	   serum	   morning	   cortisol:DHEAS	   ratios,	   and	   reduced	   cortisol	  suppression	   in	   response	   to	   dexamethasone.	   Furthermore	   cortisol	   levels	   post-­‐dexamethasone	   correlated	   positively	  with	  markers	   of	   cognitive	   and	   functional	  impairment.	   Heaney	   et	   al	   (2012)	   found	   that	   salivary	   cortisol	   (12	   hour	   day-­‐profile)	   was	   positively	   correlated	   with	   age	   in	   a	   cohort	   of	   independent	   adults	  aged	  between	  65-­‐86	  years	  (n=36).	  A	  study	  comparing	  30	  pre-­‐menopausal	  (aged	  20-­‐25	  years)	  with	  35	  post-­‐menopausal	  (aged	  55-­‐68	  years)	  healthy	  women	  found	  that	  while	  both	  basal	  and	  post-­‐dexamethasone	  serum	  cortisol	  levels	  were	  similar	  between	  groups,	  basal	  serum	  levels	  of	  DHEA,	  DHEAS,	  and	  androstenedione	  were	  lower	   in	   the	   post-­‐menopausal	   group.	   Cortisol	   response	   to	   ACTH	   was	   greater,	  whereas	  DHEA	  response	  was	  lower	  in	  the	  post-­‐menopausal	  group	  (Parker	  et	  al.,	  2000).	   Ahn	   et	   al	   (Ahn	   et	   al.,	   2007)	   reported	   lower	   serum	   cortisol	   levels	   in	  subjects	  aged	  over	  40	  years	  vs.	  those	  in	  their	  20s.	  No	  change	  was	  seen	  in	  salivary	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cortisol	  levels	  (p=0.69).	  Serum	  and	  salivary	  DHEA	  levels	  also	  decreased	  with	  age	  with	  each	  decade	  over	  the	  age	  of	  40	  (p<0.001).	  	  	  	  
1.7.2.13.	   Summary	  of	  Ageing	  and	  the	  HPA-­‐Axis	  There	   are	   clear	   associations	   between	   increased	   cortisol	   exposure	   and	   age-­‐related	  chronic	  disease	  states,	  however	  the	  mechanisms	  and	  drivers	  of	  this	  have	  not	  been	  fully	  delineated.	  Changes	  in	  HPA-­‐axis	  activity	  occur	  with	  age,	  which	  are	  broadly	  characterized	  by	  mild	   increases	   in	  mean	  cortisol	  secretion,	  an	   increase	  in	  the	  nocturnal	  nadir,	  and	  reduced	  amplitude	  of	  the	  diurnal	  variation.	  Dynamic	  testing	   reveals	   evidence	   of	   reduced	   negative	   feedback	   response	   to	   GCs,	   and	  largely	   preserved	   adrenal	   response	   to	   ACTH.	   There	   is	   an	   increase	   in	  cortisol:DHEA	  ratios	  with	  ageing,	  which	   is	   largely	  driven	  by	  age-­‐related	   falls	   in	  DHEA	  after	  the	  age	  of	  30.	  	  	  
1.7.3.	  11β-­‐HSD	  and	  Ageing	  	  The	  phenotypic	  similarities	  between	  aspects	  of	  Cushing’s	  syndrome	  and	  ageing,	  including	  obesity,	  muscle	  atrophy,	  osteoporosis,	  skin	  thinning,	  hypertension,	  and	  insulin	  resistance	  has	  led	  to	  interest	  in	  the	  contribution	  of	  chronic	  GC	  exposure	  to	  age-­‐related	  disease.	  As	  outlined	  above,	  there	  are	  associations	  between	  levels	  of	   circulating	  GCs	   and	   some	   chronic	  diseases,	   so	   it	   seems	   logical	   that	   this	  may	  extend	   to	   increased	   local	   tissue	   GC	   generation.	   	   In	   addition,	   these	   conditions	  affect	  tissues	  where	  11β-­‐HSD1	  is	  expressed	  and	  functionally	  active,	  providing	  a	  potential	  therapeutic	  target	  with	  the	  advent	  of	  selective	  inhibitors.	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1.7.3.1.	   Ageing,	  11β-­‐HSD1	  and	  the	  Brain	  It	   is	  well	   established	   that	   chronic	  GC	   exposure	   is	   associated	  with	  hippocampal	  atrophy,	  cognitive	  impairments	  and	  dementia	  (Landfield	  et	  al.,	  1978,	  MacLullich	  et	   al.,	   2005).	   Aged	   rodents,	   who	   perform	   poorly	   in	   water	   maze	   tests,	   have	  significantly	  higher	  CORT	  levels	  than	  those	  who	  perform	  well	  (Issa	  et	  al.,	  1990).	  Hippocampal	  and	  parietal	  11β-­‐HSD1	  expression	  is	  upregulated	  with	  age	  in	  mice	  and	   correlates	  with	  water	  maze	   performance	   (Holmes	   et	   al.,	   2010).	   11β-­‐HSD1	  global	  knockout	  mice	  have	  attenuation	  of	  age-­‐associated	  cognitive	  impairments	  (Yau	  et	  al.,	  2001).	  Furthermore,	  mice	  with	  targeted	  forebrain	  overexpression	  of	  11β-­‐HSD1	  exhibit	  accelerated	  cognitive	  decline	  (Holmes	  et	  al.,	  2010).	  In	  humans	  11β-­‐HSD1	   activity	   predicts	   imaging	   parameters	   of	   hippocampal	   and	   cerebral	  atrophy,	  and	  declines	  in	  processing	  speed	  over	  6-­‐years	  follow	  up	  in	  elderly	  men	  (n=41,	   age	   range	   65-­‐70	   years)(MacLullich	   et	   al.,	   2012).	   Proof-­‐of-­‐concept	  interventional	   studies	   have	   yielded	   promising	   initial	   results	   with	   use	   of	  carbenoxolone	   found	   to	   be	   associated	  with	   improvements	   in	   verbal	   fluency	   in	  healthy	  elderly	  men	  (n=10,	  age	  range	  55-­‐75	  years,	  100mg	  tds	  4	  weeks	  duration)	  and	   verbal	   memory	   in	   type	   II	   diabetics	   (age	   range	   52-­‐72	   years,	   6	   weeks	  duration)	   independently	   of	   changes	   in	   glycaemic	   control,	   lipid	   profile	   and	  circulating	  GC	  levels	  (Sandeep	  et	  al.,	  2004).	  	  	  
1.7.3.2.	   Ageing,	  11β-­‐HSD1	  and	  Bone	  Pre-­‐receptor	  GC	  metabolism	  in	  bone	  is	  of	  interest	  clinically	  in	  view	  of	  the	  highly	  prevalent	   problems	   of	   age	   and	   GC-­‐induced	   osteoporosis.	   Studies	   within	   our	  department	   showed	   that	   11β-­‐HSD1	   is	   expressed	   in	   human	   osteoblasts	   and	  osteoclasts,	   and	   that	   dehydrogenase	   and	   oxo-­‐reductase	   activity	   is	   present	   in	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fresh	  bone	  tissue.	  Carbenoxolone	  administration	  (300mg/day	  for	  7	  days)	  results	  in	  reductions	   in	  bone	  resorption	  markers	  (Cooper	  et	  al.,	  2000).	  11β-­‐HSD1	  oxo-­‐reductase	   activities	   of	   human	   osteoblast	   primary	   cultures	   were	   positively	  correlated	  with	  donor	  age	  (Cooper	  et	  al.,	  2002).	  Transgenic	  mice	  with	  osteocyte	  and	   osteoblast	   specific	   overexpression	   of	   11β-­‐HSD2	  were	   protected	   from	   age-­‐associated	  effects	  on	  cell	  apoptosis,	  bone	  formation,	  bone	  angiogenesis,	  vascular	  volume	  and	  interstitial	  fluid	  (Weinstein	  et	  al.,	  2010).	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1.7.3.4.	   Ageing,	  11β-­‐HSD1	  and	  Fat	  As	   outlined	   elsewhere	   in	   this	   thesis,	   ageing	   is	   associated	   with	   increasing	   fat	  mass,	   and	   shifting	   patterns	   of	   fat	   distribution	   to	   that	   associated	  with	   elevated	  cardiovascular	  risk.	  Some	  recent	  studies	  have	  focused	  on	  changes	  in	  expression	  of	  11β-­‐HSD1	  in	  fat	  with	  age.	  HSD11B1	  gene	  expression	  correlated	  positively	  with	  age	   in	   childhood	   in	   omental	   but	   not	   subcutaneous	   adipose	   biopsies	   during	  abdominal	   surgery	   (n=54,	   age	   0.17-­‐16.0	   years,	   BMI	   12.5-­‐28.3kg/m(2))(Li	   et	   al.,	  2007).	   This	   observation	   was	   independent	   of	   gender	   or	   BMI.	   Andersson	   et	   al	  (2009)	  observed	  an	  up-­‐regulation	  in	  HSD11B1	  gene	  expression	  in	  subcutaneous	  adipose	   tissue	   of	   post-­‐menopausal	   women.	   Cortisol	   generation	   from	   oral	  cortisone	  challenge	  was	  also	   increased	   following	   the	  menopause	  (n=46).	  These	  results	  were	  supported	  in	  a	  study	  of	  19	  premenopausal	  and	  23	  postmenopausal	  women,	  who	  also	  found	  close	  associations	  in	  expression	  levels	  of	  11β-­‐HSD1	  and	  oestrogen	  receptor	  β	  (McInnes	  et	  al.,	  2012).	  	  	  
1.7.3.5.	   Ageing,	  11β-­‐HSD2	  and	  the	  Kidney	  Hypertension	   is	   highly	   prevalent	   with	   age	   and	   is	   a	   dominant	   risk	   factor	   for	  vascular	   disease.	   Campino	   et	   al	   (2013)	   found	   evidence	   for	   a	   reduction	   in	   11β-­‐HSD2	  activity	  with	  an	  increasing	  serum	  cortisol	  to	  cortisone	  ratio	  with	  age	  in	  a	  study	   of	   196	   healthy	   normotensive	   subjects.	   Previous	   studies	   in	   rats	   failed	   to	  show	  significant	  alterations	   in	  11β-­‐HSD2	  activity	  across	  the	   lifespan	  (Audige	  et	  al.,	   2002).	   11β-­‐HSD2	   activity	   has	   been	   implicated	   in	   the	   pathogenesis	   of	   age-­‐associated	   hypertension,	   although	   it	   is	   possible	   that	   the	   observed	   changes	  represent	  a	  compensatory	  response	  to	  increasing	  HPA-­‐axis	  or	  11β-­‐HSD1	  activity.	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1.7.3.6.	   Ageing,	  11β-­‐HSD1	  and	  Skeletal	  Muscle	  Changes	   in	   11β-­‐HSD1	   expression/activity	   in	   muscle	   with	   age	   have	   not	   been	  investigated	   to	   date,	   however	   as	   outlined	   previously	   it	   has	   been	   shown	   to	   be	  expressed	  and	  functionally	  active	  (Jang	  et	  al.,	  2006).	  This	  area	  is	  the	  central	  focus	  of	  this	  thesis	  as	  it	  is	  hoped	  that	  we	  will	  reveal	  information	  on	  therapeutic	  targets	  in	  the	  treatment	  of	  conditions	  related	  to	  skeletal	  muscle	  ageing.	  Studies	  utilising	  transgenic	   mouse	   models	   to	   assess	   functional	   outcomes	   of	   11β-­‐HSD1	  modulation	  on	  skeletal	  muscle	  ageing	  and	  muscle	  atrophy	  pathways,	  along	  with	  human	  studies	  characterising	  expression	  and	  activity	  across	  age	  are	  required	  in	  addition	  to	  clinical	  studies	  of	  selective	  inhibitors	  in	  sarcopenia.	  	  	  
1.8.	  Sarcopenia	  Irwin	  Rosenberg	  coined	  the	  term	  sarcopenia	  meaning	  'poverty	  of	  flesh'	  to	  focus	  attention	  on	  a	  neglected	  area	  of	  great	  clinical	  importance	  (Rosenberg,	  1989).	  The	  past	   2	   decades	   have	   seen	   much	   attention	   on	   this	   phenomenon	   and	   its	  associations	   with	   adverse	   effects	   on	   metabolic	   and	   physical	   function.	   The	  reductions	  in	  muscle	  mass	  are	  marked,	  with	  estimates	  between	  15-­‐42%	  between	  20-­‐80	   years,	   and	   1-­‐2%/year	   beyond	   the	   age	   of	   50	   (Doran	   et	   al.,	   2009,	  Baumgartner	  et	  al.,	  1998,	  Lindle	  et	  al.,	  1997).	  Reductions	  in	  muscle	  strength	  are	  more	  more	  prominent	  with	  increasing	  age	  at	  “1.5%/year	  after	  the	  age	  of	  50”	  and	  3%/year	  after	  the	  age	  of	  60	  (von	  Haehling	  et	  al.,	  2010,	  Abellan	  van	  Kan,	  2009).	  Longitudinal	  studies	  have	  shown	  that	  skeletal	  muscle	  ageing	  is	  characterized	  by	  declining	   muscle	   quality	   (as	   defined	   by	   force/unit),	   and	   reduced	   shortening	  velocity	  (Delmonico	  et	  al.,	  2009,	  Mitchell	  et	  al.,	  2012,	  D'Antona	  et	  al.,	  2003).	  This	  is	  partly	  explained	  by	  reductions	  in	  fibre	  number	  (25%	  reduction	  from	  mean	  age	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30-­‐72	   years),	   preferential	   loss	   of	   fast-­‐twitch	   fibres,	   and	   presence	   of	   immature	  and	  mixed	  MHC	  isoforms	  (Lexell	  et	  al.,	  1983,	  D'Antona	  et	  al.,	  2003),	  furthermore	  intramuscular	  lipid	  accumulation	  could	  also	  contribute.	  	  	  
1.8.1.	  Prevalence	  of	  Sarcopenia	  Baumgartner	  et	  al	  (1998)	  used	  appendicular	  muscle	  mass	  (kg)/height(2)(m2)	  as	  a	  relative	   measure	   of	   muscle	   mass	   (muscle	   mass	   index	   (MMI)),	   and	   defined	  sarcopenia	  as	  <2	  standard	  deviations	  below	  the	  young	  adult	  mean	  (aged	  18-­‐40	  years).	  This	  method	  was	  used	  to	  control	  for	  the	  correlation	  between	  height	  and	  muscle	  mass,	  although	  the	  diagnostic	   threshold	   itself	  was	  an	  arbitrary	  decision	  and	  was	  not	  based	  on	  risk	  of	  adverse	  outcome.	  A	  sub-­‐group	  (n=199)	  of	  patients	  with	  DEXA	  data	  available	  from	  the	  New	  Mexico	  Elder	  Health	  Survey	  was	  used	  to	  devise	  an	  equation	  for	  predicting	  appendicular	  muscle	  mass	  extrapolated	  to	  the	  group	  as	  a	  whole	  (n=883,	  mean	  age	  74	  years).	  Prevalences	  were	  13-­‐24%	  in	  those	  <70	  years,	  increasing	  to	  18-­‐33%	  at	  70-­‐74	  years,	  26-­‐36%	  at	  75-­‐80	  years	  and	  43-­‐60%	   in	   the	   over	   80s.	   This	   was	   the	   first	   report	   of	   an	   association	   between	  sarcopenia	  and	  functional	  impairment	  in	  a	  population-­‐based	  cohort.	  Sarcopenia	  was	  associated	  with	  odds	  ratios	  of	  3.66	  for	  3	  disabilities	  or	  more	  in	  men	  and	  4.08	  in	  women.	  Since	  then	  several	  studies	  have	  reported	  sarcopenia	  prevalence	   in	  a	  variety	   of	   settings,	   patients	   groups,	   analytical	   techniques	   (including	  DEXA	   and	  bioimpedence)	   and	   diagnostic	   thresholds,	   outlined	   in	   table	   1-­‐6.	   Due	   to	   their	  heterogeneity	  it	  is	  difficult	  to	  draw	  clear	  conclusions	  from	  comparisons,	  however	  there	   are	   some	   patterns	   that	   have	   emerged.	   Sarcopenia	   is	   highly	   prevalent	   in	  those	  over	   the	  age	  of	  65,	  with	  subsequent	  studies	  reporting	  prevalences	  of	  14-­‐27%	   (men),	   and	   1-­‐33%	   (women)	   in	   community	   studies.	   There	   is	   a	   further	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increase	   in	   prevalence	   in	   octogenarians	   at	   16-­‐52%	   in	   men	   and	   13-­‐43%	   in	  women.	   As	   would	   be	   expected	   it	   is	   even	   more	   common	   in	   nursing	   home	  residents	   (70-­‐98%	   in	   men,	   21-­‐44%	   women),	   in	   keeping	   with	   the	   functional	  impairments	   and	   disabilities	   seen	   in	   these	   populations	   (Bahat	   et	   al.,	   2010,	  Masanes	   et	   al.,	   2012,	   Landi	   et	   al.,	   2012a).	   Baumgartner	   et	   al	   (1998),	   reported	  that	   sarcopenia	   was	   more	   common	   in	   Hispanics.	   Other	   studies	   have	   reported	  prevalences	   of	   4-­‐27%	   (men),	   and	   21-­‐23%	   (women)	   in	   North	   America,	   3-­‐13%	  (men)	  and	  1-­‐33%	  (women)	  in	  Europe	  and	  8-­‐24%	  (men)	  and	  5-­‐19%	  (women)	  in	  South	   East	   Asia,	   conclusions	   here	   are	   limited	   by	   heterogeneity	   of	   studies.	   A	  recent	   study	   demonstrated	   a	   remarkably	   low	   prevalence	   of	   sarcopenia	   in	  Finnish	  women	  aged	  between	  70-­‐80	  years	  (0.9-­‐2.7%)(Patil	  et	  al.,	  2013).	  Criteria	  and	  cut-­‐off	  points	  also	  determine	  prevalence,	  with	  most	  studies	  using	   the	  MMI	  and	  more	  than	  2	  SD	  below	  the	  young	  adult	  mean,	  and	  some	  studies	  using	  skeletal	  mass	  index	  (SMI)	  calculated	  by	  appendicular	  muscle	  mass*100/weight.	  Tichet	  et	  al	   (2008)	   found	   that	   estimates	  of	   sarcopenia	   frequency	  were	  higher	  using	   SMI	  (12.5%	  men	  and	  23.6%	  women)	  than	  MMI	  (3.6%	  and	  2.8%	  respectively	  n=218	  age	  range	  60-­‐78	  years).	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Authors,	  year	   Age	  (years)	   Prevalence	  (%)	  
(m)	   Prevalence	  (%)	  (f)	   N	  
Baumgartner	  et	  al	  
(1998)	   <70	  	  70-­‐74	  	  75-­‐80	  	  >80	  
16.9	  (Hispanic)	  13.5	  (Non-­‐Hispanic)	  18.3	  (Hispanic)	  19.8	  (Non-­‐Hispanic)	  36.4	  (Hispanic)	  26.7	  (Non-­‐Hispanic)	  57.6	  (Hispanic)	  52.6	  (Non-­‐Hispanic)	  
24.1	  (Hispanic)	  23.1	  (Non-­‐Hispanic)	  35.1	  (Hispanic)	  33.3	  (Non-­‐Hispanic)	  35.3	  (Hispanic)	  35.9	  (Non-­‐Hispanic)	  60.0	  (Hispanic)	  43.2	  (Non-­‐Hispanic)	  
883	  
Janssen	  et	  al	  (2002)	   >60	   >1	  SD:	  45.0	  >2	  SD:	  7.0	   <1	  SD:	  59.0	  <2	  SD:	  10.0	   4504	  
Iannuzzi-­‐Sucich	  et	  al	  
(2002)	  
64-­‐92	  (m)	  64-­‐93	  (f)	   27.0	   23.0	   142	  (m)	  195	  (f)	  
Castillo	  et	  al	  (2003)	   70-­‐75	  >85	   4.0	  16.0	   3.0	  13.0	   694	  (m)	  1006	  (f)	  
Rolland	  et	  al	  (2003)	   >70	   N/A	   9.5	   1458	  
Newman	  et	  al	  (2003)	   70-­‐79	   11.5	   21.0	   2984	  
Chien	  et	  al	  (2008)	   >65	   24.0	   19	   302	  
Tichet	  et	  al	  (2008)	   60-­‐78	   3.6	  (MMI)	  12.5	  (SMI)	   2.8	  (MMI)	  23.6	  (SMI)	   112	  (m)	  106	  (f)	  
Masanes	  et	  al	  (2012)	   73.9	  (mean	  m)	  74.9	  (mean	  f)	   10.0	   33.0	   110	  (m)	  90	  (f)	  
Landi	  et	  al	  (2012)	   >80	   Men	  and	  women	  combined	  25.4	   N/A	   260	  
Patil	  et	  al	  (2013)	   70-­‐80	   N/A	   0.9	  (IWG	  criteria)	  2.7	  (EWGSOP	  criteria)	   409	  
Patel	  et	  al	  (2013)	   73	  (mean,	  sub-­‐cohort)	  67	  (mean,	  total	  group)	  
6.8	  (sub-­‐cohort)	  4.6	  (total	  group)	   7.9	   763	  (sub-­‐cohort)	  1022	  (total	  group)	  
Cheng	  et	  al	  (2013)	   >70	   13.2	   4.8	   1766	  (m)	  1778	  (f)	  
Tanimoto	  et	  al	  (2013)	   >65	   7.8	   10.2	   743	  	  
Table	  1-­‐6:	  Summary	  of	  Studies	  Examining	  Prevalence	  of	  Sarcopenia	  in	  Community-­‐Dwelling	  
Individuals.	  (m=male,	  f=female).	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1.8.2.	  Association	  of	  Sarcopenia	  with	  Functional	  Impairment	  Janssen	  et	  al	   (2002)	  confirmed	  previous	   findings	   (Baumgartner	  et	  al.,	  1998)	  of	  an	  association	  between	  sarcopenia	  and	  functional	  impairment	  by	  reporting	  a	  “2-­‐fold	   increase	   in	   risk	   of	   functional	   impairment	   in	  men	   and	   a	   3-­‐fold	   increase	   in	  women	   over	   60”,	   in	   the	   presence	   of	   sarcopenia,	   using	   data	   from	   the	   “National	  Health	   and	   Nutrition	   Examination	   Survey	   (NHANES	   III)”.	   This	   association	   has	  been	  reproducible	  in	  many	  studies,	  with	  outcome	  measures	  including	  gait	  speed,	  overall	  physical	  function	  scores	  and	  self-­‐reported	  health	  scores	  (Patil	  et	  al.,	  2013,	  Patel	  et	  al.,	  2013).	  Chien	  MY	  et	  al	  (Chien	  et	  al.,	  2010)	  found	  that	  cardiopulmonary	  fitness	  may	  account	  for	  this,	  in	  a	  study	  of	  275	  Taiwanese	  elderly	  subjects	  (aged	  >65	  years),	  where	  the	  3-­‐fold	  increase	  in	  disability	  in	  those	  with	  sarcopenia	  was	  attenuated	  when	  controlling	  for	  cardiopulmonary	  fitness.	  Tanimoto	  et	  al	  (2012)	  found	  an	  association	  between	  sarcopenia	  and	  “higher-­‐level	  functional	  capacity”,	  as	   measured	   by	   the	   “Tokyo	   Metropolitan	   Institute	   of	   Gerontology	   Index	   of	  Competence	   (TMIG-­‐IC)”,	   over	   the	   age	   of	   65	   years,	   in	   a	   community	   dwelling	  Japanese	  cohort	  (n=1158).	  It	  is	  intuitive	  therefore,	  that	  sarcopenia	  is	  a	  predictor	  of	   future	   decline,	   and	   this	   was	   confirmed	   by	   Guralnik	   et	   al	   (1995)	   using	   data	  from	  physical	  performance	  tests	  in	  1122	  community-­‐dwelling	  subjects	  aged	  over	  71	  years,	  over	  4	  years	  follow	  up.	  On	  this	  theme,	  Taekema	  et	  al	  (2010)	  found	  that	  lower	  handgrip	  was	  associated	  with	  reduced	  social,	  psychological	  and	  functional	  health	   scores	   and	   was	   a	   predictor	   of	   cognitive	   and	   functional	   decline	   while	  Tanimoto	  et	  al	  (2013)	  found	  that	  37%	  and	  19%	  of	  sarcopenic	  men	  and	  women	  (n=743)	  developed	  dependency	  in	  activities	  of	  daily	  living	  after	  2	  year’s	  of	  follow	  up.	  Furthermore	  sarcopenia	  is	  a	  risk	  factor	  for	  falls,	  as	  evidenced	  by	  the	  “Rancho	  Bernardo	   study”	   (Castillo	   et	   al.,	   2003)	   where	   community-­‐dwelling	   men	   with	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sarcopenia	   had	   double	   the	   incidence	   in	   the	   year	   prior	   to	   screening	   (n=694).	  Landi	   et	   al	   (2012b)	   found	   that	   18	   out	   of	   66	   (27.3%)	   subjects	  with	   sarcopenia	  suffered	   falls	   over	   2	   years	   of	   follow	   up	   compared	   to	   and	   19/194	   (9.8%)	  with	  normal	  muscle	  mass	  (p<0.001).	  	  	  
1.8.3.	  Association	  of	  Sarcopenia	  with	  Chronic	  Disease	  Sarcopenia	   has	   been	   found	   to	   be	   associated	   with	   a	   range	   of	   chronic	   disease	  states,	  although	  at	  present	  the	  directions	  of	  causation	  are	  yet	  to	  be	  established.	  Type	   II	   diabetes	   mellitus,	   and	   the	   continuum	   of	   glucose	   intolerance	   is	  significantly	   associated	   with	   weak	   grip	   strength	   and	   poor	   physical	   function	  (Sayer	   et	   al.,	   2005).	   Sarcopenia	   was	   an	   independent	   risk	   factor	   for	  cardiovascular	   disease	   using	   data	   from	   subjects	   aged	   over	   65	   in	   the	   “Korea	  National	   Health	   and	   Nutrition	   Examination	   Survey	   (KNHANES)”	   (Chin	   et	   al.,	  2013).	  Osteoporosis	  was	   associated	  with	   a	   “2-­‐fold”	   excess	   sarcopenia	   risk	   in	   a	  recent	   Japanese	   population	   based	   study	   (20.4%	   vs.	   10.8%,	   n=2400,	   age	   range	  40-­‐88	  years)(Miyakoshi	  et	  al.,	  2013).	  Sarcopenia	  is	  distinct	  from	  cachexia,	  which	  includes	  muscle	  wasting	  in	  the	  presence	  of	  a	  range	  of	  diseases	  including	  cancer	  and	   inflammatory	   disorders,	   but	   also	   involves	   loss	   of	   fat,	   with	   weight	   loss	  exceeding	  5%	  of	  body	  weight	  with	  acute	  onset,	  and	  is	  combined	  with	  symptoms	  such	  as	  fatigue	  and	  biochemical	  abnormalities	  (Evans	  et	  al.,	  2008).	  	  	  
1.8.4.	  Association	  of	  Sarcopenia	  with	  Mortality	  Landi	   et	   al	   (2013)	  made	   the	   link	   between	   sarcopenia	   and	   excess	  mortality	   in	  subjects	   aged	   between	   80-­‐85	   (n=197).	   There	   were	   deaths	   in	   29	   of	   43	   (67%)	  subjects	  with	  sarcopenia	  over	  7	  years	  follow	  up,	  vs.	  63	  of	  154	  (41%)	  with	  normal	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muscle	   mass	   (p<0.001,	   Hazard	   ratio:	   2.32	   CI:	   1.01-­‐5.43).	   A	   similar	   risk	   for	  mortality	  was	  observed	   in	  a	   study	  of	   elderly	   subjects	  with	   sarcopenia	   living	   in	  Mexico	  City	  (n=346,	  mean	  age	  78.5	  years)(Arango-­‐Lopera	  et	  al.,	  2013).	  Increases	  in	  mortality	  were	   also	   seen	   in	   hospital	   inpatients	   and	   nursing	   home	   residents	  with	   sarcopenia	   compared	   to	   those	   with	   normal	   muscle	   mass	   (Gariballa	   and	  Alessa,	  2013,	  Kimyagarov	  et	  al.,	  2012).	  	  
1.8.5.	  Sarcopenia	  vs.	  Dynapenia	  	  Clark	  and	  co-­‐workers	  (2008)	  proposed	  the	  term	  “dynapenia”	  meaning	  “poverty	  of	   strength”	   to	  describe	   the	  phenomenon	  of	   reduced	  muscle	   strength	  with	   age	  and	  to	  make	  the	  distinction	  from	  changes	  in	  muscle	  mass.	  The	  central	  reason	  for	  this	   was	   growing	   evidence	   that	   strength	   is	   more	   closely	   linked	   with	   adverse	  ageing	  outcomes	  than	  muscle	  bulk	  (Newman	  et	  al.,	  2006,	  Gale	  et	  al.,	  2007,	  Cesari	  et	  al.,	  2009).	  There	  is	  a	  clear	  variability	  in	  the	  relationship	  between	  strength	  and	  muscle	  mass,	  with	   the	   latter	  accounting	   for	  only	  6-­‐8%	  of	  variability	  of	   force	  of	  knee	   extension	   (Delmonico	   et	   al.,	   2009).	   Manini	   and	   Clark	   (2012)	   proposed	   a	  dynapenia	   diagnostic	   protocol	   which	   involves	   screening	   people	   aged	   over	   60	  years	   for	  risk	   factors	  and	  proceeding	   to	  knee	  extension	  strength	  assessment	   in	  high	   risk	   cases,	   or	   grip	   strength	   if	   low	   risk.	  Use	  of	   electromyelographic,	  motor	  unit	  and	  nerve	  conduction	  studies,	  serological	  and	  endocrine	  tests	  is	  proposed	  to	  exclude	   secondary	   causes.	   However	   there	   is	   a	   paucity	   of	   evidence	   behind	   this	  diagnostic	  approach,	  specifically	  there	  does	  not	  seem	  to	  be	  any	  consideration	  of	  the	  clinical	  presentation	  prior	  to	  committing	  to	  potentially	  invasive	  tests,	  or	  for	  the	   health	   economic	   and	   logistical	   constraints.	   Furthermore	   the	   maxim	   that	  diagnostic	  tests	  should	  be	  reserved	  for	  cases	  which	  will	  change	  the	  management	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of	   a	   patient	   for	   the	   better	   in	   an	   important	   one,	   and	   the	   currently	   there	   is	   an	  absence	   of	   accepted	   interventions.	   In	   summary,	   age-­‐related	   muscle	   weakness	  appears	   to	   have	   important	   associations	  with	   functional	   status,	   chronic	   disease	  and	  mortality.	  Further	  research	   to	  delineate	   the	  mechanisms	  underlying	   this	   is	  much	   needed	   and	   it	   is	   imperative	   that	   any	   clinical	   decision	   making	   tools	   are	  evidence	  based	  and	  rational,	  with	  a	  sound	  economic	  case	  behind	  them.	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1.8.7.	  Consensus	  Statements	  for	  Sarcopenia	  Diagnosis	  In	  recent	  years,	  several	  expert	  panels	  have	  convened	  to	  decide	  upon	  diagnostic	  criteria	   for	   sarcopenia.	   There	   is	   some	   broad	   agreement	   between	   these	   groups	  that	   diagnosis	   should	   include	   assessment	   of	   functional	   status	   and	   strength	   in	  addition	   to	   muscle	   bulk.	   “The	   European	   Working	   Group	   on	   Sarcopenia	  (EWGSOP)”	  decided	  the	  diagnosis	  should	  be	  considered	  in	  all	  adults	  over	  the	  age	  of	  65.	  	  A	  timed	  walking	  speed	  of	  less	  than	  0.8	  m/s	  is	  used	  as	  a	  screening	  test	  for	  functional	  impairment,	  with	  those	  with	  a	  positive	  result	  being	  referred	  for	  DEXA	  assessment	   of	   muscle	   mass,	   and	   grip	   strength	   assessment	   if	   negative.	   Normal	  grip	   strength	   excludes	   sarcopenia,	   whereas	   a	   low	   reading	   results	   in	   DEXA	  analysis.	   EWGSOP	  also	  propose	   the	  use	   of	   the	   terms	   ‘Primary’	   and	   ‘Secondary’	  (to	  reduced	  activity,	  disease	  or	  inadequate	  nutrition)	  sarcopenia,	  which	  may	  be	  a	  useful	  distinction	  clinically.	  The	  International	  Working	  Group	  (IWG)	  agreed	  that	  the	   diagnosis	   should	   be	   considered	   in	   patients	   with	   evidence	   of	   functional	  impairment.	  The	  suggested	  protocol	  suggests	  formal	  assessment	  of	  muscle	  mass	  by	   DEXA,	   in	   patients	   who	   are	   bedridden,	   unable	   to	   stand	   independently	   from	  sitting,	   or	   with	   a	   “gait	   speed	   <1	   m/s”.	   Thresholds	   for	   sarcopenia	   were	   set	   at	  “≤7.23	  kg/m(2)	  in	  men	  and	  ≤5.67	  kg/m(2)”	  in	  women	  using	  appendicular	  muscle	  mass/height(2)	   (Fielding	  et	   al.,	   2011).	   “The	  Society	  of	   Sarcopenia,	  Cachexia	   and	  Wasting	   Disorders	   Consensus	   Conference”	   advocated	   universal	   screening	   of	  elderly	   patients	   for	   sarcopenia.	   	   Criteria	   for	   diagnosis	   includes	   evidence	   of	  reduced	  muscle	  mass	  as	  defined	  by	  the	  MMI,	  2SD	  or	  more	  below	  the	  ethnicity-­‐matched	  young	  adult	  mean,	  combined	  with	  a	  walking	  speed	  of	  	  <1	  m/s	  or	  <400m	  during	   a	   6	   minute	   walk	   (Morley	   et	   al.,	   2011)	   with	   identifiable	   secondary	  pathologies	  would	  preclude	  a	  diagnosis	  of	  sarcopenia.	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1.8.8.	  Potential	  Mechanisms	  of	  Skeletal	  Muscle	  Ageing	  On	   current	   evidence,	   sarcopenia	   is	   widely	   believed	   to	   be	   a	   multifactorial	  syndrome,	  involving	  reductions	  in	  anabolic	  hormones,	  chronic	  inflammation,	  cell	  stress,	   mitochondrial	   dysfunction,	   denervation,	   disuse	   and	   nutritional	   factors,	  with	   resulting	   effects	   on	   myofibrillar	   protein	   synthesis	   and	   degradation	   (see	  Table	  1-­‐7).	  	  	  
Putative	  Mechanism	   Reference	  
Increased	  Proteolysis	   Welle	  et	  al	  (2003),	  Giresi	  et	  al	  (2005)	  
Reduced	  Protein	  Synthesis	   Balagopal	  et	  al	  (1997)	  
Reduced	  Growth	  Hormone/IGF-­‐I	   Sakuma	  and	  Yamaguchi	  (2012)	  
Chronic	  Inflammation	   Jo	  et	  al	  (2012)	  
Denervation	   Jang	  et	  al	  (2011)	  
Mitochondrial	  dysfunction	   Marzetti	  et	  al	  (2013)	  
Oxidative	  Stress	   Jozsi	  et	  al	  (2000)	  
Satellite	  cell	  dysfunction	   Barberi	  et	  al	  (2013),	  Sajko	  et	  al	  (2004)	  
Insulin	  Resistance	   Guillet	  et	  al	  (2005),	  Workeneh	  and	  Bajaj	  (2013b)	  
Disuse	   Vandenburgh	  et	  al	  (1999),	  Wall	  et	  al	  (2013)	  
Malnutrition	   Morley	  et	  al	  (2001)	  	  
Table	  1-­‐7:	  Putative	  Mechanisms	  of	  Skeletal	  Muscle	  Ageing.	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1.8.8.1.	   Ageing	  and	  Muscle	  Protein	  Turnover	  It	   is	   understood	   that	   the	   reduction	   in	   skeletal	   muscle	   mass	   seen	   with	   age	   is	  underpinned	  by	   reductions	   in	   protein	   synthesis	   and	   elevations	   in	   degradation.	  Balagopal	   et	   al	   (1997b)	   observed	   declining	   MHC	   synthesis	   rates	   in	   a	   cross-­‐sectional	   muscle	   biopsy	   study	   (n=24,	   aged	   20-­‐92	   years).	   Studies	   investigating	  function	  of	  proteolytic	  systems	  however	  have	  provided	  variability	  in	  results	  with	  some	  studies	  demonstrating	  increases	  in	  expression	  of	  MuRF1,	  MAFbx/Atrogin1	  and	  the	  26S	  proteasome	  in	  aged	  rat	  muscle	  (Clavel	  et	  al.,	  2006,	  Altun	  et	  al.,	  2010)	  and	  others	  observing	  downregulation	  of	  components	  of	  the	  UPS	  (Edstrom	  et	  al.,	  2006).	  Other	  intermediaries	  known	  to	  effect	  protein	  turnover	  such	  as	  FOXOs	  and	  myostatin	   also	  have	   variable	   results	   across	   age	   in	  different	   animal	   and	  human	  studies	  (Kawada	  et	  al.,	  2001,	  Baumann	  et	  al.,	  2003,	  Welle	  et	  al.,	  2002,	  Raue	  et	  al.,	  2006,	  Sandri	  et	  al.,	  2013).	  
	  
1.8.8.2.	   Skeletal	  Muscle	  Ageing	  and	  Chronic	  Inflammation	  	  Across	  the	  human	  lifespan	  marked	  changes	  in	  the	  immune	  system	  are	  observed,	  with	   an	   attenuated	   immune	   response,	   labelled	   ‘immune	   senescence’	   and	  development	   of	   low-­‐grade	   systemic	   inflammation,	   known	   as	   ‘inflamm-­‐ageing’	  (Butcher	   and	   Lord,	   2004).	   ‘Inflamm-­‐ageing’	   is	   defined	   by	   an	   exaggerated	  response	   to	   cell	   stressors	   causing	   damage	   at	   a	   molecular	   and	   tissue	   level	  (Franceschi	   and	   Bonafe,	   2003).	   Cytokines	   are	   secreted	   by	   a	   variety	   of	   sources	  over	  the	  ageing	  process,	  including	  immune	  cells,	  and	  those	  in	  peripheral	  tissues	  including	   adipose,	   and	  muscle,	   which	   are	   known	   as	   adipokines	   and	  myokines	  respectively	   (Keller	   et	   al.,	   2003,	   Cevenini	   et	   al.,	   2010).	   Local	   TNF-­‐α	   levels	   are	  increased	  with	  age	  in	  muscle	  (Greiwe	  et	  al.,	  2001)	  whilst	  higher	  systemic	  levels	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of	  TNF-­‐α	  and	   IL-­‐6	  were	   found	   to	  be	  associated	  with	   reduced	  muscle	  mass	  and	  strength	  in	  baseline	  data	  from	  the	  “Health	  Ageing	  and	  Body	  Composition	  study”	  (n=3075,	  age	  range	  70-­‐79	  years)(Visser	  et	  al.,	  2002).	  TNF-­‐α	  and	  IL-­‐6	  were	  also	  associated	   with	   excess	   mortality	   in	   participants	   in	   the	   “Framingham	   Heart	  Study”	  (n=525,	  baseline	  age	  range	  72-­‐92	  years,	  follow	  up	  4	  years)	  (Roubenoff	  et	  al.,	   2003).	   Numerous	   subsequent	   studies	   have	   been	   carried	   out	   that	   outline	  associations	   between	   TNF-­‐α,	   IL-­‐6	   and	   CRP	   and	  measures	   of	   reduced	   strength	  and	   muscle	   mass,	   poor	   physical	   function,	   gait	   speed	   and	   functional	   capacity	  (Brinkley	   et	   al.,	   2009,	   Schaap	  et	   al.,	   2009,	  Verghese	   et	   al.,	   2011,	  Cappola	   et	   al.,	  2003,	  Penninx	  et	  al.,	  2004).	  A	  recent	  review	  found	  that	  IL-­‐6,	  which	  increases	  2-­‐4-­‐fold	   with	   age,	   had	   the	   most	   robust	   relationship	   with	   chronic	   disease	   status,	  functional	  capacity	  and	  mortality	  (Singh	  and	  Newman,	  2011).	  Pro-­‐inflammatory	  cytokines	  promote	  muscle	  atrophy	  in	  cachectic	  states.	  Mice	  over-­‐expressing	  IL-­‐6	  or	  given	  exogenous	  TNF-­‐α	  have	  reduced	  muscle	  mass	  secondary	   to	  proteolysis	  (Llovera	  et	  al.,	  1993,	  Tsujinaka	  et	  al.,	  1996).	  In	  healthy	  individuals	  cytokines	  are	  secreted	   in	   response	   to	   tissue	   injury,	   where	   they	   are	   linked	   to	   the	   tissue	  regeneration,	  although	  this	  relationship	  appears	  to	  breakdown	  with	  age.	  There	  is	  evidence	   that	   chronic	   inflammation	   impairs	   satellite	   cell	   function	   and	   muscle	  regenerative	   capacity	   (Degens,	   2010).	   Muscle	   trauma	   results	   in	   release	   of	  inflammatory	  cytokines,	  macrophage	  migration,	  and	  neutrophil	  action	  resulting	  in	   reactive	   oxygen	   species	   release.	   TNF-­‐α	   has	   pleiotropic	   effects,	   signalling	   via	  various	   pathways,	   with	   NF-­‐κB	   signalling	   important	   in	   muscle	   atrophy	  (Bhatnagar	   et	   al.,	   2010).	   The	   “canonical”	   pathway	   of	   NF-­‐κB	   is	   activated	   with	  skeletal	   muscle	   ageing,	   and	   inhibition	   prevents	   muscle	   wasting	   by	   promoting	  satellite	   cell	   activation	   (Hunter	   and	   Kandarian,	   2004,	   Bar-­‐Shai	   et	   al.,	   2005,	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Mourkioti	   et	   al.,	   2006).	   Muscle	   atrophy	   and	   reduced	   strength	   results	   from	  activation	   of	   the	   UPS	   and	   apoptotic	   pathways	   (Degens,	   2010,	   Whitman	   et	   al.,	  2005).	   Exercise	   may	   modulate	   pro-­‐inflammatory	   cytokine	   levels	   across	   age	  although	   the	   data	   on	   this	   are	   not	   uniform	   (Greiwe	   et	   al.,	   2001,	   Nicklas	   et	   al.,	  2008,	  de	  Gonzalo-­‐Calvo	  et	  al.,	  2012,	  Beavers	  et	  al.,	  2010).	  
	  
1.8.8.3.	   Skeletal	  Muscle	  Ageing	  and	  Oxidative	  Stress	  	  Reactive	   oxygen	   species	   are	   generated	   by	   mitochondria	   as	   a	   consequence	   of	  aerobic	   metabolism	   and	   have	   been	   shown	   to	   accumulate	   with	   increasing	   age.	  Their	   effects	   are	   counteracted	   by	   anti-­‐oxidant	   defence	   mechanisms,	   and	   it	   is	  theorized	   that	   imbalance	   in	   this	   redox	   system	   may	   account	   for	   changes	   in	  senescent	   muscle.	   Mitochondrial	   DNA	   is	   susceptible	   to	   oxidative	   damage	   and	  may	   result	   in	  mitochondrial	   dysfunction.	   	   It	   has	   been	   proposed	   that	   this	   may	  develop	   into	  a	   “vicious	  cycle	  of	  mitochondrial	  damage”	  giving	  rise	   to	   increased	  oxidative	  damage	  (Doria	  et	  al.,	  2012).	  Muscle	  fibres	  with	  mitochondrial-­‐electron-­‐transport	   chain	   abnormalities	   increase	   from	   x5-­‐fold	   between	   the	   5th	   and	   9th	  decades	   in	   association	  with	  mitochondrial	   DNA	   deletion	  mutations	   (Bua	   et	   al.,	  2006).	  Senescent	  mitochondria	  become	  enlarged,	  rounded	  and	  develop	  vacuoles	  (Peterson	  et	  al.,	  2012).	  Skeletal	  muscle	  is	  highly	  active	  in	  aerobic	  metabolism,	  so	  is	   particularly	   vulnerable	   to	   the	   effects	   of	   reactive	   oxygen	   species	   on	  mitochondrial	  DNA	  and	  cellular	  proteins	   (Doria	  et	   al.,	   2012).	  Oxidative	  protein	  damage	   (protein	   carbonyl	   levels)	   are	   negatively	   correlated	   with	   reduced	   grip	  strength	  in	  old-­‐age	  (Howard	  et	  al.,	  2007,	  Dayhoff-­‐Brannigan	  et	  al.,	  2008).	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1.8.8.4.	   Skeletal	  Muscle	  Ageing	  and	  Satellite	  Cells	  Satellite	  cells	  are	  responsible	  for	  regeneration	  of	  adult	  skeletal	  muscle	  following	  trauma.	  When	  activated,	   these	  undifferentiated	  cells	   fuse	   together	   to	   form	  new	  fibres.	   Cross-­‐sectional	   studies	   using	   muscle	   biopsies	   and	   post-­‐mortem	  specimens	   have	   shown	   that	   satellite	   cell	   numbers	   decline	  with	   age	   in	   humans	  (Kadi	  et	  al.,	  2004,	  Sajko	  et	  al.,	  2004).	  There	  is	  evidence	  that	  a	  fibre-­‐type	  specific	  reduction	   in	   satellite	   cell	   number	   underlies	   the	   age-­‐related	   decline	   in	   type	   II	  fibres	   (Verdijk	   et	   al.,	   2007).	   Carlson	   and	   Faulkner	   (1989)	   showed	   that	   the	  environment	  of	  muscle	  cells	  was	  important	  in	  determining	  regenerative	  capacity	  in	  experiments	  involving	  grafting	  muscle	  from	  young	  or	  old	  donors	  into	  young	  or	  old	   hosts.	   Old	  muscle	   grafted	   into	   young	   hosts	  was	   no	   different	   from	   those	   of	  young	   muscle	   grafted	   into	   the	   same	   hosts	   and	   young	   muscle	   grafted	   into	   old	  hosts	  had	  no	  difference	  in	  regenerative	  capacity	  compared	  to	  old	  muscle.	  	  
1.8.8.5.	   Skeletal	  Muscle	  Ageing	  and	  Denervation	  Ageing	   is	   characterized	   by	   denervation	   of	   skeletal	   fibres	   by	   loss	   of	   spinal	  motorneurones,	   with	   resulting	   increases	   in	   the	   size	   of	   motor	   units.	   Spinal	  motorneurone	   number	   is	   reduced	   by	   a	   quarter	   between	   the	   age	   of	   20	   and	   90	  (Tomlinson	   and	   Irving,	   1977).	   Adaptive	  mechanisms	   such	   as	   axonal	   sprouting	  result	   in	   a	   denervation-­‐renervation	   cycle,	   and	   over	   time	   this	   capacity	   is	  diminished.	  In	  addition,	  there	  are	  reductions	  in	  axonal	  conduction,	  partly	  due	  to	  demyelination	   (McNeil	   et	   al.,	   2005,	   Aagaard	   et	   al.,	   2010).	   Degeneration	   of	   the	  neuromuscular	  junction	  is	  also	  a	  well-­‐established	  feature	  of	  senescence	  (Chai	  et	  al.,	   2011).	   Some	   authors	   have	   proposed	   that	   sarcopenia	   is	   a	   consequence	   of	  denervation,	   noting	   that	   several	   known	   aetiological	   factors	   including	   reduced	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anabolic	   hormones,	   increasing	   cell	   stress,	   mitochondrial	   dysfunction,	  malnutrition,	   disuse	   and	   chronic	   inflammation	   have	   adverse	   effects	   on	  motorneurones	  as	  well	  as	  muscle	  (Kwan,	  2013).	  Recent	  studies	  in	  aged	  rats	  have	  shown	   that	   myofibres	   expressing	   the	   denervation	   marker,	   sodium	   channel	  isoform	   Nav1.5,	   are	   smaller,	   have	   higher	   expression	   of	   ubiquitin	   ligases	  MAFbx/Atrogin1	   and	  MuRF1,	   and	   higher	   co-­‐expression	   of	   MHC	   isoforms	   than	  Nav1.5	  negative	  fibres,	  suggesting	  that	  denervation	  may	  be	  the	  primary	  driver	  of	  muscle	  features	  of	  muscle	  senescence	  (Rowan	  et	  al.,	  2012).	  Whether	  sarcopenia	  is	   driven	   by	   a	   primary	   event	   at	   the	   level	   of	   motorneurones,	   neuromuscular	  junction	  or	  muscle	  itself	  remains	  to	  be	  established.	  	  
	  
1.8.8.6.	   Skeletal	  Muscle	  Ageing	  and	  Gene	  Expression	  Array	  Studies	  	  The	  advent	  of	  DNA	  microarray	  technology	  led	  to	  numerous	  studies	  investigating	  gene	  expression	   in	  ageing	  muscle.	  Lee	  et	  al	   (1999)	  observed	  a	  gene	  expression	  profile	  indicative	  of	  cell	  stress	  and	  declining	  metabolic	  and	  biosynthetic	  function	  in	   aged	   mouse	   muscle,	   by	   utilizing	   high-­‐density	   oligonucleotide	   arrays	  containing	  6347	  probe	  sets,	  with	  these	  changes	  attenuated	  by	  caloric	  restriction.	  Mitochondrial	  gene	  suppression	  was	  the	  predominant	  feature	  of	  skeletal	  muscle	  ageing	   in	   a	   rat	   model.	   Genes	   involved	   in	   the	   function	   of	   the	   neuromuscular	  junction,	   proteolysis	   and	   inflammation	   were	   altered	   in	   a	   recent	   animal	   study	  (Ibebunjo	  et	  al.,	  2013).	   	  Welle	  and	  colleagues	  (2000)	  compared	  pooled	  samples	  from	  human	   vastus	   lateralis	   biopsies	   in	   young	   (age	   21-­‐24	   years)	   compared	   to	  older	   (age	   66-­‐77	   year)	   subjects	   and	   observed	   changes	   in	  MHC,	  mitochondrial,	  and	  glucose	  metabolism	  genes	  with	  increasing	  age.	  Jozsi	  et	  al	  (2000)	  performed	  gene	  expression	  analyses	  of	  pooled	  mRNA	  extracts	  from	  vastus	  lateralis	  muscle	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biopsies	   in	   young	   (n=11,	   age	   range	   20-­‐30)	   and	   older	   (n=12,	   age	   range	   62-­‐75	  years)	   men.	   At	   baseline,	   muscle	   from	   older	   men	   was	   found	   to	   express	   genes	  characteristic	  of	  stress	  response	  (including	  heat	  shock	  proteins)	  with	  reduction	  of	   genes	   involved	   in	   DNA	   repair.	   After	   an	   exercise	   intervention	   muscle	   from	  younger	   men	   also	   had	   increased	   expression	   of	   genes	   involved	   in	   the	   stress	  response	  (heat	  shock	  proteins,	  MAP	  kinases,	  VEGF	  and	  IL-­‐1β),	  effects	  that	  were	  absent	   in	   older	  men.	   The	   authors	   suggested	   that	   this	   provided	   evidence	   of	   an	  impaired	   inflammatory	   response	   that	  may	   impact	   on	  muscle	   regeneration	   and	  hypertrophy	  with	  age.	  Roth	  et	  al	   (2002)	   identified	  50	  genes	   that	   changed	  with	  age	   (>1.7-­‐fold),	   involved	   in	  structural,	  metabolic	  and	  gene	  regulatory	   functions	  in	   a	   study	   of	   untrained	   individuals.	   Welle	   et	   al	   (2003)	   performed	   a	   more	  comprehensive	   gene	   expression	   analysis,	   comparing	   vastus	   lateralis	   biopsies	  from	  young	  (n=8,	  age	  range	  21-­‐27	  years)	  and	  older	  (n=8,	  age	  range	  67-­‐75	  years)	  men	  using	  44000	  probe	  sets	  with	  adequate	  signals	  on	  18000.	  Genes	  involved	  in	  energy	  metabolism	  and	  mitochondrial	  function	  tended	  to	  be	  downregulated	  with	  age.	   Up-­‐regulation	   of	   genes	   encoding	   UPS	   components,	   RNA	   binding	   and	  ribonuclear	  proteins	  and	  evidence	  of	  increased	  heterogeneity	  of	  transcripts	  was	  seen	  with	  age.	  Giresi	  et	  al	  (2005)	  attempted	  to	  identify	  a	  “molecular	  signature	  of	  ageing”,	  defined	  as	  the	  “minimum	  set	  of	  genes	  that	  can	  be	  used	  to	  distinguish	  old	  from	  young	  muscle”	  using	  Affymetrix	  GeneChip	  analysis	  of	  young	  (n=10,	  19-­‐25	  years)	  vs.	  old	  (n=12,	  70-­‐80	  years)	  vastus	   lateralis	  biopsy	  samples	   from	  healthy	  but	   sedentary	  male	   volunteers.	  The	  bioinformatics	  method	  employed	   excluded	  genes	   that	   exhibit	   high	   intra-­‐group	   variability.	   Using	   approximately	   22000	  probe-­‐sets,	  45	  genes	  were	  identified	  whose	  expression	  was	  most	  discriminatory	  between	  groups,	  expression	  of	  27	  was	   increased	  and	  18	  reduced	  with	  age.	  The	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authors	   proposed	   that	   this	   might	   be	   of	   translational	   use	   in	   assessing	  effectiveness	   of	   future	   therapeutic	   interventions	   in	   ageing	   muscle.	   Genes	   up-­‐regulated	   in	   the	   signature	   are	   involved	   in	   resistance	   to	   cell	   stress,	   RNA	  processing,	  and	   include	  a	  number	  of	   transcription	   factors	  and	  co-­‐regulators.	  Of	  particular	  interest	  in	  the	  signature	  are	  GC-­‐regulated	  genes	  such	  as	  FOXO3a	  and	  C/EBP.	  Also	  of	  note	  from	  an	  endocrine	  perspective,	   is	   the	   increased	  expression	  of	   retinoid	   X	   receptor-­‐beta	   (RXRB)	   a	   nuclear	   receptor,	   which	   dimerises	   with	  receptors	   for	   vitamin	   D,	   thyroid	   hormone	   and	   peroxisome	   proliferators	   to	  mediate	   responses.	   Similarly	   the	   “circadian	   period-­‐2	   (PER2)”	   gene,	   which	   is	  involved	  in	  maintenance	  of	  circadian	  rhythms	  relating	  to	  sleep	  and	  metabolism,	  is	   increased.	   	   A	   study	   using	  muscle	   biopsies	   from	   81	   individuals	   identified	   an	  age-­‐related	  gene	  expression	  profile	  characterized	  by	  increases	  in	  genes	  involved	  in	   “cell	  growth,	   complement	  activation,	   the	  ribosome”,	  and	  reductions	   in	  genes	  involved	  in	  “chloride	  transport	  and	  the	  mitochondrial	  electron	  transport	  chain”,	  interestingly	  these	  changes	  were	  also	  found	  in	  diverse	  tissues	  such	  as	  brain	  and	  kidney	   (Zahn	   et	   al.,	   2006). A	   recent	   study	   has	   examined	   microRNA	   (miRNA)	  changes	   with	   age	   in	   muscle	   biopsy	   samples	   from	   young	   (n=36,	   mean	   age	   31	  years)	   and	   elderly	   (n=17,	   mean	   age	   73)	   subjects.	   Expression	   of	   18	   miRNAs	  changed	  with	  age,	  including	  genes	  involved	  in	  cell	  cycle	  regulation.	  In	  support	  of	  this	   expression	   of	   cell	   cycle	   regulator	   genes	   (mRNA)	   declined	   with	   age	  (Drummond	  et	  al.,	  2011).	  There	  have	  been	  recent	  advances	   in	  high	  throughput	  proteomic	   analysis	   of	   skeletal	  muscle	   allowing	   global	   profiling	  of	   peptides	   and	  proteins.	   These	   studies	   have	   demonstrated	   the	   switch	   to	   slow	   twitch	   aerobic	  fibres,	   reductions	   in	   heat	   shock	   proteins,	   alterations	   in	   phosphoproteins	  involved	  in	  mitochondrial	  metabolism	  and	  the	  cytoskeleton	  (Doran	  et	  al.,	  2009).	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1.8.9.	  Potential	  Therapies	  for	  Sarcopenia	  
1.8.9.1.	   Exercise	  Interventions	  in	  Sarcopenia	  Disuse	   has	   been	   proposed	   as	   a	   contributor	   to	   sarcopenia	   of	   age,	   with	   healthy	  elderly	   subjects	   experiencing	   a	   3-­‐fold	   increase	   in	  muscle	   loss	   observed	   during	  bed	   rest	   compared	   to	  young	   individuals	   (Paddon-­‐Jones	  and	  Rasmussen,	  2009).	  Disuse	   stimulates	   pathways	   that	   are	   active	   in	   muscle	   atrophy	   of	   other	  aetiologies,	  involving	  UPS,	  myostatin	  and	  NF-­‐κB	  signaling	  (Chopard	  et	  al.,	  2009).	  Exercise	   interventions	   have	   been	   assessed	   as	   therapeutic	   strategies	   to	   combat	  sarcopenia.	  Fiatarone	  et	   al	   (1994)	   found	   that	  high	   intensity	   resistance	   training	  over	   10	   weeks	   in	   100	   frail	   nursing	   home	   residents	   resulted	   in	   increases	   in	  strength,	  walking	  speed,	   stair	   climbing	  power	  and	  cross-­‐sectional	   thigh-­‐muscle	  area	  compared	  to	  a	  group	  receiving	  no	  exercise	  intervention.	  A	  Cochrane	  review	  (Liu	  and	  Latham,	  2009)	  of	  the	  effects	  of	  progressive	  resistance	  training	  (PRT)	  in	  elderly	   people	   assessed	   121	   RCTs	   (n=6700),	   and	   found	   evidence	   of	   large	  increases	  in	  muscle	  strength,	  modest	  to	  large	  effects	  on	  getting	  out	  of	  a	  chair,	  and	  modest	   improvements	   in	  gait	  speed.	  Adverse	  events	  were	  poorly	  recorded,	  but	  appeared	   to	   be	   rare.	   Peterson	   et	   al	   (2011)	   performed	   a	   meta-­‐analysis	   of	   49	  studies	   (n=1328)	   and	   found	   that	   resistance	   exercise	   is	   effective	   at	   increasing	  lean	   body	   mass	   in	   elderly	   individuals,	   although	   this	   effect	   reduced	   with	  increasing	   age.	   Some	   studies	   have	   studied	   gene	   expression	   changes	   following	  exercise	   intervention	   in	   elderly	   subjects.	   There	   is	   evidence	   that	   baseline	  expression	  of	  myogenic	  genes	  is	  increased	  with	  age	  at	  baseline,	  and	  that	  there	  is	  further	   upregulation	   in	   response	   to	   resistance	   exercise	   (Raue	   U	   et	   al	   J	   Appl	  Physiol	   2006).	   Expression	   of	   E3-­‐ubiquitin	   ligases	   are	   increased	   in	   response	   to	  exercise	   (Raue	  et	   al.,	   2007).	  Melov	   et	   al	   (2007)	  observed	   increases	   in	   strength	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along	   with	   attenuation	   of	   age-­‐associated	   changes	   in	   mitochondrial	   gene	  expression	   following	   a	   6	  months	   of	   resistance	   training.	  However	   some	   studies	  have	  shown	  that	  elderly	  muscle	  is	  resistant	  to	  exercise	  induced	  gene	  expression	  changes	   (Dennis	   et	   al.,	   2008).	   	   Exercise	   appears	   to	   be	   of	   benefit	   with	   ageing,	  however	   further	   research	   is	   required	   to	   refine	   the	   intervention	   to	   ensure	  compliance,	   provide	   optimum	   benefits	   on	   strength,	   and	   functional	   abilities	  whilst	  reducing	  adverse	  events.	  	  
 
1.8.9.2.	   Future	  Perspectives	  for	  Sarcopenia	  Therapy	  Phase	   II	   trials	   are	   being	   carried	   for	   novel	   compounds	   to	   treat	   and	   prevent	  sarcopenia	   and	   consensus	   criteria	   for	   outcomes	   in	   such	   studies	   are	   being	  decided	   (Chumlea	  et	  al.,	  2011,	  Papanicolaou	  et	  al.,	  2013).	  Clinical	   trials	   to	  date	  have	  focused	  on	  diet,	  exercise,	  anabolic	  and	  hormone	  supplementation.	  Potential	  therapeutic	   targets	   relate	   to	   our	   increased	   knowledge	   of	   pathways	   regulating	  sarcopenia	   with	   potential	   for	   modulation	   of	   inflammatory	   pathways,	   the	   UPS,	  myostatin,	   and	   pre-­‐receptor	   glucocorticoid	   metabolism	   (Landi	   et	   al.,	   2013a,	  Landi	  et	  al.,	  2013b).	  	  	  
1.9.	  Summary	  	  Endogenous	   Cushing’s	   syndrome	   is	   associated	   with	   an	   early	   death	   when	  untreated,	   although	   studies	   to	   date	   report	   normalization	   of	   survival	   when	  biochemical	   ‘cure’	   is	   achieved.	   Unfortunately	   however,	   there	   is	   evidence	   of	  persisting	   cardiovascular	   disease	   risk	   on	   long-­‐term	   follow	   up,	   even	   in	   ‘cured’	  patients.	  There	  are	  similarities	  between	   the	  body	  composition	   (central	  obesity,	  muscle	   atrophy,	   osteoporosis,	   skin	   thinning)	   and	   chronic	   disease	   (Type	   2	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Diabetes,	   Hypertension	   and	   CVD)	   phenotypes	   of	   Cushing’s	   and	   ageing.	   In	  particular	   GC-­‐induced	   myopathy	   and	   age-­‐related	   sarcopenia	   appear	   to	   share	  some	   common	   mechanistic	   pathways.	   Sarcopenia	   is	   associated	   with	   falls,	  functional	   decline,	   and	   increased	   mortality,	   and	   currently	   has	   no	   effective	  treatment.	   Previous	   studies	   have	   demonstrated	   that	   11β-­‐HSD1	  expression/activity,	  which	  yields	  cortisol	  from	  cortisone,	  is	  increased	  with	  age	  in	  tissues	  including	  bone,	  brain	  and	  skin	  and	  may	  contribute	  to	  the	  aged	  phenotype.	  Expression/activity	  of	  11β-­‐HSD1	  has	  been	  demonstrated	  in	  skeletal	  muscle,	  but	  has	   not	   been	   assessed	   with	   human	   ageing.	   In	   addition	   transgenic	   mice	   with	  global	  11β-­‐HSD1	  KO	  are	  protected	  from	  an	  adverse	  metabolic	  profiles	  associated	  with	   stress	   and	   obesity,	   however	   their	   aged	   muscle	   phenotype	   has	   not	   been	  assessed.	  The	  advent	  of	  selective	  11β-­‐HSD1	  inhibitors	  provides	  a	  novel	  potential	  therapeutic	  avenue	  for	  age-­‐related	  diseases	  including	  sarcopenia.	  
1.10.	  Hypotheses	  
1. Cushing’s	   disease	   is	   associated	   with	   persisting	   excess	   mortality,	   body	  composition	   and	   cardiovascular	   disease	   risk	   profiles	   in	   spite	   of	  biochemical	  cure	  (Chapter	  3).	  2. GC	  myopathy	   is	   associated	  with	   similar	   gene	   expression	   changes	   to	   age	  related	  sarcopenia	  in	  mice	  (Chapter	  5).	  	  3. Modulation	   of	   pre-­‐receptor	   GC	   metabolism	   by	   selective	   inhibition	   (in	  vitro)	   or	   transgenic	   knockout	   (mouse	   in-­‐vivo)	   of	   11β-­‐HSD1	   results	   in	  attenuation	  of	  muscle	  atrophy	  gene	  changes	  and	  protection	  against	  age-­‐related	  sarcopenia	  (Chapters	  4	  and	  5).	  	  4. 11β-­‐HSD1	  skeletal	  muscle	  gene	  expression	  and	  global	  enzyme	  activity	  are	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increased	  with	  age	  in	  humans	  and	  are	  correlated	  with	  adverse	  phenotypic	  features	   of	   ageing	   such	   as	   (sarcopenia,	   dynapenia,	   fat	   mass,	   adverse	  metabolic	  profile	  markers)	  (Chapter	  5	  and	  6).	  
1.11.	  Thesis	  Aims	  
1. To	   assess	   whether	   mortality	   persists	   in	   a	   clinical	   cohort	   of	   Cushing’s	  disease	   patients	   following	   surgical	   treatment,	   and	   whether	   clinical	  features	  such	  as	  obesity	  or	  hypertension	  resolve	  over	  follow	  up	  (Chapter	  3).	  	  2. To	   identify	   genes	   involved	   in	   GC-­‐induced	   muscle	   atrophy	   using	   a	   cell	  culture	  model,	  and	  to	  assess	  the	  role	  of	   inhibition	  of	  11β-­‐HSD1	  (Chapter	  4).	  3. To	  identify	  GC-­‐induced	  atrophy	  genes	  in	  wild-­‐type	  mice	  and	  to	  investigate	  whether	  these	  genes	  also	  change	  with	  age	  (Chapter	  5).	  	  4. To	   confirm	   expression	   of	   11β-­‐HSD1	   in	   skeletal	  muscle.	   In	   particular,	   to	  assess	  the	  role	  of	  11β-­‐HSD1	  gene	  knockout	  on	  muscle	  strength	  and	  size,	  along	  with	  atrophy	  gene	  profiles	  (Chapter	  5).	  	  5. To	   perform	   a	   comprehensive	   assessment	   of	   11β-­‐HSD1	   skeletal	   muscle	  gene	   expression	   and	   global	   enzyme	   activity	   and	   relationships	   with	  strength	  and	  body	  composition	   in	  a	   cross-­‐sectional	  human	  ageing	   study	  (Chapter	  6).	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2.1.	  C2C12	  Cell	  Culture	  
2.1.1.	  C2C12	  Cell	  Line	  C2C12	   myotubes	   were	   used	   to	   study	   mechanisms	   of	   GC-­‐mediated	   skeletal	  muscle	  wasting	  and	  the	  role	  of	  11β-­‐HSD1.	  The	  C2	  line	  of	  cells	  originated	  from	  the	  thigh	   muscles	   of	   young	   C3H	   mice,	   following	   an	   experimentally	   induced	   crush	  injury.	   Cultures	  were	   prepared	   70	   hours	   following	   injury,	  with	   selective	   serial	  passage	   of	   myoblasts	   (Yaffe	   and	   Saxel,	   1977).	   The	   cell	   line	   has	   been	   used	  previously	   within	   the	   group	   to	   study	   11β-­‐HSD1	   and	   subsequently	   developed	  protocols	  have	  been	  adhered	  to	  (Morgan	  et	  al.,	  2009).	  	  
2.1.2.	  Proliferation	  Frozen	  cells	  (Catalogue	  No:	  91031101)	  were	  obtained	  from	  “European	  Collection	  of	   Cell	   Cultures	   (ECACC)”	   (Salisbury,	   UK).	   	   Cells	   were	   cultured	   in	   12ml	   high	  glucose	   Dulbecco’s	   modified	   eagle	   medium	   (DMEM)	   (D5671)	   (Sigma-­‐Aldrich,	  Dorset,	  UK)	  supplemented	  with	  10%	  Foetal	  Calf	  Serum	  (FCS)	  in	  75cm2	  TC	  flasks	  (Greiner	  Bio-­‐One,	  Frickenhausen,	  Germany),	  at	  37°C	  in	  a	  humidified	  atmosphere	  with	   5%	   CO2.	   At	   70%	   confluence	   cells	   were	   split	   by	   agitating	   the	   flask	   after	  addition	  of	  2ml	  Trypsin-­‐EDTA	  solution	  (Sigma,	  Dorset,	  UK),	  and	  placed	  in	  fresh	  flasks.	  Proliferation	  media	  was	  changed	  every	  2	  days	  at	  37°C.	  For	  experiments,	  cells	  were	  split	  as	  above	  at	  1:4	  dilution,	  with	  1ml/well	  transferred	  into	  12-­‐well	  TC	  plates	   and	   incubated	  until	   70%	  confluent	   (Greiner	  Bio-­‐One,	   Frickenhausen,	  Germany).	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2.1.3.	  Differentiation	  Cells	  were	  differentiated	  at	  70%	  confluence	  using	  DMEM	  supplemented	  with	  5%	  Horse	   Serum.	   Prior	   to	   this	   proliferation	   media	   was	   removed	   and	   wells	   were	  washed	   with	   serum	   free	   DMEM	   warmed	   to	   37°C.	   Differentiation	   media	   was	  changed	  every	  2	  days,	  by	  7	  days	  cells	  had	  fully	  differentiated	   into	  myotubes	  as	  confirmed	  morphologically.	  	  	  
2.1.4.	  Freezing	  Down	  Cells	  Cells	   grown	   in	   75cm2	  TC	   flasks	  were	   trypsinised,	   as	   above	  when	   they	   reached	  70%	   confluence.	   They	   were	   re-­‐suspended	   in	   10ml	   of	   proliferation	   media	   and	  centrifuged	   at	   1000g	   for	   10	  minutes.	   Proliferation	  medium	  was	   aspirated	   and	  the	  pellet	  was	  re-­‐suspended	  in	  3ml	  FCS	  supplemented	  with	  10%	  DMSO.	  The	  cell	  suspension	   was	   aliquoted	   into	   1.5ml	   cryovials,	   which	   were	   placed	   in	   a	   “Cryo	  Freezing	  container”	  (Nalgene,	  Hereford,	  UK)	  containing	   isopropanol	  and	   frozen	  at	  a	  rate	  of	  1°C	  per	  minute.	  The	  cells	  were	  kept	  in	  liquid	  nitrogen	  for	  long-­‐term	  storage.	  	  	  
2.2.	  RNA	  Extraction	  
2.2.1.	  Principles	  The	  one-­‐step	  protocol	  described	  by	  Chomcynski	  and	  Sacchi	  (1987)	  was	  used	  to	  extract	  RNA	   from	  cultured	   cell	  monolayers,	  mouse	   tissue	   explants,	   and	  human	  biopsy	  specimens.	  This	  method	  uses	  TRI-­‐reagent®	  (Sigma-­‐Aldrich,	  Dorset,	  UK),	  which	   is	   a	  mono-­‐phasic	   solution	   containing	   phenol	   and	   guanidine	   thiocyanate,	  which	   rapidly	   inhibits	   RNAase	   activity.	   Cell	  monolayers	  were	   lysed	   and	   tissue	  specimens	   homogenized	   in	   TRI-­‐reagent®.	   The	   resulting	   homogenate	  was	   then	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separated	  into	  aqueous	  and	  organic	  phases	  using	  chloroform	  and	  centrifugation	  and	  RNA	  was	  precipitated	  using	  isopropanol.	  	  
	  
2.2.2.	  Method	  Culture	  medium	  was	  removed	  from	  cell	  monolayers,	  which	  were	  then	  washed	  in	  PBS	   prior	   to	   incubation	   for	   5	   minutes	   with	   1ml	   TRI-­‐reagent®	   per	   well.	   Cells	  were	   removed	   from	   the	   surface	   of	   wells	   and	   lysed	   using	   the	   tip	   of	   a	   P1000	  pipette.	   Approximately	   20mg	   of	   tissue	   explants	   and	   biopsy	   specimens	   were	  taken	  and	  homogenised	  in	  1ml	  of	  TRI-­‐reagent®	  in	  a	  cell	  culture	  hood.	  All	  lysates	  were	  transferred	  to	  1.5mL	  eppendorf	  tubes	  and	  200μl	  of	  chloroform	  was	  added.	  	  Tubes	   were	   shaken	   vigorously	   for	   20	   seconds	   and	   incubated	   at	   room	  temperature	  for	  30	  minutes.	  Samples	  were	  centrifuged	  at	  12000G	  for	  15	  minutes	  at	  4°C.	  The	  clear	  aqueous	  phase	  was	   transferred	   to	  a	   fresh,	   labelled	  eppendorf	  tube	   and	  200μl	   isopropanol	  was	   added.	  Tubes	  were	   inverted	   and	   incubated	   at	  room	   temperature	   for	  15	  minutes	  prior	   to	  being	   centrifuged	  at	  12000G	   for	  30	  minutes	  at	  4°C.	  The	  supernatant	  was	  removed	  with	  care	  was	  taken	  not	  to	  disrupt	  the	  pellet,	  which	  was	  washed	  twice	  in	  70%	  ethanol	  and	  centrifuged.	  Ethanol	  was	  fully	  aspirated	  and	  the	  RNA	  was	  re-­‐suspended	  in	  30μl	  nuclease	  free	  water.	  RNA	  was	   quantified	   using	   a	   NanoDrop	   ND-­‐1000	   UV	   Spectrophotometer	  (Thermofisher,	   Surrey,	   UK).	   1.5μl	   of	   RNA	   solution	   was	   analysed	   at	   260	   and	  280nm	  to	  determine	  the	   level	  of	  protein	  contamination,	  and	  only	  samples	  with	  OD260/OD280	  ratios	  of	  between	  1.8-­‐2.0	  used.	  	  1	  OD260	  was	  taken	  as	  equalling	  40μg	  of	  RNA.	  RNA	  integrity	  was	  determined	  by	  agarose	  gel	  (1%)	  electrophoresis	  with	  0.15μg/ml	   ethidium	   bromide	   allowing	   visualisation	   under	   ultraviolet	   light.	   2	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clear	  bands	  corresponding	  to	  28S	  and	  18S	  rRNA	  are	  observed	  when	  RNA	  is	  non-­‐degraded.	  	  	  
2.3.	  Reverse	  Transcription	  (RT)	  Reaction	  	  
2.3.1.	  Method	  This	   method	   was	   performed	   using	   the	   high	   capacity	   RT	   kit	   from	   Applied	  Biosystems	   (Warrington,	   UK).	   The	   x2	   RT	   mastermix	   was	   made	   up	   in	   an	  eppendorf	  using	  the	  reagents	  in	  the	  proportions	  shown	  in	  Table	  2-­‐1.	  	  
Reagent	   Volume	  per	  sample	  (µl)	  10x	  RT	  buffer	   2.0	  MgCl2	  	  (25nM)	   4.4	  dNTPs	  (10mM)	   4.0	  Random	  Hexamers	   1.0	  RNAase	  inhibitor	   0.4	  Multiscribe	  Reverse	  Transcriptase	   1.2	  Volume	  (RNA	  +	  Nuclease	  Free	  water)	   7.0	  
Final	  Reaction	  Volume	   20	  
	  
Table	  2-­‐1:	  Reverse	  Transcriptase	  Reaction	  Volumes	  
	  1μg	  of	  RNA	  was	  diluted	  with	  nuclease	  free	  water	  to	  a	  volume	  of	  7μl	  and	  added	  to	  13μl	   of	   x2	   RT	   Mastermix	   in	   a	   PCR	   tube	   to	   give	   a	   final	   volume	   of	   20μl.	   The	  reaction	  tubes	  were	  placed	  in	  a	  thermal	  cycler	  (Applied	  Biosystems,	  Warrington,	  UK)	  for	  incubation	  at	  25°C	  for	  10	  minutes	  (denaturation/annealing	  stage),	  48°C	  for	  30	  minutes	  (transcription)	  and	  95°C	  for	  5	  minutes	  (inactivation).	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2.4.	  Conventional	  Polymerase	  Chain	  Reaction	  (PCR)	  
2.4.1.	  Method	  Conventional	  PCR	  was	  performed	  using	  a	  kit	  from	  Promega	  (Southampton,	  UK).	  A	  mastermix	  was	  made	  up	  in	  an	  eppendorf	  in	  the	  proportions	  shown	  in	  table	  2-­‐2.	  	  	  
Reagent	   Volume	  (µl)	  5x	  PCR	  buffer	  	   4	  MgCl2	   1.6	  dNTP	   0.5	  Forward	  primer	   1.0	  Reverse	  primer	   1.0	  Taq	  polymerase	   0.1	  Nuclease	  Free	  Water	   10.8	  cDNA	   1	  
Final	  Reaction	  Volume	   20	  	  
Table	  2-­‐2:	  Conventional	  PCR	  Reaction	  Volumes	  
	  Each	  20µl	  reaction	  mixture	  was	  made	  up	  in	  a	  PCR	  tube,	  and	  placed	  in	  a	  thermal	  cycler	   (Applied	   Biosystems,	   Warrington,	   UK)	   set	   at	   95°C	   for	   5	   minutes	  (initiation),	  followed	  by	  20	  cycles	  at	  94°C	  for	  30	  seconds	  (denaturation),	  60°C	  for	  30	   seconds	   (annealing)	   and	  72°C	   for	  30	   seconds	   (elongation),	   and	  a	   final	  72°C	  stage	  for	  7	  minutes	  (final	  elongation).	  	  	  
2.5.	  Relative	  Quantitative	  (Real	  Time)	  PCR	  
2.5.1.	  Method	  This	  was	   performed	  using	  Applied	  Biosystems	   reagents	   and	   expression	   assays	  (Applied	  Biosystems,	  Warrington,	  UK).	   18s	   rRNA	  was	  used	  as	   a	  house	  keeping	  gene	   for	   singleplex	   analysis.	   Reactions	  were	   performed	   in	   duplicate	   using	   96-­‐
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well	  plates	  (Applied	  Biosystems,	  Warrington,	  UK).	  Reaction	  mixtures	  for	  18S	  and	  target	  genes	  were	  made	  up	  in	  the	  proportions	  as	  shown	  in	  Table	  2-­‐3.	  For	  18S	  VIC	  labelled	  probes	  were	  used,	  whilst	  FAM	  labels	  were	  used	  for	  target	  genes.	  	  Plates	  were	  sealed	  with	  a	  clear	  adhesive	  film	  and	  analysed	  on	  a	  7500	  Real-­‐time	  PCR	  machine	  (Applied	  Biosystems,	  Warrington,	  UK).	  Data	  were	  expressed	  as	  Ct	  and	  ΔCt	  values	  as	  outlined	  previously,	  and	  arbitrary	  units	  (AU)	  [AU	  =	  1000x(2-­‐
ΔCt)]	  and	  fold-­‐change	  	  [fold-­‐change	  =	  2-­‐ΔΔCt]	  values	  were	  calculated.	  	  	   Volume	  (µl)	  2x	  Taqman®	  Universal	  PCR	  Mastermix	   5	  Primers	  and	  Probes	   0.5	  Water	   3.5	  cDNA	  sample	   1	  (100ng)	  
Final	  Reaction	  Volume	   10	  	  
Table	  2-­‐3:	  Real-­‐time	  PCR	  Reaction	  Volumes	  	  
2.6.	  Microfluidic	  Gene	  Expression	  Analysis	  The	   Biomark™	   system	   (Fluidigm,	   San	   Francisco,	   California,	   US)	   was	   used	   to	  perform	   a	   high-­‐throughput	   targeted	   gene	   expression	   array	   of	   up	   to	   92	   genes	  using	  Real-­‐time	  PCR	  technology	  available	  in-­‐house.	  The	  system	  uses	  a	  single	  use	  dynamic	   array	   integrated	   fluidic	   circuit	   (IFC),	   which	   allows	   analysis	   of	   96	  samples	   using	   96	   assays,	   in	   up	   to	   9216	   separate	   reactions	   by	   utilizing	   an	  automated	  network	  of	   channels	  and	  valves.	  An	   IFC	  Controller	   is	  used	   to	  prime	  and	  load	  the	  dynamic	  array	  IFC,	  and	  the	  Biomark™	  HD	  Reader	  is	  used	  to	  perform	  Real-­‐time	  PCR.	  Manufacturers	  protocols	  were	   adhered	   to.	  Genes	  were	   selected	  following	   an	   extensive	   literature	   review	   and	   covered	   a	   range	   of	   functions	  (including	   glucocorticoid	   metabolism/signalling,	   anabolic	   hormone	   signalling,	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negative	  growth	  regulation,	  proteolysis,	  protein	  synthesis,	   cell	   cycle	  regulation,	  DNA	   repair,	   apoptosis,	   inflammation,	   and	   mitochondrial	   function	   and	   energy	  metabolism).	  	  
2.6.1.	  Method	  Specific	   target	   amplification	   was	   performed	   using	   2.5µl	   2x	   Taqman®	   PreAmp	  mastermix	   (Applied	   Biosystems,	   Warrington,	   UK),	   1.25µl	   of	   pooled	   Taqman®	  gene	  expression	  assay	  mix	  (1µl/assay	  combined	  with	  4µl	  x1	  TE	  buffer	  (Fluidigm,	  San	  Francisco,	  California,	  US),	  0.2x	   final	  assay	  concentration)	  and	  1.25µl	   cDNA,	  making	  a	   final	  volume	  of	  5µl.	  The	  reactions	  were	  mixed	  by	  vortexing	  and	  brief	  centrifugation	   before	   being	   placed	   in	   a	   thermal	   cycler	   (Applied	   Biosystems,	  Warrington,	   UK)	   programmed	   to	   heat	   to	   95°C	   for	   10	  minutes,	   followed	   by	   14	  cycles	  of	  95°C	  for	  15	  seconds	  and	  60°C	  for	  4	  minutes.	  Samples	  were	  then	  diluted	  1:5	  with	  20µl	   of	   1x	  TE	  buffer	   (Fluidigm,	   San	  Francisco,	   California,	  US).	   Sample	  mixtures	  were	  prepared	  in	  a	  96	  well	  PCR	  plate	  with	  2.7µl	  of	  pre-­‐amplified	  cDNA,	  3µl	   of	   Taqman®	   Universal	   PCR	   Mastermix	   (2x)	   (Applied	   Biosystems,	  Warrington,	   UK),	   and	   0.3µl	   of	   GE	   loading	   reagent	   (Fluidigm,	   San	   Francisco,	  California,	  US).	  Assays	  were	  also	  prepared	  in	  a	  96	  well	  PCR	  plate	  with	  3µl	  of	  20x	  Taqman®	  Gene	  Expression	  Assay	  (Applied	  Biosystems,	  Warrington,	  UK)	  and	  3µl	  of	   2x	  Assay	  Loading	  Reagent,	  making	   a	   final	   concentration	  of	   9µM	   for	  primers	  and	  2µM	  for	  probes.	  The	  Dynamic	  Array	  IFC	  was	  then	  injected	  with	  control	  line	  fluid	   from	   a	   pre-­‐filled	   syringe	   (Fluidigm,	   San	   Francisco,	   California,	   US)	   and	  primed	  using	  the	  IFC	  Controller.	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5µl	   of	   each	   sample	   and	   assay	  were	  pipetted	   into	   their	   respective	   inlets	   on	   the	  IFC,	  which	  was	   then	   returned	   to	   the	   IFC	   controller	  where	   the	   Load	   script	  was	  ran.	   The	   IFC	   was	   then	   loaded	   onto	   the	   Biomark™	   HD	   Reader	   (Fluidigm,	   San	  Francisco,	   California,	   US)	   for	   Real-­‐time	   PCR	   and	   analysis.	   ΔCt	   values	   were	  generated	   as	   described	   using	   3	   housekeeping	   genes	   (18S,	   Cyclophilin	   B,	   and	  HPRT)(Representative	  plot	  shown	  in	  Figure	  2-­‐1).	  	  
	  
Figure	  2-­‐1:	  Representative	  Amplification	  plot	  following	  Real-­‐time	  PCR	  protocol	  on	  Biomark™	  
HD	  Reader.	  	  	  
2.7.	  Statistical	  Analysis	  	  Prism	   for	   Mac	   Version	   5.0	   (La	   Jolla,	   California,	   US)	   was	   used	   to	   perform	  statistical	  analysis.	  For	  PCR	  data,	  statistical	  tests	  were	  performed	  on	  ∆Ct	  values	  only.	  Comparisons	  between	  multiple	   treatments,	  doses	  or	   times	  were	  analysed	  using	   one-­‐way	   analysis	   of	   variance	   (ANOVA).	   If	   normality	   tests	   failed,	   non-­‐parametric	   tests	   were	   used.	   Continuous	   data	   were	   expressed	   as	   means	   and	  standard	   deviations	   (or	   standard	   errors)	   if	   normally	   distributed	   and	   medians	  and	   interquartile	   ranges	   if	   non-­‐parametrically	   distributed.	   The	   threshold	   for	  statistical	  significance	  was	  set	  at	  P<0.05.	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3.1.	  Introduction	  Harvey	   Cushing	   reported	   a	   grave	   prognosis	   (4.6	   year	   median	   survival)	   in	   the	  original	  case	  series	  describing	  his	  eponymous	  syndrome	  (1932).	  The	  condition	  is	  underpinned	  by	  an	  adverse	  metabolic	  profile	   (dyslipidaemia,	   insulin	  resistance	  and	  hypertension)	  and	  dramatic	  changes	  in	  body	  composition	  (muscle	  atrophy,	  osteoporosis	  and	  central	  obesity)(Fernandez-­‐Rodriguez	  et	  al.,	  2009).	  The	  past	  80	  years	  have	  seen	  great	  improvements	  in	  the	  prognosis	  of	  Cushing’s	  disease	  (CD),	  largely	   due	   to	   effective	   therapies	   such	   as	   transsphenoidal	   surgery	   (TSS)	  (Sherlock	  et	  al.,	  2010).	  Historically	  wide	  variations	   in	  post-­‐TSS	  remission	  rates	  were	  seen	  between	  centres	  (between	  10-­‐100%),	  with	  the	  best	  results	  occurring	  in	   specialized	   centres	  with	  dedicated	   surgeons	   (Burch,	   1983).	  Modern	   surgical	  series	   have	   suggested	   that	   biochemical	   remission	   of	   hypercortisolaemia	  normalizes	  mortality	  to	  that	  of	  the	  background	  population,	  whilst	  active	  disease	  is	   associated	  with	  ongoing	  excess	   risk	  of	  between	  x3-­‐5-­‐fold	   (Swearingen	  et	   al.,	  1999,	  Pikkarainen	  et	  al.,	  1999,	  Hammer	  et	  al.,	  2004).	  Conversely	  since	  the	  turn	  of	  the	   century,	   evidence	   has	   mounted	   that	   clinical	   features	   including	   skeletal	  muscle	   atrophy,	   osteoporosis,	   truncal	  obesity,	   health-­‐related	  quality	  of	   life	   and	  cardiovascular	   risk	  markers	   continue	   to	  manifest	   after	   biochemical	   cure	   of	   CD	  (Colao	  et	  al.,	  1999,	  Pirlich	  et	  al.,	  2002,	  Faggiano	  et	  al.,	  2003,	  Lindsay	  et	  al.,	  2006,	  Barahona	  et	  al.,	  2009b,	  Barahona	  et	  al.,	  2009a,	  Geer	  et	  al.,	  2012).	  In	  this	  context	  we	  assessed	  long-­‐term	  outcomes	  of	  CD	  following	  TSS	  in	  a	  large	  cohort	  of	  patients	  managed	  in	  our	  centre	  (Queen	  Elizabeth	  Hospital	  Birmingham)	  over	  2	  decades,	  with	  surgery	  performed	  by	  Mr	  Alan	  Johnson	  and	  endocrine	  management	  led	  by	  Professor	  Paul	  Stewart.	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3.2.	  Hypothesis	  Our	   central	   hypothesis	   is	   that	   although	   biochemical	   cure	   of	   CD	   dramatically	  improves	  clinical	  features	  and	  mortality,	  long-­‐term	  effects	  persist.	  	  	  
3.3.	  Study	  Aims	  Studying	   outcomes	   and	   mortality	   in	   this	   large	   cohort	   of	   patients	   provides	   an	  opportunity	  to	  improve	  the	  post-­‐surgical	  management	  of	  this	  rare	  condition.	  In	  addition	   it	   enables	   us	   to	   study	   Cushing’s	   disease	   as	   a	   paradigm	   for	   the	   ageing	  process	   by	   assessing	   the	   long-­‐term	   effects	   of	   excess	   GC	   exposure,	   on	   body	  composition	  (obesity,	  osteoporosis),	  and	  adverse	  metabolic	  parameters	  (insulin	  resistance,	  hypertension,	  dyslipidaemia).	  	  	  Our	  aims	  were:	  1. To	   assess	   surgical	   performance	   by	   determining	   initial	   remission,	   long-­‐term	  cure	  and	  complication	  rates.	  	  2. To	   assess	   mortality	   in	   the	   group	   overall,	   as	   well	   as	   in	   long-­‐term	   cure,	  recurrent	  and	  persistent	  disease	  subgroups.	  	  3. To	  assess	  the	  effects	  of	  disease	  remission	  on	  resolution	  of	  clinical	  features	  including	  blood	  pressure	  (BP)	  and	  body	  mass	  index	  (BMI).	  	  4. To	   assess	   prevalence	   of	   clinical	   features	   at	   diagnosis	   that,	   have	   links	   to	  the	  ageing	  phenotype	  including	  myopathy,	  osteoporosis,	  obesity,	  diabetes	  mellitus,	  dyslipidaemia	  and	  hypertension.	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3.4.	  Subjects	  and	  Methods	  
3.4.1.	  Subjects	  and	  Data	  Collection	  All	   patients	   with	   CD	   (n=80)	   who	   underwent	   TSS	   at	   our	   centre	   as	   first-­‐line	  therapy	   (Queen	   Elizabeth	   Hospital	   Birmingham)	   between	   1988-­‐2009	   were	  identified	  from	  surgical	  lists	  of	  our	  dedicated	  surgeon.	  	  Median	  age	  at	  diagnosis	  was	   40	   years	   (IQR	   31-­‐50),	   with	   women	   outnumbering	  men	   3.7	   to	   1.	   	   Median	  post-­‐surgical	  follow	  up	  was	  5	  years	  (IQR	  2-­‐10)	  for	  clinical	  data	  and	  11	  years	  (IQR	  5-­‐16)	   for	  mortality.	  Microscopic	   TSS	   (n=58)	  was	   routine	   until	   2005,	  when	   the	  endoscopic	  approach	  was	   introduced	  (n=14).	  Case	  notes	  and	  full	  clinical	   follow	  up	   data	   were	   obtained	   in	   72	   patients,	   where	   notes	   were	   unavailable	   (n=8)	  patients	   were	   included	   in	   a	   National	   Health	   Service	   (NHS)	   electronic-­‐registry	  search	  for	  mortality	  only	  (see	  Figure	  3-­‐1).	  Clinicians	  responsible	  were	  contacted	  to	   obtain	   most	   recent	   clinical	   information	   in	   patients	   whose	   follow	   up	   was	  carried	  out	  in	  other	  units	  (n=14).	  Mortality	  status	  as	  of	  29th	  November	  2010	  was	  recorded	   following	   registry	   searches	   and	   death	   certificates	   were	   obtained	   to	  establish	  causes	  of	  death.	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Figure	  3-­‐1:	  Study	  Flowsheet	  and	  Treatment	  Outcome	  Groups.	  Review	  of	  surgical	  lists	  identified	  
80	  patients	  with	  CD	  treated	  by	  TSS.	  Information	  on	  clinical	  features,	  test	  results	  and	  outcomes	  were	  
recorded	  using	  a	   standardized	  proforma.	  Patients	  were	  assigned	   to	  outcome	  groups	  according	   to	  
biochemical	  criteria.	  (Adapted	  from	  Hassan-­‐Smith	  et	  al	  (2012))	  	  
	  
3.4.2.	  Diagnostic	  Criteria	  CD	  was	  diagnosed	  in	  the	  Endocrinology	  Department	  of	  Queen	  Elizabeth	  Hospital	  Birmingham	  using	  standardized	  local	  protocols.	  Biochemical	  tests	  used	  included	  Urinary	   Free	   Cortisol	   (UFC),	   serum	   ACTH	   and	   diurnal	   cortisol	   measurements;	  low	   and	   high	   dose	   dexamethasone	   suppression	   tests,	   and	   the	   CRH-­‐test	   (See	  Table	   3-­‐1).	   Pituitary	   Computerized	   Tomography	   (CT)	   was	   superseded	   by	  Magnetic	  Resonance	   Imaging	   (MRI)	   in	  1992	  (CT	  n=16,	  MRI	  n=56).	   	  Films	  were	  reported	   by	   Specialist	   Neuroradiologists,	   and	   reviewed	   by	   both	   Surgeons	   and	  Endocrinologists	   in	   a	   joint	   clinic	   and	   from	   2008,	   a	   multidisciplinary	   team	  meeting.	  Where	  results	  were	  discordant	  inferior	  Petrosal	  Sinus	  Sampling	  (IPSS)	  was	  performed	  prior	  to	  first	  TSS	  (n=13).	  	  
	  




Proportion	  of	  Cases	  with	  
Positive	  Results	  
	  




24	  hour	  UFC	  
	  100%	   	  >350nmol/24h	  
	  
Overnight	  DST	  (1mg)	  
	  93%	   	  Serum	  Cortisol	  >50nmol/L	  
	  
LDDST	  (2mg/48h)	  
	  100%	   	  Serum	  Cortisol	  >50nmol/L	  
	  
Midnight	  Serum	  Cortisol	  
	  100%	   	  >50nmol/L	  
	  
Differential	  Diagnostic	  Tests	  
	  
HDDST	  (4mg/48h)	  
	  40%	   	  Serum	  Cortisol	  <50nmol/L	  
	  
CRH-­‐test	  
	  77%	   	  >50%	  increase	  in	  serum	  ACTH	  
	  
IPSS	  
	  100%	  (13/13	  completed)	   	  Central-­‐to-­‐peripheral	  gradient	  	  =	  2:1	  unstimulated;	  and	  =	  3:1	  stimulated	  
	  
MRI	  
	  76%	   	  Evidence	  of	  pituitary	  adenoma	  
	  
Table	  3-­‐1:	  Diagnostic	  Tests	  and	  Proportion	  of	  Cases	  with	  Positive	  Results	  
	  
3.4.3.	  Baseline	  Clinical	  Features	  Baseline	   outpatient	   clinic	   tests	   were	   assessed	   to	   characterize	   the	   cohort,	  however	  baseline	  clinical	  features	  were	  not	  systematically	  recorded,	  so	  this	  data	  is	   not	  presented.	  Electrocardiogram	   (ECGs)	   abnormalities	  were	   common	   (22%	  of	   patients),	   consisting	   of	   left	   ventricular	   hypertrophy	   and	   ischaemic	   changes.	  DEXA	   bone	   densitometry	   analysis	   revealed	   evidence	   of	   osteopenia	   in	   33%	   of	  assessed	  cases	  and	  osteoporosis	  in	  22%,	  compared	  to	  33%	  who	  had	  previously	  been	   given	   a	   clinical	   diagnosis	   of	   osteoporosis.	   Unfortunately	   due	   to	   the	  retrospective	   nature	   of	   the	   study	   full	   body	   composition	   analysis	   data	   was	  unavailable.	  Hypokalaemia	  was	  present	   in	  6%	  of	   cases	   and	   in	   association	  with	  increased	  UFC	  levels.	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3.4.4.	  Surgical	  Approach	  The	  primary	  surgical	  aim	  was	  complete	  adenoma	  resection	  with	  preservation	  of	  normal	   tissue.	   When	   a	   suspected	   adenoma	   was	   identified	   at	   surgery,	   it	   was	  resected	   with	   a	   thin	   rim	   of	   neighbouring	   tissue	   to	   ensure	   clear	   histological	  margins.	   Pre-­‐operative	  MRI	  was	   used	   to	   lateralize	   tumor	   and	   guide	   the	   initial	  site	  of	  surgical	  exploration.	  If	  a	  surgical	  target	  was	  absent	  from	  MRI,	  full	  pituitary	  exploration	  was	  carried	  out,	  with	  the	  suspected	  adenoma	  removed	  if	  identified.	  If	  search	  for	  adenoma	  was	  unsuccessful,	  approximately	  70-­‐90%	  of	  the	  gland	  was	  resected.	  	  
3.4.5.	  Biochemical	  Outcomes:	  Definitions	  Patients	  were	  categorized	   into	   ‘Initial	  Remission’	  or	   ‘Persistent	  Disease’	  groups	  as	   defined	   by	   a	   biochemical	   definition	   of	   outcome	   following	   TSS.	   A	   post-­‐operative	  morning	   cortisol	   level	   of	   <50nmol/L	   (measured	  up	   to	  6	  weeks	  post-­‐operatively)	   defined	   initial	   remission,	   with	   failure	   of	   this	   defining	   persistent	  disease.	  Patients	  achieving	   initial	  remission	  were	  further	  categorized	   into	   long-­‐term	   outcome	   groups	   of	   ‘Cure’,	   ‘Recurrent	   Disease.	   Patients	   were	   defined	   as	  ‘cured’	  if	  they	  attained	  resolution	  of	  hypercortisolism	  with	  a	  single	  surgery	  that	  lasted	   throughout	   subsequent	   follow	   up,	   requiring	   no	   further	   treatment.	  	  Recurrent	   disease	   was	   defined	   biochemically	   by	   raised	   UFC	   or	   failure	   of	  dexamethasone	  suppression	  following	  initial	  remission.	  	  	  
3.4.6.	  Statistical	  Analysis	  of	  Mortality	  Mortality	  was	  expressed	  using	  standardized	  mortality	  ratios	  (SMR)	  calculated	  as	  the	  ratio	  of	  observed	  to	  expected	  deaths	  (Breslow	  and	  Day,	  1987).	  Estimates	  of	  expected	   deaths	   were	   derived	   by	   multiplying	   age,	   calendar	   year,	   and	   sex	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stratum-­‐specific	  mortality	  for	  the	  background	  population	  of	  England	  &	  Wales	  by	  the	   corresponding	   person-­‐years	   at	   risk	   among	   the	   Cushing’s	   disease	   cohort.	  Overall	   survival	  by	   clinical	   follow-­‐up	  was	  estimated	  by	  Kaplan-­‐Meier	   curves.	  A	  multivariable	   Cox	   regression	   model	   with	   attained	   age	   as	   the	   time	  metric	   was	  utilised	  to	  derive	  hazard	  ratios	  (HRs)	  for	  sex	  and	  age	  (analysis	  refers	  to	  diagnosis	  and	  follow	  up	  age	  <40	  year	  vs.	  >=40	  years).	  P<0.05	  was	  taken	  as	  the	  threshold	  for	   statistical	   significance.	   Statistical	   advice	  was	   provided	   by	  Dr.	   Raoul	   Reulen	  Senior	  Lecturer	  in	  the	  School	  of	  Health	  and	  Population	  Sciences	  at	  the	  University	  of	  Birmingham.	  	  	  	  
3.4.7.	  Ethical	  Opinion	  This	   study	   involved	   no	   intervention	   or	   alteration	   in	   individual	   patient	  management	  and	  was	  entirely	  retrospective.	  For	  these	  reasons	  it	  was	  registered	  and	   approved	   by	   the	   University	   Hospitals	   Birmingham	   Clinical	   Audit	  Department.	  	  	  
3.5.	  Results	  
3.5.1.	  Treatment	  Outcome	  following	  Transsphenoidal	  Surgery	  Initial	  remission	  was	  achieved	  in	  sixty	  of	  the	  72	  patients	  (83%)	  with	  full	  clinical	  details	   available	   (See	   Figure	   3-­‐1).	   Fifty-­‐two	   out	   of	   72	   patients	   (72%)	   achieved	  ‘Cure’,	   twelve	   (17%)	   had	   ‘Persistent	   disease’,	   and	   eight	   (11%)	   had	   ‘Recurrent	  disease’.	  Median	  time	  to	  disease	  recurrence	  was	  2	  years	  (IQR	  1-­‐3	  years).	  There	  was	   no	   difference	   in	   ‘initial	   remission’	   numbers	   in	   those	   who	   underwent	   TSS	  between	  1988-­‐1999	  and	  2000-­‐2009	   (27	  out	  of	  34	  =	  79%,	  33	  out	  of	  38	  =	  87%	  respectively	  p	  =	  0.53,	  using	  Fisher’s	  exact	  test).	  All	  cases	  undergoing	  endoscopic	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TSS	   achieved	   cure,	   however	   the	  median	   follow	  up	  period	  was	   only	   25	  months	  (IQR	  18-­‐39).	  Second-­‐line	  therapies	  for	  active	  disease	  included	  repeat	  TSS	  (n=16),	  bilateral	   adrenalectomy	   (n=9),	   and	   radiotherapy	   (RT)	   (n=8).	   	   Taking	   into	  account	   all	   treatments,	   only	   one	   patient	   in	   the	   group	   as	   a	   whole	   had	   active	  disease	  at	  final	  follow	  up,	  with	  all	  others	  achieving	  remission.	  	  	  
3.5.2.	   Resolution	   of	   Clinical	   Features	   following	   Transsphenoidal	  
Surgery	  
	  
3.5.2.1.	   Hypertension	  Fifty-­‐six	  of	  72	  patients	  (78%)	  had	  arterial	  hypertension	  at	  baseline,	  and	  of	  these	  thirty-­‐seven	   had	   been	   prescribed	   anti-­‐hypertensives.	   Eleven	   (30%)	   of	   these	  patients	   reduced	   their	   medications	   within	   the	   6	   post-­‐operative	   weeks	   and	  twelve	   patients	   of	   37	   (32%)	   discontinued	   their	   anti-­‐hypertensives.	   Median	  systolic	  and	  diastolic	  blood	  pressures	  declined	  from	  diagnosis	  to	  6	  weeks	  post-­‐operatively	  to	  final	   follow	  up.	  There	  was	  no	  difference	  between	  blood	  pressure	  at	  6	  weeks	  and	  final	  follow	  up	  (see	  table	  3-­‐2).	  	  	  
3.5.2.2.	   Body	  Mass	  Index	  (BMI)	  Median	  BMI	  for	  the	  overall	  group	  was	  in	  the	  obese	  range	  (30.4	  kg/m2	  (IQR	  26.6-­‐35.0))	   at	   baseline.	   This	   value	   declined	   significantly	   6	  weeks	   following	   surgery	  and	  this	  was	  sustained	  at	  the	  final	  clinic	  visit	  (see	  table	  3-­‐2).	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   BMI	  (kg/m2)	   SBP	  (mmHg)	   DBP	  (mmHg)	  
Diagnosis	   30	  (27-­‐35)	   150	  (130-­‐162)	   90	  (80-­‐100)	  
6	  weeks	  post-­‐TSS	   29	  (27-­‐34)	   124	  (110-­‐150)	   80	  (76-­‐90)	  
Final	  Follow	  up	   27	  (23-­‐32)	   130	  (116-­‐140)	   82	  (76-­‐86)	  	  
Table	   3-­‐2:	   Resolution	   of	   Body	   Mass	   Index	   and	   Blood	   Pressure	   following	   Transsphenoidal	  
Surgery	   (TSS).	  Medians	   and	   Interquartile	   Ranges	   (IQRs)	   shown.	   Reductions	   in	   body	  mass	   index	  
(BMI)	  (P=0.006	  and	  P=0.0004),	   systolic	  blood	  pressure	  (SBP)	  (Both	  P<0.0001)	  and	  diastolic	  blood	  
pressure	  (DBP)	  (Both	  P<0.0001)	  were	  seen	  at	  6	  weeks	  and	  at	  final	  follow	  up.	  Adapted	  from	  Hassan-­‐
Smith	  et	  al	  (2012).	  	  
3.5.3.	  General	  Post-­‐Operative	  Complications	  Common	   complications	   of	   surgery	   included	   transient	   diabetes	   insipidus	   (DI)	  (35%),	   CSF	   leak	   (11%),	   whilst	   meningitis	   (n=3),	   sinusitis	   (n=2),	   septal	  perforation	   (n=1)	   and	   blocked	   lacrimal	   ducts	   (n=1)	   were	   also	   reported.	  Recorded	  complication	  rates	  did	  not	  differ	  between	  Endoscopic	  and	  Microscopic	  approaches.	  	  	  
3.5.4.	  Endocrine	  Complications	  Although	  there	  were	  limited	  data	  on	  pre-­‐operative	  hypopituitarism,	  frequencies	  of	  11%	  (4	  out	  of	  38)	  for	  TSH	  deficiency	  and	  17%	  (7	  out	  of	  41)	  for	  gonadotrophin	  deficiency	   were	   recorded.	   	   Post-­‐operatively	   all	   patients	   were	   prescribed	  hydrocortisone	   replacement	   (median	   dose	   30mg/day,	   IQR	   30-­‐30mg	   for	   cured	  and	   persistent/recurrent	   disease	   groups,	   p=0.98)	   with	   patients	   having	  reassessment	  of	   the	  HPA-­‐axis	  on	  an	  outpatient	  basis.	  Of	   the	  patients	   achieving	  cure	   (n=52),	   HPA	   axis	   recovery	   was	   observed	   in	   23	   (44%)	   patients	   over	   the	  follow	  up	  period.	  Overall	  16%	  of	  patients	  achieved	  the	  optimal	  surgical	  outcome	  of	   cure	   at	   1st	   surgery	   with	   intact	   endocrine	   function,	   although	   the	   largest	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outcome	   group	   (53%)	   was	   made	   up	   of	   those	   cured	   at	   the	   expense	   of	  hypopituitarism	  (See	  Table	  3-­‐3a).	   	  Results	  for	  ACTH	  status	  by	  group	  followed	  a	  similar	  pattern	  (See	  Table	  3-­‐3b).	  	  	  
a)	  
Disease	  Outcome	   Pituitary	  Function	  
	   Intact	   Deficient	  
Cure	   16%	   53%	  
Persistent/Recurrent	   3%	   28%	  	  
b)	  	  
Disease	  Outcome	   ACTH	  Status	  
	   Intact	   Deficient	  
Cure	   21%	   48%	  
Persistent/Recurrent	   12%	   19%	  	  
	  
Tables	   3-­‐3:	   (a)	   Pituitary	   Function	   and	   (b)	   ACTH	   Status,	   at	   final	   follow	   up	   according	   to	  
Cushing’s	   Outcome	   Group.	   16%	   of	   patients	   achieved	   the	   most	   favourable	   outcome	   of	   normal	  
pituitary	   function	   and	   cure	   of	   Cushing’s,	   compared	   to	   53%	   with	   cure	   and	   hypopituitarism,	   3%	  
Persistent/Recurrent	   Disease	   and	   normal	   pituitary	   function	   and	   28%	   with	   Persistent/Recurrent	  
Disease	   and	   hypopituitarism.	   Results	   for	   ACTH	   status	   were	   20%	   (Cure/ACTH	   intact),	   48%	  
(Cure/ACTH	   deficiency),	   11%	   (Persistent/Recurrent	   Disease/	   ACTH	   intact),	   and	   19%	  
(Persistent/Recurrent	   Disease/	   ACTH	   deficient).	   Differences	   between	   groups	  were	   non-­‐significant	  
(P=0.58,	  P=0.32	  respectively)	  	  
3.5.5.	  Mortality	  Following	  Transsphenoidal	  Surgery	  Thirteen	  deaths	  occurred	  over	  follow	  up	  (median	  duration,	  11	  years),	  five	  in	  the	  ‘Cure’	   group,	   two	  with	   ‘Recurrent	   disease’	   group,	   two	  with	   ‘Persistent	   disease’	  and	  four	  with	  NHS	  registry	  data	  available	  only.	  Causes	  of	  mortality	  according	  to	  death	   certificates	   included	   “CV	   disease”	   (n=8),	   “malignancy”	   (n=3),	   “infective	  disease”	   (n=1)	   and	   “Cushing’s”	   itself	   (n=1).	   SMR	   for	   the	   group	   as	   a	  whole	  was	  3.17	  (95%	  CI,	  1.70-­‐5.43;	  13	  observed	  deaths	  vs.	  to	  4.10	  expected)(see	  Table	  3-­‐4).	  When	   patients	   were	   divided	   into	   Cushing’s	   outcome	   groups,	   SMR	   for	   ‘cured’	  patients	  was	  2.47	   (95%	  CI:	   0.80-­‐5.77),	   compared	   to	  4.12	   (95%	  CI:	   1.12-­‐10.54)	  for	  Recurrent/Persistent	  disease.	  Kaplan	  Meier	  Analysis	  was	  performed	  for	   the	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total	  group	  and	  treatment	  outcome	  groups,	  and	  revealed	  a	  trend	  towards	  earlier	  death	   for	   those	   with	   persistent/recurrent	   disease	   vs.	   cured	   patients	   however	  this	  did	  not	  reach	  statistical	  significance.	  Median	  age	  at	  death	  was	  57	  years	  (IQR	  57-­‐64),	  with	  an	  increased	  risk	  of	  death	  for	  women	  (relative	  risk	  (RR)	  =	  4.5	  (95%	  CI	  0.58-­‐34.54)).	  




SMR	   95%	  CI	   P	  value	  
Overall	   13	  	   4.10	   3.17	   1.70-­‐5.43	   <0.001	  
Persistent	  /Recurrent	  
Disease	  
4	   0.97	   4.12	   1.12-­‐10.54	   0.34	  
Cure	   5	  	   2.02	   2.47	   0.80-­‐5.77	   0.03	  
	  
Table	  3-­‐4:	  Mortality	  by	  Cushing’s	  Disease	  Outcome	  Group.	  The	  overall	  standardized	  mortality	  
ratio	  (SMR)	  was	  3.17,	  calculated	  according	  to	  the	  13	  observed	  deaths	  compared	  to	  4.10	  as	  would	  be	  
expected	   in	   the	   background	   population.	   There	   was	   no	   difference	   in	   age	   between	   the	   cure	   and	  
persistent/recurrent	   disease	   groups,	   median	   age	   41	   years	   (IQR	   29-­‐51)	   vs	   39	   years	   (IQR	   32-­‐50)	  
respectively,	  p=0.96.	  Adapted	  from	  Hassan-­‐Smith	  et	  al	  (2012)	  	  
3.5.6.	  Prognostic	  Indicators	  Logistic	   regression	  analysis,	  with	  models	  adjusted	   for	  age	  at	  diagnosis,	   gender,	  and	   age	   at	   final	   follow	   up,	   was	   used	   to	   identify	   prognostic	   indicators	   of	   cure.	  Factors	  assessed	  included	  ACTH	  positive	  histology	  (odds	  ratio	  (OR):	  4.4	  for	  cure,	  95%	  CI:	   1.3-­‐15.3,	   p=0.015),	   pre-­‐operative	  UFC	   	   <1000nmol/24	  hours	   (OR:	   3.6,	  95%	  CI:	  0.9-­‐14.1,	  p=0.05),	  systolic	  blood	  pressure	  (OR:	  1.0,	  95%	  CI:	  0.3-­‐3.3	  N/S)	  surgical	  target	  on	  MRI	  (OR:	  1.9,	  95%	  CI:	  0.5-­‐7.6,	  N/S).	  	  	  
3.6.	  Discussion	  With	   80	   subjects,	   this	   is	   currently	   the	   largest	   UK	   study	   examining	   long-­‐term	  outcomes	  and	  mortality	  in	  CD	  following	  TSS.	  In	  addition	  the	  follow	  up	  duration	  for	  mortality	  is	  only	  surpassed	  by	  one	  study,	  which	  included	  historical	  data	  from	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as	   far	   back	   as	   1960	   (Clayton	   et	   al.,	   2011).	   Having	   a	   relatively	   large	   cohort	   of	  subjects	  with	  a	  rare	  disease,	  operated	  on	  by	  a	  single	  surgeon	  with	  standardized	  Endocrine	  care,	  provides	  a	  valuable	  opportunity	  to	  add	  to	  our	  knowledge	  of	  the	  long-­‐term	  effects	  of	  endogenous	  GC	  excess	  and	  impact	  on	  patient	  care.	  
	  Our	   treatment	   outcomes	   compare	   favourably	   with	   those	   reported	   in	   the	  literature	   from	   world	   leading	   specialist	   centres,	   with	   ‘Initial	   Remission’	  	  ‘Persistent	   Disease’,	   and	   ‘Recurrent	   Disease’	   rates	   of	   83%,	   17%	   and	   13%	  respectively.	  These	  compare	   to	   rates	  of	  between	  65-­‐90%,	  10-­‐24%,	  and	  5-­‐22%,	  respectively	  in	  the	  literature	  (Lindholm	  et	  al.,	  2001,	  Yap	  et	  al.,	  2002,	  Hammer	  et	  al.,	  2004,	  Atkinson	  et	  al.,	  2005,	  Dekkers	  et	  al.,	  2007,	  Clayton	  et	  al.,	  2011).	  Median	  time	   to	  recurrence	  was	  also	  within	   the	  range	  reported	  by	  previous	  studies	   (20	  and	   84	   months)	   (Pereira	   et	   al.,	   2003,	   Esposito	   et	   al.,	   2006).	   Our	   cure	   rates	  following	   1st	   surgery	   (72%)	   are	   at	   the	   top	   end	   of	   those	   previously	   described	  (56-­‐72%).	   It	   should	  also	  be	  noted	   that	  although	  patients	  were	  categorized	   into	  “Cure”,	   “Persistent”	   and	   “Recurrent	   Disease”	   groups	   for	   analysis,	   almost	   all	  (98%)	  were	  in	  disease	  remission	  at	  final	  follow	  up.	  	  	  Whilst	  our	  initial	  remission	  and	  long-­‐term	  cure	  rates	  are	  favourable,	  the	  optimal	  outcome	  of	  CD	  therapy	  also	  involves	  preservation	  of	  pituitary	  function,	  and	  this	  was	  achieved	  in	  16%	  of	  patients	  at	  first	  surgery.	  Our	  rates	  of	  TSH	  (33%),	  LH/FSH	  (29%),	  and	  GH	  deficiencies	  (29%)	  over	   follow	  up,	  are	  comparable	  to	  an	  earlier	  report	   from	  a	  specialist	  centre	   in	  the	  Netherlands	  (TSH	  32%,	  LH/FSH	  30%,	  GH	  32%)	  (Dekkers	  et	  al.,	  2007).	  However	  our	  rates	  of	  hypopituitarism	  of	  any	  degree	  (71%)	  and	  ACTH	  deficiency	  in	  particular	  (57%)	  are	  in	  the	  upper	  end	  of	  the	  range	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described	  in	  the	  literature	  (37-­‐59%)	  (Rees	  et	  al.,	  2002,	  Dekkers	  et	  al.,	  2007).	  We	  could	   speculate	   that	   this	   is	   secondary	   a	   number	   of	   factors	   such	   as	   aggressive	  pursuit	   of	   cure,	   prolonged	   use	   of	   GC	   treatment,	   improved	   recognition	   of	   GH	  deficiency	  compared	  to	  historical	  series	  or	   limited	  clinical	   follow	  up	  (Cavagnini	  et	  al.,	  2008).	  This	  study	  demonstrates	  significant	   increases	   in	  TSH	  and	  LH/FSH	  deficiencies	   in	   those	  with	   recurrent	  and	  persistent	  disease,	   suggesting	   that	   the	  aggressive	   approach	   taken	   in	   these	   patients	   may	   play	   a	   role.	   Surgical	  complications	  were	  comparable	  to	  those	  reported	  in	  the	  literature	  with	  transient	  DI	  and	  post-­‐operative	  CSF	  leak	  the	  most	  prevalent	  (transient	  DI	  6-­‐58%,	  CSF	  leak	  2-­‐13%)	  (Prevedello	  et	  al.,	  2008).	  	  
	  The	   classical	   clinical	   phenotype	   of	   CD	   involves	   altered	   body	   composition	  consisting	   of	   sarcopenia,	   osteoporosis,	   thinning	   of	   the	   skin,	   fatty	   liver	   and	  visceral	   obesity;	   major	   morbidity	   and	   mortality	   resulting	   from	   CV	   disease	  (Souverein	  et	  al.,	  2004,	  Clayton	  et	  al.,	  2011).	  The	  elevated	  cardiovascular	  disease	  risk	  seen	  in	  CD,	  is	  largely	  mediated	  by	  arterial	  hypertension	  and	  features	  of	  the	  metabolic	  syndrome.	  This	  area	  was	  recently	  reviewed	  by	  Pimenta	  et	  al	   (2012),	  who	   also	   highlighted	   the	   potential	   effects	   of	   mineralocorticoid	   receptor	  activation	   in	  GC	  excess	   in	  mediating	  renal	  and	  cardiac	  damage.	   Interestingly	   in	  our	  study	  hypokalaemia	  was	  present	  at	  a	  frequency	  of	  6%,	  which	  is	  indicative	  of	  the	   state	   of	   apparent	   mineralocorticoid	   excess	   induced	   by	   saturation	   of	   11β-­‐HSD2,	  which	  is	  commonly	  seen	  with	  the	  high	  cortisol	  production	  rates	  of	  ectopic	  ACTH	  secretion	  (Stewart	  et	  al.,	  1995).	  	  Mineralocorticoid	  receptor	  activation,	  and	  pre-­‐receptor	   GC	   regulation	   provide	   targets	   that	  may	   prove	   to	   be	   of	   benefit	   in	  reducing	  cardiovascular	  risk	  in	  Cushing’s.	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As	   outlined	   in	   the	   introduction,	   despite	   biochemical	   cure	   of	   CD	   resulting	   in	  marked	   improvements	   in	   clinical	   features,	   there	   is	   growing	   evidence	   of	  persisting	  abnormalities.	  However	  much	  of	  this	  data	   is	   limited	  by	  small	  sample	  sizes	  and	  durations	  of	  follow	  up,	  so	  evidence	  from	  larger	  studies	  is	  much	  needed.	  We	  were	   able	   to	   extract	   information	   retrospectively	   on	   resolution	   of	   BMI	   and	  hypertension	  between	  base	  line,	  6	  weeks	  post-­‐operatively	  and	  at	  final	  follow	  up.	  It	  was	   striking	   that	   improvements	   in	  blood	  pressure,	  were	  both	   rapid	   in	  onset	  and	   sustained	   long-­‐term.	   In	   addition	   a	  more	   gradual	   reduction	   in	  median	  BMI	  was	  observed,	   from	   the	  obese	   range	   to	   the	  middle	   of	   the	  overweight	   range	  by	  final	   follow	   up.	   A	   raised	   BMI	   post	   CD	   cure,	   may	   contribute	   to	   the	   persisting	  excess	   CV	   risk	   as	   observed	   by	   Colao	   et	   al	   (1999).	   Patients	   who	   were	  biochemically	  cured	  of	  CD	  for	  5	  years	  were	  found	  to	  have	  increased	  prevalence	  of	   obesity,	   hypertension,	   insulin	   resistance,	   dyslipidaemia	   and	   atherosclerosis	  compared	   to	   the	   background	   population.	   Furthermore	   increased	   CV	   risk	   was	  highly	   correlated	   with	   insulin	   resistance	   and	   waist-­‐hip-­‐ratio,	   a	   measure	   of	  central	   obesity.	   In	   recent	   years,	   several	   studies	   have	   investigated	   body	  composition	  changes	  and	  CV	  disease	  risk	  during	  following	  effective	  treatment	  of	  Cushing’s,	   and	   have	   provided	   evidence	   of	   a	   legacy	   effect	   in	   the	   aftermath	   of	  disease.	  Geer	  et	  al	  (2012)	  showed	  that	  CD	  remission	  resulted	  in	  reductions	  in	  all	  fat	  depots,	  and	  a	  further	  decline	  in	  skeletal	  muscle	  mass	  6	  months	  after	  stopping	  GC	  replacement.	  Pirlich	  et	  al	  (2002)	  performed	  a	  prospective	  study	  of	  Cushing’s	  at	   baseline	   and	   6	   months	   post-­‐operatively,	   with	   similar	   results.	   Potential	  mechanisms	   for	   the	   lack	   of	   improvement	   in	   skeletal	  muscle	   following	   CD	   cure	  include	   excessive	   GC	   replacement,	   with	   Geer	   et	   al	   reporting	   an	   inverse	  relationship	   between	   duration	   of	   exposure	   and	   skeletal	   muscle	   mass,	   loss	   of	  
	   114	  
anabolic	   drive	   due	   to	  GH	  or	   LH/FSH	  deficiencies,	   or	   reduced	   levels	   of	   activity.	  Barahona	  et	  al	   (2009a),	   followed	  up	  women	   for	  a	  mean	  of	  11	  years	  and	   found	  that	   those	   that	  were	   oestrogen	  deficient	   (due	   to	  menopause	   or	   gonadotrophin	  deficiency)	   had	   higher	   total	   and	   truncal	   body	   fat	   post	   remission	   of	   Cushing’s,	  compared	  women	  with	  pre-­‐menopausal	  levels.	  Absence	  of	  oestrogen	  appears	  to	  have	   a	   profound	   effect	   on	   visceral	   fat	   deposition	   following	   cure	   of	   Cushing’s,	  although	  the	  mechanism	  of	  this	  has	  not	  been	  confirmed.	  Barahona	  et	  al	  (2009a)	  hypothesized	   that	   GC	   induced	   ‘hyperactivation’	   of	   11β-­‐HSD1	   in	   omental	   tissue	  stimulated	  differentiation	  of	  pre-­‐adipocytes	   to	  adipocytes	  during	  active	  disease	  resulting	   in	   increased	   fat	   deposits	   that	   persist	   after	   cure.	   It	   is	   interesting	   to	  speculate	   that	  post-­‐menopausal	  visceral	  obesity	  after	  cure	  of	  Cushing’s	  may	  be	  caused	   by	   an	   absence	   of	   the	   suppressive	   effects	   of	   oestrogen	   on	   11β-­‐HSD1	  expression	  and	  activity,	  for	  which	  there	  is	  some	  evidence	  (Andersson	  et	  al.,	  2010,	  Yamatani	  et	  al.,	  2012).	  A	   finding	  that	  may	  be	   linked	   in	  our	  study	   is	   that	   female	  gender	  is	  linked	  to	  excess	  mortality	  (RR	  =	  4.5)	  and	  visceral	  obesity	  in	  oestrogen	  deficient	   Cushing’s	   patients	   is	   a	   promising	   candidate	   mechanism.	   In	   addition,	  there	  are	  established	  gender	  differences	  in	  CD	  (Sherlock	  et	  al.,	  2010),	  including	  a	  female	   preponderance	   as	   seen	   in	   our	   study	  with	   a	   3.7	   to	   1	   ratio,	   this	  may	   be	  explained	   by	   oestrogen	   responsiveness	   of	   corticotroph	   adenomatous	   tissue	  (Chaidarun	  et	  al.,	  1998).	  	  	  Mortality	   is	   clearly	   increased	   in	  CD	   (Etxabe	  and	  Vazquez,	  1994,	  Pikkarainen	  et	  al.,	  1999,	  Dekkers	  et	  al.,	  2007).	  The	  uncertainty	  relates	  to	  whether	  there	   is	  any	  long-­‐term	   excess	   risk	   following	   effective	   biochemical	   cure	   using	   modern	  treatments.	   Several	   surgical	   series	   suggest	   that	   remission	   of	   hypercortisolism	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results	  in	  normalization	  of	  mortality	  rates	  (Swearingen	  et	  al.,	  1999,	  Lindholm	  et	  al.,	  2001,	  Hammer	  et	  al.,	  2004),	  whilst	  active	  disease	  is	  associated	  with	  reduced	  survival,	  providing	  an	  evidence	  base	  for	  the	  aggressive	  pursuit	  of	  cure	  (Sherlock	  et	  al.,	  2010).	  As	  CD	  is	  a	  rare	  condition,	  conclusions	  are	  drawn	  from	  studies	  with	  limited	   sample	   sizes	   and	   subsequent	   deaths	   with	   durations	   of	   surveillance	   of	  under	   a	   decade	   (see	   Table	   3-­‐5).	  We	   report	   an	   excess	  mortality	   rate	   of	   >3-­‐fold	  overall	  with	  a	  trend	  towards	  reduced	  ratios	  in	  patients	  achieving	  cure	  compared	  to	   those	  with	  recurrent	  or	  persistent	  disease,	  although	  this	  difference	  does	  not	  reach	  statistical	  significance.	  With	  an	  SMR	  of	  2.47	  (95%	  CI:	  0.80-­‐5.77),	  there	  may	  be	  an	  ongoing	  excess	  mortality	  even	  after	  cure	  of	  CD.	  	  	  
First	   Author,	  
year	  (Ref)	  



















49	   1975-­‐	  1992	  (17	  y)	   88	   56	   5/49	   N/A	   N/A	   3.80	  (2.5-­‐	  17.9)	  
Swearingen	  
1999	  
161	   1978-­‐1996	  (18	  y)	   90	   96	   6/159	   N/A	   N/A	   0.98	  (0.44-­‐	  2.2)	  
Pikkarainen	  
1999	  
63	   1981-­‐	  1994	  (13y)	   34	   84	   6/43	   N/A	   N/A	   2.67	  (0.89-­‐	  5.2)	  
Lindholm	  
2001	  
73	   1985-­‐	  1995	  (10	  y)	   66	   96	   7/73	   0.31	   5.1	   1.70	  (0.7-­‐	  3.5)	  
Hammer	  	  
2004	  
289	   1975-­‐	  1998	  (23	  y)	   82	   132	   25/289	   1.18	  (N/S)	   2.8	   1.42	  (0.95-­‐2.1)	  
Dekkers	  	  
2007	  
74	   1977-­‐2005	  (28	  y)	   80	   120	   12/74	   1.8	  (N/S)	   4.38	   2.39	  (1.2-­‐3.9)	  
Clayton	  	  
2011	  
60	   1960-­‐	  2009	  (49	  y)	   90	   180	   13/60	   3.3	   16	   4.80	  (2.8-­‐8.3)	  
This	  Study	   80	   1988-­‐	  2009	  (21	  y)	   83	   132	   13/80	   2.47	   4.12	   3.17	  (1.7-­‐	  5.3)	  	  
Table	   3-­‐5:	   Comparison	   of	   Studies	   Examining	   Remission	   Rates	   and	  Mortality	   for	   Cushing’s	  
Disease	  Patients	  Post-­‐Transsphenoidal	  Surgery	  (TSS).	  SMR	  =	  Standardized	  Mortality	  Ratio,	  N/A	  
=	  Not	  Available,	  N/S	  =	  Non-­‐significant.	  Adapted	  from	  Hassan-­‐Smith	  et	  al	  (2012).	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Data	   from	   Clayton	   et	   al	   (2011),	   which	   also	   had	   a	   long	   duration	   of	   follow	   up	  (median	  15	   years)	   support	   these	   findings	  with	   a	   SMRs	   overall	   of	   4.8	   (95%	  CI:	  2.8-­‐8.3),	   	   13.8	   (95%	   CI:	   7.2-­‐36.5)	   for	   CV	   disease,	   and	   3.3	   (95%	   CI:	   1.7-­‐6.7)	   in	  remission.	   Our	   cohort	   appeared	   to	   receive	   high	   quality	   specialist	   care	   as	  evidenced	   by	   the	   favourable	   remission	   and	   cure	   rates,	   along	  with	   evidence	   of	  improvements	  in	  blood	  pressure	  and	  BMI.	  However	  there	  was	  evidence	  of	  end-­‐organ	   cardiovascular	   effects	   including	   LVH	   by	   voltage	   criteria	   and	  myocardial	  ischaemia	  on	  ECG.	  Excess	  mortality	  could	  be	  iatrogenic	  in	  nature,	  stemming	  from	  treatment-­‐induced	   hypopituitarism	   or	   non-­‐physiological	   glucocorticoid	  replacement,	   however	   this	   study	   was	   not	   designed	   to	   assess	   this.	   In	   order	   to	  address	   these	   issues,	   large	   population	   based	   studies	   of	  mortality	   are	   required,	  coordinated	   nationally	   or	   internationally.	   Furthermore,	   long-­‐term	   prospective	  studies	  of	  the	  cardiovascular	  effects	  of	  CD,	   involving	  detailed	  body	  composition	  and	  risk	   factor	  analysis,	   along	  with	  sampling	  of	   clinical	   tissues,	  are	   required	   in	  order	  to	  develop	  future	  treatment	  targets.	  	  	  Identification	  of	  prognostic	  factors	  for	  disease	  remission,	  such	  as	  ACTH	  positive	  histology	   and	   pre-­‐operative	   UFC	   level	   as	   seen	   in	   this	   study,	   are	   important	   for	  patient	  counseling	  and	  risk	  stratification.	  Previously	  identified	  prognostic	  factors	  include	  age	  at	  diagnosis,	  presence	  of	  hypertension	  and	  diabetes	   (Clayton	  et	  al.,	  2011),	  post-­‐operative	  serum	  cortisol	  (Esposito	  et	  al.,	  2006,	  Martino	  et	  al.,	  2007)	  and	  ACTH	  (Flitsch	  et	  al.,	  2003),	  ACTH	  response	  to	  CRH	  stimulation	  (Nishizawa	  et	  al.,	   1999),	   post-­‐operative	  metyrapone	   (Alwani	   et	   al.,	   2010),	   desmopressin	   test	  (Losa	   et	   al.,	   2009),	   and	   low	   dose	   dexamethasone	   suppression	   (McCance	   et	   al.,	  1993),	  identification	  of	  adenoma	  intra-­‐operatively,	  and	  positive	  histology	  as	  seen	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in	   this	   study	   (Acebes	  et	  al.,	  2007,	  Martino	  et	  al.,	  2007).	  With	  regards	   the	   latter	  however,	   it	   is	   important	   to	  note	   that	  60%	  of	   those	  with	  negative	  histology	  still	  achieved	  cure	  without	  need	  for	  revision	  (Pouratian	  et	  al.,	  2007).	  Our	  data	  are	  at	  odds	  with	   a	   recent	   study	   that	   appeared	   to	   suggest	   that	   positive	   pre-­‐operative	  MRI	   findings	   were	   associated	   with	   a	   increased	   chance	   of	   achieving	   disease	  remission	  (Ciric	  et	  al.,	  2011),	  but	   in	   line	  with	  an	  earlier	  report	   (Salenave	  et	  al.,	  2004).	  	  	  In	  summary,	  this	  study	  comprises	  the	  UK’s	  largest	  cohort	  study	  of	  CD	  outcomes	  and	  mortality.	  Following	  preparation	  of	   this	  chapter	  the	  analyses	  outlined	  here	  have	  been	  published	   (Hassan-­‐Smith	  et	   al.,	   2012).	  The	   centre’s	   initial	   remission	  and	   cure	   rates	   are	   similar	   to	   those	   seen	   in	   leading	   specialist	   centres	  internationally	  and	  highlight	  the	  importance	  of	  dedicated	  surgical	  and	  endocrine	  expertise	  and	  experience	   in	   the	  management	  of	  CD.	  Our	  results	   suggest	   that	   in	  spite	   of	   improvements	   in	   BMI	   and	   blood	   pressure	   post-­‐operatively,	   there	  remains	  excess	  mortality	  after	  effective	  treatment	  of	  CD.	  Long-­‐term	  management	  must	  be	   improved	  by	  aggressive	  risk	   factor	  reduction,	  prevention	  of	   iatrogenic	  illness,	   and	   generation	   of	   novel	   medical	   therapies.	   	   Prospective	   studies	   of	   CD	  with	   assessment	   of	   full	   body	   composition	   analysis,	   strength	   testing,	   protein	  turnover,	   11β-­‐HSD1	   activity	   and	   skeletal	   muscle	   gene	   expression	   before	   and	  after	   treatment	   would	   provide	   insights	   into	   disease	   mechanisms	   and	   may	  highlight	   potential	   therapeutic	   targets.	   Furthermore	   centres	   should	   be	  encouraged	  to	  report	  their	  data	  on	  CD	  outcomes	  in	  order	  to	  generate	  sufficient	  statistical	   power	   for	   an	   effective	   meta-­‐analysis.	   	   The	   effects	   of	   physiological	  replacement	  of	  hydrocortisone,	  reversal	  of	  oestrogen	  deficiency	  and	  use	  of	  11β-­‐
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4.1.	  Introduction	  Since	   Harvey	   Cushing’s	   seminal	   case	   series	   skeletal	   muscle	   atrophy	   (and	  proximal	  myopathy	  in	  particular)	  has	  become	  recognized	  as	  a	  key	  discriminatory	  feature	  of	  hypercortisolism.	  The	  dramatic	  effects	  of	  GCs	  on	  skeletal	  muscle,	  and	  current	  knowledge	  of	  molecular	  mechanisms	  involved	  was	  described	  in	  detail	  in	  chapter	   1.	   To	   summarise,	   in	   addition	   to	   effects	   on	   carbohydrate	   and	   lipid	  metabolism,	   GCs	   act	   to	   reduce	   protein	   synthesis	   and	   promote	   myofibrillar	  degradation	  via	  activation	  of	  the	  major	  proteolytic	  systems.	  The	  UPS	  appears	  to	  be	  central	  in	  muscle	  atrophy	  caused	  by	  a	  range	  of	  aetiologies	  including	  GC	  excess	  (Lecker	   et	   al.,	   2004,	   Schakman	   et	   al.,	   2008).	   This	   is	  mediated	   by	   E3	   ubiquitin	  ligases	  MAFbx/Atrogin1	  and	  MuRF1,	  and	  transcription	  factors	  including	  FOXO1	  and	  FOXO3a	  (Schakman	  et	  al.,	  2008).	   Inhibition	  of	  protein	  synthesis	  appears	  to	  be	   mediated	   largely	   via	   effects	   on	   IGF-­‐I/Akt/PI3K	   and	   mTOR	   signaling.	   	   In	  addition,	  the	  negative	  growth	  factor	  myostatin	  is	  critical	  to	  GC-­‐mediated	  atrophy	  in	   mice	   (Gilson	   et	   al.,	   2007).	   These	   genes,	   which	   are	   expressed	   in	   C2C12	  myotubes,	   form	  the	  central	  atrophy	  targets	   that	  will	  be	  studied	   in	   this	  chapter.	  The	   clinical	   significance	   of	  GC	   signaling	   in	  muscle	   atrophy	   extends	   beyond	   the	  rare	  condition	  of	  endogenous	  Cushing’s	  Syndrome,	   to	  populations	   treated	  with	  exogenous	   steroids	   (Up	   to	   1%	   total	   population	   and	   2.5%	   of	   those	   aged	   70-­‐79	  years)	  (Walsh	  et	  al.,	  1996,	  van	  Staa	  et	  al.,	  2000),	   to	  those	  with	  a	  range	  of	  acute	  and	   chronic	   diseases	   and	   potentially	   those	   with	   age-­‐associated	   sarcopenia	   (in	  range	  of	  5-­‐30%	  of	  those	  aged	  >65	  years)(Morley	  et	  al.,	  2001).	  Muscle	  atrophy	  is	  linked	   to	   disability,	   and	   reduced	   survival	   and	   currently	   has	   no	   effective	  pharmacological	   therapy	   (Baumgartner	   et	   al.,	   1998,	   Swallow	   et	   al.,	   2007,	  Kalantar-­‐Zadeh	  et	  al.,	   2010).	   Selective	  11β-­‐HSD1	   inhibition	   is	   a	  potential	  novel	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therapeutic	   target	   in	   the	   treatment	   of	   muscle	   atrophy	   and	   other	   features	   of	  ageing.	   GCs	   are	   important	   mediators	   of	   muscle	   atrophy	   in	   a	   number	   of	  pathological	  states	  including	  starvation,	  sepsis	  and	  metabolic	  acidosis	  (Wing	  and	  Goldberg,	   1993,	   Tiao	   et	   al.,	   1996,	   Smith	   et	   al.,	   2010,	   May	   et	   al.,	   1986).	  Furthermore	  11β-­‐HSD1	  appears	  to	  be	  involved	  in	  the	  ageing	  process	  in	  a	  range	  of	  tissues	  including	  bone,	  brain	  and	  skin	  (Cooper	  et	  al.,	  2002,	  	  Seckl	  and	  Walker.,	  2004,	  Tiganescu	  et	  al.,	  2011).	  Whilst	  in	  recent	  years,	  knowledge	  of	  GC-­‐regulated	  atrophy	  pathways	  has	  increased	  there	  is	  a	  paucity	  of	  data	  on	  their	  modulation	  by	  11β-­‐HSD1	   inhibitors.	   Furthermore,	   muscle	   atrophy	   may	   represent	   a	   novel	  therapeutic	   use	   for	   selective	   inhibitors	   of	   11β-­‐HSD1,	   in	   view	   of	   their	   modest	  effects	  on	  metabolic	  syndrome	  parameters	  to	  date	  (Rosenstock	  et	  al.,	  2010,	  Feig	  et	  al.,	  2011,	  Gathercole	  et	  al.,	  2013).	  	  
	  
	  There	  is	  a	  need	  to	  identify	  potential	  regulators	  of	  11β-­‐HSD1	  in	  skeletal	  muscle	  to	  provide	   insights	   into	   the	   mechanism	   of	   any	   age-­‐associated	   changes	   in	  expression.	   So-­‐called	   ‘Inflamm-­‐Ageing’	   has	   been	   proposed	   as	   the	   driver	   of	   age	  associated	   declines	   in	   physical	   function,	   and	   development	   of	   chronic	   disease	  (Cevenini	  et	  al.,	  2013).	  As	  outlined	   in	  chapter	  1,	  population-­‐based	  studies	  have	  revealed	  increased	  cytokines	  including	  TNF-­‐α	  in	  the	  elderly	  (Visser	  et	  al.,	  2002,	  Roubenoff	  et	  al.,	  2003).	  Furthermore,	  TNF-­‐α	  regulates	  11β-­‐HSD1	  expression	   in	  many	  cell	  and	  tissue	  types	  including	  those	  of	  hepatic,	  adipose,	  bone,	  and	  smooth	  muscle	   origin	   (Tomlinson	   et	   al.,	   2004).	   Finally	   it	   has	   been	   hypothesized	   that	  insulin	  resistance	  may	  affect	  protein	   turnover	   in	  addition	  to	  well-­‐characterized	  effects	  on	  glucose	  metabolism	  (Guillet	  and	  Boirie,	  2005,	  Dhar	  and	  Castillo,	  2011,	  Bailey,	  2013).	  	  
	   122	  
4.2.	  Hypothesis	  Two	  hypotheses	  will	  be	  tested.	  Firstly	  that	  glucocorticoid	  exposure	  results	  in	  up-­‐regulation	   of	   genes	   involved	   in	   muscle	   atrophy	   in	   skeletal	   myotubes	   and	  selective	  inhibition	  of	  11β-­‐HSD1	  attenuates	  these	  changes.	  Secondly,	  that	  TNF-­‐α	  and	   insulin	   influence	   muscle	   atrophy	   pathways	   and	   11β-­‐HSD1	   in	   skeletal	  myotubes.	  	  	  
4.3.	  Research	  Strategy	  and	  Aims	  Day	  8	  differentiated	  C2C12	  skeletal	  myotubes	  were	  utilized	  to	  assess	  the	  effects	  of	   GCs	   and	   11β-­‐HSD1	   on	   muscle	   atrophy	   gene	   expression,	   to	   inform	   our	  subsequent	   in	   vivo	   studies	   of	   skeletal	  muscle	   ageing	   in	  mice	   and	  humans.	   The	  following	  specific	  areas	  were	  covered:	  	   1. To	   assess	   the	   impact	   of	   high	   dose	   synthetic	   GC,	   and	   GR	   blockade	   on	  expression	   of	   genes	   with	   anabolic	   and	   catabolic	   functions	   in	   skeletal	  muscle.	  	  2. To	   assess	   the	   effects	   of	   inactive	   murine	   GC	   (11-­‐dehydrocorticosterone	  (11DHC))	  on	  expression	  of	   the	  above	  genes,	   and	   the	   impact	  of	   selective	  inhibition	  of	  11β-­‐HSD1	  on	  these	  changes.	  	  3. To	   establish	   dose	   and	   time	   course	   relationships	   between	   active	  murine	  GC	  treatments	  and	  HSD11B1	  and	  muscle	  atrophy/	  protein	  synthesis	  gene	  expression.	  	  4. To	   assess	   impact	   of	   potential	   age-­‐associated	   regulators	   of	   11β-­‐HSD1	  (TNF-­‐α	   and	   insulin)	   on	   muscle	   atrophy/protein	   synthesis	   gene	  expression.	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4.4.	  Methods	  
	  
4.4.1.	  C2C12	  cell	  culture	  
	  Previous	   data	   from	   within	   our	   group	   showed	   that	   11β-­‐HSD1	   is	   present	   and	  functionally	   active	   in	   C2C12	   murine	   myotubes,	   with	   oxo-­‐reductase	   activity	  increasing	   across	   differentiation	   (Morgan	   et	   al.,	   2009,	   Sherlock,	   2011).	   On	   this	  background,	  day	  8	  differentiated	  myotubes	  were	  used	  to	   investigate	  the	  effects	  of	   pre-­‐receptor	   GC	   regulation	   on	   muscle	   atrophy	   gene	   expression.	   	   C2C12	  myoblasts	  were	  seeded	  onto	  12-­‐well	  plates	   in	  proliferation	  media	  (DMEM	  with	  10%	  FCS).	  When	  ~70%	  confluence	  was	  reached,	  media	  was	  changed	  to	  DMEM	  with	  5%	  horse	   serum	  and	  cells	  were	  differentiated	   for	  8	  days	   (see	   figure	  4-­‐1).	  Before	  experimental	  treatments	  cells	  were	  washed	  and	  incubated	  in	  serum	  free	  media	  for	  4	  hours.	  	  
	  
Figure	  4-­‐1:	  Differentiation	  of	  C2C12	  Myoblasts:	  C2C12	  myoblasts	  at	  day	  0	  and	  
following	  8	  days	  incubation	  with	  DMEM	  supplemented	  with	  5%	  horse	  serum	  when	  
fully	  differentiated	  into	  myotubes.	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4.4.2.	  Cell	  Culture	  Treatments	  
4.4.2.1.	   Dexamethasone	  Dexamethasone	  is	  a	  synthetic	  GC,	  which	  is	  generated	  by	  addition	  of	  a	  16α-­‐methyl	  group	  to	  Δ1-­‐fludrocortisone.	  It	  has	  a	  hydroxyl	  group	  at	  carbon-­‐11,	  and	  does	  not	  require	   further	   activation	   for	   biological	   action	   (Wilson	   and	  Williams,	   1998).	   It	  has	   ~30-­‐times	   the	   GC	   potency	   of	   hydrocortisone	   but	   lacks	   mineralocorticoid	  activity.	   It	   is	   used	   therapeutically	   for	   a	   wide	   range	   of	   indications	   including	  inflammatory,	  autoimmune	  and	  malignant	  diseases.	  For	  experimental	  use,	   cells	  were	   treated	  with	  1μM	  dexamethasone	  and	   incubated	   for	  16	  hours,	   conditions	  previously	   shown	   to	   increase	   11β-­‐HSD1	   activity	   and	   protein	   degradation	  (Biedasek	  et	  al,	  2011).	  	  	  	  
4.4.2.2.	   Murine	  Glucocorticoids	  Cells	   were	   treated	   with	   the	   inactive	   murine	   GC,	   11-­‐dehydrocorticosterone	  (11DHC;	   Kendall’s	   Compound	   A)	   and	   active	   corticosterone	   (CORT;	   Kendall’s	  compound	  B).	  Dose	  response	  and	  time	  course	  experiments	  were	  carried	  out	  with	  CORT,	  whilst	  11DHC	  treatment	  (250nm;	  16	  hours	  incubation)	  was	  carried	  out	  in	  a	   series	   of	   experiments	   investigating	   the	   effects	   of	   selective	   inhibition	   of	   11β-­‐HSD1.	  	  
	  
4.4.2.3.	   RU486	  (Mifepristone)	  (GR	  Antagonist)	  RU486	   is	   a	   glucocorticoid	   receptor	   (GR)	   antagonist	   that	   also	   blocks	   the	  progesterone	  receptor,	  which	  has	  medical	  uses	  in	  the	  management	  of	  Cushing’s	  and	  pregnancy	  termination	  (Fleseriu	  et	  al.,	  2012).	  It	  competes	  with	  GCs	  to	  bind	  GR,	   preventing	   activation	   and	   nuclear	   translocation.	   In	   experiments	   using	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RU486,	   C2C12	   myotubes	   were	   treated	   with	   10μM	   for	   16	   hours.	   Short-­‐term	  treatment	  was	  used	  due	   to	  previous	  reports	   that	   long-­‐term	  use	   interferes	  with	  myotube	  proliferation	  (Sherlock,	  2011).	  	  	  
4.4.2.4.	   LJ2	  (PF-­‐877423)	  (Selective	  11β-­‐HSD1	  Inhibitor)	  LJ2	   (Pfizer	   Global	   R&D,	   La	   Jolla,	   California,	   US)	  was	   shown	   to	   be	   a	   potent	   and	  highly	   selective	   reversible	   and	   competitive	   inhibitor	   of	   the	   type	   1	   isozyme	   of	  11β-­‐HSD,	   in	   studies	   using	   human	   adipocyte	   primary	   cultures	   in	   addition	   to	  human	  and	  murine	   cell	   lines	   (Bujalska	  et	   al.,	   2008,	  Cheng	  et	   al.,	   2010).	  100nm	  LJ2	  inhibits	  both	  oxo-­‐reductase	  and	  dehydrogenase	  activities	  of	  11β-­‐HSD1	  whilst	  having	   no	   effect	   on	   11β-­‐HSD2.	   In	   experiments	   using	   LJ2,	   differentiated	   C2C12	  myotubes	  were	  treated	  with	  100nm	  for	  16	  hours	  incubation.	  	  
4.4.3.	  RNA	  Extraction	  and	  RT-­‐PCR	  
	  RNA	   was	   extracted	   from	   myotubes	   using	   Tri-­‐reagent®,	   as	   described	   in	   the	  general	  introduction.	  In	  summary,	  concentration	  was	  determined	  at	  OD260	  using	  a	  NanoDrop	  ND-­‐1000	  UV	  spectrophotometer	  (Thermofisher,	  Surrey,	  UK).	  1μg	  of	  RNA	   was	   used	   for	   generation	   of	   cDNA	   using	   the	   high	   capacity	   RT	   kit	   from	  Applied	  Biosystems	  (Warrington,	  UK).	  	  	  
	   4.4.4.	  Relative	  Quantitative	  (Real-­‐time)	  PCR	  Target	   gene	   expression	   was	   determined	   using	   Applied	   Biosystem	   “assay	   on	  demands”	   and	   related	   reagents	   (Applied	   Biosystems,	   Warrington,	   UK)	   with	  samples	   loaded	   in	  duplicate	   analysed	   relative	   to	  18S	  on	   a	  7500	  Real-­‐time	  PCR	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machine	  (Applied	  Biosystems,	  Warrington,	  UK).	  Data	  were	  expressed	  as	  Ct	  and	  ΔCt	  values	  as	  outlined	  previously,	  and	  arbitrary	  units	  (AU)	  [AU	  =	  1000x(2-­‐ΔCt)].	  	  	  
4.5.	  Results	  
	  
4.5.1.	   Expression	   of	   genes	   involved	   in	   muscle	   atrophy	   following	  
treatment	  with	  active	  synthetic	  glucocorticoid	  (dexamethasone)	  and	  
a	  GR	  antagonist	  (RU486)	  
	  
	  The	   effects	   of	   high	  dose	   synthetic	  GC	  on	   ‘atrogenes’	   (genes	   involved	   in	  muscle	  atrophy),	  MAFbx/Atrogin1,	  and	  myostatin	  was	  examined	  by	  treatment	  with	  1μM	  dexamethasone	  (DEX).	  The	  rationale	  of	  this	  experiment	  was	  to	  provide	  evidence	  of	   GC-­‐regulation	   of	   muscle	   atrophy	   genes	   that	   can	   be	   further	   investigated	   in	  subsequent	  experiments	  using	  selective	   inhibitors	  of	  11β-­‐HSD1.	  DEX	  treatment	  resulted	   in	   up-­‐regulation	   of	   MAFbx/Atrogin1	   (2.25±1.38	   vs.	   8.09±1.42AU,	  p<0.01)	   and	  myostatin	   (0.005±0.001	   vs.	   0.013±0.002AU,	   p<0.05).	  However	  GR	  Antagonism	  with	  co-­‐treatment	  of	  RU486	  and	  dexamethasone	  resulted	  in	  down-­‐regulation	   of	   MAFbx/Atrogin1	   (0.013±0.002	   vs.	   0.003±0.001AU,	   p<0.01),	   and	  myostatin	   (0.013±0.002	   vs.	   0.003±0.001AU,	   p<0.01)	   compared	   to	   DEX	   (see	  figure	   4-­‐2).	   No	   significant	   changes	   in	   gene	   expression	   were	   observed	   with	  treatment	  of	  cells	  with	  RU486	  alone.	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Figure	  4-­‐2:	  mRNA	  expression	  of	  muscle	  atrophy	  genes	   in	  C2C12s	   following	   treatment	  with	  
DEX	  alone	  and	  with	  the	  GR	  Antagonist,	  RU486.	  Experiments	  performed	  in	  differentiated	  murine	  
myotubes	   (C2C12s)	   analysed	   by	   real-­‐time	   PCR	   following	   treatment	   with	   dexamethasone	   (DEX)	  
(1μM/16	   hours)	   alone	   and	   in	   combination	   with	   the	   GR	   antagonist,	   RU486	   (10μM).	   Data	   are	  
expressed	   as	   mean	   of	   n=7	   experiments	   in	   arbitrary	   units	   (AU)	   ±	   Standard	   Error	   (S.E.).	   Overall,	  
P=0.004	   for	  MAFbx/Atrogin1,	   P=0.009	   for	  myostatin,	   (N/S	  =	  non-­‐significant,	   **p<0.01	   vs.	   control,	  
§p<0.05	  vs.	  DEX	  γp<0.05	  vs.	  control)	  (DEX	  =	  dexamethasone,	  CTRL	  =	  control).	  	  	  	  
	  
	  
4.5.2.	   The	   impact	   of	   treatment	  with	   inactive	  murine	   glucocorticoid	  
(11-­‐dehydrocorticosterone)	   and	   a	   selective	   11β-­‐HSD1	   inhibitor	  
(LJ2)	  on	  muscle	  atrophy	  gene	  expression	  	  The	   effects	   of	   pre-­‐receptor	   GC	   metabolism	   on	   muscle	   atrophy	   pathways	   was	  assessed	   by	   treating	   cells	   with	   inactive	   GC	   (A,	   250nm)	   and	   the	   selective	   11β-­‐HSD1	   inhibitor,	   LJ2	   (100nm).	   Treatment	   with	   A	   resulted	   in	   up-­‐regulation	   of	  MAFbx/Atrogin1	   only	   (7.7±1.4	   vs.	   20.4±2.5AU,	   p<0.01),	   with	   a	   non-­‐significant	  trend	   towards	   up-­‐regulation	   seen	   with	   myostatin	   (18.4±0.1	   vs.	   17.5±0.1,	  p=N/S)(see	  figure	  4-­‐3).	  Treatment	  with	  LJ2	  resulted	  in	  attenuation	  of	  A	  induced	  up-­‐regulation	  of	  MAFbx/Atrogin1	  (20.4±2.5AU	  vs.	  9.13±0.5AU,	  p<0.05),	  and	  no	  changes	   seen	   with	   myostatin	   (17.5±0.1	   vs.	   18.5±0.6AU,	   p=N/S).	   Treatment	   of	  cells	  with	  LJ2	  alone	  was	  without	  effect.	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Figure	   4-­‐3:	   mRNA	   expression	   of	   genes	   involved	   in	   muscle	   atrophy	   in	   C2C12s	   following	  
treatment	   with	   11-­‐DHC(A)	   alone	   and	   with	   the	   selective	   inhibitor	   of	   11β-­‐HSD1,	   LJ2.	  
Experiments	   performed	   in	   differentiated	   C2C12	   myotubes,	   analysed	   by	   real-­‐time	   PCR	   after	  
treatment	  with	  11-­‐dehydrocorticosterone	   (A)(250nm/16	  hours)	  alone	  or	   in	   combination	  with	   the	  
selective	  inhibitor	  of	  11β-­‐HSD1,	  LJ2	  (100nm).	  Data	  are	  expressed	  as	  the	  mean	  of	  n=4	  experiments,	  in	  
arbitrary	   units	   (AU)	   ±	   S.E.	   (Overall,	   P=0.003	   for	   MAFbx/Atrogin1	   and	   P=0.17	   for	   Myostatin;	  
**p<0.01	  vs.	  CTRL	  (control),	  §p<0.05	  vs.	  A).	  
	  
4.5.3.	   The	   impact	   of	   glucocorticoid	   treatment,	   GR	   blockade	   and	  
selective	  11β-­‐HSD1	  inhibition	  on	  HSD11B1	  gene	  expression	  
	  There	  was	  a	  trend	  towards	  up-­‐regulation	  of	  HSD11B1	  expression	  with	  treatment	  with	  A	   (250nm/16	  hours)	   (10.7±1.4	   vs.	   15.9±1.5AU,	  p=0.06)	   and	   co-­‐treatment	  with	   LJ2	   (100nm)	   resulted	   in	   reduced	   expression	   in	   comparison	   to	   A	   alone	  (15.9±1.5	  vs.	  8.2±2.1AU,	  p<0.05).	  
    HSD11B1 
	  
	  
Figure	  4-­‐4:	  mRNA	  expression	  of	   the	  HSD11B1	  gene	   in	  C2C12s	   following	  treatment	  with	  11-­‐
DHC(A)	  alone	  and	  with	  the	  selective	  inhibitor	  of	  11β-­‐HSD1,	  LJ2.	  Experiments	  were	  performed	  in	  
differentiated	   C2C12	   myotubes	   analysed	   by	   real-­‐time	   PCR	   following	   treatment	   with	   11-­‐
dehydrocortisone	   (A)(250nm/16	   hours)	   alone	   or	   in	   combination	   with	   LJ2	   (100nm);	   (n=4	  
experiments)	  §P<0.05	  vs.	  A,	  P=0.06	  CTRL	  vs.	  A,	  Overall	  P=0.06.	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4.5.4.	   Dose	   and	   time	   course	   relationships	   between	   active	  
glucocorticoid	   treatments	   (corticosterone)	   and	   HSD11B1	   and	  
MAFbx/Atrogin1	  gene	  expression	  	  
	  
	  Treatment	  with	  the	  active	  murine	  GC,	  corticosterone	  (B)(250nm)	  resulted	  in	  up-­‐regulation	  of	  HSD11B1	  and	  MAFbx/Atrogin1	  at	  48	  hours	  incubation	  (4.3	  ±	  1.2	  vs.	  56.1	  ±	  9.5AU,	  p<0.001	  and	  (3.4±0.4	  vs.	  157.2±54.4AU,	  p<0.01	  respectively)(see	  figure	  4-­‐5).	  At	  other	  time	  points	  there	  was	  a	  trend	  towards	  increasing	  expression	  of	  HSD11B1	  (Control	  vs.	  12h	  (4.3±1.2	  vs.	  9.8±1.9AU	  p=N/S,	  vs.	  24h,	  13.1±3.6AU,	  p=N/S)	  also	  seen	  with	  MAFbx/Atrogin	  (Control	  vs.	  B	  12h,	  3.4±0.4	  vs.	  4.8±1.3AU,	  p=N/S	  and	  vs.	  24h,	  19.7±9.5AU,	  p=N/S),	  that	  did	  not	  reach	  significance.	  	  	  
	  
Figure	   4-­‐5:	   Time	   Course	   Corticosterone	   (B,	   250nm):	   mRNA	   expression	   of	   HSD11B1	   and	  
MAFbx/Atrogin1	   in	   day	   8	   differentiated	   C2C12	   myotubes,	   is	   increased	   in	   response	   to	   48	   hours	  
incubation	   with	   B	   (250nm),	   earlier	   time	   points	   did	   not	   reach	   statistical	   significance.	   Data	   are	  
expressed	  as	   the	  mean	  and	   S.E.	   of	   n=4	   experiments.	   §§§P<0.001	   vs.	   CTRL,	   and	   **P<0.01	   vs.	   CTRL.	  
Overall	   P-­‐values	   P=0.0005	   for	   HSD11B1	   and	   P=0.0009	   for	   MAFbx/Atrogin1.	   CTRL	   =	   control,	   B=	  
Corticosterone.	  	  
	  MAFbx/Atrogin1	  expression	  was	  upregulated	  in	  a	  dose	  dependent	  manner	  with	  corticosterone	   (B)	   treatment	   over	   24	   hours,	   in	   C2C12	   differentiated	  myotubes	  (control	  vs.	  250nm,	  2.2±0.4	  vs.	  23.2±11.5AU,	  P<0.05;	  control	  vs.	  1μm,	  2.2±0.4	  vs.	  62.5±30.5AU	   P<0.01)(see	   figure	   4-­‐6).	   Although	   there	   was	   a	   trend	   towards	  increasing	   HSD11B1	   with	   increasing	   doses	   of	   B,	   this	   did	   not	   reach	   statistical	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significance	  (control	  vs.	  B	  250nm,	  5.5	  ±	  0.9	  vs.	  9.4	  ±	  3.5AU,	  p=N/S;	  control	  vs.	  B	  1μm,	  5.48	  ±	  0.9	  vs.	  21.5	  ±	  10.8AU,	  P=0.09).	  
	  
Figure	   4-­‐6:	   Dose	   Response	   Corticosterone	   (B,	   250nm):	   mRNA	   expression	   of	   HSD11B1	   and	  
MAFbx/Atrogin1	  in	  day	  8	  differentiated	  skeletal	  myotubes	  treated	  with	  B	  for	  24	  hours.	  There	  was	  a	  
trend	   towards	   increased	   expression	   of	  HSD11B1	  with	   increasing	  doses	   of	  B,	   however	   this	   did	   not	  
reach	   statistical	   significance	   (CTRL	  vs.	  B	  1μm	  P=0.09;	  Overall	   P=0.17).	  However	  MAFbx/Atrogin1	  
expression	   increased	   in	   a	   dose	   dependent	  manner	   (*P<0.05	   vs.	   CTRL;	   §§P<0.01	   vs.	   CTRL,	   Overall	  
P=0.001).	  CTRL	  =	  Control,	  B	  =	  corticosterone.	  
	  
	  
4.5.5.	   The	   impact	   of	   TNF-­‐α	   and	   synthetic	   glucocorticoid	  
(dexamethasone)	  treatments	  on	  HSD11B1	  and	  muscle	  atrophy	  gene	  
expression	  	  Potential	   age-­‐associated	   regulators	   of	   HSD11B1	  were	   investigated	   to	   establish	  whether	   they	   had	   an	   effect	   on	  muscle	   atrophy	   gene	   expression.	   In	   the	   first	   of	  these	   experiments	  TNF-­‐α	  was	   found	   to	  have	  no	   effect	   on	  HSD11B1	  expression	  alone,	  however	  it	  was	  found	  to	  have	  a	  synergistic	  effect	  with	  DEX	  (1μm/16	  hours	  incubation)	  (Control	  vs.	  DEX	  9.4±1.3	  vs.	  10.7±3.4AU	  p=N/S;	  Control	  vs.	  DEX+TNF	  9.4±1.3	  vs.	  24.6±8.2AU,	  p<0.05)	  (See	  table	  4-­‐1	  and	  figure	  4-­‐7a).	  DEX	  and	  TNF	  did	  not	  alter	  gene	  expression	  of	  other	  genes	   involved	   in	  muscle	  atrophy	  or	  protein	  synthesis,	  such	  as	  FOXO1,	  MuRF1,	  myostatin,	  myogenin	  and	  mTOR	  (see	  table	  4-­‐1).	   Dramatic	   up-­‐regulation	   of	   the	   known	   GC	   responsive	   gene,	   glutamine	  synthetase	  was	  observed	  in	  response	  to	  DEX	  alone	  and	  in	  combination	  with	  TNF-­‐α	  (Control	  vs.	  DEX	  4.6	  ±	  1.3	  vs.	  18.6	  ±	  1.9AU,	  p<0.0001;	  Control	  vs.	  DEX+TNF	  4.6	  ±	  1.3	  vs.	  15.2	  ±	  2.5AU	  p<0.0001)	  (see	  table	  4-­‐1	  and	  figure	  4-­‐7b).	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  9.3	  ±	  0.4	   	  10.6	  ±	  1.2	   	  9.4	  ±	  0.3	   	  9.3	  ±	  0.2	   	  P=0.71	  	  
Table	   4-­‐1:	   mRNA	   expression	   of	   genes	   involved	   in	   muscle	   metabolism,	   atrophy	   and	  
differentiation	  following	  treatment	  with	  DEX,	  TNF-­‐α	  alone	  and	  in	  combination.	  Experiments	  
were	  performed	   in	  differentiated	  C2C12	  myotubes,	  gene	  expression	  was	  measured	  using	  real-­‐time	  
PCR,	   following	   treatment	   with	   dexamethasone	   (DEX)(1μM/16	   hours),	   Tumour	   Necrosis	   Factor-­‐
alpha	  (TNF-­‐α)(10μg/mL).	  Data	  are	  expressed	  as	  mean	  delta	  CT	  values	  (±S.E)	  of	  n=7	  experiments.	  
Overall	  p-­‐value	  from	  one-­‐way	  anova	  is	  shown	  in	  the	  right	  column.	  	  	  
	  
Figure	   4-­‐7:	  mRNA	   expression	   of	   HSD11B1	   and	   gluatamine	   synthetase	   following	   DEX	   and	  
TNF-­‐α	   treatments	   in	   C2C12s.	   Experiments	   were	   performed	   in	   differentiated	   C2C12,	   following	  
treatment	   with	   dexamethasone	   (DEX)(1μM/16	   hours),	   Tumour	   Necrosis	   Factor-­‐alpha	   (TNF-­‐
α)(10μg/mL)	  alone	  or	  in	  combination;	  §P<0.05	  vs.	  control	  (CTRL);	  b)	  of	  the	  Glutamine	  Synthetase	  
gene,	  ****P<0.0001	  vs.	  CTRL	  and	  §§§§P<0.0001	  vs.	  TNF-­‐α.	  Expression	  was	  measured	  using	  real-­‐time	  
PCR,	  and	  data	  are	  expressed	  as	  mean	  values	  of	  n=7	  experiments	  in	  arbitrary	  units	  (AU)	  ±	  S.E.	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4.5.6.	   Impact	  of	   insulin	  and	  dexamethasone	  treatment	  on	  HSD11B1	  
and	  muscle	  atrophy	  gene	  expression	  	  GC	   exposure	   induces	   insulin	   resistance,	  which	   can	   be	   reduced	   by	   inhibition	   of	  11β-­‐HSD1	   (Morgan	   et	   al.,	   2009).	  Whether	   insulin	   signaling	   plays	   a	   role	   in	   the	  pathogenesis	   of	   GC	   and	   age-­‐associated	   muscle	   atrophy	   is	   of	   interest.	   In	   a	  preliminary	  experiment,	  differentiated	  C2C12	  myotubes	  were	  treated	  with	  high	  dose	  DEX	  (1μm/16	  hours)	  alone,	  and	   in	  combination	  with	   insulin	  (12nM).	  DEX	  increased	   expression	   of	   MAFbx/Atrogin1,	   whilst	   co-­‐treatment	   with	   insulin	  attenuated	   this	   change	   (Control	   vs.	  DEX	  4.51	  ±	  0.67	  vs.	  4.39	  ±	  0.56AU,	  p=N/S)	  (see	   table	   4-­‐2).	   No	   increase	   in	   HSD11B1	   expression	   was	   seen	   with	   DEX	  treatment	   at	   16	   hours,	   however	   co-­‐treatment	   with	   insulin	   down-­‐regulated	  expression.	  Other	  genes	  involved	  in	  protein	  synthesis	  and	  muscle	  atrophy	  were	  unchanged	  (see	  table	  4-­‐2).	  	  
	  
	   	  
































	  5.2	  ±	  0.4	   	  5.1	  ±	  0.4	   	  5.9	  ±	  0.3	   	  P=0.23	  
	  
Table	   4-­‐2:	   mRNA	   expression	   of	   genes	   involved	   in	   muscle	   atrophy	   and	   differentiation	  
measured	   using	   Real-­‐time	   PCR,	   following	   treatment	   with	   DEX	   and	   Insulin	   alone	   and	   in	  
combination.	   Experiments	   were	   performed	   using	   differentiated	   C2C12	   myotubes	   with	   gene	  
expression	  measured	  using	  real-­‐time	  PCR.	  Treatments:	  dexamethasone	   (DEX)(1μM/24	  hours)	  and	  
Insulin	  (12nM)	  alone	  and	  in	  combination.	  Data	  are	  expressed	  as	  mean	  delta	  CT	  values	  (±S.E)	  of	  n=7	  
experiments.	  Overall	  P-­‐values	  from	  one-­‐way	  anova	  test	  are	  shown	  in	  right	  column.	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4.6.	  Discussion	  	  This	  chapter	  outlines	  novel	  data	  on	  the	  effects	  of	  selective	  11β-­‐HSD1	  inhibitors	  on	   skeletal	  muscle	   atrophy	   pathways.	   11β-­‐HSD1	   is	   expressed	   and	   functionally	  active	  in	  skeletal	  muscle	  and	  although	  previous	  work	  has	  focused	  largely	  on	  its	  metabolic	   effects	   there	   is	   evidence	   for	   a	   role	   in	   regulation	   of	   the	   ubiquitin	  proteosome	   system	   (Whorwood	   et	   al.,	   2001,	   Jang	   et	   al.,	   2006,	   Morgan	   et	   al.,	  2009,	   Biedasek	   et	   al.,	   2011).	   Furthermore,	   the	   results	   reported	   in	   this	   chapter	  add	  to	  this,	  by	  examining	  the	  effects	  of	  pre-­‐receptor	  GC	  regulation	  on	  expression	  of	  targets	  including	  myostatin,	  FOXOs	  and	  myogenin.	  Finally,	  the	  effects	  of	  TNF-­‐α	  and	   insulin,	   which	   are	   known	   regulators	   of	   11β-­‐HSD1,	   on	   key	   genes	   involved	  protein	  synthesis	  and	  degradation	  was	  assessed.	  	  	  	  	  
	  In	   keeping	   with	   previous	   studies,	   we	   have	   shown	   that	   MAFbx/Atrogin1	   and	  myostatin	   gene	   expression	   are	   upregulated	   in	   response	   to	   high	   dose	   synthetic	  GC.	   The	   muscle	   specific	   ubiquitin	   ligase,	   MAFbx/Atrogin1	   is	   central	   to	   the	  common	  gene	  programme	  that	  characterizes	  skeletal	  muscle	  atrophy	  caused	  by	  range	   of	   aetiologies	   (Lecker	   et	   al.,	   2004).	   Studies	   of	   skeletal	   myotubes	   and	  animal	  models	  have	  shown	  that	  GCs	  regulate	  myostatin	  gene	  transcription	  via	  a	  GR	   dependent	   mechanism	   (Ma	   et	   al.,	   2001,	   Ma	   et	   al.,	   2003).	   Furthermore,	   a	  transgenic	   model	   revealed	   that	   myostatin	   was	   required	   for	   development	   of	  dexamethasone	   induced	  muscle	  atrophy	   (Gilson	  et	   al.,	   2007).	   	  We	  showed	   that	  dexamethasone	   induced	   changes	   were	   attenuated	   by	   treatment	   with	   RU486,	  consistent	   with	   a	   GR	   dependent	   pathway.	   FOXO	   mRNA	   expression	   did	   not	  change	  with	  dexamethasone	  treatment	  and	  it	  is	  possible	  that	  this	  is	  due	  to	  post-­‐translational	   regulation.	   Myogenin	   mRNA	   expression	   was	   also	   unaffected,	   in	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contrast	   to	   a	   previous	   report,	   which	   also	   used	   day	   8	   differentiated	   C2C12	  myotubes	  (Nishimura	  et	  al.,	  2008),	  the	  reason	  for	  this	  is	  unclear.	  	  We	  also	  showed	  that	  pre-­‐receptor	  GC	  regulation	  plays	  a	  role	  in	  proteolysis	  with	  the	   observation	   that	   MAFbx/Atrogin1	   expression	   is	   increased	   in	   response	   to	  treatment	   with	   the	   inactive	   murine	   GC,	   11-­‐dehydrocorticosterone	   (A).	   This	   is	  consistent	  with	   reports	   from	  previous	  studies	   (Biedasek	  et	  al.,	  2011),	   although	  the	   observation	   that	   treatment	  with	   a	   selective	   11β-­‐HSD1	   inhibitor	   attenuates	  this	   change	   is	   novel.	   This	   is	   an	   important	   finding	   as	   it	   confirms	   that	   the	  attenuation	   of	   protein	   degradation	   seen	   in	   response	   to	   the	   non-­‐selective	   11β-­‐HSD,	  carbenoxolone	  is	  due	  to	  a	  specific	  effect	  on	  the	  type	  1	  isozyme	  (Biedasek	  et	  al.,	  2011).	  It	  is	  possible	  that	  this	  study	  was	  underpowered	  to	  detect	  more	  subtle	  changes	   in	  MuRF1	  and	  myostatin	   in	  response	  to	  A	  and	  that	  regulation	  of	  FOXO	  may	  be	  post-­‐translational.	  	  Our	  studies	  of	  GC	  regulation	  of	  HSD11B1	  revealed	  that	  expression	  was	  increased	  with	  48	  hours	  exposure	  to	  the	  active	  murine	  GC,	  corticosterone	  (B)	  at	  a	  dose	  of	  250nm.	   	   There	   was	   a	   trend	   towards	   a	   dose	   dependent	   relationship	   between	  HSD11B1	   expression	   and	   B	   treatment	   that	   did	   not	   reach	   significance	   (P=0.09,	  1μm/24	  hour	  incubation).	  Dose	  dependent	  upregulation	  of	  HSD11B1	  mRNA	  and	  oxo-­‐reductase	   activity,	   was	   described	   in	   the	   paper	   that	   first	   characterized	   its	  expression	   and	   function	   in	   skeletal	   muscle	   (Whorwood	   et	   al.,	   2001).	  Furthermore,	  we	  report	  a	  trend	  towards	  increased	  HSD11B1	  expression	  with	  the	  inactive	  murine	  GC	  11-­‐dehydrocorticosterone	  (A),	  and	  a	  significant	  reduction	  in	  expression	  with	  treatment	  with	  the	  selective	  inhibitor	  of	  11β-­‐HSD1,	  LJ2.	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TNF-­‐α	  has	  been	  shown	  to	  increase	  HSD11B1	  expression	  in	  a	  range	  of	  tissues	  and	  cell	   lines	   including	   rat	   glomerular	   cells,	   MG63	   osteosarcoma	   cells,	   human	  preadipocytes	  and	  adipocytes,	  osteoblasts,	   aortic	  and	  bronchial	   smooth	  muscle	  cells	  (Tomlinson	  et	  al.,	  2004).	  We	  have	  demonstrated	  that	  although	  they	  have	  no	  effect	   in	   isolation,	   dexamethasone	   and	   TNF-­‐α,	   have	   a	   synergistic	   effect	   on	  increasing	  HSD11B1	   expression	   in	   skeletal	  myotubes,	  which	   is	   consistent	  with	  previous	   reports	   in	   synovial	   fibroblasts,	   primary	   osteoblasts	   and	  undifferentiated	  C2C12	  myoblasts	  (Cooper	  and	  Stewart,	  2009,	  Kaur	  et	  al.,	  2010,	  Ahasan	  et	  al.,	  2012).	  It	  should	  be	  noted	  that	  the	  TNF-­‐α	  dose	  used	  (10μg/mL)	  is	  supraphysiological,	   so	   observing	   the	   effects	   of	   lower	   doses	   may	   be	   a	   more	  accurate	  model	   of	   ageing.	   These	   observations	   potentially	   implicate	   local	   tissue	  GC	  generation	  in	  scenarios	  characterized	  by	  increased	  TNF-­‐α	  levels,	  such	  as	  the	  increased	   muscle	   atrophy	   seen	   in	   the	   GC	   treated	   elderly	   or	   those	   with	  inflammatory	   disease	   (Dardevet	   et	   al.,	   1995,	   Touno	   et	   al.,	   1996,	   Seene	   and	  Kaasik,	  2012).	   In	   these	   scenarios,	   it	   is	  possible	   that	  TNF-­‐α	  may	  be	   secreted	  by	  immune	  cells	  to	  increase	  systemic	  levels,	  and	  locally	  by	  immune	  infiltration	  and	  myofibre	  response	  to	  tissue	  damage	  (Collins	  and	  Grounds,	  2001).	  	  Our	   initial	   data	   showing	   that	   HSD11B1	   and	   MAFbx/Atrogin1	   expression	   are	  suppressed	   in	   response	   to	   insulin,	   is	   consistent	   with	   its	   known	   pro-­‐anabolic	  effects	  (Workeneh	  and	  Bajaj,	  2013a).	  Previous	  studies	  have	  examined	  the	  role	  of	  11β-­‐HSD1	   in	   insulin	   resistance	   but	   have	   focused	   on	   metabolic	   effects.	   These	  studies	  have	  shown	  evidence	  of	  increased	  skeletal	  muscle	  11β-­‐HSD1	  expression	  in	   skeletal	   muscle	   from	   a	   rat	   model	   of	   diabetes	   (Zhang	   et	   al.,	   2009),	   and	   in	  myotubes	   isolated	   from	   diabetics	   (Abdallah	   et	   al.,	   2005).	   However	   another	  human	   study	   did	   not	   support	   these	   findings	   (Jang	   et	   al.,	   2007).	   Our	   group	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uncovered	  phosphorylation	  of	  serine	  residue	  307	  of	  IRS1	  as	  a	  mechanism	  of	  GC	  induced	  insulin	  resistance,	  and	  demonstrated	  attenuation	  of	  this	  effect	  with	  the	  use	  of	  a	  selective	  11β-­‐HSD1	   inhibitor	   (Morgan	  et	  al.,	  2009).	  Other	  groups	  have	  confirmed	   the	   insulin	   sensitizing	   effects	   of	   11β-­‐HSD1	   on	   skeletal	   muscle	   with	  regards	  glucose	  uptake,	  but	  no	  previous	  investigations	  have	  been	  made	  on	  genes	  involved	  in	  anabolic/catabolic	  pathways	  (Abdallah	  et	  al.,	  2005,	  Salehzadeh	  et	  al.,	  2009).	   Whether	   insulin	   resistance,	   induced	   by	   GCs,	   or	   pro-­‐inflammatory	  cytokines	  plays	  a	  role	  in	  the	  sarcopenia	  of	  ageing	  remains	  to	  be	  seen	  (Katsuki	  et	  al.,	  1998).	  	  In	  summary	  the	  main	  contribution	  of	   this	  chapter	   is	   to	  provide	  evidence	  of	   the	  role	   of	   modulation	   of	   11β-­‐HSD1	   in	   skeletal	   muscle	   atrophy,	   via	   selective	  inhibition	  on	   the	  key	  ubiquitin	  proteasome	  system	  mediator,	  MAFbx/Atrogin1.	  This	   is	   of	   potential	   translational	   importance,	   as	   it	   opens	   up	   a	   new	   potential	  therapeutic	  application	   in	  muscle	  atrophy	   for	   selective	   inhibitors	  of	  11β-­‐HSD1,	  that	   have	   been	   developed	   by	   industry	   for	   the	   treatment	   of	   diabetes,	   which	   to	  date	   they	   have	   had	   only	   modest	   success.	   Muscle	   atrophy	   secondary	   to	   side	  effects	   of	   therapeutic	   GCs,	   skeletal	   muscle	   ageing,	   and	   aetiologies	   where	   GCs	  have	  been	  found	  to	  play	  a	  role	  (sepsis	  and	  metabolic	  acidosis)	  are	  obvious	  initial	  targets	   (Tiao	  et	  al.,	  1996b,	  Smith	  et	  al.,	  2010,	  May	  et	  al.,	  1986).	  Other	  potential	  areas	   for	   further	   investigation	   include	   as	   a	   medical	   therapy	   for	   Cushing’s	  Syndrome,	  where	  current	  treatments	  are	   limited	  (Tritos	  and	  Biller,	  2012).	  This	  study	  provides	  a	  background	  to	  the	  novel	  and	  detailed	  in-­‐vivo	  studies	  examining	  the	  impact	  of	  11β-­‐HSD1	  global	  gene	  knockout	  on	  age-­‐associated	  skeletal	  muscle	  atrophy,	  and	  the	  cross-­‐sectional	  study	  of	  human	  ageing	  presented	  in	  subsequent	  chapters.	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5.1	  Introduction	  
	  Cushing’s	   syndrome	   is	   characterised	   by	   an	   adverse	   body	   composition	   profile,	  consisting	  of	  visceral	  obesity,	  hepatic	  steatosis,	  muscle	  atrophy	  and	  osteoporosis,	  along	  with	   development	   of	   hypertension,	   insulin	   resistance,	   dyslipidaemia	   and	  excess	   cardiovascular	   disease	   risk.	   Conversion	   of	   cortisone	   in	   humans,	   and	  11dehydrocorticosterone	   (11DHC),	   in	   mice	   to	   their	   active	   11-­‐hydroxylated	  forms	  (cortisol	  and	  corticosterone,	  respectively)	  by	  the	  oxo-­‐reductase	  activity	  of	  11β-­‐HSD1,	   results	   in	   amplification	   of	   GC	   action	   at	   the	   local	   tissue	   level.	   Pre-­‐receptor	  GC	  metabolism	  has	  been	  shown	  to	  play	  a	  role	  in	  obesity	  and	  metabolic	  disease	   (Gathercole	   et	   al.,	   2013).	   To	   date,	   animal	  models	   have	   shown	   that	   the	  global	   11β-­‐HSD1	   KO	   is	   associated	   with	   a	   beneficial	   metabolic	   phenotype,	  characterised	   by	   reduced	   visceral	   adiposity,	   hepatic	   steatosis,	   and	   improved	  glucose	  tolerance,	  insulin	  sensitivity,	  and	  lipid	  profile	  (Kotelevtsev	  et	  al.,	  1997).	  Conversely,	  overexpression	  of	  11β-­‐HSD1	  in	  adipose	  tissue	  of	  transgenic	  mice	  has	  adverse	  metabolic	  effects	  (Masuzaki	  et	  al.,	  2001,	  Masuzaki	  et	  al.,	  2003).	  Absence	  of	   11β-­‐HSD1	   also	   has	   beneficial	   effects	   on	   age-­‐related	   features	   including	   skin	  structure	   (Tiganescu	   et	   al.,	   2013)	   and	   wound	   healing,	   and	   cognitive	   function	  (Yau	   et	   al.,	   2007).	   11β-­‐HSD1	   is	   expressed	   and	   functionally	   active	   in	   skeletal	  muscle,	   however	   to	   date,	   most	   published	   work	   has	   focused	   on	   its	   effects	   on	  metabolic	   parameters	   and	   not	   muscle	   contractile	   function	   (Jang	   et	   al.,	   2006,	  Morgan	   et	   al.,	   2009).	   A	   recent	   cell	   culture	   study	   has	   examined	   effects	   of	   non-­‐selective	   11β-­‐HSD1	   inhibition	   on	   expression	   of	   proteolytic	   genes	   including	  MAFbx/Atrogin1	  and	  MuRF1,	  however	  to	  date	  no	  published	  work	  has	  examined	  the	  effects	  in	  vivo	  (Biedasek	  et	  al.,	  2011).	  Sarcopenia	  appears	  to	  be	  determined	  by	   a	   complex	   network	   of	   signaling	   pathways,	   with	   mechanisms	   including	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reduced	  anabolic	  hormones,	   insulin	  resistance,	  chronic	   inflammation,	  nutrition,	  disuse,	  denervation,	  satellite	  cell	  function	  and	  oxidative	  stress	  potentially	  driving	  the	   condition	   (See	   table	  1-­‐7),	  underlying	   the	  need	   for	   in-­‐vivo	   studies.	  Whether	  local	   tissue	  regeneration	  contributes	   to	  age-­‐associated	  sarcopenia	   is	  a	  question	  of	   great	   importance,	   as	   this	   condition	   has	   no	   effective	   treatment	   and	   would	  provide	   a	   potential	   therapeutic	   target,	   for	   recently	   developed	   selective	   11β-­‐HSD1	  inhibitors.	  By	  outlining	  the	  clinical	  importance	  of	  GC	  excess	  on	  factors	  such	  as	  body	  mass	  and	  mortality,	  and	  detailing	  evidence	  of	  modulation	  of	  proteolytic	  gene	  expression	  by	  selective	  11β-­‐HSD1	  inhibitors,	  in	  vitro,	  the	  previous	  chapters	  in	  this	  thesis	  have	  set	  the	  scene	  for	  a	  detailed	  in	  vivo	  assessment	  of	  the	  impact	  of	  11β-­‐HSD1	  gene	  deletion	  on	  GC-­‐	  and	  age-­‐induced	  myopathy.	  	  	  	  
5.2	  Hypotheses	  Our	   central	   hypothesis	   is	   that	   local	   tissue	   GC	   generation	   contributes	   to	   age-­‐associated	   myopathy,	   resulting	   in	   activation	   of	   a	   GC-­‐regulated	   gene	   atrophy	  programme.	   	  Furthermore,	  absence	  of	  11β-­‐HSD1	  results	  in	  attenuation	  of	  these	  gene	   expression	   changes	  with	   resulting	   protection	   from	  muscle	  weakness	   and	  atrophy.	  	  
	  
	  
5.3	  Research	  Strategy	  and	  Aims	  
	  In	   this	   chapter,	   animal	  models	  developed	   in-­‐house	   (global	  11βHSD1	  knock	  out	  mice:	  GC-­‐excess	  and	  aged	  colonies),	  are	  utilized	  to	  probe	  our	  hypothesis.	  Firstly	  the	   phenotypes	   of	   young	   and	   old	   WT	   and	   11β-­‐HSD1	   KO	   C57BL/6	   mice	   were	  characterized	  with	   glucose	  metabolism,	  muscle	   strength	   and	   tissue	  weights.	   A	  targeted	  microfluidic	  gene	  expression	  array	  was	  performed	  to	  provide	  an	  insight	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into	   the	   pathways	   that	   are	  most	   robustly	   regulated	   by	   age	   and	  modulation	   of	  pre-­‐receptor	   GC	   metabolism.	   Subsequently	   these	   targets	   were	   assessed	   in	  muscle	  samples	  from	  WT	  and	  11β-­‐HSD1	  KO	  C57BL/6	  mice	  that	  had	  been	  treated	  with	   active	   and	   inactive	   GCs	   in	   drinking	   water,	   and	   had	   undergone	   similar	  phenotyping.	   The	   purpose	   of	   this	  was	   to	   identify	  whether	  myopathy	   of	   ageing	  and	  GC-­‐excess	  share	  common	  gene	  expression	  changes.	  	  	  
	  
5.4	  Materials	  and	  Methods	  
	  
5.4.1.	  Animal	  Protocols	  
	  
General:	   Procedures	   were	   performed	   in	   line	   with	   the	   UK	   Animals	   (Scientific	  Procedures)	  Act,	  1986.	  These	  experiments	  were	  carried	  out	  in	  collaboration	  with	  Dr	   Stuart	  Morgan	  who	   took	   a	   central	   role	   in	  managing	   the	   colony.	  Mice	  were	  housed	   in	   standard	   conditions	  with	   a	   12h:12h	   light-­‐dark	   cycle.	   The	   11β-­‐HSD1	  KO	  mouse	  was	  generated	  in-­‐house	  by	  Dr	  Gareth	  Lavery	  as	  described	  previously	  (Semjonous	  et	  al.,	  2011).	  
	  
Ageing	  Model:	  Young	  (≈12	  weeks	  of	  age)	  and	  old	  (22-­‐24	  months)	  C57BL/6	  mice	  on	  high	  fat	  diet	  (58%	  kcal	  fat	  -­‐	  Research	  Diets	  –	  D12331)	  with	  ad	  libitum	  access	  to	  water	  were	  compared.	  	  High	  fat	  diet	  was	  originally	  chosen	  in	  order	  to	  ‘stress’	  the	  potential	  metabolic	  phenotype	  of	  the	  animals.	  	  
Muscle	   Phenotyping:	   Grip-­‐strength	   was	   assessed	   using	   a	   digital	   grip-­‐strength	  meter	  (Linton	  Instrumentation,	  Norfolk,	  UK).	  This	  allows	  measurement	  of	  peak	  grip	   strength,	   whereby	   animals	   are	   suspended	   by	   the	   base	   of	   the	   tail,	   whilst	  grasping	  a	  metal	  grid.	  Each	  mouse	  underwent	  4	   repeat	   readings	  before	   results	  were	  averaged	  and	  normalised	  to	  body	  weight.	  Animals	  were	  culled	  by	  cervical	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dislocation	  and	   tissues	  dissected	  out,	  muscles	  were	  weighed	  before	  being	  snap	  frozen	  in	  liquid	  nitrogen.	  	  
Measurement	   of	   serum	   corticosterone	   levels:	   This	   was	   analysed	   using	   an	  immunoassay	  kit	  (Cambridge	  Biosciences,	  Cambridge,	  UK).	  	  
Glucose	   Tolerance	   Testing:	   Insulin	   resistance	   is	   known	   to	   contribute	   to	  dysregulation	   of	   muscle	   protein	   metabolism.	   The	   impact	   of	   study	  group/genotype	   on	   glucose	   metabolism	   was	   quantified	   by	   glucose	   tolerance	  testing.	   This	  was	  performed	  by	   fasting	  mice	  5	  hours	  before	  blood	   glucose	  was	  assessed	  from	  tail	  vein	  nicks	  at	  using	  a	  glucometer	  at	  0,	  15,	  30,	  60,	  90	  and	  120	  minutes	  following	  intraperitoneal	  glucose	  injection	  (2	  g/kg).	  A	  blood	  sample	  was	  taken	  from	  tail	  vein	  nicks	  at	  baseline	  for	  analysis	  using	  the	  Ultra	  Sensitive	  Mouse	  Insulin	  ELISA	  kit	  (Crystal	  Chem,	  Inc.,	  Downers	  Grove,	  IL).	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5.4.2.	  Urine	  Steroid	  Analysis	  by	  Gas	  Chromatography/Mass	  
Spectrometry	  
	  Beverley	   Hughes	   carried	   this	   out	   in-­‐house	   using	   a	  well-­‐established	  method	   as	  previously	  described	  (Shackleton,	  1993,	  Lavery	  et	  al.,	  2006).	  Urine	  was	  collected	  from	   young	   and	   old	   mice	   on	   to	   filter	   paper	   from	   5	   animals	   from	   each	  experimental	  group.	  A	  Hewlett	  Packard	  5970	  mass	  spectometer	  and	  15m	  fused	  silica	   capillary	   column,	   0.25mmID,	   0.25μm	   film	   thickness	   (J	   and	   B	   Scientific,	  Folsom,	  CA,	  US)	  was	  used.	  Metabolites	  were	   identified	  according	   to	   their	  mass	  spectra,	   and	   quantified	   relative	   to	   peak	   areas	   of	   internal	   standards.	   Data	   are	  expressed	  as	  %	  of	  metabolites	  of	  11DHC	  (containing	  an	  11-­‐oxo	  group)	  with	  the	  remainder	  being	  metabolites	  of	  CORT	  (containing	  an	  11-­‐hydroxyl	  group).	  For	  a	  full	  description	  see	  general	  methods	  section.	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5.5.	  Results	  
	  




5.5.1.1.	   Urinary	   GC/MS	   characterization	   of	   corticosteroid	   metabolites	  
across	  age	  in	  11β-­‐HSD1	  knockout	  and	  wildtype	  mice	  	  
	  The	   percentage	   of	   urinary	   corticosteroids	   that	   were	   metabolites	   of	   11-­‐dehydrocorticosterone	  (11DHC	  or	  A)	  on	  GC/MS	  analysis	  was	  used	  as	  a	  surrogate	  measure	  of	  global	  11β-­‐HSD1	  activity	  in	  vivo.	  Young	  and	  old	  11β-­‐HSD1	  KO	  mice	  had	  increased	  %A	  metabolites	  compared	  to	  age-­‐matched	  WT	  mice	  (Young	  11β-­‐HSD1	  KO:	  24.2	  ±	  1.5%	  vs.	  Young	  WT:	  8.0	  ±	  1.1%,	  p<0.01	  and	  Old	  11β-­‐HSD1	  KO:	  25.0	  ±	  5.3%	  vs.	  Old	  WT:	  5.4	  ±	  0.4%,	  p<0.01	  respectively),	  consistent	  with	  lack	  of	  11β-­‐HSD1	   activity	   (Figure	   5-­‐1).	   Aged	   WT	   mice	   had	   reduced	   %A	   metabolites	  compared	  to	  young	  controls.	  
	  
	  
Figure	  5-­‐1:	  Urinary	  steroid	  analysis	  confirmed	  increased	  %	  of	  corticosteroids	  as	  metabolites	  
of	   A	   in	   both	   young	   and	   old	   11β-­‐HSD1	   KO	   C57BL/6	   mice	   compared	   to	   age-­‐matched	   WT	  
controls,	   (n=8).	  Mean	   and	   S.E.	   are	   shown.	   A	   =	   11-­‐dehydrocorticosterone	   (11DHC).	   **P<0.01	   and	  
*P<0.05	   vs.	   young	  WT;	   §§p<0.01	   vs.	   old	  WT	   (n=6-­‐7	   per	   group).	  WT	   =	   wildtype,	   KO	   =	   11β-­‐HSD1	  
knockout	  mice.	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5.5.1.2.	   Characterisation	   of	   serum	   corticosterone	   and	   adrenal	   gland	  
weights	  across	  age	  in	  11β-­‐HSD1	  knockout	  and	  wildtype	  mice:	  	  
	  Morning	   serum	   corticosterone	   levels	   were	   increased	   in	   11β-­‐HSD1	   KO	   mice	  compared	   to	   age	  matched	   controls,	   and	   levels	  were	   increased	  with	   age	   in	  WT	  mice.	  Adrenal	  gland	  weights	  of	  young	  and	  old	  11β-­‐HSD1	  KO	  mice	  were	  increased	  compared	   to	   age	   matched	   WT	   controls	   (Figure	   5-­‐2).	   This	   is	   indicative	   of	  compensatory	   HPA-­‐axis	   activation	   in	   the	   11β-­‐HSD1	   KO	   mice.	   There	   were	   no	  differences	  with	  age	  between	  WT	  or	  11β-­‐HSD1	  KO	  mice.	  	  	  
	  
Figure	  5-­‐2:	  Serum	  morning	  CORTs	  and	  adrenal	  tissue	  weights	  in	  WT	  and	  11β-­‐HSD1	  KO	  mice.	  
A)	   Serum	   Corticosterone	   measured	   in	   the	   morning	   was	   increased	   in	   old	   11β-­‐HSD1	   KO	   mice	  
compared	   to	   aged-­‐matched	   WT	   mice.	   Serum	   corticosterone	   was	   increased	   in	   Aged	   WT	   mice	  
compared	  to	  young	  WT	  mice.	  *P<0.05	  compared	  to	  aged	  matched	  WT	  mice,	  §§P<0.01	  compared	  to	  
young	  WT	  mice.	  B)	  Adrenal	  tissue	  weights	  were	  increased	  in	  young	  and	  old	  11β-­‐HSD1	  KO	  mice	  on	  
C57BL/6	  background	  compared	   to	  age-­‐matched	  wildtype	  control	  mice.	  Mean	  and	  S.E.	  are	   shown.	  
*P<0.05	  compared	  to	  age-­‐matched	  control	  group	  (n=6	  per	  group).	  WT	  =	  wildtype,	  KO	  =	  11β-­‐HSD1	  
knockout	  mice.	  	  
	  
	  
5.5.1.3. Skeletal	  muscle	  gene	  expression	  array	  analysis	  of	  wildtype	  and	  
11β-­‐HSD1	  knockout	  mice	  across	  age	  	  
	  mRNA	   expression	   of	   88	   target	   genes	   in	   skeletal	   muscle	   (quadriceps)	   was	  analysed	  in	  a	  gene	  expression	  array	  using	  a	  microfluidic	  chip	  (Table	  5.1i	  and	  ii).	  Central	  focus	  was	  placed	  on	  identifying	  genes	  that	  were	  differentially	  regulated	  with	  age,	  and	  were	  modulated	  by	  11β-­‐HSD1	  background.	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 Gene Expression (AU ± S.E.)  
 
 
Young Old  
Gene WT KO WT KO 
Overall 
P-value 
mTOR 415 ± 62 292 ± 30 426 ± 43 307 ± 45 0.12 
DDIT 26 ± 4 19 ± 4 21 ± 3 20 ± 2 0.41 
p300 141 ± 15 115 ± 13 141 ± 21 120 ± 13 0.56 
GSK3β 788 ± 100 772 ± 101 1190 ± 92 818 ± 132 0.06 
MAFbx/ 
Atrogin1 1510 ± 181  1243 ± 163 2585 ± 642 1489 ± 173 0.03 
MuRF1 978 ± 87 892 ± 96 1684 ± 148§§ 898 ± 46ΦΦ 0.0002 
Cathepsin-L 520 ± 45 339 ± 32 457 ± 112 438 ± 42 0.10 
Calpain-1 422 ± 26 351 ± 24 385 ± 62 297 ± 31 0.046 
Calpain-2 317 ± 35 217 ± 19 357 ± 37 267 ± 28 0.02 
GADD45a 360 ± 36 332 ± 52 1208 ± 157§§§§ 756 ± 57Φ 
<0.000
1 
USP19 1189 ± 122 829 ± 102 1339 ± 172 985 ± 74 0.03 
ATF-4 785 ± 77 561 ± 64 812 ± 113 658 ± 82 0.16 
Caspase-3 1.2 ± 0.3 1.1 ± 0.2 0.5 ± 0.1 1.0 ± 0.2  0.31 
eiF4bp 649 ± 87 508 ± 41 1059 ± 127§ 834 ± 102 0.003 
eiF4e 75 ± 13 52 ± 6 72 ± 13 61 ± 11 0.64 
FOXO1 170 ± 20 141 ± 13 192 ± 16 162 ± 18 0.27 
FOXO3a 307 ± 37 236 ± 17 370 ± 51 327 ± 30 0.046 
MYH1 16617 ± 4446 7408 ± 1491 15376 ± 3470 12058 ± 2070 0.10 
MYH2 5462 ± 1283 2183 ± 894 1223 ± 632 1684 ± 625 0.08 
MYH4 260226 ± 21327 249550 ± 28280 345095 ± 80764 266677 ± 24652 0.71 
PSMA2 497 ± 43 376 ± 44 576 ± 66 499 ± 39 0.03 
PSMD1 1256 ± 132 1035 ± 107 1578 ± 181 1146 ± 104 0.06 
PSMD2 2022 ± 161 1481 ± 144 2551 ± 222 1968 ± 166 0.005 
PSMD3 515 ± 46 384 ± 37 627 ± 61 464 ± 28 0.01 
PSMD4 320 ± 24 241 ± 22 368 ± 32 254 ± 24 0.007 
PSMD11 2241 ± 252 1957 ± 213 3469 ± 302§ 2450 ± 304 0.008 
PSMD6 977 ± 65 764 ± 87 1095 ± 133 830 ± 79 0.06 
PSMD7 1460 ± 133 1183 ± 125 1928 ± 267 1525 ± 97 0.03 
PSMD12 937 ± 84 735 ± 66 1181 ± 149 994 ± 90 0.03 
PSMC1 78 ± 11 53 ± 7 85 ± 10 67 ± 9 0.08 
PSMC2 1967 ± 204 1503 ± 180 2431 ± 303 1626 ± 239 0.046 
PSMC4 319 ± 27 242 ± 27 383 ± 28 327 ± 26 0.01 
PSMC5 1294 ± 132 947 ± 100 1577 ± 217 1305 ± 144 0.04 
PSMC6 796 ± 65 651 ± 65 948 ± 115 780 ± 58 0.08 
S6K1 146 ± 16 109 ± 12 153 ± 31 112 ± 14 0.25 
SIRT1 103 ± 13 73 ± 9 118 ± 16 94 ± 8 0.09 
SIRT3 94 ± 13 58 ± 7 84 ± 12 73 ± 11 0.11 
WRN 57 ± 22 38 ± 4 59 ± 9 41 ± 4 0.09 
Myostatin 716 ± 67 753 ± 138 1610 ± 250§§ 731 ± 60ΦΦ 0.0009 
SMAD2 82 ± 10 56 ± 4 74 ± 10 67 ± 6 0.13 
SMAD3 55 ± 5 51 ± 4 53 ± 6 47 ± 3 0.73 
SMAD4 1006 ± 112 842 ± 72 803 ± 172 504 ± 66 0.002 
SMAD7 16 ± 3 11 ± 1 21 ± 4 18 ± 2 0.09 
ACVR2b 166 ± 9 142 ± 11 119 ± 22 114 ± 10 0.03 
Calveolin3 239 ± 23 180 ± 20 148 ± 27§ 115 ± 16 0.0007 
	  
Table	  5.1i:	  Skeletal	  muscle	  gene	  expression	  profile	  in	  young	  and	  old	  WT	  and	  11β-­‐HSD1	  KO	  
mice.	  Overall	  P-­‐value	  from	  1-­‐way	  ANOVA	  is	  shown.	  Full	  details	  in	  Table	  5.1ii	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Table	  5.1ii:	  Skeletal	  muscle	  (quadriceps)	  gene	  expression	  in	  WT	  and	  11β-­‐HSD1KO	  C57BL/6	  
mice	   across	   age.	   Analysed	   by	   Fluidigm	   dynamic	   array.	   MuRF1,	   GADD45a,	   eif4bp,	   PSMD11,	  
myostatin,	   NCAM1,	   and	   CHARNB	   were	   upregulated	   with	   age	   in	   WT	   mice.	   Calveolin3	   was	  
downregulated	  with	  age	   in	  WT	  mice.	  Age	  associated	  changes	   in	  MuRF1,	  GADD45a	  and	  myostatin	  
were	   attenuated	   with	   11β-­‐HSD1	   KO.	   Data	   expressed	   as	   A.U.	   with	   means	   and	   S.E.s.	   *P<0.05,	  
****p<0.0001	  vs.	  young	  WT,	  §p<0.05,	  §§p<0.01,	  §§§p<0.001,	  §§§§p<0.0001	  vs.	  young	  WT,	  Φp<0.05,	  
 Gene Expression (AU ± S.E.)  
 Young Old  
Gene WT KO WT KO 
Overall 
P-value 
RelA 127 ± 19 88 ± 9 152 ± 16 131 ± 14 0.07 
Rely 3.3 ± 0.3  2.8 ± 0.4 4.4 ± 0.4 3.2 ± 0.5 0.047 
TNF-α 3.5 ± 0.9 3.0 ± 0.4 4.3 ± 0.8 5.1 ± 0.6 0.24 
IL-6 3.2 ± 0.5 2.7 ± 0.6 3.3 ± 0.3 7.3 ± 2.9 0.52 
IL-1β 0.6 ± 0.2 0.3 ± 0.1* 1.4 ± 0.6 1.9 ± 0.6 0.01 
Galactin1 6925 ± 1042 5106 ± 775 9024 ± 916 8951 ± 896 0.01 
NF-κB1 225 ± 24 161 ±18 279 ± 35 265 ± 30 0.016 
NF-κB2 44 ± 6 32 ± 4 74 ± 11 60 ± 9 0.003 
MIPEP 611 ± 80 501 ± 53 568 ± 86 504 ± 41 0.73 
ACOX1 1124 ± 173 745 ± 85 1137 ± 154 1077 ± 90 0.11 
ATP8 877704 ± 157651 764282 ± 94044 1036283 ± 144736 763812 ± 147177 0.51 
ATP5f1 171 ± 17 153 ± 12 138 ± 27 91 ± 13 0.005 
ATP5h 4410 ± 706 2954 ± 481 3695 ± 528 2606 ± 373 0.10 
ATP5k 271 ± 36 183 ± 30 248 ± 32 187 ± 23 0.12 
ATP5s 162 ± 24 122 ± 14 168 ± 24 141 ± 16 0.48 
ATPsg2 280 ± 24 189 ± 20 267 ± 45 213 ± 35 0.09 
Cox10 169 ± 26 114 ± 16 155 ± 23 123 ± 12 0.24 
Cytochrome C 69 ± 9 47 ± 5 64 ± 11 59 ± 9 0.37 
NCAM2 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.6 ± 0.1 0.95 
NCAM1 14 ± 2 13 ± 2 27 ± 4§ 20 ± 3 0.013 
CHARNA1 53 ± 5 57 ± 8 110 ± 16 94 ± 18 0.013 
CHARNB 130 ± 12 114 ± 13 254 ± 22§§§ 218 ± 32 <0.0001 
INSR 214 ± 25 154 ± 17 221 ± 28 174 ± 17 0.14 
IRS-1 778 ± 72 809 ± 125 117 ± 231 1058 ± 145 0.41 
AKT1 453 ± 51 303 ± 27 580 ± 56 475 ± 58 0.005 
PI3K(p85) 766 ± 159 490 ± 60 712 ± 85 557 ± 56 0.31 
Pi3K(p110) 297 ± 39  249 ± 26 350 ± 74 210 ± 19 0.14 
AMPKa 89 ± 15 65 ± 8 122 ± 13 25 ± 10 0.047 
11β-HSD1 72.6 ± 17.4 0.1 ± 0.0**** 63.9 ± 12.9 0.2 ± 0.1ΦΦΦΦ <0.0001 
H6PDH 132 ± 17 99 ± 15 179 ± 36 124 ± 17 0.16 
Glut Synth 227 ± 30 176 ± 28 257 ± 44 320 ± 30 0.04 
HSP90aa 288 ± 51 200 ± 27 380 ± 31 282 ± 25 0.03 
HSP90b 316 ± 40 222 ± 23 380 ± 47 264 ± 22 0.03 
GR 608 ± 67 468 ± 56 684 ± 113 530 ± 49 0.26 
GHR 11726 ± 267 1418 ± 163 1766 ± 393 1428 ± 131 0.85 
IGF-1 392 ± 77 303 ± 57 407 ± 69 413 ± 56 0.54 
HIF-1a 610 ± 99 449 ± 52 669 ± 85 589 ± 62 0.26 
RXRb 186 ± 18 144 ± 17 183 ± 38 143 ± 13 0.27 
eif6 197 ± 25 139 ± 20 235 ± 25 157 ± 23 0.04 
Eif2b1 853 ± 77 689 ± 62 889 ± 96 783 ± 78 0.25 
PDK4 10584 ± 1946 6248 ± 1024 13046 ± 2023 14140 ± 7473 0.24 
Irisin 425 ± 102 227 ± 55 352 ± 154 255 ± 49 0.44 
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ΦΦp<0.01	   and	   ΦΦΦΦp<0.0001	   vs.	   old	  WT.	  WT	   =	   wildtype	   and	   KO	   =	   11β-­‐HSD1	   knock	   out	  mice.	  
Overall	  p-­‐value	  from	  1-­‐way	  ANOVA	  is	  tabulated	  (n=7-­‐9	  per	  group).	  	  
	  
	  
The	  impact	  of	  11β-­‐HSD	  knockout	  on	  age-­‐regulated	  genes	  in	  skeletal	  muscle:	  	  Three	   genes	   (MuRF1,	   myostatin	   and	   GADD45a)	   of	   the	   88	   studied	   had	   age-­‐associated	   increases	   in	   expression	   that	   were	   attenuated	   with	   11β-­‐HSD1	   KO	  (Figure	  5-­‐3).	  	  	  
	  
Figure	  5-­‐3:	  Skeletal	  muscle	  gene	  expression	  of	  MuRF1,	  Myostatin	  and	  GADD45a	  with	  age	  in	  
WT	  and	  11β-­‐HSD1	  KO	  mice.	  Quadriceps	  gene	  expression	  of	  (A)	  MuRF1,	  (B)	  Myostatin,	  and	  (C)	  was	  
GADD45a	  increased	  with	  age	  in	  WT	  mice	  on	  a	  C57BL/6	  background.	  An	  effect	  that	  was	  completely	  
attenuated	   in	   Old	   11β-­‐HSD1	   KO	   mice	   for	   MuRF1	   and	   Myostatin,	   and	   partially	   attenuated	   for	  
GADD45a.	  §§P<0.01	  vs.	  Young	  WT,	  §§§§p<0.0001	  vs.	  Young	  WT,	  Φp<0.05	  vs.	  Old	  WT,	  and	  ΦΦp<0.01	  
vs.	  Old	  WT.	  Means	  and	  S.E.	  are	  shown	  (n	  =	  7-­‐9	  per	  group)	  WT	  =	  wildtype,	  KO	  =	  11β-­‐HSD1	  knock	  out	  
mice.	  	  	  Expression	   of	   four	   other	   genes	   (PSMD11,	   eif4bp,	   CHARNB,	   NCAM1)	   was	  upregulated	  with	  age,	  however	  there	  was	  no	  statistically	  significant	  attenuation	  of	  these	  changes	  in	  11β-­‐HSD1	  KO	  mice	  (Figure	  5-­‐4).	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Figure	  5-­‐4:	  Skeletal	  muscle	  gene	  expression	  of	  PSMD11,	  eif4bp,	  CHARNB	  and	  NCAM1	  with	  age	  
in	  WT	  mice.	  Quadriceps	  gene	  expression	  of	   these	  4	   increased	  with	  age	   in	  WT	  mice	  on	  a	  C57BL/6	  
background.	  There	  was	  a	  trend	  towards	  attenuation	  of	  this	  effect	  in	  11β-­‐HSD1	  KO	  mice	  that	  did	  not	  
reach	   statistical	   significance.	   §P<0.05	   vs.	   young	  WT	   and	   §§§p<0.001.	  Means	   and	   S.E.s	   are	   shown	  
(n=7-­‐9	  per	  group)	  WT	  =	  wildtype,	  KO	  =	  11β-­‐HSD1	  knock	  out	  mice.	  	  
	  
	  
5.5.1.4.	   The	  impact	  of	  global	  11β-­‐HSD1	  knockout	  on	  muscle	  phenotype	  
(grip	  strength	  and	  muscle	  tissue	  weights)	  across	  age	  	  
	  Grip	  strength	  was	  reduced	  with	  age	  in	  WT	  mice	  (Old	  WT:	  3.86	  ±	  0.80	  vs.	  Young	  WT:	  4.98	  ±	  0.67	  per	  g	  bodyweight,	  p<0.05),	  whereas	  strength	  was	  preserved	  in	  11β-­‐HSD1	   KO	   mice	   (Old	   WT:	   3.86	   ±	   0.80	   vs.	   Old	   KO:	   4.44	   ±	   0.78	   per	   g	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bodyweight,	   p<0.05)(Figure	   5-­‐5).	   Quadriceps	   and	   tibialis	   anterior	   muscle	  weights	  were	  reduced	  with	  age	  in	  both	  WT	  and	  11β-­‐HSD1	  KO	  mice	  (Figure	  5-­‐6).	  	  
	  
Figure	  5-­‐5:	  Grip	  Strength	  in	  Young	  and	  Old	  WT	  and	  11β-­‐HSD1	  KO	  C57BL/6	  mice.	  *P<0.05	  vs.	  
young	  WT;	  §P<0.05	  vs.	  Old	  WT	  (N	  =	  7-­‐8	  per	  group).	  Means	  and	  S.E.s	  are	  shown.	  WT	  =	  wildtype,	  KO	  =	  
11β-­‐HSD1	  knockout	  mice.	  	   	  	  	  	  
Figure	  5-­‐6:	  Tissue	  weights	  of	  A)	  Quadriceps	  B)	  Tibialis	  anterior	   in	  young	  and	  old,	  wildtype	  
and	  11β-­‐HSD1	  KO	  mice	  on	  C57BL/6	  background.	  Mean	  and	  S.E.s	  are	  shown.	  *P<0.05	  vs.	  young	  
genotype	  matched	  mice	  (n=6-­‐8	  per	  group).	  WT	  =	  wildtype,	  KO	  =	  11β-­‐HSD1	  KO	  mice.	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5.5.2.	  Treatment	  of	  C57BL/6	  wildtype	  and	  11β-­‐HSD1	  knockout	  mice	  
with	  supraphysiological	  doses	  of	  glucocorticoids	  
	  A	  mouse	  model	  was	  used	  to	  investigate	  the	  effects	  of	  exogenous	  glucocorticoid	  treatment	  on	  the	  skeletal	  muscle	  genes,	  which	  were	  differentially	  expressed	  in	  the	  preceding	  ageing	  experiments.	  	  	  
5.5.2.1.	   Characterisation	  of	  serum	  GC	  levels	  and	  adrenal	  gland	  weights	  	  
	  WT	  mice	   treated	  with	  CORT	  and	  11DHC	  had	  elevated	   serum	  CORT	   levels	   (2.1-­‐fold	   [CORT],	   p<0.001;	   1.7-­‐fold,	   p<0.01).	   Serum	   CORT	   was	   also	   raised	   in	   11β-­‐HSD1	  KO	  mice	   following	   CORT	   (but	   not	   11DHC)	   treatment	   (2.1-­‐fold,	   p<0.001)	  (Figure	  5-­‐7).	  Serum	  CORT	  levels	  were	   increased	  in	  WT	  and	  11β-­‐HSD1	  KO	  mice	  following	   CORT	   and	   11DHC	   treatment	   (Figure	   5-­‐7a).	   The	   dose	   of	   CORT	  administered	  in	  this	  study	  was	  effective	  at	  inducing	  adrenal	  atrophy	  in	  both	  WT	  (0.15-­‐fold,	   p<0.001)	   and	   11β-­‐HSD1	   KO	   	   (0.17-­‐fold,	   p<0.001)	   mice,	   consistent	  with	   suppression	   of	   endogenous	   GC	   production	   (Figure	   5-­‐7b).	   11DHC	   also	  induced	  adrenal	   atrophy	   in	  WT	  mice	   (0.15-­‐fold,	   p<0.001)	  whilst	   11β-­‐HSD1	  KO	  animals	  were	  protected	  (Figure	  5-­‐7b).	  	  
	  
Figure	  5-­‐7:	  Serum	  CORT	  and	  left	  adrenal	  weights	  in	  WT	  and	  11β-­‐HSD1	  KO	  mice	  treated	  with	  
GCs	  in	  drinking	  water	  or	  control.	  C57BL/6	  wildtype	  and	  11β-­‐HSD1	  knockout	  mice	  on	  a	  C57BL/6	  
background	   were	   treated	   with	   CORT	   (100μg/mL,	   0.66%	   ethanol),	   11DHC	   (100μg/mL,	   0.66%	  
ethanol)	   or	   vehicle	   (0.66%	   ethanol)	   for	   5	   weeks	   (n=7-­‐9).**P<0.01,	   ***p<0.001	   vs.	   WT	   vehicle;	  
$$$p<0.001	  vs.	  KO	  vehicle.	  CORT	  =	  corticosterone,	  11DHC	  =	  11-­‐dehydrocorticosterone.	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5.5.2.2.	   Skeletal	   muscle	   mRNA	   expression	   of	   atrophy	   genes	   in	   GC	  
treated	  mice	  	  
	  Expression	   of	   an	   array	   of	   genes	   known	   to	   be	   involved	   in	  muscle	   atrophy	  was	  increased	   GC-­‐treated	   WT	   mice	   including:	   the	   E3	   ubiquitin	   ligases,	   MuRF1	  (vehicle-­‐treated	  WT:	  0.33	  ±	  0.03	  vs.	  CORT-­‐treated	  WT:	  1.41	  ±	  0.28	  and	  11DHC-­‐treated	  WT:	   0.95	  ±	   0.16AU,	   p<0.01)	   and	  MAFbx/atrogin1	   (vehicle-­‐treated	  WT:	  0.40	   ±	   0.04	   vs.	   CORT-­‐treated	  WT:	   1.25	   ±	   0.22	   and	   11DHC	   treated	  WT:	   0.90	   ±	  0.13AU,	  p<0.01),	  the	  negative	  growth	  factor,	  myostatin	  (vehicle	  treated	  WT:	  0.20	  vs.	  0.02	  vs.	  CORT-­‐treated	  WT	  mice:	  0.63	  ±	  0.11	  and	  11DHC-­‐treated	  WT:	  0.55	  ±	  0.13AU,	  p<0.01)	  and	  the	  transcription	  factor,	  FOXO1	  (vehicle-­‐treated	  WT:	  0.03	  ±	  0.00	  vs.	  CORT-­‐treated	  WT:	  0.08	  ±	  0.02	  and	  11DHC-­‐treated	  WT:	  0.07	  ±	  0.01AU,	  p<0.01)(See	  Figure	  5-­‐8).	  11β-­‐HSD1	  KO	  mice	  had	  attenuation	  of	  11DHC-­‐mediated	  atrophy	   gene	   expression	   changes	   (MuRF1;	   vehicle-­‐treated	   KO:	   0.29	   ±	   0.07	   vs.	  CORT-­‐treated	   KO:	   0.71	   ±	   0.16,	   p<0.05	   and	   11DHC-­‐treated	   KO:	   0.32	   ±	   0.08AU,	  MAFbx/atrogin1;	   vehicle-­‐treated	   KO:	   0.29	   ±	   0.07	   vs.	   CORT-­‐treated	   KO:	   0.63	   ±	  0.19,	   p<0.05	   and	  11DHC-­‐treated	  KO:	  0.29	  ±	  0.05AU,	  myostatin;	   vehicle-­‐treated	  KO:	  0.18	  ±	  0.03	  vs.	  CORT	  treated	  KO:	  0.41	  ±	  0.04,	  p<0.01	  and	  11DHC	  treated	  KO:	  0.20	  ±	  0.03AU	  and	  FOXO1;	  vehicle-­‐treated	  KO:	  0.03	  ±	  0.01	  vs.	  CORT-­‐treated	  KO:	  0.05	  ±	  0.00	  and	  11DHC-­‐treated	  KO:	  0.02	  ±	  0.00AU)	  (Figure	  5-­‐8).	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Figure	   5-­‐8:	   GC	   treatment	   resulted	   in	   upregulation	   of	   genes	   involved	   in	   muscle	   atrophy	  
(quadriceps)	   including	  MuRF1	  (A),	  MAFbx/Atrogin-­‐1	  (B),	  myostatin	  (C)	  and	  FOXO1	  (D),	  and	  these	  
changes	   were	   attenuated	   in	   11DHC	   treated	   11β-­‐HSD1	   KO	   C57BL/6	   mice	   (n=7-­‐9	   in	   each	   group)	  
(**p<0.01	  vs.	  WT	  vehicle;	  ∅p<0.05,	  ∅∅p<0.01	  vs.	  WT	  CORT).	  
	  
	  
Expression	   of	   other	   age-­‐regulated	   genes	   in	   skeletal	   muscle	   of	   glucocorticoid-­‐
treated	   wildtype	   and	   11β-­‐HSD1	   knock	   out	   mice:	   Genes	   that	   were	   differentially	  expressed	   with	   age	   in	   the	   mRNA	   expression	   array	   were	   analysed	   by	  conventional	   real-­‐time	   PCR	   in	   skeletal	   muscle	   samples	   (quadriceps)	   from	   GC-­‐treated	  mouse	  experiments,	  in	  order	  to	  assess	  if	  regulated	  by	  GCs.	  Of	  the	  6	  genes	  assessed,	  4	  were	  confirmed	  to	  be	  GC-­‐regulated,	  in	  vivo	  (eif4bp	  CHARNB,	  NCAM1	  and	   GADD45a.	   This	   induction	  was	   attenuated	   in	   11DHC-­‐treated	   11β-­‐HSD1	   KO	  mice	  (Table	  5-­‐2	  and	  Figure	  5-­‐9).	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Figure	  5-­‐9:	  Impact	  of	  GC-­‐treatment	  on	  expression	  of	  age-­‐regulated	  genes	  in	  skeletal	  muscle.	  
(A)	  GADD45a	  expression	  was	  upregulated	  in	  CORT	  and	  11DHC-­‐treated	  WT	  mice,	  and	  CORT-­‐treated	  
but	  not	  11DHC-­‐treated	  11β-­‐HSD1	  KO	  mice.	  (B)	  Eif4bp	  and	  (C)	  CHARNB	  expression	  was	  increased	  by	  
both	  CORT	  and	  11DHC-­‐treatment	   in	  WT	  mice	  but	  not	  11β-­‐HSD1	  KO	  mice.	   (D)	  NCAM1	  expression	  
was	   increased	   in	   WT	   mice	   by	   CORT	   treatment	   but	   not	   11DHC	   treatment.	   *P<0.05,	   **p<0.01,	  
****p<0.0001	  vs.	  vehicle-­‐treated	  WT	  and	  Øp<0.05	  vs.	  vehicle-­‐treated	  11β-­‐HSD1	  KO	  mice.	  Data	  are	  
shown	  as	  means	  and	  S.E.s.	  	  	  	  	  	  	  	  
	   154	  




Gene	   Vehicle	   CORT	   11DHC	   Vehicle	   CORT	   11DHC	   Overall	  
P-­‐value	  
Eif4bp	   	  0.14	  ±	  0.01	  	   	  0.48	  ±	  0.10	   	  0.43	  ±	  0.08	   	  0.16	  ±	  0.04	   	  0.34	  ±	  0.05	   	  0.14	  ±	  0.01	   	  <0.0001	  
CHARNB	   	  0.03	  ±	  0.00	  	   	  0.07	  ±	  0.01	   	  0.05	  ±	  0.00	   	  0.03	  ±	  0.00	   	  0.04	  ±	  0.01	   	  0.02	  ±	  0.00	   	  <0.0001	  
NCAM1	   	  0.01±	  0.00	  	   	  0.03	  ±	  0.01	   	  0.01	  ±	  0.00	   	  0.01	  ±	  0.00	   	  0.01	  ±	  0.00	   	  0.00	  ±	  0.00	   	  0.0002	  
GADD45a	   	  0.10	  ±	  0.01	  	   	  0.30	  ±	  0.06	   	  0.29	  ±	  0.09	   	  0.09	  ±	  0.02	   	  0.28	  ±	  0.06	   	  0.08	  ±	  0.02	   	  0.001	  
PSMD11	   	  0.44	  ±	  0.04	  	   	  0.55	  ±	  0.07	   	  0.51	  ±	  0.05	   	  0.39	  ±	  0.08	   	  0.53	  ±	  0.09	   	  0.40	  ±	  0.04	   	  0.27	  
Calveolin3	   	  0.05	  ±	  0.00	  	   	  0.05	  ±	  0.01	   	  0.05	  ±	  0.00	   	  0.06	  ±	  0.02	   	  0.07	  ±	  0.01	   	  0.05	  ±	  0.01	   	  0.35	  
	  
Table	   5-­‐2:	  Gene	   expression	   of	   genes	   regulated	   by	   age	   or	   11β-­‐HSD1	   in	   the	   ageing	   study	   in	  
skeletal	   muscle	   was	   assessed	   by	   real-­‐time	   PCR	   in	   glucocorticoid	   treated	   mouse	   study	   samples	  
(quadriceps).	   Data	   are	   expressed	   as	  mean	   and	   S.E.	   of	   A.U.	   Statistical	   analysis	   was	   performed	   on	  
mean	  dCT	  values	  using	  1-­‐way	  anova.	  Statistically	  significant	  differences	  in	  gene	  expression	  between	  




5.5.2.3.	   Impact	   of	   11β-­‐HSD1	   KO	   on	   muscle	   phenotype	   (grip	   strength	  
and	  muscle	  weights)	  of	  GC-­‐treated	  mice:	  	  
	  GC	   treated	   WT	   mice	   had	   reduced	   grip-­‐strength	   (Figure	   5-­‐10).	   These	   changes	  were	  paralleled	  by	  reductions	  in	  type	  IIb	  fibre	  rich	  muscle	  beds	  (for	  quadriceps	  vehicle-­‐	  treated	  WT:	  0.15	  ±	  0.01	  vs.	  CORT-­‐treated	  WT:	  0.07	  ±	  0.01	  and	  11DHC-­‐treated	  WT	  0.09	  ±	  0.01g,	  p<0.05	  and	  for	  tibialis	  anterior	  vehicle-­‐	  treated	  WT	  0.04	  ±	   0.01	   vs.	   CORT-­‐treated	  WT	   0.02	   ±	   0.01	   and	   11DHC-­‐treated	  WT	   0.03	   ±	   0.00g,	  p<0.05)(Figure	  5-­‐11).	  Conversely,	  GC-­‐treated	  11β-­‐HSD1	  KO	  mice	  had	  preserved	  grip-­‐strength,	   and	   those	   treated	   with	   11DHC	   were	   protected	   from	   muscle	  atrophy	   (for	   quadriceps	   vehicle	   treated	   11β-­‐HSD1	  KO:	   0.18	   ±	   0.01g	   vs.	   CORT-­‐treated	   11β-­‐HSD1	  KO:	   0.15	   ±	   0.02g,	   p<0.05	   and	  11DHC-­‐treated	   11β-­‐HSD1	  KO:	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0.20	  ±	  0.01g	  p=N/S,	  and	  for	  tibialis	  anterior	  vehicle-­‐treated	  11β-­‐HSD1	  KO:	  0.04	  ±	  0.01g	   vs.	   CORT-­‐treated	   11β-­‐HSD1	   KO:	   0.04	   ±	   0.01g	   and	   11DHC-­‐treated	   11β-­‐HSD1	  KO:	  0.05	  ±	  0.01g)(Figure	  5-­‐11).	  	  
	  
Figure	   5-­‐10:	   Grip-­‐strength	   was	   reduced	   in	   CORT	   and	   11DHC	   treated	   WT	   C57BL/6	   mice,	  
whereas	  11β-­‐HSD1	  KO	  C57BL/6	  mice	  were	  protected	  from	  these	  effects	  (n=7-­‐9	  in	  each	  group)	  




Figure	   5-­‐11:	  Quadriceps	   (A)	   and	   tibialis	   anterior	  muscle	   bed	   weight	   (B)	   were	   reduced	   in	  
CORT	   and	   11DHC	   treated	   WT	   C57BL/6	   mice,	   whereas	   11β-­‐HSD1	   KO	   C57BL/6	   mice	   were	  
protected	   from	   these	   effects	   (n=7-­‐9	   in	   each	   group)	   (*p<0.05	   vs.	   WT	   vehicle;	  ∅p<0.05,	   vs.	   WT	  
CORT).	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5.6	  Discussion	  
	  In	   summary	   we	   have	   identified	   a	   set	   of	   gene	   expression	   changes	   in	   skeletal	  muscle	   that	   are	   common	   to	  both	  GC	  excess	  and	  ageing	  and	  parallel	   changes	   in	  muscle	   function.	  Absence	  of	  11β-­‐HSD1	  attenuates	   these	   changes	  and	   results	   in	  protection	   from	   muscle	   weakness,	   implicating	   local	   GC	   generation	   in	   the	  development	   of	  muscle	   atrophy	   and	   indicating	   a	   potential	   therapeutic	   role	   for	  selective	  11β-­‐HSD1	  inhibitors.	  	  	  This	  study	  represents	  the	  first	  in-­‐vivo	  assessment	  of	  the	  impact	  of	  11β-­‐HSD1	  on	  skeletal	  muscle	  function	  with	  age	  and	  GC-­‐excess.	  Previous	  studies	  have	  revealed	  the	   beneficial	   metabolic	   effects	   of	   global	   11β-­‐HSD1	   KO,	   characterized	   by	  favourable	   fat	   distribution,	   and	   lipid	   profiles,	   resistance	   to	   hyperglycaemia,	  absent	   oxo-­‐reductase	   activity	   and	   compensatory	   adrenal	   hyperplasia	  (Kotelevtsev	   et	   al.,	   1997,	   Morton	   et	   al.,	   2001)	   and	   the	   adverse	   effects	   of	  overexpression	   of	   the	   gene	   (Masuzaki	   et	   al.,	   2001,	   Masuzaki	   et	   al.,	   2003).	  Recently,	   studies	   of	   liver-­‐specific	   11β-­‐HSD1	   KO	   mice,	   demonstrated	   a	   lack	   of	  metabolic	  abnormilities,	  normal	  urine	  steroid	  markers	  of	  11β-­‐HSD1	  activity	  and	  ability	  to	  generate	  cortisol	  to	  40%	  of	  control,	  suggesting	  that	  extra-­‐hepatic	  sites	  make	   a	   more	   significant	   contribution	   to	   global	   GC	   generation	   than	   was	  previously	  accepted	  (Lavery	  et	  al.,	  2012).	  	  	  Our	   initial	   characterization	   studies	   confirmed	   that	   %A	   metabolites	   were	  increased	   in	   11β-­‐HSD1	   KO	   mice,	   consistent	   with	   absence	   of	   oxo-­‐reductase	  activity,	   as	   seen	   in	  previous	   reports	   (Abrahams	  et	   al.,	   2012).	   Serum	  CORT	  was	  increased	   with	   both	   age	   and	   absence	   of	   11β-­‐HSD1,	   in-­‐keeping	   with	   HPA-­‐axis	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activation.	   It	   is	   striking	   therefore,	   that	   we	   demonstrate	   functional	   effects	  (improved	  strength)	  and	  attenuation	  of	  glucocorticoid	  sensitive	  gene	  expression	  changes	   in	   the	   11β-­‐HSD1	   KO,	   indicating	   that	   absence	   of	   local	   tissue	   GC	  amplification	   overrides	   the	   effects	   of	   increased	   circulating	   CORT	   levels.	   As	  outlined	   in	   chapter	   1,	   some	   animal	   and	   human	   studies	   have	   demonstrated	  modest	   increases	   in	   circulating	   GCs	   over	   with	   advancing	   age	   (Belanger	   et	   al.,	  1994,	  Barrett-­‐Connor,	  1997,	  Ferrari	  et	  al.,	  2001b,	  Zhao	  et	  al.,	  2003),	  whilst	  others	  have	   shown	   shown	   changes	   in	   diurnal	   variation	   (Sherman	   et	   al.,	   1985,	   van	  Coevorden	  et	   al.,	   1991)(Table	  1-­‐5).	   Increased	   serum	  CORT	   in	  global	  11β-­‐HSD1	  KO	  mice,	  is	  thought	  to	  reflect	  a	  compensatory	  HPA-­‐Axis	  activation	  in	  response	  to	  reduced	  local	  generation	  of	  active	  GC	  (Harris	  et	  al.,	  2001).	  Adrenal	  glands	  of	  11β-­‐HSD1	  KO	  mice	  were	  enlarged,	  which	  is	  also	  consistent	  with	  HPA-­‐axis	  activation	  although	  there	  were	  no	  changes	  in	  adrenal	  weights	  with	  age	  in	  WT	  mice.	  	  	  11β-­‐HSD1	   KO	   mice	   had	   preservation	   of	   muscle	   strength	   with	   age	   when	  compared	   to	  WT	   animals.	   There	  was	   however	   no	   preservation	   of	  muscle	   bulk	  with	   age	   in	   knockout	   animals.	   Our	   study	   of	   skeletal	   muscle	   gene	   expression	  consisted	   of	   an	   array	   of	   88	   target	   genes.	   Of	   these,	   3	   genes	   (MuRF1,	   MSTN,	  GADD45a)	  increased	  with	  age	  in	  WT	  mice,	  with	  these	  changes	  attenuated	  in	  11β-­‐HSD1	   KO	   mice,	   which	   appear	   to	   underpin	   the	   preserved	   muscle	   strength.	  Interestingly	  4	  genes,	  which	  have	  not	  been	  previously	  investigated	  with	  respect	  to	  pre-­‐receptor	  GC	  regulation	  (PSMD11,	  eif4bp,	  CHARNB,	  NCAM1)	  increase	  with	  age	   although	   effects	   of	   11β-­‐HSD1	   KO	   did	   not	   reach	   statistical	   significance.	  Furthermore,	   GADD45a,	   eif4bp,	   CHARNB,	   NCAM1,	   in	   addition	   to	   MuRF1	   and	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myostatin,	  were	   found	   to	  be	  GC	   inducible,	   supportive	  of	   an	   important	   effect	  of	  chronic	  GC	  exposure	  in	  skeletal	  muscle	  ageing.	  	  	  MuRF1,	   is	   an	   E3-­‐ubiquitin	   ligase,	   which	   is	   known	   to	   be	   involved	   in	   muscle	  atrophy	  associated	  with	  a	  range	  of	  conditions.	  Upregulation	  of	  MuRF1	  with	  age	  has	   been	   demonstrated	   in	   other	   rodent	   models	   (Altun	   et	   al.,	   2010).	   It	   is	  interesting	  that	  MuRF1	  but	  not	  MAFbx1,	  was	  elevated	  with	  age	  and	  GC	  treatment	  in	   this	   study,	   as	   previous	   data	   has	   shown	   that	   MuRF1	   KO	   but	   not	  MAFbx/Atrogin1	  KO	  mice	  are	  protected	  against	  DEX-­‐induced	  myopathy	  (Baehr	  et	   al.,	   2011).	   Myostatin	   is	   a	   “negative	   regulator”	   of	   muscle	   growth,	   which	   has	  been	  the	  focus	  of	  much	  recent	  study.	  Myostatin	  KO	  mice	  are	  protected	  from	  GC-­‐induced	   myopathy	   and	   maintain	   double-­‐muscle	   phenotype	   with	   ageing	  compared	  to	  controls	  (Gilson	  et	  al.,	  2007,	  Morissette	  et	  al.,	  2009).	  Most	  intriguing	  is	  GADD45a,	   a	   small	  myonuclear	  protein,	  which	   is	   a	   regulator	  of	   the	   cell	   cycle,	  cell	  stress	  response,	  and	  is	  also	  involved	  in	  muscle	  atrophy	  (Ebert	  et	  al.,	  2012).	  	  It	  is	   required	   for	   muscle	   wasting	   secondary	   to	   of	   different	   aetiologies	   including	  disuse,	   denervation	   and	   fasting	   (Bongers	   et	   al.,	   2013).	   It	   was	   upregulated	   in	  previous	   skeletal	  muscle	   ageing	   array	   studies	   (Welle	   et	   al.,	   2004).	   It	   has	   been	  suggested	  that	  the	  protein	  acts	  as	  a	  “convergence	  point”	  for	  upstream	  regulators	  of	  muscle	  atrophy,	  and	  in	  common	  with	  E3-­‐ubiquitin	  ligases,	  and	  myostatin	  it	  is	  inducible	  by	  FOXO1	  (Schakman	  et	  al.,	  2013).	  In	  this	  context	  our	  data	  suggest	  that	  GADD45a	   may	   also	   be	   important	   in	   myopathies	   of	   ageing	   and	   GC-­‐excess.	   We	  could	   speculate	   that	   a	   pathway	   exists	   by	   which,	   11β-­‐HSD1	   modulates	   GR	  activation	   and	   subsequent	   induction	   of	   FOXO1	   and	   myostatin	   thus	   promoting	  activity	  of	  MuRF1	  and	  MAFbx/Atrogin1	  and	   the	  ubiquitin-­‐proteosomal-­‐system.	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Eif4bp	  is	  known	  to	  have	  a	  role	  in	  the	  regulation	  of	  muscle	  protein	  synthesis	  via	  eiF4E	  binding	  (Shah	  et	  al.,	  2000b).	  	  	  The	   roles	   and	   significance	   of	   the	   other	   genes	   that	   were	   upregulated	   with	   age	  (PSMD11,	  NCAM1,	  and	  CHARNB)	  in	  muscle	  atrophy	  are	  less	  well	  characterized.	  PSMD11	   is	   a	   proteosomal	   subunit	   that	   is	   involved	   in	   cell	   senescence	  (Chondrogianni	  et	  al.,	  2003,	  Vilchez	  et	  al.,	  2012).	  NCAM1	  is	  a	  molecule	  involved	  in	   cell-­‐to-­‐cell	   interactions	   and	   is	   important	   for	   maintenance	   of	   the	  neuromuscular	   junction.	  However	   it	   has	  not	  previously	  been	   investigated	  with	  respect	   to	   sarcopenia	   or	   GC-­‐induced	   muscle	   atrophy	   (Chipman	   et	   al.,	   2010).	  CHRNB1	   encodes	   the	   b1	   subunit	   of	   the	   nicotinic	   acetylcholine	   receptor,	  which	  sits	   on	   the	   post-­‐synaptic	   side	   of	   the	   neuromuscular	   junction.	   Whether	   these	  changes	  represent	  deleterious	  or	  protective	  compensatory	  effects	  remains	  to	  be	  seen.	  	  	  GC-­‐treated	  WT	  mice	  shared	  common	  changes	  in	  skeletal	  muscle	  gene	  expression	  with	  old	  WT	  mice	  (MuRF1,	  Myostatin,	  GADD45a,	  eiF4bp,	  CHARNB	  and	  NCAM1),	  and	   these	   changes	   were	   attenuated	   in	   11-­‐DHC	   treated	   11β-­‐HSD1	   KO	   animals.	  Knockout	  mice	   on	  11-­‐DHC	  also	  had	  preserved	   grip	   strength	   and	  muscle	   tissue	  weights	   compared	   to	  WT	   animals.	   It	   is	   interesting	   however	   that	   CORT-­‐treated	  11β-­‐HSD1	   KO	  mice	   had	   a	  much	   lower	  magnitude	   of	   induction	   of	   key	   atrophy	  genes	   including	  MuRF1,	   MAFbx/Atrogin1,	   Myostatin	   and	   FOXO1,	   compared	   to	  WT	  mice,	  in	  spite	  of	  similar	  circulating	  CORT	  levels.	  We	  could	  speculate	  that	  this	  may	   be	   due	   to	   loss	   of	   the	   ‘feed-­‐forward’	   action	   of	   CORT	   on	   11β-­‐HSD1,	   and	  inability	  to	  reactivate	  11DHC,	  that	  has	  been	  inactivated	  by	  11β-­‐HSD2.	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We	   have	   found	   that	   11β-­‐HSD1	   KO	   mice	   are	   protected	   from	   GC-­‐mediated	  myopathy,	   exhibiting	   preservation	   of	   grip	   strength	   and	  muscle	   tissue	  weights.	  This	   is	   a	   novel	   observation,	   with	   previous	   studies	   providing	   only	   cell	   culture	  evidence	   for	   a	   role	   of	   11β-­‐HSD1	   in	   regulating	   genes	   involved	   in	   muscle	  proteolysis	   in	   cell	   culture	   models	   (E3	   ubiquitin	   ligases:	   MAFbx/Atrogin1	   and	  MuRF1)(Biedasek	   et	   al.,	   2011).	  We	   have	   developed	   this	   work	   by	   examining	   a	  larger	  number	  of	  key	  atrophy	  genes	  using	  our	  in	  vivo	  model,	  demonstrating	  the	  importance	   of	   the	   GC	   mediated	   increases	   in	   FOXO1,	   and	   myostatin	   with	  downstream	  effects	  on	  ubiquitin	  ligases.	  We	  also	  confirm	  previous	  reports	  of	  GCs	  potentiating	  11-­‐HSD1	  oxo-­‐reductase	  activity	  in	  ex-­‐vivo	  muscle	  samples	  allowing	  local	  amplification.	  
	  We	  have	  demonstrated	   that	  our	  model	  of	  GC-­‐excess	  using	  CORT-­‐supplemented	  drinking	   water	   was	   effective	   with	   elevated	   serum	   CORT	   levels	   in	   WT	   treated	  animals	  that	  are	  comparable	  to	  those	  seen	  in	  previous	  studies	  (Kotelevtsev	  et	  al.,	  1997).	   Treatment	   induced	   insulin	   resistance,	   glucose	   intolerance	   and	   muscle	  atrophy	  and	  weakness	  in	  accordance	  with	  a	  ‘Cushing’s’	  phenotype.	  Adrenal	  gland	  weights	  suggested	  evidence	  of	  suppression	  of	  HPA	  axis	   in	  GC	  treated	  WT	  mice,	  and	   a	   lack	   of	   effect	   in	   11DHC-­‐treated	   KO	   mice.	   Compensatory	   HPA-­‐axis	  activation	  in	  11β-­‐HSD1	  KO	  mice	  as	  manifested	  by	  adrenal	  enlargement	  as	  seen	  in	  this	   study,	   has	   been	   noted	   previously	   (Kotelevtsev	   et	   al.,	   1997).	   Adrenal	  enlargement	   in	   this	   study	   is	   comparable	   to	   that	  described	  previously	   from	  our	  group	   (≈45%	   enlargement).	   This	   parallels	   the	   situation	   seen	   in	   patients	   with	  CRD/ACRD	   secondary	   to	   mutations	   in	   the	   11β-­‐HSD1	   and	   H6PDH	   genes	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respectively	   (Phillipov	   et	   al.,	   1996,	   Jamieson	   et	   al.,	   1999,	   Biason-­‐Lauber	   et	   al.,	  2000,	  Lavery	  et	  al.,	  2008,	  Lawson	  et	  al.,	  2011)	  
	  GCs	   induce	   insulin	   resistance,	   however	   the	   mechanisms	   for	   this	   are	   not	   fully	  elucidated,	   with	   effects	   on	   glucose	   and	   lipid	   metabolism	   in	   tissues	   including	  liver,	  skeletal	  muscle,	  and	  adipose	  tissue	  (Gathercole	  et	  al.,	  2013).	  We	  observed	  that	  11DHC-­‐treated	  11β-­‐HSD1	  KO	  mice	  were	  protected	   from	   insulin	   resistance	  and	  glucose	  intolerance,	  in	  keeping	  with	  previous	  studies	  using	  high	  fat	  diet	  and	  stress	   (Supplementary	   Figure	   S.5.2)	   (Kotelevtsev	   et	   al.,	   1997,	   Morton	   et	   al.,	  2001).	   	  Furthermore	  aged	  11β-­‐HSD1	  KO	  mice	  had	  reduced	  serum	  insulin	  levels	  and	  area	  under	  the	  curve	  results	  for	  glucose	  on	  GTTs	  compared	  to	  age-­‐match	  WT	  animals	   (Supplementary	   Figure	   S.5.1.).	   It	   is	   possible	   that	   effects	   of	   improved	  insulin	  sensitivity	  on	  protein	  metabolism	  in	  11β-­‐HSD1	  KO	  mice	  may	  contribute	  to	  the	  preservation	  of	  muscle	  strength	  with	  ageing	  and	  GC-­‐excess.	  	  Further	  characterization	  of	  muscle	  phenotype	  in	  aged	  mice	  would	  be	  useful	  and	  measures	   of	   speed,	   endurance	   and	   ex-­‐vivo	   strength,	   along	   with	   histological	  examination	   of	   cross-­‐sectional	   area,	   morphology	   and	   fibre-­‐type	   distribution	  could	   be	   considered.	   Future	   work	   could	   also	   include	   investigation	   of	   whether	  dietary	  manipulation	  (use	  of	  control	  or	   ‘western’	  diets)	  would	  affect	  outcomes.	  Animal	  studies	  have	  inherent	  limitations,	  with	  variability	  between	  backgrounds,	  and	  species,	  meaning	  that	  there	  is	  a	  need	  for	  human	  studies	  of	  the	  effects	  of	  11β-­‐HSD1	  on	  muscle	  phenotype	  with	  ageing	  and	  GC-­‐treatment.	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6.1.	  Introduction	  The	  preceding	  chapters	  have	   illustrated	   that	  GC	  metabolism	  plays	  a	  role	   in	   the	  regulation	   of	   skeletal	   muscle	   atrophy	   pathways	   in	   cell	   culture	   and	   in	   animal	  studies.	  The	  central	  focus	  this	  chapter	  is	  to	  investigate	  whether	  changes	  in	  global	  activity	   and	   skeletal	  muscle	   gene	   expression	  of	   11β-­‐HSD1	  occur	   across	  human	  ageing,	   thus	   providing	   an	   insight	   into	   a	   potential	   novel	   therapeutic	   target	   to	  improve	   healthy	   lifespan.	   Ageing	   is	   associated	   with	   a	   myriad	   of	   physiological	  changes,	   characterised	   by	   alterations	   in	   body	   composition	   (sarcopenia,	   central	  obesity,	   osteoporosis),	   development	   of	   metabolic	   dysfunction	   (insulin	  resistance)	   and	   chronic	   disease	   states	   (cardiovascular	   disease,	  hypertension)(Barzilai	   et	   al.,	   2012).	   Skeletal	   muscle	   has	   dual	   roles,	   as	   a	  contractile	   tissue	   determining	   locomotor	   function	   and	   as	   a	   metabolic	   tissue	  important	   in	   the	   endocrine	   system,	   making	   it	   an	   important	   target	   in	   the	  prevention	  of	  adverse	  ageing.	  As	  outlined	  in	  Chapter	  1,	  age-­‐associated	  declines	  in	  various	   hormonal	   axes	   are	   well	   characterised	   and	   underpin	   the	   ‘menopause’,	  ‘andropause’,	   ‘adrenopause’,	   and	   ‘somatopause’.	   Studies	   assessing	   the	  effectiveness	  of	  hormonal	  replacement	  of	  these	  axes	  in	  preventing	  features	  of	  the	  ageing	   phenotype	   have	   had	  mixed	   results,	   and	   are	   limited	   by	   efficacy	   or	   long-­‐term	  safety	  concerns	  (Chahal	  and	  Drake,	  2007).	  	  	  Circulating	  cortisol	  levels	  are	  maintained	  under	  negative	  feedback	  regulation	  via	  the	  HPA-­‐axis.	  Local	  glucocorticoid	  exposure	  is	  also	  regulated	  at	  the	  pre-­‐receptor	  level	   by	   the	   11β-­‐HSD	   enzymes,	   which	   interconvert	   “inactive”	   cortisone	   and	  “active”	   cortisol,	  with	   the	   type	  1	   isoform	  acting	   primarily	   as	   an	   oxo-­‐reductase.	  Many	  studies	  have	  investigated	  changes	  in	  HPA-­‐axis	  function	  with	  age,	  and	  these	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were	   reviewed	   in-­‐depth	   in	   Chapter	   1.	   To	   summarise,	   HPA-­‐axis	   activation	   and	  increases	  in	  mean	  24-­‐hour	  cortisol	  secretion,	  of	  between	  20-­‐50%	  over	  the	  adult	  lifespan	  were	   seen	   in	   some	  studies	   (Dodt	  et	   al.,	   1994,	  Van	  Cauter	  et	   al.,	   1996).	  	  Alterations	  in	  diurnal	  variation	  of	  cortisol	  secretion,	  characterized	  by	  an	  earlier	  acrophase	   and	   reduced	   amplitude	   (Sherman	   et	   al.,	   1985,	   van	  Coevorden	   et	   al.,	  1991),	   increases	   in	   serum	   morning	   cortisol	   (20-­‐30%	   over	   adult	   lifespan)	  (Belanger	   et	   al.,	   1994,	   Giordano	   et	   al.,	   2001,	   Ferrari	   et	   al.,	   2001a,	   Zhao	   et	   al.,	  2003),	   reduced	   sensitivity	   to	   dexamethasone	   suppression	   (Wilkinson	   et	   al.,	  1997,	  Magri	  et	  al.,	  1997),	  and	  delayed	  normalization	  of	  cortisol	  following	  stress	  (Traustadottir	  et	  al.,	  2004)	  have	  all	  been	  reported	  with	  increasing	  age.	  Activation	  of	  the	  HPA-­‐axis	  has	  been	  associated	  with	  morbidity	  including	  dementia	  and	  the	  metabolic	  syndrome	  (Magri	  et	  al.,	  1997,	  Lupien	  et	  al.,	  1994,	  Phillips	  et	  al.,	  1998,	  Jang	  et	  al.,	  2012).	  	  	  Pre-­‐receptor	   GC	   metabolism	   by	   11β-­‐HSD1	   has	   been	   implicated	   in	   the	  pathogenesis	   of	   the	   metabolic	   syndrome	   and	   a	   range	   of	   conditions	   including	  osteoporosis,	   inflammatory	   arthritis	   and	   glaucoma	   (Gathercole	   et	   al.,	   2013).	  Recently	  studies	  have	  indicated	  that	  11β-­‐HSD1	  expression/activity	  is	  elevated	  in	  key	  tissues	  with	  ageing	  and	  may	  be	  implicated	  in	  the	  development	  of	  associated	  disease	  states.	   	  Our	  group	  found	  a	  positive	  correlation	  between	  11β-­‐HSD1	  oxo-­‐reductase	   activity	   and	   donor	   age	   in	   primary	   cultures	   of	   human	   osteoblasts	  (n=18,	   r=0.58,	   p<0.01)	   implicating	   local	   tissue	   GC	   amplification	   in	   the	  pathogenesis	   of	   age-­‐associated	   osteoporosis	   and	   GC	   sensitivity	   (Cooper	   et	   al.,	  2002).	  Furthermore	  the	  non-­‐selective	  11β-­‐HSD-­‐inhibitor	  carbenoxolone	  reduced	  bone	   resorption	  markers	   in	   healthy	   volunteers	   (Cooper	   et	   al.,	   2000).	   A	   recent	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study	  suggests	  that	  local	  tissue	  11β-­‐HSD1	  has	  a	  putative	  role	  in	  the	  pathogenesis	  of	  post-­‐menopausal	  metabolic	  dysfunction	  (Andersson	  et	  al.,	  2009).	  In	  this	  study	  of	   23	   pre-­‐menopausal	   and	  23	  post-­‐menopausal	  women,	   there	  was	   evidence	   of	  global	  increases	  in	  11β-­‐HSD1	  activity,	  subcutaneous	  gene	  expression	  and	  hepatic	  1st	  pass	  metabolism	  of	  cortisone	  in	  the	  latter	  group.	  The	  authors	  concluded	  that	  enhanced	  local	  tissue	  generation	  of	  active	  GCs	  may	  underpin	  adverse	  metabolic	  features	   seen	   after	   the	  menopause	   including	   central	   obesity,	   insulin	   resistance	  and	   dyslipidaemia.	   This	   is	   of	   particular	   clinical	   interest	   in	   view	   of	   the	  controversies	   surrounding	   the	   risk	   benefit	   profile	   of	   conventional	   Hormone	  Replacement	   Therapy	   (HRT)	   post-­‐menopausally,	   with	   a	   recent	   Cochrane	  systematic	   review	   of	   13	   trials	   (n=38171	   patients)	   showing	   no	   difference	   in	  myocardial	  infarctions,	  cardiovascular	  disease	  death,	  and	  all	  cause	  mortality	  and	  increased	   risk	   of	   stroke,	   venous	   thromboembolism	   and	   pulmonary	   embolism,	  with	  treatment	  (Main	  et	  al.,	  2013).	  Concerns	  over	  long-­‐term	  safety	  risks	  of	  HRT	  also	   limit	   its	   use	   in	   prevention	   of	   osteoporosis	   and	   sarcopenia	   (Maltais	   et	   al.,	  2009,	  de	  Villiers	  and	  Stevenson,	  2012).	  On	   this	  background	   there	   is	  a	  need	   for	  alternative	   preventative	   therapies	   for	   co-­‐morbidities	   associated	   with	   the	  menopause.	  	  	  	  	  Gender-­‐specific	  differences	  in	  HPA-­‐Axis	  function	  cortisol	  metabolism	  have	  been	  described	   in	   a	   number	   of	   studies.	   Animal	   studies	   indicate	   that	   11β-­‐HSD1	  expression/activity	  is	  increased	  in	  males	  vs.	  females.	  There	  is	  evidence	  that	  this	  may	   be	   regulated	   by	   a	   suppressive	   effect	   of	   oestrogen	   on	   gene	   expression.	  However	   sex-­‐specific	   patterns	   of	   GH-­‐secretion	   have	   also	   been	   implicated	  with	  continuous	   secretion	   suppressing	   hepatic	   11β-­‐HSD1	   expression	   in	   females	   in	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contrast	  to	  the	  pulsatile	  secretion	  seen	  in	  males,	  which	  has	  no	  effect	  (Low	  et	  al.,	  1994,	   Albiston	   et	   al.,	   1995,	   Liu	   et	   al.,	   1997).	   Sexual	   dimorphism	   in	   cortisol	  metabolism	   is	   also	   apparent	   in	   human	   studies	   of	   hypopituitary	   patients	  (n=44)(Weaver	  et	  al.,	  1998)	  and	  healthy	  elderly	  subjects	  (n=22)	  (Toogood	  et	  al.,	  2000b).	  However	   the	   factors	   that	   regulate	   the	   observed	  differences	   in	   enzyme	  activity	  have	  not	  been	  fully	  elucidated	  with	  GH	  status,	  insulin	  resistance	  and	  fat	  mass	  implicated.	  	  	  	  Although	   11β-­‐HSD1	   has	   been	   shown	   to	   be	   present	   and	   functionally	   active	   in	  human	   vastus	   lateralis	   samples,	   and	   several	   studies	   have	   investigated	   its	  relationship	  with	   insulin	   resistance	  and	  physiological	   stress,	   its	   role	   in	   skeletal	  muscle	  ageing	  has	  not	  been	  assessed	  (Jang	  et	  al.,	  2006,	  Jang	  et	  al.,	  2007,	  Morgan	  et	  al.,	  2009,	  Salehzadeh	  et	  al.,	  2009,	  Jang	  et	  al.,	  2009,	  Dovio	  et	  al.,	  2010).	  Biedasek	  et	  al	  (2011)	  were	  the	  first	  to	  publish	  on	  the	  link	  between	  11β-­‐HSD1	  and	  muscle	  atrophy	  by	  demonstrating	  increased	  protein	  degradation	  and	  E3-­‐ubiquitin	  ligase	  expression	  in	  primary	  human	  myoblasts	  treated	  with	  cortisone,	  and	  attenuation	  of	   this	   effect	   in	   response	   to	   pre-­‐treatment	   with	   the	   non-­‐selective	   11β-­‐HSD	  inhibitor,	  carbenoxolone.	  The	   in-­‐vitro	  work	  outlined	   in	  chapter	  4	  of	   this	   thesis,	  has	   confirmed	   these	   findings	   by	   using	   a	   selective	   11β-­‐HSD1	   inhibitor.	  Furthermore,	   the	   novel	   in	   vivo	   mouse	   studies	   outlined	   in	   chapter	   5	   have	  confirmed	   that	   skeletal	   muscle	   ageing	   is	   associated	   with	   activation	   of	   key	   GC	  regulated	  genes,	   and	   that	   these	   changes	  are	  attenuated	   in	  both	  GC-­‐treated	  and	  aged	  11β-­‐HSD1	  KO	  mice	  on	  high-­‐fat	  diet	  in	  combination	  with	  preserved	  muscle	  strength.	   	  An	  assessment	  of	  skeletal	  muscle	  gene	  expression	  changes	  seen	  with	  ageing	  in	  humans	  is	  important	  in	  order	  to	  provide	  a	  rationale	  for	  potential	  future	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studies	  using	  selective	  11β-­‐HSD1	  inhibitors	  in	  sarcopenia.	  Furthermore,	  to	  date	  no	  definitive	  assessment	  of	  pre-­‐receptor	  GC	  metabolism	  has	  been	  made	  in	  both	  genders,	  across	  the	  age	  spectrum.	  The	  studies	  that	  have	  been	  completed	  tend	  to	  be	   small,	  with	   recruitment	   of	   subjects	   limited	   to	   one	   sex	   and	   extremes	   of	   age.	  Also	  many	  studies	  rely	  on	  tissue-­‐banked	  samples,	  and	  have	  absent	  or	  insufficient	  assessment	  of	   important	  baseline	  characteristics	   including	  serum	  biochemistry,	  body	   composition,	   and	   strength	   testing	   parameters.	   On	   this	   background,	   the	  study	  outlined	  in	  this	  chapter	  represents	  the	  most	  in	  depth	  assessment	  of	  global	  activity	   and	   the	   first	   assessment	   local	   skeletal	   muscle	   11β-­‐HSD1	   expression	  across	  human	  ageing	  in	  both	  genders.	  In	  addition,	  detailed	  phenotyping	  has	  been	  carried	   out	   to	   enable	   assessment	   of	   relationships	   between	   11β-­‐HSD1	  expression/activity	   with	   body	   composition	   markers,	   hormone	   levels	   and	  cardiovascular	  risk	  factors.	  	  	  In	   addition	   our	   gene	   expression	   array	   study	   of	   skeletal	   muscle	   ageing	  contributes	   to	   previous	   data,	   which	   is	   reliant	   on	   smaller	   subject	   cohorts,	   in	  restricted	  age	  groups	  and	  pooled	  samples	   (Welle	  et	  al.,	  2000,	   Jozsi	  et	  al.,	  2000,	  Welle	   et	   al.,	   2003,	   Giresi	   et	   al.,	   2005).	   Finally	   these	   studies	   will	   provide	   an	  invaluable	   resource	   to	   be	   interrogated	   in	   future	   studies	   of	   mechanisms	   of	  skeletal	  muscle	  ageing,	  and	  their	  functional	  and	  metabolic	  consequences	  and	  will	  provide	   gender	   and	   age-­‐specific	   normative	   data	   of	   urine	   steroid	   profiles	   that	  could	  help	  future	  clinical	  practice	  (Deutschbein	  et	  al.,	  2011).	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6.2.	  Hypotheses	  Our	   central	   hypothesis	   is	   that	   local	   tissue	   11β-­‐HSD1	   expression	   and	   global	  activity	   is	  upregulated	  with	  age	   in	  humans	  and	  that	  this	  contributes	  to	  adverse	  phenotypic	   features	   in	   affected	   tissues.	   The	   central	   focus	   of	   this	   chapter	   is	  skeletal	   muscle	   where	   we	   hypothesize	   that	   local	   tissue	   GC	   generation	  contributes	  to	  muscle	  weakness	  and	  sarcopenia	  of	  ageing.	  	  	  
6.3.	  Research	  Strategy	  and	  Aims	  Healthy	   human	   volunteers	   of	   both	   genders,	   aged	   between	   20-­‐80	   years	   were	  recruited	   to	   the	   study.	   They	   attended	   the	   Wellcome	   Trust	   Clinical	   Research	  Facility	   at	   the	   Queen	   Elizabeth	   Hospital,	   Birmingham	   where	   they	   underwent	  assessment	  of	  anthropometric	  variables,	  body	  composition,	  and	  strength	  testing,	  along	  with	  collection	  of	  serum	  for	  biochemical	  analysis,	  24-­‐hour	  urine	  collection	  for	  GC/MS	  and	  muscle	  biopsies	  for	  gene	  expression	  analysis.	  Our	  Aims	  are	  listed	  below:	  a) To	   determine	   whether	   there	   are	   age-­‐associated	   changes	   in	   skeletal	  muscle	  11β-­‐HSD1	  expression.	  b) To	   determine	   whether	   there	   are	   age-­‐associated	   changes	   in	   global	  activity	  of	  11β-­‐HSD1.	  c) To	   determine	   which	   genes	   are	   involved	   in	   skeletal	   muscle	   ageing	  using	  a	  focused	  array	  approach.	  	  d) To	   determine	   age-­‐associated	   changes	   in	   global	   corticosteroid	  secretion	   and	   metabolism	   using	   GC/MS	   analysis	   of	   24-­‐hour	   urine	  collections.	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e) To	  establish	  whether	  there	  are	  significant	  correlations	  between	  11β-­‐HSD1	   expression/activity	   and	   phenotypic	   features	   (demographic	  information,	   body	   composition,	   strength,	   metabolic	   profile	   and	  hormone	  levels).	  	  
6.4.	  Methods	  
6.4.1.	  Human	  Study	  Protocol	  135	   healthy	   volunteers	   were	   recruited	   to	   take	   part	   in	   a	   study	   designed	   to	  investigate	   the	   role	   of	   11β-­‐HSD1	   expression	   and	   activity	   in	   normal	   human	  ageing.	   Volunteers	   were	   of	   both	   sexes,	   aged	   between	   20-­‐80	   years.	   Inclusion	  criteria	  were	  BMI	   between	  20-­‐30kg/m2.	   Female	   subjects	  were	   in	   the	   follicular	  phase	   of	   the	   menstrual	   cycle,	   or	   if	   post-­‐menopausal	   were	   not	   on	   hormone	  replacement	   therapy.	   Subjects	   prescribed	   aspirin	   were	   asked	   to	   discontinue	  treatment	  3	  days	  prior	  to	  muscle	  biopsy.	  Exclusion	  criteria	  included	  pregnancy,	  significant	   past	   medical	   history	   including	   diabetes	   mellitus,	   ischaemic	   heart	  disease,	  cerebrovascular	  disease,	  severe	  respiratory	  disease,	  and	  epilepsy.	  Other	  exclusion	   criteria	   were	   glucocorticoid	   therapy	   in	   the	   past	   12	   months,	   use	   of	  drugs	   known	   to	   effect	   GH	   release,	   and	   use	   of	   oral	   anticoagulants.	   Procedures	  were	  carried	  out	  over	  a	  day	  visit	  to	  the	  Wellcome	  Trust	  Clinical	  Research	  Facility	  at	   the	  Queen	  Elizabeth	  Hospital	  Birmingham,	  University	  Hospitals	  Birmingham	  NHS	  Foundation	  Trust.	   Patients	   arrived	   fasted	  at	  0845h	  having	   collected	  a	  24-­‐hour	  urine	  sample.	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6.4.1.1.	   Initial	  Observations	  Research	  nurses	  measured	  height	  and	  weight	  of	  subjects	  on	  arrival.	  Three	  blood	  pressure	  measurements	  were	  recorded	  using	  an	  automatic	  sphygmomanometer	  with	  the	  subject	  seated.	  	  	  
6.4.1.2.	   24-­‐hour	  Urine	  Collection	  Volunteers	  performed	  this	  during	  a	  convenient	  24-­‐hour	  period	  in	  the	  week	  prior	  to	  the	  Wellcome	  Trust	  Clinical	  Research	  Facility	  visit.	  Volunteers	  were	  advised	  to	  empty	  their	  bladder	  into	  the	  toilet	  normally	  on	  waking	  on	  the	  morning	  that	  the	  collection	   is	   started	   with	   the	   time	   being	   noted.	   All	   urine	   produced	   over	   the	  subsequent	   24	   hours	   was	   collected	   into	   a	   plain	   3-­‐litre	   collection	   bottle.	   On	  receipt	   of	   the	   sample	   total	   urine	   volume	  was	   collected	   and	   an	   aliquot	   of	   30ml	  was	  transferred	  to	  a	  universal	  container	  and	  stored	  at	  -­‐80°C	  pending	  analysis.	  	  	  
6.4.1.3.	   Urine	   Steroid	   Profiling	   by	   Gas	   Chromatography/Mass	  
Spectrometry	  
	  Beverly	  Hughes	  performed	  GC/MS	  analysis	   in-­‐house	  using	  a	  method	  described	  previously	   (Shackleton,	   1986,	   Shackleton,	   1993).	   The	   protocol	   involves	  hydrolysis,	  extraction	  and	  derivatisation	  stages	  prior	  to	  injection	  into	  the	  GC/MS.	  1ml	  of	  urine	  was	  transferred	   from	  the	  universal	  container	  to	  a	  glass	   tube.	  Free	  steroids	  were	  extracted	  using	  C18	  Sep	  pak	  cartridges.	  The	  Sep	  pak	  cartridge	  was	  washed	  in	  4ml	  methanol	  followed	  by	  4ml-­‐distilled	  water.	  The	  sample	  was	  added	  to	  the	  Sep	  pak	  cartridge,	  applied	  one	  drop	  at	  a	  time.	  The	  tube	  was	  then	  washed	  in	  4ml-­‐distilled	  water.	  The	  sample	  was	  then	  eluted	  into	  a	  clean	  glass	  tube	  with	  4ml	  methanol.	  The	  methanol	  was	  evaporated	  under	  nitrogen	  at	  55°C.	  Hydrolysis	  mix	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was	   made	   up	   (3ml	   0.1M	   acetate	   buffer	   (20ml	   1M	   acetic	   acid+30ml	   1MNa	  acetate+450mldH2O–pH4.8-­‐5),	   10mg	   ascorbate	   (Sigma),	   10mg	   sulphatase	  (Sigma,	  Dorset,	  UK)).	  	  3ml	  of	  the	  mix	  was	  added	  to	  each	  tube	  and	  was	  heated	  at	  55°C	  for	  3h.	  The	  tubes	  were	  then	  allowed	  to	  cool	  to	  room	  temperature.	  The	  Sep	  pak	  cartridge	  was	  washed	  in	  4ml	  methanol	  then	  in	  the	  same	  volume	  of	  distilled	  water.	  The	  sample	  was	  added	  to	  the	  column,	  washed	  in	  4ml-­‐distilled	  water	  and	  eluted	   into	   a	   clean	   glass	   tube	   containing	   4ml	   methanol.	   100μl	   of	   internal	  standard	   (stigmasterol	   and	   cholesterol	   butyrate)	   was	   added	   to	   each	   sample	  using	  a	  glass	  syringe.	  Methanol	  was	  evaporated	  under	  nitrogen	  at	  55°C.	  3	  drops	  of	   2%	   methoxyamine-­‐pyridine	   as	   added	   to	   tubes,	   which	   were	   then	   vortexed.	  Tubes	  were	  heated	  at	  55°C	  for	  1h.	  50µl	  TMSi	  was	  added	  to	  each	  sample,	  which	  was	   then	   vortexed.	   	   Tubes	   were	   heated	   to	   120oC	   in	   an	   oven	   overnight.	   2ml	  cyclohexane	  was	  added	  to	  each	  sample,	  and	  tubes	  were	  vortexed.	  2ml	  of	  distilled	  water	  was	  then	  added	  and	  samples	  were	  vortexed.	  The	  top	  layer	  was	  transferred	  to	   a	   clean	   glass	   tube	   and	   evaporated	   under	   nitrogen	   at	   55°C.	   350µl	   of	  cyclohexane	   was	   added	   to	   sample,	   which	   was	   vortexed	   and	   transferred	   to	  injection	  vials.	   Samples	  were	   injected	   into	  GC/MS	   (Hewlett	  Packard	  5970)	  and	  15m	  fused	  silica	  capillary	  columns	  with	  an	  external	  standard	  to	  allow	  calibration	  of	   the	   run.	   Individual	  metabolites	  were	   quantified	   by	   calculating	   relative	   peak	  areas	   by	   comparison	   of	   peak	   area	   of	   sample	   to	   corresponding	   peak	   in	   the	  standard.	   Diagnostic	   ratios	   were	   then	   calculated,	   and	   high	   THF+5αTHF/THE,	  cortols/cortolones,	   and	   11OH-­‐androsterone+11OH-­‐etiocholanolone/11-­‐oxoetiocholanolone	   ratios	   are	   accepted	   markers	   of	   global	   11β-­‐HSD1	   oxo-­‐reductase	  activity,	  assuming	  normal	  11β-­‐HSD2	  activity	  indicated	  by	  urinary	  F/E	  (UFF/UFE)	  ratios.	  	  The	  coefficient	  of	  variance	  (inter	  and	  intra-­‐assay)	  was	  	  <10%.	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6.4.1.4.	   Dual-­‐Energy	  X-­‐ray	  Absorptiometry	  (DEXA)	  Scan	  DEXA	  scanning	  (DPX	  Lunar	  Corp,	  Madison,	  WI,	  USA)	  was	  used	  to	  assess	  full	  body	  composition	  and	  bone	  mineral	  density.	  	  	  
6.4.1.5.	   Strength	  Testing	  
Jumping	  mechanography	  using	  Leonardo	  Force	  Plate	  System:	  This	  method	  utilises	  forces	  measured	  by	  ground	  reaction	  force	  plates	  (Novotec,	  Pforzheim,	  Germany),	  over	   the	  course	  of	  a	   range	  of	  movements,	   including	  speed	   tests	   (single	   two	   leg	  jump,	  chair	  rising	  test,	  heel	  rise	  test),	  and	  force	  tests	  (multiple	  one	  leg	  jump,	  and	  multiple	   two	   leg	  hop).	  Maximum	  forces	   (Fmax),	  velocity	   (Vmax),	  power	  output	  (Pmax),	  and	  height	  of	   jump	  were	  calculated.	  Volunteers	  performed	   the	   tests	  as	  described	  below.	  Single	  two-­‐legged	  jump:	  Volunteers	  were	  asked	  to	  perform	  one	  jump	  as	  high	  as	  possible	  bending	  their	  legs	  before	  the	  jump	  and	  using	  their	  arms	  to	  aid	  them.	  They	  were	  asked	  to	  stand	  still	  and	  upright	  following	  the	  jump.	  This	  test	   was	   repeated	   a	   total	   of	   3	   times.	   Outcome	   parameters	   were	   Fmax/BW,	  Pmax/BW,	  Vmax	  and	  jump	  height,	  which	  have	  precision	  values	  (Veilleux	  and	  Rauch,	  2010)	   of,	   13.1%,	   3.4%,	   2.3%	   &	   5.0%,	   respectively. Chair	   rising	   test:	   This	   was	  used	  to	  provide	  a	  measure	  of	  muscle	  power	  in	  those	  who	  were	  unable	  to	  jump.	  The	  volunteer	  was	  asked	  to	  sit	  on	  a	  bench	  with	  their	  arms	  crossed	  holding	  their	  shoulders.	  They	  were	  then	  asked	  to	  stand	  up	  straight	  and	  sit	  down	  as	  quickly	  as	  possible	   for	   a	   total	   of	   5	   repetitions.	   Outcome	   parameters	   were	   Fmax/BW,	  Pmax/BW	   &	   Vmax,	   which	   have	   precision	   values	   of,	   7.9%,	   15.6%,	   &	   10.5%,	  respectively. Heel-­‐Rise	  Test:	  This	   test	   is	  useful	   in	  volunteers	   that	  are	  unable	   to	  perform	  the	  2	  previously	  mentioned	  tests.	  They	  were	  asked	  to	  stand	  on	  tiptoes	  with	   straight	   knees,	   for	   5	   repetitions.	   Outcome	   parameters	   were	   Fmax/BW,	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Pmax/BW	   &	   Vmax,	   and	   have	   precision	   values	   of,	   3.7%,	   13.5%,	   &	   10.5%,	  respectively. Multiple	   one-­‐leg	   jumps:	   The	   volunteer	   was	   asked	   to	   hop	  rhythmically	   with	   stiff	   knees.	   The	   outcome	   parameter	   was	   Fmax/BW,	   and	  precision	  was	  4.2%.	  Multiple	   two-­‐leg	  hops:	  The	  volunteer	  was	  asked	  to	  hop	  on	  both	   forefeet	   as	   high	   as	   possible	  with	   stiff	   knees.	   Again	   the	   output	   parameter	  was	  Fmax/BW,	  and	  precision	  was	  5.4%.	  	  
Hand-­‐held	   dynamometry: The	   testing	   procedure	   involved	   the	   use	   of	   a	   grip	  strength	   dynamometer	   (Takei	   Instruments,	   Niigata	   City,	   Japan).	   3	   maximal	  contractions	  on	   either	   side	  were	  obtained	  with	  15	   seconds	   rest.	   Peak	   absolute	  strength	  in	  kg	  and	  relative	  handgrip	  strength	  (kg	  force	  per	  kg	  bodyweight)	  were	  recorded.	   	  
6.4.1.6.	   Fasting	  Bloods	  In	   the	   fasted	   state,	   a	   20G	   intravenous	   cannula	   was	   inserted	   peripherally,	   and	  baseline	   bloods	  were	   taken	   for	   analysis.	   Samples	   were	   analysed	   using	   clinical	  assays	   at	   the	   University	   Hospital	   Birmingham	   NHS	   Foundation	   Trust	  laboratories.	   Assay	   details	   (Types	   of	   Assay	   in	   brackets;	   Manufactured	   by	   Roche	  
Diagnostics	   Limited,	  West	   Sussex,	   UK,	   unless	   otherwise	   stated):	   total	   cholesterol	  (enzymatic	   colourmetric),	   HDL	   (homogenous	   enzymatic	   colourmetric),	   glucose	  (enzymatic	   reference	   method	   with	   hexokinase),	   CRP	   (particle	   enhanced	  immunoturbidimetric	  assay),	  Na+,	  K+	  (ion-­‐selective	  electrode),	  Urea	  (kinetic	  test	  with	   urease	   and	   glutamate	   dehydrogenase),	   creatinine	   (kinetic	   colourmetric	  assay	   (Jaffe	   Method)),	   cortisol,	   TSH,	   FT4	   (chemiluminescence	   immunoassay,	  Advia	   Centaur,	   Bayer	   Diagnostics,	   Newbury,	   UK),	   DHEAS,	   SHBG	   and	   GH	  (Immulite	  Immunoassay	  Siemens	  AG,	  Erlangen,	  Germany).	  
	   175	  
6.4.1.7.	   Vastus	  Lateralis	  Muscle	  Biopsy	  I	   performed	   all	   biopsy	   procedures	   in	   this	   study.	   A	   percutaneous	   Bergstrom	  technique	   was	   used,	   which	   has	   advantages	   over	   open	   biopsy	   of	   having	   lower	  complication	   rates,	   quicker	   healing,	   and	   reduced	   scarring	   (Bergstrom,	   1975).	  Suction	   was	   used	   in	   order	   to	   increase	   sample	   yield	   (Evans	   et	   al.,	   1982).	   This	  technique	  has	  been	  widely	  adopted	  by	  researchers	  investigating	  skeletal	  muscle	  metabolism	   and	   physiology	   (Tarnopolsky	   et	   al.,	   2011).	   The	   procedure	   was	  carried	  out	  under	  sterile	  conditions.	  The	  tip	  of	  a	  8	  French	  gauge	  (2.7mm)	  suction	  catheter	  (SP	  Services,	  Donnington	  UK)	  was	  cut	  at	  an	  oblique	  angle	  and	  inserted	  into	   the	   end	   of	   the	   trochar	  which	  was	   then	   inserted	   into	   the	  Bergstom	  biopsy	  needle.	   An	   area	   of	   skin	  measuring	   approximately	   15cm	   in	   diameter,	   overlying	  the	   lateral	   aspect	   of	   the	   right	   thigh	  was	   cleaned	  with	   iodine	   solution.	  A	   sterile	  drape	  (Ref	  1020	  40x40cm,	  adhesive	  area	  10x12cm,	  aperture	  circle	  6cm)	  (3M,	  St.	  Paul,	   Minnesota,	   USA)	   was	   applied.	   1-­‐2ml	   of	   1%	   lignocaine	   solution	   was	  infiltrated	  into	  the	  skin	  via	  a	  23G	  (0.6mm)	  needle	  connected	  to	  a	  10ml	  syringe.	  Subsequently	   between	   2-­‐6ml	   were	   infiltrated	   to	   subcutaneous	   tissue	   down	   to	  the	  muscle	  fascia,	  using	  a	  21G	  (0.8mm)	  needle.	  A	  5mm	  linear	  stab	  incision	  was	  made	   in	   the	   skin	   and	   subcutaneous	   tissue	   midway	   up	   the	   thigh.	   The	   biopsy	  needle	   was	   inserted	   through	   this	   incision,	   and	   advanced	   into	   the	   muscle,	  indicated	  by	  loss	  of	  resistance	  when	  passing	  through	  the	  fascia.	  	  The	  trochar	  was	  retracted	  to	  open	  the	  cutting	  window.	  The	  research	  nurse	  assisting	  then	  applied	  suction	  by	  connecting	  a	  50ml	  syringe	  to	  the	  end	  of	  the	  catheter.	  The	  trochar	  was	  then	  advanced	  to	  its	  previous	  position,	  closing	  the	  cutting	  window.	  The	  trochar	  was	  rotated	  360°.	  The	  needle	  was	  then	  removed	  and	  the	  sample	  was	  inspected.	  If	  the	   sample	  was	   inadequate	   the	   above	   procedure	  was	   repeated.	   Samples	  were	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placed	   in	   labelled	   cryovials	   and	   transferred	   immediately	   to	   liquid	   nitrogen.	  Long-­‐term	  storage	  occurred	  at	  -­‐80°C.	  Pressure	  was	  applied	  for	  5	  minutes,	  using	  sterile	  gauze	   to	  obtain	  wound	  haemostasis.	  The	  wound	  was	   closed	  using	   steri-­‐strips	  in	  a	  ‘star	  formation’.	  It	  was	  covered	  with	  sterile	  gauze	  and	  a	  dressing	  and	  pressure	  bandage	  were	  applied.	  	  Subjects	  stayed	  in	  bed	  for	  30-­‐60	  minutes	  post-­‐procedure.	   Aftercare	   advice	   to	   remove	   the	   pressure	   bandage	   at	   6	   hours,	   and	  keep	  the	  wound	  dry	  for	  2	  days	  post-­‐procedure	  was	  given.	  	  	  
6.4.1.8.	  Microfluidic	  Gene	  Expression	  Array	  	  
	  See	  chapter	  2	  for	  full	  method.	  Target	  genes	  had	  functions	  in	  atrophy,	  proteolysis,	  protein	   synthesis,	   fibre-­‐type	   switching,	   apoptosis,	   GC	   metabolism,	   endocrine	  signalling,	  inflammation,	  cell	  stress	  response	  and	  mitochondrial	  biogenesis.	  	  
	  
6.4.1.9.	  Ethical	  Approval	  	  Ethical	   approval	   was	   obtained	   by	   the	   Coventry	   and	   Warwickshire	   Research	  Ethics	   Committee	   (REC	   Reference	   Number	   07/H1211/168).	   The	   protocol	   was	  approved	   by	   the	   Scientific	   Committee,	   of	   the	  Welcome	   Trust	   Clinical	   Research	  Facility,	   at	   Queen	   Elizabeth	   Hospital	   Birmingham.	   The	   study	   commenced	   in	  October	   2010	   and	   was	   completed	   in	   March	   2013.	   Volunteers	   were	   recruited	  from	   e-­‐mails,	   website	   postings,	   and	   notices	   placed	   at	   the	   University	   of	  Birmingham,	  University	  Hospitals	  Birmingham	  NHS	  Foundation	  Trust,	  and	  in	  the	  local	   community.	   They	   were	   given	   full	   written	   information	   on	   the	   study,	   and	  gave	   written	   informed	   consent.	   After	   study	   completion	   they	   received	   travel	  expenses	  and	  clinically	  relevant	  results	  were	  passed	  on	  to	  General	  Practitioners.	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6.5.	  Results	  	  
6.5.1.	  Subject	  Characteristics	  
	  135	   patients	   were	   recruited	   in	   total	   (77	   women	   and	   58	   men)	   with	   an	   age	  distribution	   as	   shown	   in	   tables	   6-­‐1	   and	   6-­‐2.	   Care	   should	   be	   taken	   when	  interpreting	   results	   in	   sub-­‐group	   analyses	   (i.e.	   age	   groups	   and	   gender)	   due	   to	  loss	  of	  statistical	  power.	  Ethnic	  backgrounds	  of	  female	  subjects	  were	  as	  follows:	  84%	  Caucasian,	  14%	  Asian	  and	  2%	  African-­‐Caribbean.	  Male	  subjects	  were	  also	  84%	  Caucasian,	  14%	  Asian	  and	  2%	  Mixed	  Race.	  A	  full	  breakdown	  of	  ethnicities	  by	  age	  and	  sex	  are	  shown	  in	  supplementary	  tables	  S6.1	  and	  S6.2.	  An	  analysis	  of	  urine	   steroid	   markers	   of	   global	   11β-­‐HSD1	   activity	   and	   skeletal	   muscle	   gene	  expression	   revealed	   no	   differences	   between	   Caucasians	   and	   Asians	  (supplementary	   tables	   S6.3	   and	   S6.4).	   Medical	   conditions	   of	   subjects	   included	  hypertension	   (n=17),	   dyslipidaemia	   (n=12),	   asthma	   (not	   on	   steroids)(n=10),	  previous	  fractures	  (n=7),	  benign	  prostatic	  hypertrophy	  (n=5)	  and	  osteoarthritis	  (n=6).	  17	  subjects	  prescribed	  anti-­‐hypertensives	  and	  12	  prescribed	  statins	  were	  included	   in	   the	   study.	  Three	  volunteers	   treated	  with	   finasteride	  or	  dutasteride	  were	  excluded	  from	  the	  study.	  	  	  
6.5.2.	  Baseline	  Observations	  Across	  Human	  Ageing	  Cohort	  
	  As	  illustrated	  in	  Table	  6-­‐1,	  systolic	  blood	  pressure	  was	   increased	  in	  those	  aged	  60-­‐70	  and	  over	  70	  years	  vs.	  those	  in	  the	  youngest	  age	  group,	  in	  women	  (142	  and	  141	  mmHg	  vs.	  113	  mmHg,	  p-­‐values	  <0.001	  and	  <0.05	  respectively).	  In	  addition	  middle-­‐aged	   women	   had	   increased	   BMIs	   compared	   to	   the	   young	   women	   (26	  kg/m2	  in	  40-­‐50	  and	  50-­‐60	  year	  age	  groups	  vs.	  21	  kg/m2	  in	  20-­‐30	  year	  age	  group,	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p<0.001	   and	   p<0.05,	   respectively).	   In	   men,	   no	   significant	   differences	   in	   blood	  pressure	  or	  BMI	  were	  seen	  between	  groups	  (see	  table	  6-­‐2).	  	  	  
	  



















































21	  	  (21-­‐24)	  	   23	  	  (21-­‐25)	  	   26***	  	  (25-­‐29)	  	   26**	  	  (25-­‐27)	  	   24	  	  (23-­‐27)	  	   24	  	  (22-­‐26)	  	  	  
Table	  6-­‐1:	  Observational	  data	  from	  female	  ageing	  study	  participants	  (n=77).	  SBP	  values	  were	  
increase	  in	  60-­‐70	  and	  >70	  year	  age	  groups	  compared	  to	  those	  aged	  20-­‐30	  years.	  BMI	  values	  for	  40-­‐
50	  and	  50-­‐60	  year	  age	  groups	  were	  increased	  compared	  to	  the	  20-­‐30	  year	  age	  group.	  Statistically	  
significant	  differences	  from	  the	  20-­‐30	  year	  age-­‐group	  as	  derived	  from	  Dunn’s	  multiple	  comparison	  
test	  are	  highlighted	  in	  bold	  *p<0.05,	  **p<0.01	  and	  ***p<0.001.	  Overall	  p-­‐values	  from	  Kruskal-­‐Wallis	  
analysis	  were	   as	   follows:	   SBP:	   p<0.0001,	   DBP:	   p=0.51	   and	   BMI:	   p=0.0005.	   Data	   are	   expressed	   as	  
medians	   and	   interquartile	   ranges	   (IQRs).	   SBP	   =	   systolic	   blood	   pressure,	   DBP	   =	   diastolic	   blood	  
pressure	  and	  BMI	  =	  body	  mass	  index.	  	  	  
	  








































	  24	  	  (24-­‐25)	  	   22	  	  (21-­‐25)	  	   28	  	  (27-­‐28)	  	   26	  	  (25-­‐27)	  	   27	  	  (24-­‐31)	  	   25	  	  (25-­‐27)	  	  	  
Table	  6-­‐2:	  Observational	  data	   from	  male	  ageing	   study	  participants	   (n=58).	  Overall	   p-­‐values	  
from	  Kruskal-­‐Wallis	  analysis	  were	  as	  follows:	  SBP:	  p=0.05,	  DBP:	  p=0.53	  and	  BMI:	  p=0.01.	  However,	  
there	  were	   no	   statistically	   significant	   differences	   from	   the	   20-­‐30	   year	   age	   group	  as	   derived	   from	  
Dunn’s	  multiple	  comparison	  test.	  Data	  are	  expressed	  as	  medians	  and	  interquartile	  ranges	  (IQRs).	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6.5.3.	  Serum	  Biochemistry	  Across	  Human	  Ageing	  Cohort	  
	  Baseline	  serum	  biochemical	   test	   results	   for	  women	  and	  men,	  by	  age	  group	  are	  summarized	  in	  tables	  6-­‐3	  and	  6-­‐4,	  respectively.	  Lower	  levels	  of	  serum	  IGF-­‐I	  and	  DHEAS	  were	  observed	  in	  the	  older	  age	  groups	  in	  both	  sexes	  (IGF-­‐I:	  women,	  60-­‐70	  years	  =	  11.9	  nmol/L,	  >70	  years	  =	  11.6	  nmol/L	  vs.	  20-­‐30	  years	  =	  26.8	  nmol/L	  p<0.001;	   indicative	   of	   the	   so-­‐called	   somatopause	   and	   andropause.	   DHEAS:	  women,	  60-­‐70	  years	  =	  1.4	  nmol/L,	  >70	  years	  2.0	  nmol/L	  vs.	  20-­‐30	  years	  =	  4.5	  nmol/L,	  p-­‐values	  <0.001	  and	  <0.01,	  respectively;	  men	  IGF-­‐I,	  60-­‐70	  years	  =	  17.1	  nmol/L,	  >70	  years	  =	  15.9	  nmol/L,	  vs.	  20-­‐30	  years	  =	  26.7	  nmol/L,	  p-­‐values	  <0.01;	  men	   DHEAS	   60-­‐70	   years	   =	   2.5	   nmol/L	   and	   >70	   years	   =	   2.8	   nmol/L	   vs.	   20-­‐30	  years	  =	  8.8	  nmol/L,	  p-­‐values	  <0.001),	  indicative	  of	  the	  normal	  somatopause	  and	  andropause.	   	   Elevations	   in	   LH	   and	   FSH	   levels	   were	   also	   seen	   in	   women	   in	  keeping	  with	   the	  menopause	   (LH:	  50-­‐60	  years	  =	  41.2	   IU/L,	  60-­‐70	  years	  =	  30.8	  IU/L	  vs.	  20-­‐30	  years	  =	  7.4	  IU/L,	  p-­‐values	  <0.001;	  FSH:	  50-­‐60	  years	  =	  61.3	  IU/L,	  60-­‐70	   years	   =	   73.2	   IU/L,	   >70	   years	   =	   54.3	   IU/L	   vs.	   20-­‐30	   years	   =	   4.6	   IU/L,	   p-­‐values	   <0.001).	   There	   appeared	   to	   be	   a	   trend	   towards	   reduced	   9am	   cortisol	  levels	  with	  increasing	  age,	  with	  statistically	  significant	  differences	  seen	  in	  the	  40-­‐50	  and	  60-­‐70	  year	  age	  groups	   (9am	  cortisol	  40-­‐50	  years	  =	  217	  nmol/L,	  60-­‐70	  years	  =	  209	  nmol/L	  vs.	  20-­‐30	  years	  =	  496	  nmol/L,	  p-­‐values	  <0.01).	  No	  significant	  differences	   in	   9am	   cortisol	   were	   observed	   in	   men.	   Statistically	   significant	  changes	  for	  women	  and	  men	  are	  illustrated	  in	  Figures	  6-­‐1	  and	  6-­‐2,	  respectively.	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3.9	  	  (3.8-­‐4.5)	  	  	  
4.6	  	  (3.7-­‐4.8)	  	  	  
4.8	  	  (4.7-­‐5.1)	  	  	  
5.7	  	  (5.4-­‐5.8)	  	  	  
5.6	  	  (4.5-­‐6.5)	  	  	  





1.6	  	  (1.2-­‐1.8)	  	   1.5	  	  (1.4-­‐1.6)	  	   1.6	  	  (1.4-­‐1.8)	  	   1.8	  	  (1.4-­‐2.2)	  	   2.0	  	  (1.8-­‐2.1)	  	   1.8	  	  (1.7-­‐1.9)	  	  
	  
9am	  Cortisol	  	  
(nmol/L)	  
	  





















































4.5	  	  (3.6-­‐5.8)	  	   3.0	  	  (2.5-­‐4.7)	  	   3.0	  (2.3-­‐3.4)	  	   3.0	  (1.7-­‐3.7)	  	   1.4***	  	  (0.7-­‐2.1)	  	   2.0**	  	  (1.1-­‐2.3)	  	  	  
Table	  6-­‐3:	  Serum	  biochemistry	  results	   for	   female	  ageing	  study	  subjects	   (n=77).	   	  Statistically	  
significant	  differences	  from	  the	  20-­‐30	  year	  age-­‐group	  as	  derived	  from	  Dunn’s	  multiple	  comparison	  
test	  are	  highlighted	  in	  bold	  *p<0.05,	  **p<0.01	  and	  ***p<0.001.	  Data	  are	  expressed	  as	  medians	  and	  
interquartile	  ranges.	  




Figure	   6-­‐1:	   Serum	   hormone	   levels	   for	   female	   ageing	   study	   subjects	   (n=77).	   There	   were	  
increases	   in	  A)	  LH	  and	  B)	  FSH	   in	  older	  age	  groups	  and	  reductions	   in	  C)	  9am	  cortisol,	  D)	   IGF-­‐I,	  E)	  
DHEAS	   and	   F)	   Testosterone	   in	   older	   age	   groups.	   *P<0.05,	   **P<0.01	  &	   ***P<0.001	   vs.	   20-­‐30	   years	  
age-­‐group;	  γP<0.05,	  γγP<0.01	  and	  γγγP<0.001	  vs.	  30-­‐40	  years	  age-­‐group;	  ΦP<0.05	  and	  ΦΦP<0.01	  
vs.	  40-­‐50	  years	  age-­‐group	  and	  ΩP<0.05	  vs.	  50-­‐60	  years	  age-­‐group.	  Overall	  p-­‐values	   from	  Kruskal-­‐
Wallis	  tests:	  	  a),	  b),	  d)	  and	  e)	  P<0.0001;	  c)	  P<0.001	  and	  f)	  P=0.05.	  Medians	  and	  Interquartile	  ranges	  
(IQRs)	  shown.	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Serum	  Biochemistry:	  Male	  Ageing	  Study	  Subjects	  
	  
	  






























Fasting	  Glucose	  	  
(mmol/L)	  
	  
5.0	  	  (4.4-­‐5.1)	  	   5.0	  	  (4.8-­‐5.3)	  	   4.7	  	  (4.6-­‐5.1)	  	   5.1	  	  (4.9-­‐5.3)	  	   5.1	  	  (4.8-­‐5.6)	  	   5.1	  	  (4.9-­‐5.5)	  	  
	  
Total	  Cholesterol	  	  
(mmol/L)	  
	  
4.2	  	  (3.8-­‐4.7)	  	  	  
4.5	  	  (4.1-­‐4.9)	  	  	  
5.1	  	  (4.3-­‐5.7)	  	  	  
5.0	  	  (4.8-­‐5.0)	  	  	  
5.4	  	  (5.0-­‐6.3)	  	  	  





1.3	  	  (1.1-­‐1.5)	  	   1.4	  	  (1.2-­‐1.4)	  	   1.3	  	  (1.1-­‐1.3)	  	   1.3	  	  (1.2-­‐1.4)	  	   1.5	  	  (1.4-­‐1.6)	  	   1.4	  	  (1.2-­‐1.6)	  	  
	  
9am	  Cortisol	  	  
(nmol/L)	  
	  





































8.8	  	  (7.5-­‐9.9)	  	   7.6	  	  (7.4-­‐9.8)	  	   5.6	  	  (4.9-­‐7.0)	  	   4.7	  	  (3.6-­‐5.4)	  	   2.5***	  	  (2.2-­‐3.7)	  	   2.8***	  	  (2.3-­‐3.0)	  	  
	  
Table	   6-­‐4:	   Serum	   biochemistry	   results	   for	   male	   ageing	   study	   subjects	   (n=58).	   Statistically	  
significant	  differences	  from	  the	  20-­‐30	  year	  age-­‐group	  as	  derived	  from	  Dunn’s	  multiple	  comparison	  
test	  are	  highlighted	  in	  bold	  *p<0.05,	  **p<0.01	  and	  ***p<0.001.	  Data	  are	  expressed	  as	  medians	  and	  
interquartile	  ranges	  (IQRs).	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Figure	  6-­‐2:	  Serum	  hormone	  levels	  for	  male	  ageing	  study	  subjects	  (n=58).	  There	  were	  increases	  
in	  a)	  LH	  and	  b)	  FSH	  levels	  in	  the	  oldest	  age	  group	  and	  reductions	  in	  d)	  IGF-­‐I	  and	  e)	  DHEAS	  in	  the	  
oldest	  2	  age-­‐groups.	  There	  were	  no	  significant	  differences	  between	  groups	  for	  c)	  9am	  cortisol	  or	  f)	  
testosterone.	  *P<0.05,	  **P<0.01	  and	  ***P<0.001	  vs.	  20-­‐30	  year	  age-­‐group;	  γP<0.05,	  and	  γγγP<0.001	  
vs.	  30-­‐40	  year	  age-­‐group.	  Overall	  p-­‐values	  from	  Kruskal-­‐Wallis	  tests:	  a)	  and	  b)	  P<0.05,	  c)	  P=0.05,	  d)	  
P<0.001,	  e)	  P<0.0001	  and	  f)	  P=0.46.	  Median	  and	  interquartile	  ranges	  (IQRs)	  shown.	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6.5.4.	  Body	  Composition	  Analysis	  Across	  Human	  Ageing	  in	  Females	  	  	  Table	   6-­‐5	   and	   figure	   6-­‐3	   summarise	   the	   DEXA	   body	   composition	   analysis	  findings	  observed	  in	  female	  ageing	  study	  subjects.	  Fat	  mass	  and	  body	  fat	  %	  were	  higher	   in	  middle	  and	  older	  age	  groups	  in	  women	  (total	   fat	  mass,	  40-­‐50	  years	  =	  23.9kg,	   IQR	   20.2-­‐27.4,	   50-­‐60	   years	   =	   24.8kg,	   IQR	   24.0-­‐26.7	   vs.	   20-­‐30	   years	   =	  16.1kg,	  IQR	  14.1-­‐18.2	  p-­‐values	  <0.05	  and	  <0.001	  respectively;	  body	  fat	  %	  50-­‐60	  years	   =	   36.8kg,	   IQR	   35.5-­‐38.1,	   60-­‐70	   years	   =	   35.0kg,	   IQR	   31.7-­‐37.8	   vs.	   20-­‐30	  years	  27.5kg,	  IQR	  25.3-­‐31.1,	  p-­‐values	  <0.01	  and	  <0.05,	  respectively).	  In	  addition	  women	  aged	  60-­‐70	  years	  had	  lower	  bone	  mineral	  content	  and	  density	  compared	  those	  in	  the	  youngest	  age	  group	  (BMC:	  60-­‐70	  years	  =	  1.8kg,	  IQR	  1.7-­‐1.9	  vs.	  20-­‐30	  years	  2.0kg,	  IQR	  1.9-­‐2.1,	  p<0.01;	  BMD:	  60-­‐70	  years	  =1.0g/cm2,	  IQR	  0.9-­‐1.0	  vs.	  20-­‐30	  years	  =	  1.1g/cm2,	  IQR	  1.0-­‐1.2,	  p<0.01).	  	  	  
	  
Body	  Composition	  Analysis	  (DEXA):	  Female	  Ageing	  Study	  
Subjects	  
(Medians	  and	  IQRs)	  
Age	  Group	  (years)	   20-­‐30	   30-­‐40	   40-­‐50	   50-­‐60	   60-­‐70	   >70	  
	  
N	   15	   12	   15	   12	   16	   7	  
	  
Total	  Lean	  Mass	  
(kg)	  
37.8	  	  (36.2-­‐42.7)	   42.2	  	  (39.8-­‐44.4)	   43.3	  	  (39.4-­‐45.5)	   41.3	  	  (39.9-­‐43.0)	   39.9	  	  (36.3-­‐41.9)	   40.4	  	  (37.4-­‐42.7)	  
Total	  Fat	  Mass	  (kg)	  
16.1	  (14.1-­‐18.2)	   18.3	  	  (14.4-­‐20.6)	   	  23.9*	  	  (20.2-­‐27.4)	   24.8***	  	  (24.0-­‐26.7)	   21.2	  	  (19.2-­‐24.2)	   21.3	  	  (19.6-­‐22.7)	  
Body	  Fat	  (%)	  
	  
27.5	  	  (25.3-­‐31.1)	   28.2	  	  (25.2-­‐31.7)	   34.7	  	  (31.2-­‐37.7)	   	  36.8**	  	  (35.5-­‐38.1)	   35.0*	  	  (31.7-­‐37.8)	   33.9	  	  (32.2-­‐34.5)	  
BMC	  (kg)	  
	  
	  2.0	  	  (1.9-­‐2.1)	   2.3	  	  (1.9-­‐2.4)	   2.2	  	  (2.0-­‐2.3)	   2.0	  	  (2.0-­‐2.1)	   1.8**	  	  (1.7-­‐1.9)	   2.0	  	  (1.9-­‐2.2)	  
BMD	  (g/cm2)	  
	  
	  1.1	  	  (1.0-­‐1.2)	   1.1	  	  (1.0-­‐1.2)	   1.1	  	  (1.1-­‐1.2)	   1.1	  	  (1.0-­‐1.1)	   1.0**	  	  (0.9-­‐1.0)	   1.1	  	  (1.0-­‐1.1)	  
	  
Table	   6-­‐5:	   DEXA	   body	   composition	   analysis	   from	   female	   subjects	   in	   ageing	   study	   (n=77).	  
Statistically	  significant	  differences	  from	  the	  20-­‐30	  year	  age-­‐group	  as	  derived	  from	  Dunn’s	  multiple	  
comparison	   test	   are	  highlighted	   in	  bold	   *p<0.05,	   **p<0.01	  and	   ***p<0.001.	  Data	  are	   expressed	  as	  
medians	   and	   interquartile	   ranges	   (IQRs).	   BMC	   =	   bone	  mineral	   content	   and	   BMD	   =	   bone	  mineral	  
density.	  	  





Figure	   6-­‐3:	  DEXA	   body	   composition	   analysis	   in	   female	   ageing	   study	   subjects	   (n=77).	   There	  
were	   no	   differences	   between	   age	   groups	   in	   a)	   Total	   Lean	   Mass,	   however	   there	   was	   evidence	   of	  
reduced	  BMD	  (b)	  in	  the	  60-­‐70	  year	  age-­‐group	  and	  increased	  total	  fat	  mass	  (c)	  in	  the	  ‘middle-­‐aged’	  
groups	  and	  d)	  %	  body	  fat	  in	  the	  middle	  and	  older-­‐age	  groups.	  *P<0.05,	  **P<0.01	  and	  ***P<0.001	  vs.	  
20-­‐30	  year	  age-­‐group;	  γP<0.05	  and	  γγP<0.01	  vs.	  30-­‐40	  year	  age-­‐group;	  ΦP<0.05	  vs.	  40-­‐50	  year	  age	  
group.	  Overall	  P-­‐values	  from	  Kruskal-­‐Wallis	  tests:	  a)	  P=0.34,	  b)	  P<0.01,	  c)	  and	  d)	  P<0.001.	  Medians	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6.5.5.	  Body	  Composition	  Analysis	  Across	  Human	  Ageing	  in	  Male	  
Subjects	  	  No	   statistically	   significant	   differences	   in	   body	   composition	   parameters	   were	  seen	  with	  age	  in	  men	  (see	  table	  6-­‐6	  and	  figure	  6-­‐4).	  	  
	  
	  
Body	  Composition	  Analysis	  (DEXA):	  Male	  Ageing	  Study	  
Subjects	  
(Medians	  and	  IQRs)	  
Age	  Group	  (years):	   20-­‐30	   30-­‐40	   40-­‐50	   50-­‐60	   60-­‐70	   >70	  
	  
N	   13	   9	   10	   4	   13	   9	  
	  
Total	  Lean	  Mass	  
(kg)	  
59.0	  (57.4-­‐61.0)	   51.2	  (48.1-­‐58.0)	   68.1	  (61.3-­‐74.1)	   60.7	  (61.3-­‐74.1)	   58.3	  (54.8-­‐66.3)	   52.1	  (50.8-­‐54.3)	  
	  
Total	  Fat	  Mass	  (g)	  
	  15.2	  (13.1-­‐16.4)	   13.7	  (11.5-­‐20.8)	   17.5	  (14.1-­‐20.3)	   17.5	  (15.7-­‐18.5)	   20.2	  (15.3-­‐25.3)	   16.2	  (14.0-­‐17.9)	  
	  
Body	  Fat	  (%)	  








1.2	  (1.1-­‐1.2)	   1.1	  (1.1-­‐1.2)	   1.2	  (1.1-­‐1.2)	   1.2	  (1.1-­‐1.2)	   1.2	  (1.1-­‐1.2)	   1.2	  (1.1-­‐1.2)	  
	  
	  
Table	  6-­‐6:	  DEXA	  body	  composition	  analysis	  from	  male	  subjects	  in	  ageing	  study	  (n=58).	  There	  
were	   no	   statistically	   significant	   differences	   between	   groups	   using	   Kruskal-­‐Wallis	   analysis	   with	  
Dunn’s	  multiple	  comparison	  tests.	  Data	  are	  expressed	  as	  medians	  and	  interquartile	  ranges	  (IQRs).	  

















Figure	  6-­‐4:	  DEXA	  body	  composition	  analysis	  in	  male	  ageing	  study	  subjects	  (n=58).	  There	  were	  
no	   statistically	   significant	   differences	   between	   age	   groups	   in	   a)	   total	   lean	   mass	   (b)	   total	   bone	  
mineral	  density	  c)	   total	   fat	  mass	  d)	  %	  body	   fat,	  using	  Kruskal-­‐Wallis	  analysis	   in	  conjunction	  with	  
Dunn’s	  multiple	  comparison	  tests.	  Overall	  p-­‐values	  from	  Kruskal-­‐Wallis	  tests:	  a)	  P=0.05,	  b)	  P=0.30,	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6.5.6.	  Strength	  Testing	  Parameters	  Across	  Human	  Ageing	  in	  Female	  
Subjects	  




Strength	  Testing	  Analysis:	  Female	  Ageing	  Study	  Subjects	  
(Medians	  and	  IQRs)	  
	  
Age	  Group	  (years)	   20-­‐30	   30-­‐40	   40-­‐50	   50-­‐60	   60-­‐70	   >70	  
	  
N	   15	   12	   15	   12	   16	   7	  
Grip	  Strength	  	  
(kg)	  
	  29.5	  	  (25.6-­‐33.3)	   28.0	  (25.3-­‐29.4)	   29.3	  	  (27.1-­‐30.6)	   27.9	  	  (26.5-­‐29.0)	   26.0	  	  (20.5-­‐30.7)	   27.0	  (25.7-­‐27.8)	  
	  
S2LJ	  Pmax	  	  
(w/kg)	  
	  39.0	  	  (32.2-­‐43.9)	   34.8	  	  (33.2-­‐38.8)	   33.2	  	  (28.6-­‐35.9)	   30.6	  	  (29.2-­‐31.5)	   26.0***	  	  (22.8-­‐28.4)	   25.8**	  	  (25.2-­‐28.2)	  
	  
S2LJ	  Vmax	  	  
(m/s)	  
	  2.2	  	  (2.0-­‐2.4)	   2.0	  	  (2.0-­‐2.1)	   1.9	  	  (1.8-­‐1.9)	   1.8	  	  (1.8-­‐1.9)	   1.7***	  	  (1.5-­‐1.8)	   1.8*	  	  (1.7-­‐1.9)	  
	  
S2LJ	  Height	  	  
(cm)	  
	  34	  (29-­‐40)	   30	  	  (29-­‐34)	   25	  (23-­‐28)	   26	  (23-­‐28)	   24**	  	  (20-­‐27)	   25	  (23-­‐27)	  
Chair	  Rise	  Pmax	  	  
(w/kg)	  
	  10.4	  	  (8.6-­‐11.0)	   10.5	  	  (8.9-­‐11.4)	   9.7	  	  (8.4-­‐10.6)	   9.4	  	  (8.0-­‐10.0)	   7.6*	  	  (6.8-­‐8.6)	   7.7	  (7.4-­‐9.7)	  
Heel	  Rise	  Pmax	  	  
(w/kg)	  
	  4.5	  	  (4.1-­‐5.2)	   5.5	  	  (3.7-­‐6.5)	   5.5	  	  (3.7-­‐5.8)	   4.6	  	  (3.7-­‐5.2)	   3.8	  	  (3.4-­‐4.1)	   3.8	  	  (3.2-­‐4.3)	  
	  
Table	  6-­‐7:	  Strength	  testing	  by	  grip	  strength	  dynamometry	  and	  jump-­‐plate	  mechanography	  
in	   female	  ageing	  study	  subjects	   (n=77).	  Statistically	   significant	  differences	   from	  the	  20-­‐30	  year	  
age	  group	  are	  highlighted	  in	  bold.	  *P<0.05,	  **p<0.01	  and	  ***p<0.001.	  Data	  are	  expressed	  as	  medians	  
and	  interquartile	  ranges	  (IQRs).	  S2LJ	  =	  standing	  2-­‐legged	  jump,	  Vmax	  =	  maximal	  velocity,	  Pmax	  =	  
maximal	  power.	  	  





Figure	  6-­‐5:	  Strength	  testing	  by	  jump-­‐plate	  mechanography	  in	  female	  ageing	  study	  subjects	  
(n=77).	   Values	   of	   a)	   S2LJ	   Pmax,	   b)	   S2LJ	   Vmax	  were	   reduced	   in	   the	   60-­‐70	   and	   >70	   year	   old	   age	  
groups	   compared	   to	   the	   20-­‐30	   and	  30-­‐40	   year	   age	   groups.	   Values	   of	   c)	   S2LJ	   Jump	  height	   and	   d)	  
chair	  rise	  Pmax	  were	  reduced	  in	  the	  60-­‐70	  year	  age	  group	  compared	  to	  the	  20-­‐30	  and	  30-­‐40	  year	  
age	   groups.	   *P<0.05,	   **P<0.01	   and	   ***P<0.001	   vs.	   20-­‐30	   year	   age	   group;	   γP<0.05,	   γγP<0.01	   and	  
γγγP<0.001	  vs.	  30-­‐40	  year	  age	  group.	  Overall	  p-­‐values	  from	  Kruskal-­‐Wallis	  tests:	  a),	  b)	  P<0.0001,	  c)	  




6.5.7.	  Strength	  Testing	  Parameters	  Across	  Human	  Ageing	  in	  Male	  
Subjects	  
	  The	   strength	   testing	   characteristics	   of	   male	   study	   volunteers	   divided	   by	   age	  group	  are	  summarized	  in	  table	  6-­‐8	  and	  figure	  6-­‐6.	  The	  results	  followed	  a	  similar	  pattern	   to	   that	   seen	   in	   women,	   with	   reductions	   in	   several	   jump-­‐plate	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mechanography	  values	   in	   the	  oldest	   groups	   (S2LJ	  Pmax	   (w/kg):	  60-­‐70	  years	  =	  34.7,	  IQR	  31.9-­‐26.5,	  >70	  years	  =	  33.7,	  IQR	  30.5-­‐37.1	  vs.	  20-­‐30	  years	  =	  52.2,	  IQR	  47.9-­‐55.0,	   p-­‐values	   <0.001	   and	   <0.01,	   respectively;	   S2LJ	   Vmax	   (m/s):	   60-­‐70	  years	  =	  2.0,	   IQR	  1.9-­‐2.2,	  >70	  years	  =	  1.8,	   IQR	  1.7-­‐2.0	  vs.	  20-­‐30	  years	  =	  2.7,	   IQR	  2.4-­‐2.8,	  p-­‐values	  <0.01	  and	  <0.001,	  respectively;	  S2LJ	  Height	  (cm):	  60-­‐70	  years	  =	  32,	  IQR	  26-­‐34,	  >70	  years	  =	  27,	  IQR	  23-­‐29	  vs.	  20-­‐30	  years	  46,	  IQR	  42-­‐50,	  p-­‐values	  <0.01	  and	  <0.001,	   respectively;	  chair	  rise	  Pmax	  (w/kg):	  60-­‐70	  years	  =	  9.9,	   IQR	  8.7-­‐10.9,	  >70	  years	  =	  9.8,	  IQR	  9.1-­‐10.5	  vs.	  20-­‐30	  years	  =	  15.1,	  IQR	  12.0-­‐15.4,	  p-­‐values	  <0.01).	  	  
	  
	  
Strength	  Testing	  Analysis:	  Male	  Ageing	  Study	  Subjects	  
(Medians	  and	  IQRs)	  
Age	  Group	  (years)	  
	  
20-­‐30	   30-­‐40	   40-­‐50	   50-­‐60	   60-­‐70	   >70	  
	  
N	   13	   9	   10	   4	   13	   9	  
Grip	  Strength	  	  
(kg)	  
	  44.9	  	  (41.0-­‐50.6)	   42.2	  	  (40.3-­‐46.6)	   52.2	  	  (48.5-­‐61.7)	   39.4	  	  (37.7-­‐44.0)	   46.2	  	  (42.9-­‐51.2)	   37.7	  	  (34.5-­‐38.5)	  
	  
S2LJ	  Pmax	  	  
(w/kg)	  
52.2	  	  (47.9-­‐55.0)	   45.5	  	  (45.4-­‐50.9)	   41.9	  	  (38.2-­‐47.6)	   37.4	  	  (37.1-­‐40.3)	   34.7***	  	  (31.9-­‐26.5)	   33.7**	  	  (30.5-­‐37.1)	  
	  
S2LJ	  Vmax	  	  
(m/s)	  
2.7	  	  (2.4-­‐2.8)	   2.6	  	  (2.5-­‐2.8)	   2.3	  	  (2.1-­‐2.6)	   2.3	  	  (2.3-­‐2.4)	   2.0**	  	  (1.9-­‐2.2)	   1.8***	  	  (1.7-­‐2.0)	  
	  
S2LJ	  Height	  	  
(cm)	  
46	  (42-­‐50)	   45	  (43-­‐52)	   37	  (29-­‐45)	   40	  (40-­‐41)	   32**	  (26-­‐34)	   27***	  	  (23-­‐29)	  
Chair	  Rise	  Pmax	  
(w/kg)	  
	  15.1	  	  (12.0-­‐15.4)	   12.9	  	  (12.1-­‐13.6)	   13.4	  (10.0-­‐14.2)	   10.6	  (9.8-­‐10.9)	   9.9**	  	  (8.7-­‐10.9)	   9.8**	  	  (9.1-­‐10.5)	  
Heel	  Rise	  Pmax	  
(w/kg)	  
	  5.9	  (4.3-­‐6.1)	   5.1	  	  (4.2-­‐6.0)	   6.1	  	  (4.8-­‐7.1)	   4.5	  	  (3.8-­‐5.4)	   4.1	  	  (3.2-­‐4.9)	   4.3	  	  (3.6-­‐3.8)	  
	  
	  
Table	  6-­‐8:	  Strength	  testing	  by	  grip	  strength	  dynamometry	  and	  jump-­‐plate	  mechanography	  
in	  male	  ageing	  study	  subjects	  (n=58).	  Statistically	  significant	  differences	  from	  the	  20-­‐30	  year	  age-­‐
group	  are	  highlighted	  in	  bold	  *p<0.05,	  **p<0.01	  and	  ***p<0.001.	  Data	  are	  expressed	  as	  medians	  and	  
interquartile	   ranges	   (IQR).	   S2LJ	   =	   standing	   2-­‐legged	   jump,	   Vmax	   =	   maximal	   velocity,	   Pmax	   =	  








Figure	   6-­‐6:	   Strength	   testing	   by	   jump-­‐plate	  mechanography	   in	  male	   ageing	   study	   subjects	  
(n=58).	  Values	  of	  a)	  S2LJ	  Pmax,	  b)	  S2LJ	  Vmax	  and	  c)	  S2LJ	   Jump	  height	  were	  reduced	   in	  the	  60-­‐70	  
and	  >70	  year	  old	  age	  groups	  compared	  to	  the	  20-­‐30	  and	  30-­‐40	  year	  age	  groups.	  Values	  of	  d)	  chair	  
rise	   Pmax	  were	   reduced	   in	   the	   60-­‐70	   and	   >70	   year	   age	   groups	   compared	   to	   the	   20-­‐30	   year	   age	  
group	  only.	  **P<0.01	  and	  ***P<0.001	  vs.	  20-­‐30	  year	  age	  group;	  γP<0.05	  and	  γγP<0.01	  vs.	  30-­‐40	  year	  
age	   group.	   Overall	   P-­‐values	   from	   Kruskal-­‐Wallis	   tests:	   a)	   b)	   and	   c)	   P<0.0001	   and	   d)	   P<0.001.	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6.5.8.	  Steroid	  Metabolite	  Excretion	  Across	  Human	  Ageing	  in	  Female	  
Subjects	  
	  In	  order	  to	  assess	  whether	  there	  were	  any	  age	  associated	  differences	  in	  24-­‐hour	  cortisol	   secretion	  or	   global	   activity	   of	   cortisone/cortisol	  metabolizing	   enzymes	  we	  assessed	  steroid	  metabolite	  excretion	  levels	  using	  gas	  chromatography/mass	  spectrometry	   analysis	   of	   24-­‐hour	   urine	   samples	   provided	   at	   baseline	   (n=77).	  (THF+5αTHF)/THE	  ratios	  were	  used	  as	  a	  measure	  of	  global	  11β-­‐HSD1	  activity,	  along	   with	   cortols/cortolones.	   In	   addition	   11β-­‐HSD2	   activity	   was	   assessed	   by	  F/E	  ratios	  and	  5α-­‐reductase	  activities	  were	  estimated	  using	  THF/5αTHF	  ratios.	  Differences	  between	  age	  groups	  were	  assessed	  using	  Kruskal-­‐Wallis	  testing	  and	  Dunn’s	  post-­‐test	   correction.	  The	   results	   for	   female	   subjects	   are	   summarized	   in	  table	   6-­‐9,	   the	   only	   significant	   finding	   being	   an	   increased	   (THF+5αTHF)/THE	  ratio,	  indicative	  of	  higher	  11β-­‐HSD1	  activity,	  in	  the	  oldest	  age	  group	  (>70	  years	  =	  0.94,	   IQR	  0.87-­‐1.02	  vs.	   20-­‐30	  years	  =	  0.77,	   IQR	  0.69-­‐0.87,	   overall	   p=0.02).	   Full	  urine	   steroid	   analysis	   results	   for	   women	   are	   summarized	   in	   supplementary	  tables	   S6.5	   and	   S6.6,	   with	   the	   most	   marked	   changes	   being	   age-­‐associated	  reductions	  in	  androgen	  excretion	  rates.	  	  	  	  	  	  	  	  	  	  	  	  




Urine	  Steroid	  Analysis	  (GC/MS):	  Female	  Ageing	  Study	  Subjects	  
(Medians	  and	  IQRs)	  
	   	  
	  



























0.77	  (0.69-­‐0.87)	  	   0.91	  	  (0.86-­‐1.14)	  	   0.89	  	  (0.83-­‐1.14)	  	   0.80	  	  (0.66-­‐0.88)	  	   0.69	  	  (0.05-­‐0.84)	  	  
0.94	  	  
(0.87-­‐





0.42	  (0.37-­‐0.51)	  	   0.41	  	  (0.37-­‐0.48)	  	   0.42	  	  (0.36-­‐0.54)	  	   0.46	  	  (0.30-­‐0.50)	  	   0.36	  	  (0.31-­‐0.44)	  	   0.42	  	  (0.37-­‐0.53)	  	   0.62	  	  	  
	  




	  5413	  (3432-­‐7250)	  	   5565	  	  (4298-­‐6687)	  	   6562	  (5261-­‐7792)	  	   4665	  	  (4117-­‐7929)	  	   4846	  	  (4573-­‐6637)	  	  










1.57	  (0.79-­‐2.41)	  	   1.33	  	  (1.10-­‐1.65)	  	   1.35	  	  (1.14-­‐1.59)	  	   1.48	  	  (1.25-­‐1.73)	  	   1.90	  	  (1.42-­‐2.79)	  	   1.16	  	  (0.90-­‐1.33)	  	   0.24	  	  	  
	  
Table	   6-­‐9:	   Urine	   steroid	   analysis	   of	   markers	   of	   glucocorticoid	   metabolism	   by	   GC/MS	   in	  
female	  ageing	  study	  subjects	   (n=77).	  Overall	  p-­‐values	   from	  Kruskal-­‐Wallis	   testing	  are	  shown	   in	  
the	   right-­‐sided	   column.	   P-­‐values	   <0.05	   were	   used	   to	   indicate	   significant	   differences	   in	  
(THF+5αTHF)/THE	  between	  age	  groups.	  However,	  according	   to	  Dunn’s	  multiple	  comparison	   tests	  





6.5.9.	  Steroid	  Metabolite	  Excretion	  Across	  Human	  Ageing	  in	  Male	  
Subjects	  
	  Urine	  steroid	  metabolite	  ratios	  of	  markers	  of	  global	  activity	  of	  cortisone/cortisol	  metabolizing	   enzymes	   across	   age,	   derived	   from	   gas	   chromatography/mass	  spectrometry	   analysis	   of	   24	  hour	   urine	   samples	   are	   summarized	   in	   table	   6-­‐10	  (n=58).	  No	  statistically	  significant	  differences	  between	  age	  groups	  were	  seen	  in	  these	   ratios.	   Full	   details	   of	   all	   steroid	   metabolites	   analysed	   in	   men	   are	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summarized	  by	  age	  group	  in	  supplementary	  tables	  S6.7	  and	  S6.8,	  with	  the	  most	  striking	  differences	  seen	  in	  reduced	  androgen	  levels.	  	  
	  
	  
Urine	  Steroid	  Analysis	  (GC/MS):	  Male	  Ageing	  Study	  Subjects	  
(Medians	  and	  IQRs)	  















	   	  
Overall	  





	  0.98	  (0.76-­‐1.04)	  	   0.91	  	  (0.80-­‐1.11)	  	   0.85	  	  (0.81-­‐1.28)	  	   1.20	  	  (1.04-­‐1.39)	  	   0.95	  	  (0.85-­‐1.03)	  	  





0.39	  (0.36-­‐0.47)	  	   0.37	  	  (0.34-­‐0.50)	  	   0.51	  	  (0.40-­‐0.57)	  	   0.42	  	  (0.37-­‐0.48)	  	   0.42	  	  (0.37-­‐0.50)	  	  
0.39	  	  (0.34-­‐0.46)	  	   0.79	  	  
	  
Total	  F	  metabolites	  
(μg/24h)	  
	  
	  10979	  (6571-­‐15828)	  	   8904	  	  (5878-­‐13317)	  	   8118	  	  (7151-­‐10803)	  	   10192	  	  (9008-­‐10914)	  	   9611	  	  (8061-­‐12223)	  	  





	  0.73	  (0.64-­‐0.74)	  	   0.70	  	  (0.59-­‐0.84)	  	   0.67	  	  (0.64-­‐0.74)	  	   0.70	  	  (0.57-­‐0.78)	  	   0.65	  	  (0.56-­‐0.76)	  	  





0.93	  (0.74-­‐1.03)	  	   1.06	  	  (0.59-­‐1.24)	  	   0.92	  	  (0.76-­‐1.37)	  	   0.82	  	  (0.72-­‐0.91)	  	   1.49	  	  (1.10-­‐1.83)	  	  
1.09	  	  (1.05-­‐1.63)	  	   0.13	  	  	  
	  
Table	   6-­‐10:	   Urine	   steroid	   analysis	   of	   markers	   of	   glucocorticoid	   metabolism	   by	   GC/MS	   in	  
male	  ageing	   study	   subjects	   (n=58).	  Overall	   p-­‐values	   from	  Kruskal-­‐Wallis	   analysis	   are	   shown	   in	  
the	   right-­‐sided	   column.	   There	   were	   no	   significant	   differences	   between	   age	   groups.	   Data	   are	  
expressed	  as	  medians	  and	  interquartile	  ranges	  (IQRs).	  
	  
	  
6.5.10.	   Skeletal	   Muscle	   Gene	   Expression	   Across	   Human	   Ageing	   in	  
Female	  Subjects	  
	  In	   order	   to	   assess	   changes	   in	   local	   gene	   expression,	   real-­‐time	   PCR	   based	  microfluidic	  gene	  expression	  arrays	  were	  performed	  on	  vastus	   lateralis	  muscle	  biopsies	   from	   human	   study	   subjects.	   Samples	   from	   55	   women	   were	   assessed	  with	  subjects	  divided	  into	  2	  groups	  for	  statistical	  analysis.	  An	  arbitrary	  cut-­‐off	  of	  50	   years	  was	   used	   to	   divide	   the	   groups.	   This	   age	  was	   selected	   as	   it	   took	   into	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account	   the	  major	   physiological	   changes	   seen	   following	   the	  menopause	   and	   it	  allowed	   sufficient	   statistical	  power.	  Results	   for	   all	   92	   target	   genes	  analysed	  by	  age	   group	   are	   summarised	   in	   supplementary	   tables	   S6.9,	   parts	   I-­‐III.	   Delta	   CT	  values,	   normalised	   to	   reference	   gene	   expression	   (18S)	   are	   shown	   and	   lower	  numbers	   are	   indicative	   of	   increased	   gene	   expression.	   Of	   these	   92	   genes,	  statistically	   significant	   changes	   in	   expression	   were	   observed	   in	   6,	   with	   these	  results	   summarised	   in	   table	   6-­‐11.	   These	   genes	   were	   11β-­‐HSD1,	   hypoxia	  inducible	   factor	   1,	   alpha	   subunit	   (HIF-­‐1a),	   growth	   arrest	   and	   DNA-­‐damage-­‐inducible	  alpha	  (GADD45a),	   the	  proteasomal	  subunit	  alpha	  2	  (PSMA2)	  and	  26S	  subunit,	   non-­‐ATPase	   4	   (PSMD4),	   and	   skeletal	   muscle	   myosin	   heavy	   chain	   4	  (MYH4).	  	  	  	  
Human	  Skeletal	  Muscle	  Gene	  Expression:	  Female	  Ageing	  Study	  Subjects	  
Age	  Group	  




Delta	  CT	  	  
(Medians	  and	  IQRs)	  
Delta	  CT	  	  




11β-­‐HSD1	   16.81	  (16.47-­‐17.55)	   15.90	  (15.21-­‐16.39)	   	  2.26	   0.0007	  
	  
HIF-­‐1a	   13.61	  (13.43-­‐14.54)	   13.21	  (12.65-­‐13.73)	   	  1.43	   0.02	  
	  
GADD45a	   17.92	  (17.53-­‐18.26)	   17.14	  (16.45-­‐17.77)	   	  1.83	   0.005	  
	  
PSMA2	   13.91	  (13.56-­‐14.87)	   13.09	  (12.60-­‐13.80)	   	  1.90	   0.004	  
	  
PSMD4	   18.10	  (17.45-­‐18.59)	   17.07	  (16.12-­‐18.13)	   	  2.00	   0.006	  
	  
MYH4	   18.24	  (17.40-­‐18.85)	   17.28	  (16.69-­‐18.17)	   	  2.00	   <0.05	  
	  
Table	   6-­‐11:	   Human	   skeletal	   muscle	   (vastus	   lateralis)	   gene	   expression	   in	   female	   subjects	  
aged	   <50	   year	   vs.	   those	   aged	   >50,	   as	   analysed	   by	   microfluidic	   array	   (n=55).	   Statistically	  
significant	   differences	   between	   age	   groups	  were	   seen	   in	   6	   genes	   of	   the	   92	   analysed.	   Data	   for	   all	  
genes	   analysed	   are	   shown	   in	   supplementary	   tables.	   Median	   and	   inter-­‐quartile	   ranges	   (IQRs)	   for	  
delta	  CT	  values	  are	  shown.	  HIF1a	  =	  hypoxia	  inducible	  factor	  1,	  alpha	  subunit,	  GADD45a	  =	  growth	  arrest	   and	  DNA-­‐damage-­‐inducible	   alpha,	   PSMA2	  &	   PSMD4	  =	   proteasomal	   subunit	   alpha	   2	   and	  26S	  subunit,	  non-­‐ATPase	  4,	  MYH	  =	  myosin	  heavy	  chain	  4.	  





Figure	   6-­‐7:	   Human	   skeletal	   muscle	   (vastus	   lateralis)	   gene	   expression	   in	   female	   subjects	  
aged	  <50	  years	  vs.	  those	  aged	  >50,	  as	  analysed	  by	  microfluidic	  array	  (n=55).	  Of	  the	  92	  genes	  
analysed,	   the	  6,	  which	   showed	  significant	  differences	  between	  age	  groups	  are	   shown.	  Data	   for	  all	  
genes	  analysed	  are	   shown	   in	   supplementary	   tables.	  Means	  and	   S.E.s	   for	   arbitrary	  unit	   values	   are	  
shown.	  *P<0.05,	  **P<0.01,	  ***P<0.001.	  HIF1a	  =	  hypoxia	  inducible	  factor	  1,	  alpha	  subunit,	  GADD45a	  =	  growth	  arrest	  and	  DNA-­‐damage-­‐inducible	  alpha,	  PSMA2	  &	  PSMD4	  =	  proteasomal	  subunit	  alpha	  2	  and	  26S	  subunit,	  non-­‐ATPase	  4,	  MYH	  =	  myosin	  heavy	  chain	  4.	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6.5.11.	   Skeletal	   Muscle	   Gene	   Expression	   Across	   Human	   Ageing	   in	  
Male	  Subjects	  
	  Age-­‐associated	   changes	   in	   skeletal	   muscle	   gene	   expression	   changes	   were	   also	  analysed	   in	   men,	   with	   subjects	   divided	   into	   2	   groups	   according	   to	   age.	  Statistically	   significant	   changes	   were	   seen	   in	   8	   of	   the	   92	   genes	   analysed	   (see	  supplementary	  tables	  S6.10:	  parts	  I-­‐III	  for	  details	  of	  all	  genes	  and	  table	  6-­‐12	  and	  figure	  6-­‐8	  for	  details	  of	  significant	  changes	  only).	  Genes	  with	  significant	  changes	  were	   hexose-­‐6-­‐phosphate-­‐dehydrogenase	   (H6PDH),	   heat	   shock	   protein	   90kDa	  beta	  1	  (HSP90B1),	  growth	  arrest	  and	  DNA-­‐damage-­‐inducible	  alpha	  (GADD45a),	  cyclin-­‐dependent	  kinase	  inhibitor	  1A	  (CDKN1A),	  sirtuin	  3	  (SIRT3),	  SMAD	  family	  member	  3	  (SMAD3),	  v-­‐rel	  reticuloendotheliosis	  viral	  oncogene	  homolog	  A	  (relA)	  and	  proteasomal	  26S	  subunit,	  non-­‐ATPase	  4	  (PSMD4).	  	  
	  
Human	  Skeletal	  Muscle	  Gene	  Expression:	  Male	  Ageing	  Study	  Subjects	  
Age	  Group	  




Delta	  CT	  	  
(Medians	  and	  IQRs)	   Delta	  CT	  	  (Medians	  and	  IQRs)	   Fold-­‐Change	   P-­‐Value	  
	  
H6PDH	   13.45	  (13.27-­‐13.92)	   12.82	  (12.59-­‐13.12)	   	  1.66	   0.002	  
	  
HSP90B1	   12.32	  (11.89-­‐12.65)	   11.91	  (11.55-­‐12.26)	   	  1.47	   0.04	  
	  
GADD45a	   17.43	  (16.70-­‐18.24)	   16.58	  (16.30-­‐16.79)	   	  1.83	   0.04	  
	  
CDKN1A	   18.66	  (18.20-­‐19.58)	   17.99	  (16.11-­‐18.52)	   	  2.30	   0.04	  
	  
SIRT3	   16.85	  (15.85-­‐17.07)	   16.09	  (15.66-­‐16.47)	   	  1.43	   0.04	  
	  
SMAD3	   10.85	  (10.55-­‐11.23)	   10.38	  (9.83-­‐10.62)	   	  1.58	   0.01	  
	  
relA	   16.93	  (16.54-­‐17.44)	   15.94	  (15.47-­‐16.67)	   	  1.82	   0.01	  
	  
PSMD4	   17.76	  (17.40-­‐18.10)	   16.87	  (16.45-­‐17.66)	   	  1.55	   0.04	  
	  
Table	  6-­‐12:	  Human	  skeletal	  muscle	  (vastus	  lateralis)	  gene	  expression	  in	  male	  subjects	  aged	  
<50	  years	  vs.	  those	  >50,	  analysed	  by	  microfluidic	  array	  (n=24).	  Significant	  differences	  between	  
age	  groups	  were	  seen	  in	  the	  8	  genes	  shown	  (of	  92	  analysed).	  Medians	  and	  IQRs	  for	  delta	  CT	  values	  
are	  shown.	  H6PDH=hexose-­‐6-­‐phosphate-­‐dehydrogenase,	  HSP90B1=heat	  shock	  protein	  90kDa	  beta1,	  
GADD45a=growth	  arrest	  DNA-­‐damage-­‐inducible	  alpha,	  CDKN1A=cyclin-­‐dependent	  kinase	  inhibitor	  
1A,	   SIRT3=sirtuin	   3,	   SMAD3=SMAD	   family	   member	   3,	   relA=v-­‐rel	   reticuloendotheliosis	   viral	  
oncogene	  homolog	  A	  (relA),	  PSMD4=proteasomal	  26S	  subunit,	  non-­‐ATPase	  4.	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Figure	  6-­‐8:	  Human	  skeletal	  muscle	  (vastus	  lateralis)	  gene	  expression	  in	  male	  subjects	  aged	  
<50	   years	   vs.	   those	   aged	   >50,	   as	   analysed	   by	   microfluidic	   array	   (n=24).	   Of	   the	   90	   genes	  
analysed,	   the	  8,	  which	   showed	   statistically	   significant	  differences	  between	  age	  groups	  are	   shown.	  
Data	   for	  all	  genes	  analysed	  are	   shown	   in	   supplementary	   tables.	  Median	  and	   inter-­‐quartile	   ranges	  
for	  Arbitrary	  Unit	  (AU)	  values	  are	  shown.	  *P<0.05,	  **P<0.01,	  ***P<0.001.	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6.5.12.	   Correlations	   between	   Strength	   Testing/Body	   Composition	  
Parameters	   and	   Gene	   Expression	   in	   Skeletal	   Muscle	   of	   Female	  
Subjects	  




Correlation	  Coefficients	  (r)	  (Spearman)	  between	  Strength	  Testing	  

















Skeletal	  Muscle	  Gene	  	  
Expression:	  
11β-­‐HSD1	   -­‐0.37*	   -­‐0.33	   -­‐0.13	   -­‐0.10	   -­‐0.17	   0.32*	  
H6PDH	   0.12	   0.09	   0.31	   0.41*	   0.00	   -­‐0.22	  
MuRF1	   0.24	   0.15	   0.30	   0.33	   0.15	   -­‐0.25	  
MAFbx	   0.14	   0.13	   0.32	   0.34	   0.05	   -­‐0.23	  
Myostatin	   0.20	   0.25	   0.32	   0.31	   0.09	   -­‐0.22	  
GADD45a	   -­‐0.16	   -­‐0.41*	   -­‐0.30	   -­‐0.27	   -­‐0.12	   0.16	  
HSP90B1	   -­‐0.10	   -­‐0.22	   0.03	   0.04	   -­‐0.13	   0.09	  
HIF-­‐1a	   0.08	   -­‐0.44*	   -­‐0.33	   -­‐0.31	   0.11	   0.29	  
PSMA2	   -­‐0.13	   -­‐0.42*	   -­‐0.29	   -­‐0.18	   0.06	   0.19	  
PSMD4	   -­‐0.09	   -­‐0.34	   -­‐0.29	   -­‐0.22	   0.06	   0.21	  
CDKN1A	   0.04	   -­‐0.41*	   -­‐0.36*	   -­‐0.28	   -­‐0.15	   0.06	  
SIRT3	   0.20	   0.20	   0.26	   0.30	   0.12	   -­‐0.15	  
SMAD3	   0.23	   0.21	   0.32	   0.33	   0.15	   -­‐0.16	  
RelA	   0.03	   0.30	   0.25	   0.25	   -­‐0.13	   -­‐0.36*	  
MYH4	   0.20	   0.15	   0.32	   0.40*	   0.14	   -­‐0.16	  
	  
Table	  6-­‐13:	  Bivariate	  analyses	  of	  strength	   testing	  and	  DEXA	  body	  composition	  parameters	  
vs.	   skeletal	   muscle	   gene	   expression	   in	   female	   ageing	   study	   subjects	   (n=55).	   Data	   are	  
correlation	  coefficients	  (r)	  derived	  by	  Spearman	  analysis.	  *P<0.05.	  S2LJ	  =	  standing	  2-­‐legged	   jump,	  
Vmax	  =	  maximal	  velocity,	  Pmax	  =	  maximal	  power.	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6.5.13.	   Correlations	   between	   Strength	   Testing/Body	   Composition	  
Parameters	  and	  Gene	  Expression	  in	  Skeletal	  Muscle	  of	  Male	  Subjects	  
	  





Correlation	  Coefficients	  (r)	  (Spearman)	  between	  Strength	  Testing	  
















Skeletal	  Muscle	  Gene	  	  
Expression	  
11β-­‐HSD1	   	  0.46*	   -­‐0.27	   -­‐0.24	   -­‐0.29	   0.06	   -­‐0.04	  
H6PDH	   -­‐0.04	   -­‐0.37	   -­‐0.09	   -­‐0.13	   -­‐0.21	   0.12	  
MuRF1	   0.42	   0.10	   0.19	   0.03	   0.20	   0.01	  
MAFbx1	   0.30	   0.30	   0.23	   0.24	   0.25	   0.42	  
Myostatin	   -­‐0.23	   -­‐0.29	   -­‐0.09	   -­‐0.06	   -­‐0.10	   0.08	  
GADD45a	   0.03	   -­‐0.57*	   -­‐0.47	   -­‐0.41	   0.01	   0.31	  
HSP90B1	   0.09	   -­‐0.53*	   -­‐0.27	   -­‐0.31	   0.09	   0.31	  
HIF-­‐1a	   0.28	   -­‐0.15	   -­‐0.16	   -­‐0.19	   0.27	   0.08	  
PSMA2	   -­‐0.17	   -­‐0.16	   0.09	   0.13	   0.03	   0.38	  
PSMD4	   0.05	   -­‐0.20	   0.06	   0.07	   0.05	   0.28	  
CDKN1A	   -­‐0.38	   -­‐0.83****	   -­‐0.71**	   -­‐0.73***	   0.00	   0.40	  
SIRT3	   -­‐0.17	   -­‐0.27	   -­‐0.15	   -­‐0.15	   -­‐0.21	   -­‐0.15	  
SMAD3	   -­‐0.03	   -­‐0.31	   -­‐0.26	   -­‐0.25	   0.07	   0.71	  
RelA	   -­‐0.06	   -­‐0.63**	   -­‐0.54*	   -­‐0.59	   -­‐0.22	   0.14	  
MYH4	   0.28	   -­‐0.12	   -­‐0.06	   -­‐0.00	   0.42	   0.21	  
	  
Table	  6-­‐14:	  Bivariate	  analyses	  of	  strength	   testing	  and	  DEXA	  body	  composition	  parameters	  
vs.	  skeletal	  muscle	  gene	  expression	   in	  male	  ageing	  study	  subjects	   (n=24).	  Target	  genes	  were	  
found	  to	  be	  associated	  with	  ageing	  or	  GC	  administration	  in	  cell	  culture,	   in	  vivo	  mouse	  and	  human	  
experiments.	  Data	  are	   correlation	   coefficients	   (r)	  derived	  by	  Spearman	  analysis.	   *P<0.05.	   .	   S2LJ	  =	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6.5.14.	   Correlations	   for	   Skeletal	   Muscle	   11β-­‐HSD1	   Expression	   and	  
Urinary	  Steroid	  Markers	  of	  GC	  Metabolism	  vs.	  Anthropometric,	  Body	  
Composition,	   Strength	   Testing	   and	   Serum	   Biochemistry	   Data	   in	  
Female	  Subjects	  
	  In	   order	   to	   investigate	  whether	   global	   activity	   of	   11β-­‐HSD	   types	   1	   and	   2	  may	  play	  a	   role	   in	   sarcopenia,	  obesity,	  osteoporosis	  and	  adverse	  metabolic	  profiles,	  Spearman	   correlations	   between	   urine	   steroid	   ratios	   and	   anthropometric	  variables,	   and	   data	   from	   DEXA	   analysis,	   strength	   testing,	   jump-­‐plate	  mechanography,	  and	  serum	  biochemistry	  values	  were	  calculated.	  The	  results	  for	  women	   are	   summarized	   in	   table	   6-­‐15.	   Interesting	   results	   here	   include	   the	  significant	  positive	  correlations	  observed	  between	  total	  F	  metabolites	  and	  both	  total	   fat	   mass	   and	   %	   body	   fat,	   in	   addition	   to	   the	   positive	   correlation	   seen	  between	   skeletal	   muscle	   11β-­‐HSD1	   gene	   expression	   and	   %	   body	   fat.	   Some	  surprising	   and	   not	   entirely	   consistent	   results	   were	   seen	   with	   regards	   bone	  mineral	   content/density,	   with	   positive	   correlations	   observed	   with	   urinary	  markers	   of	   global	   11β-­‐HSD1	   activity	   and	   negative	   correlations	   with	   skeletal	  muscle	   11β-­‐HSD1	   gene	   expression.	   Although	   there	   was	   a	   negative	   correlation	  between	   11β-­‐HSD1	   gene	   expression	   and	   grip	   strength,	   no	   relationship	   was	  observed	  with	  urine	  steroid	  ratios.	  In	  addition	  no	  significant	  results	  correlations	  were	  observed	  between	  jump-­‐plate	  mechanography	  values	  and	  markers	  of	  11β-­‐HSD1	  expression	  or	  global	  activity.	  Serum	  gonadotrophin	  values	  were	  positively	  correlated	   with	   skeletal	   muscle	   11β-­‐HSD1	   expression,	   in	   keeping	   with	   the	  observed	   post-­‐menopausal	   changes.	   Interestingly	   gene	   expression	   was	   also	  negatively	  correlated	  with	  serum	  IGF-­‐I	  levels	  consistent	  with	  a	  suppressive	  role	  of	   the	   anabolic	   hormone.	   Finally	   skeletal	   muscle	   11β-­‐HSD1	   expression	  correlated	  positively	  with	  serum	  total	  cholesterol	  levels.	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Female	  
Subjects	  
Correlation	  Coefficients	  (r)(Spearman)	  
	  
	   	   Urine	  Steroid	  Analysis	  Results	  (by	  GC/MS)	  










Variables	  BMI	   0.19	   -­‐0.00	   0.04	   -­‐0.05	   0.02	  SBP	   0.09	   -­‐0.05	   -­‐0.13	   -­‐0.20	   0.02	  DBP	   0.25	   -­‐0.02	   -­‐0.01	   -­‐0.13	   -­‐0.02	  
Body	  Composition	  	  
Data	  (DEXA)	  
Total	  Fat	  Mass	   0.24	   0.16	   -­‐0.04	   0.35**	   -­‐0.22	  
%	  Body	  Fat	   0.33*	   0.09	   -­‐0.02	   0.29*	   -­‐0.21	  Total	  Lean	  Mass	   -­‐0.23	   0.23	   -­‐0.03	   0.19	   -­‐0.09	  
Bone	  Mineral	  
Content	  	  
-­‐0.49**	   0.29*	   0.27*	   0.04	   -­‐0.01	  
Bone	  Mineral	  
Density	  
-­‐0.43**	   0.24*	   0.25*	   -­‐0.06	   0.04	  
	  
Strength	  Testing	  Grip	  Strength	   -­‐0.37*	   0.23	   -­‐0.02	   0.19	   -­‐0.07	  
Jumping	  	  
Mechanography	  S2LJ	  Pmax	   -­‐0.26	   0.01	   0.23	   -­‐0.20	   -­‐0.05	  S2LJ	  Vmax	   -­‐0.11	   0.01	   0.17	   -­‐0.17	   0.01	  S2LJ	  Efficiency	   0.28	   -­‐0.23	   0.13	   -­‐0.19	   0.16	  S2LJ	  Jump	  Height	  	   -­‐0.11	   -­‐0.04	   0.11	   -­‐0.14	   0.05	  Chair	  Rise	  Pmax	   0.05	   0.08	   -­‐0.08	   0.07	   -­‐0.06	  
	  
Serum	  Biochemistry	  Fasting	  Glucose	   0.23	   0.03	   0.09	   0.13	   0.13	  
Total	  
Cholesterol	  
0.49**	   0.09	   0.03	   -­‐0.04	   0.08	  HDL	  Cholesterol	   0.10	   -­‐0.01	   -­‐0.18	   0.11	   -­‐0.02	  
IGF-­‐I	   -­‐0.38*	   0.15	   0.21	   -­‐0.02	   -­‐
0.26*	  
LH	   0.50***	   -­‐0.01	   -­‐0.09	   0.10	   0.17	  
FSH	   0.56***	   -­‐0.12	   -­‐0.01	   -­‐0.12	   0.20	  Testosterone	   -­‐0.03	   0.09	   0.12	   0.23	   -­‐0.11	  
SHBG	   -­‐0.14	   -­‐0.19	   -­‐0.24*	   -­‐0.16	   0.09	  9am	  Cortisol	   -­‐0.28	   0.14	   0.23	   -­‐0.07	   -­‐0.06	  DHEAS	   -­‐0.19	   0.10	   0.18	   0.05	   -­‐0.16	  
Skeletal	  Muscle	  mRNA	  	  
Expression	  data	  11β-­‐HSD1	   N/A	   -­‐0.02	   -­‐0.30	   0.17	   0.04	  
	  
Table	  6-­‐15:	  Bivariate	  correlations	  for	  skeletal	  muscle	  11β-­‐HSD1	  expression,	  urinary	  steroid	  
analysis	  markers	  (GC/MS)	  vs.	  anthropometric	  variables,	  body	  composition	  (DEXA),	  strength	  
testing,	   jumping	  mechanography	   (Leonardo	  Ground	  Force	  Plate),	   serum	  biochemistry	  and	  
mRNA	  expression	  data	  (microfluidic	  array)	  in	  female	  ageing	  study	  participants	  (n=77	  for	  all	  
analyses	   except	   those	   involving	   gene	   expression	   when	   n=55).	   (THF+5αTHF)/THE	   =	   tetra-­‐
hydrocortisol+5α-­‐tetrahydrocortisol)/tetrahydrocortisone.	   F/E	   =	   cortisol/cortisone.	   Data	   are	  
correlation	  coefficients	  (Spearman	  correlations).	  *P<0.05,	  **P<0.01	  and	  ***P<0.001.	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6.5.15.	   Correlations	   for	   Skeletal	   Muscle	   11β-­‐HSD1	   Expression	   and	  
Urinary	  Steroid	  Markers	  of	  GC	  Metabolism	  vs.	  Anthropometric,	  Body	  
Composition,	  Strength	  Testing	  and	  Serum	  Biochemistry	  Data	  in	  Male	  
Subjects	  
	  Correlations	   between	   urine	   steroid	   ratios	   and	   anthropometric	   variables,	   and	  data	   from	   DEXA	   analysis,	   strength	   testing,	   jump-­‐plate	   mechanography,	   and	  serum	   biochemistry	   values	   for	  men	   are	   summarized	   in	   table	   6-­‐16.	   As	   seen	   in	  women,	   significant	   positive	   correlations	   were	   observed	   between	   total	   F	  metabolites	   and	   total	   fat	  mass	   and	  %	   body	   fat.	   However	   positive	   correlations	  were	  also	  seen	  between	   total	  F	  metabolites	  and	  BMI,	   total	   lean	  mass	  and	  bone	  mineral	   content,	   which	  may	   be	   a	   function	   of	   fat	  mass	   and	   these	   variables	   are	  interrelated.	   	   Finally	   negative	   correlations	   were	   observed	   between	   serum	  androgens	   (testosterone	  and	  DHEAS)	  and	  urinary	  markers	  of	   global	  11β-­‐HSD1	  activity	  (see	  supplementary	  figure	  S6.1).	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Male	  Subjects	   Correlation	  Coefficients	  (r)	  (Spearman)	  
	  
	   	   Urine	  Steroid	  Analysis	  Results	  (by	  GC/MS)	  













BMI	   -­‐0.03	   0.19	   -­‐0.14	   *0.28	   -­‐0.08	  SBP	   0.02	   -­‐0.03	   -­‐0.06	   -­‐0.08	   -­‐0.06	  
DBP	   -­‐0.01	   0.05	   0.08	   *-­‐0.29	   -­‐0.24	  
Body	  Composition	  
Data	  
Total	  Fat	  Mass	   -­‐0.06	   0.22	   -­‐0.15	   ***0.48	   0.02	  
%	  Body	  Fat	   -­‐0.02	   0.19	   -­‐0.09	   *0.30	   -­‐0.06	  
Total	  Lean	  Mass	   -­‐0.04	   0.13	   -­‐0.08	   **0.40	   -­‐0.05	  
Bone	  Mineral	  
Content	  
-­‐0.06	   -­‐0.05	   -­‐0.01	   *0.31	   -­‐0.01	  Bone	  Mineral	  Density	   0.09	   -­‐0.06	   0.03	   0.05	   -­‐0.15	  
Strength	  Testing	  
	  Grip	  Strength	   0.35	   -­‐0.19	   -­‐0.17	   0.01	   0.00	  
Jumping	  
Mechanography	  S2LJ	  Pmax	   -­‐0.38	   -­‐0.19	   -­‐0.16	   0.13	   0.07	  S2LJ	  Vmax	   -­‐0.35	   -­‐0.15	   -­‐0.14	   0.12	   0.03	  S2LJ	  Efficiency	   -­‐0.04	   -­‐0.07	   -­‐0.19	   -­‐0.06	   -­‐0.13	  S2LJ	  Jump	  Height	  	   -­‐0.37	   -­‐0.11	   -­‐0.12	   0.19	   0.04	  Chair	  Rise	  Pmax	   -­‐0.22	   -­‐0.04	   -­‐0.02	   0.04	   0.06	  
Serum	  Biochemistry	  
	  Fasting	  Glucose	   -­‐0.27	   0.00	   -­‐0.17	   -­‐0.01	   0.05	  Total	  Cholesterol	   -­‐0.16	   -­‐0.02	   -­‐0.14	   0.09	   0.07	  HDL	  Cholesterol	   -­‐0.07	   -­‐0.14	   -­‐0.08	   -­‐0.22	   -­‐0.19	  IGF-­‐I	   -­‐0.28	   -­‐0.06	   -­‐0.02	   0.15	   0.08	  LH	   0.18	   -­‐0.24	   -­‐0.09	   -­‐0.08	   0.08	  FSH	   0.34	   -­‐0.13	   -­‐0.063	   -­‐0.18	   0.05	  
Testosterone	   0.26	   **-­‐0.38	   *-­‐0.32	   -­‐0.11	   0.11	  SHBG	   0.35	   0.08	   0.13	   -­‐0.1	   -­‐0.15	  9am	  Cortisol	   -­‐0.40	   0.03	   0.16	   -­‐0.273	   -­‐0.18	  
DHEAS	   -­‐0.18	   *-­‐0.31	   -­‐0.07	   0.12	   0.22	  
Skeletal	  Muscle	  mRNA	  	  
Expression	  data	  11β-­‐HSD1	   N/A	   -­‐0.12	   0.10	   0.19	   0.19	  
	  
Table	  6-­‐16:	  Bivariate	  correlations	  for	  skeletal	  muscle	  11β-­‐HSD1	  expression,	  urinary	  steroid	  
analysis	  markers	  (GC/MS)	  vs.	  anthropometric	  variables,	  body	  composition	  (DEXA),	  strength	  
testing,	   jumping	  mechanography	   (Leonardo	  Ground	  Force	  Plate),	   serum	  biochemistry	  and	  
mRNA	  expression	  data	   (microfluidic	  array)	   in	  male	  ageing	   study	  participants	   (n=58	   for	  all	  
analyses	   with	   the	   exception	   of	   those	   involving	   gene	   expression	   data	   when	   n=24).	  
(THF+5αTHF)/THE	   =	   tetra-­‐hydrocortisol+5α-­‐tetrahydrocortisol)/tetrahydrocortisone.	   F/E	   =	  
cortisol/cortisone.	  Data	  are	  correlation	  coefficients	  (Spearman	  correlations).	  *P<0.05,	  **P<0.01	  and	  
***P<0.001.	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6.5.16.	  Correlations	  between	  Fat	  Mass	  and	  Total	  F	  Metabolites	  in	  




Figure	   6-­‐9:	   Correlations	   between	   body	   fat	   determined	   by	   DEXA	   scan	   and	   urinary	   total	   F	  
metabolites	   as	  measured	   by	   GC/MS.	   Total	   F	  metabolites	  were	   positively	   correlated	  with	   a),	   c)	  
total	  fat	  mass	  and	  b),	  d),	  body	  fat	  %	  in	  women	  and	  men	  respectively.	  Full	  line	  =	  linear	  regression.	  F	  =	  
cortisol.	   R-­‐values	   represent	   correlation	   coefficients	   derived	   from	   Spearman	   Analysis.	   N=77	   for	  
Female	  study	  participants	  and	  n=58	  for	  male	  study	  participants.	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6.5.17.	   Correlations	   between	   Strength	   and	   11β-­‐HSD1	   Gene	  
Expression	  in	  Skeletal	  Muscle	  




Figure	   6-­‐10:	   Correlation	   between	   grip	   strength	   and	   skeletal	   muscle	   HSD11B1	   mRNA	  
expression	   in	   women	   (n=77).	   These	   parameters	   were	   negatively	   correlated.	   Full-­‐line	   =	   linear	  




6.5.18.	   Correlations	   between	   Serum	   Gonadotrophin	   Levels	   and	  
Skeletal	  Muscle	  11β-­‐HSD1	  Gene	  Expression	  
	  The	   positive	   correlations	   between	   serum	   LH/FSH	   levels	   and	   skeletal	   muscle	  11β-­‐HSD1-­‐gene	  expression	  shown	  in	  table	  6-­‐15	  are	  presented	  in	  figure	  6-­‐11.	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Figure	   6-­‐11:	   Correlations	   between	   serum	   gonadotrophin	   levels	   and	   skeletal	   muscle	  
HSD11B1	  mRNA	   expression	   (n=55).	   a)	   FSH	   and	   b)	   LH	   were	   positively	   correlated	   with	   skeletal	  
muscle	   HSD11B1	   gene	   expression	   in	   women.	   Full	   line	   =	   linear	   regression.	   R-­‐values	   represent	  
correlation	  coefficients	  derived	  from	  Spearman	  Analysis.	  
	  
	  
6.5.19.	  Comparisons	  of	  Patient	  Characteristics,	  Serum	  Biochemistry,	  
Skeletal	   Muscle	   Gene	   Expression	   and	   Urinary	   Steroid	   Metabolites	  
between	  Pre-­‐	  and	  Post-­‐Menopausal	  Women	  
	  In	  view	  of	  the	  observations	  that	  skeletal	  muscle	  11β-­‐HSD1	  gene	  expression	  was	  increased	  in	  women	  over	  50	  years	  of	  age	  compared	  to	  younger	  women,	  and	  the	  positive	   correlation	  between	  gene	  expression	  and	  serum	  gonadotrophin	   levels,	  the	  group	  was	  divided	  according	  to	  menopausal	  status	  (defined	  as	  the	  absence	  of	  periods	   for	  6	  months	   in	   combination	  with	  a	   serum	  FSH	   level	  of	  >25	   IU/L)	  and	  comparisons	   were	   made	   between	   patient	   characteristics,	   body	   composition,	  serum	  biochemistry,	  skeletal	  muscle	  gene	  expression	  and	  urine	  steroid	  analysis	  results	   using	  Mann-­‐Whitney	   tests	   (as	   presented	   in	   table	   6-­‐17).	   These	   analyses	  revealed	  that	  skeletal	  muscle	  11β-­‐HSD1	  gene	  expression	  was	  increased	  in	  post-­‐menopausal	  women.	   Body	   composition	   analysis	   showed	   that	   post-­‐menopausal	  women	   had	   slightly	   increased	   BMIs	   (25.1kg/m2,	   IQR	   23.0-­‐27.1	   vs.	   23.7kg/m2,	  IQR	  21.1-­‐25.8,	  p=0.03),	  and	  total	  fat	  mass	  results	  (23.2kg,	  IQR	  20.2-­‐25.0	  vs.	  20.0,	  IQR	  20.0kg,	  IQR	  14.8-­‐23.6,	  p=0.004)	  and	  reduced	  bone	  mineral	  content/density	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(BMC	  19.4kg,	  IQR	  17.2-­‐21.1	  vs.	  21.2,	  IQR	  19.3-­‐22.9,	  p=0.01;	  BMD	  1.0,	  IQR	  1.0-­‐1.1	  vs.	  1.1,	  IQR	  1.0-­‐1.2,	  p=0.006).	  Serum	  biochemistry	  revealed	  lower	  levels	  of	  IGF-­‐I,	  DHEAS	  and	  testosterone	  and	  increased	  fasting	  glucose	  and	  cholesterol	   levels	   in	  post-­‐menopausal	  women.	  No	  statistically	  significant	  differences	  in	  urine	  markers	  of	  11β-­‐HSD	  type	  1	  and	  2	  and	  5α-­‐reductase	  enzyme	  activities	  between	  groups.	  	  	  	   Subject	  Characteristics	  by	  Menopausal	  Status	  
(Medians	  and	  IQRs)	  	   Pre-­‐menopausal	   Post-­‐menopausal	   P-­‐value	  
Patient	  Characteristics	  
Age	  (years)	   34	  (25-­‐45)	   63	  (56-­‐68)	   <0.0001	  
BMI	  (kg/m2)	   23.7	  (21.1-­‐25.8)	   25.1	  (23.0-­‐27.1)	   0.03	  
Fat	  Mass	  (kg)	   20.0	  (14.8-­‐23.6)	   23.2	  (20.2-­‐25.0)	   0.004	  Lean	  Mass	  (kg)	   41.5	  (36.2-­‐45.1)	   40.9	  (37.9-­‐43.8)	   0.81	  
Bone	  Mineral	  Content	  (kg)	   21.2	  (19.3-­‐22.9)	   19.4	  (17.2-­‐21.1)	   0.01	  
Bone	  Mineral	  Density	  (g/cm2)	   1.1	  (1.0-­‐1.2)	   1.0	  (1.0-­‐1.1)	   0.006	  
Serum	  biochemistry	  
IGF-­‐I	  (nmol/L)	   23.0	  (19.1-­‐25.2)	   13.4	  (11.6-­‐15.8)	   <0.0001	  
DHEAS	  (nmol/L)	   3.3	  (2.3-­‐4.8)	   2.0	  (0.9-­‐3.1)	   <0.0001	  
Testosterone	  (nmol/L)	   0.7	  (0.6-­‐1.0)	   0.6	  (0.4-­‐0.8)	   0.009	  SHBG	  (nmol/L)	   62.3	  (44.4-­‐75.8)	   67.4	  (45.6-­‐84.6)	   0.50	  9am	  Cortisol	  (nmol/L)	   259.5	  (193.3-­‐496.3)	   219.5	  (176.5-­‐289.8)	   0.15	  
Fasting	  Glucose	  (nmol/L)	   4.5	  (4.3-­‐4.7)	   4.9	  (4.7-­‐5.2)	   <0.0001	  
Fasting	  Total	  Cholesterol	  
(nmol/L)	  
4.7	  (3.8-­‐4.9)	   5.6	  (5.2-­‐6.1)	   <0.0001	  
Skeletal	  Muscle	  mRNA	  Expression	  




0.003	  H6PDH	  (AU)	   0.07	  (0.03-­‐0.11)	   0.06	  (0.04-­‐0.15)	   0.74	  
Urine	  Steroid	  GC/MS	  Analysis	  (THF+5αTHF/THE)	  	   0.87	  (0.75-­‐1.11)	   0.81	  (0.65-­‐0.92)	   0.06	  (Cortols/Cortolones)	   0.42	  (0.36-­‐0.51)	   0.40	  (0.30-­‐0.47)	   0.19	  Total	  F	  Metabolites	  (μg/24h)	   6092	  (3966-­‐7523)	   6114	  (4587-­‐7898)	   0.61	  F/E	   0.62	  (0.52-­‐0.72)	   0.62	  (0.52-­‐0.73)	   0.74	  THF/5αTHF	   1.44	  (1.05-­‐1.83)	   1.45	  (1.16-­‐2.25)	   0.62	  	  
Table	  6-­‐17:	  Subject	  characteristics	  according	  to	  menopausal	  status	  (as	  determined	  by	  absence	  
of	   menstrual	   periods	   and	   serum	   FSH	   levels	   >25IU/L)	   (n=77	   for	   all	   analyses	   apart	   from	   those	  
involving	   gene	   expression	   when	   n=55).	   Characteristics	   include	   general	   demographics,	  
anthropometry,	  body	  composition,	   serum	  biochemistry,	   skeletal	  muscle	  gene	  expression	  and	  urine	  
steroid	   GC/MS	   data.	   P-­‐values	   shown	   are	   from	   Mann	   Whitney	   tests	   with	   statistically	   significant	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6.5.20.	  Skeletal	  Muscle	  11β-­‐HSD1	  Expression	  According	  to	  
Menopausal	  Status	  	  The	   upregulation	   in	   skeletal	   muscle	   11β-­‐HSD1	   (known	   as	   HSD11B1)	   gene	  expression	   seen	   in	   post-­‐menopausal	   women,	   described	   above	   in	   table	   6-­‐17	   is	  also	  presented	  in	  figure	  6-­‐12.	  	  
	  
Figure	   6-­‐12:	   Skeletal	   Muscle	   HSD11B1	   gene	   (mRNA)	   expression	   by	   menopausal	   status	  
(n=55).	  Menopausal	  status	  was	  determined	  by	  absence	  of	  menstrual	  periods	  and	  serum	  FSH	  levels	  
>25IU/L.	   Skeletal	  muscle	  HSD11B1	   expression	  was	   determined	   in	   vastus	   lateralis	   biopsy	   samples	  
using	   real-­‐time	  PCR	  based	  microfluidic	   gene	   expression	   array.	   **P=0.003	  as	   determined	  by	  Mann	  
Whitney	  test.	  	  
	  
	  
6.5.21.	  Comparisons	  of	  Patient	  Characteristics,	  Skeletal	  Muscle	  Gene	  
Expression	  and	  Urine	  Steroid	  Metabolites	  between	  Genders	  	  
	  In	   view	   of	   the	   increased	   skeletal	   muscle	   11β-­‐HSD1	   expression	   in	   post-­‐menopausal	   women,	   men	   and	   women	   were	   compared	   to	   assess	   whether	  differences	  exist	  that	  would	  be	  consistent	  with	  regulation	  by	  sex	  hormones	  (see	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table	  6-­‐18).	   	  No	  differences	   in	  skeletal	  muscle	  gene	  expression	  of	  11β-­‐HSD1	  or	  H6PDH	  were	  observed	  between	  sexes.	  However	  there	  was	  evidence	  of	  increased	  global	   activity	   of	   11β-­‐HSD1	  with	   higher	   (THF+5αTHF)/THE	   ratios	   and	   total	   F	  metabolites	   seen	   in	   men.	   In	   addition	   THF/5αTHF	   ratios	   were	   lower	   in	   men	  compared	  to	  women	  consistent	  with	  increased	  5α-­‐reductase	  activity.	  The	  groups	  were	  well	  matched	  with	  regards	  to	  age	  and	  BMI,	  although	  as	  expected	  men	  had	  lower	  total	  fat	  mass	  and	  higher	  total	  lean	  mass	  values	  than	  women.	  	  	  	   	   Sexual	  Dimorphism	  in	  Subject	  Characteristics	  	  
(Medians	  +	  IQRs)	  	   Women	  	   Men	  	   P-­‐value	  
Patient	  Characteristics	  Age	  (years)	   48	  (32-­‐63)	   47	  (30-­‐65)	   0.87	  BMI	  (kg/m2)	   24.5	  (22.3-­‐26.6)	   25.1	  (22.9-­‐27.3)	   0.15	  
Total	  Fat	  Mass	  (kg)	   21.1	  (16.8-­‐24.8)	   16.5	  (13.3-­‐21.0)	   <0.0001	  
Total	  Lean	  Mass	  (kg)	   41.1	  (37.0-­‐43.8)	   57.9	  (52.9-­‐63.7)	   <0.0001	  
Skeletal	  Muscle	  mRNA	  Expression	  11β-­‐HSD1	  (AU)	   0.01	  (0.01-­‐0.02)	   0.01	  (0.01-­‐0.02)	   0.41	  H6PDH	  (AU)	   0.07	  (0.04-­‐0.12)	   0.10	  (0.08-­‐0.12)	   0.06	  
Urine	  Steroid	  GC/MS	  Analysis	  
(THF+5αTHF)/THE	  	   0.85	  (0.68-­‐1.00)	   0.98	  (0.78-­‐1.18)	   0.01	  (Cortols/Cortolones)	   0.42	  (0.33-­‐0.51)	   0.42	  (0.36-­‐0.51)	   0.62	  
Total	  F	  Metabolites	  (μg/24h)	   5844	  (4515-­‐7523)	   9180	  (6973-­‐12246)	   <0.0001	  F/E	   0.62	  (0.52-­‐0.72)	   0.70	  (0.59-­‐0.78)	   0.05	  
THF/5αTHF	   1.46	  (1.14-­‐2.10)	   1.04	  (0.82-­‐1.36)	   <0.0001	  	  
Table	  6-­‐18:	   Sexual	  dimorphism	  of	   subject	   characteristics	   including	  general	  demographics,	  
anthropometry,	  body	  composition,	  skeletal	  muscle	  gene	  expression	  and	  urine	  steroid	  GC/MS	  
data	   (For	   women	   n=77,	   except	   in	   gene	   expression	   analyses	   when	   n=55,	   for	   men	   n=58,	   except	  
analyses	   involving	   gene	   expression	   when	   n=24).	   P-­‐values	   are	   from	   Mann	   Whitney	   tests	   with	  
statistically	  significant	  results	  highlighted	  in	  bold.	  	  
	  
	  
6.5.22.	  Comparisons	  of	  Patient	  Characteristics,	  Skeletal	  Muscle	  Gene	  
Expression	   and	   Urine	   Steroid	   Metabolites	   according	   to	   Total	   Fat	  
Mass	  Levels	  in	  Female	  Subjects	  	  In	  view	  of	  the	  observed	  correlations	  between	  measures	  of	  fat	  mass	  and	  skeletal	  muscle	  11β-­‐HSD1	  gene	  expression	  and	  urine	  total	  F	  metabolite	  excretion	  seen	  in	  women	   (shown	   in	   table	   6-­‐15	   and	   figure	   6-­‐9)	   we	   compared	   subject	  characteristics,	   gene	   expression	   and	   steroid	  metabolites	   in	   subjects	   whose	   fat	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mass	  was	  below	  the	  median	  compared	   to	   those	  with	  values	  above	   the	  median,	  using	  Mann-­‐Whitney	  analysis	   (see	   table	  6-­‐19).	   	  The	  higher	   fat	  mass	  group	  had	  increased	  total	  F	  metabolite	  values	  (6818μg/24h,	  IQR	  4842-­‐8077	  vs.	  4955,	  IQR	  4005-­‐6531,	  p=0.007),	  and	  lower	  serum	  IGF-­‐I,	  DHEAS	  and	  testosterone	  levels.	  	  	  	  
Female	  Subjects	   Subject	  Characteristics	  by	  Total	  Fat	  Mass	  (DEXA	  analysis)	  
(Medians	  and	  IQRs)	  	   Below	  Median	  Fat	  
Mass	  (20.87kg)	  




Age	  (years)	   37	  (26-­‐55)	   53	  (47-­‐64)	   0.0005	  
Serum	  biochemistry	  
IGF-­‐I	   23.3	  (19.6-­‐26.8)	   14.5	  (11.8-­‐18.9)	   <0.0001	  
DHEAS	   3.3	  (2.5-­‐4.6)	   2.1	  (1.0-­‐3.3)	   0.0002	  
Testosterone	   0.7	  (0.6-­‐1.0)	   0.6	  (0.4-­‐0.9)	   0.02	  SHBG	   61.6	  (43.4-­‐74.6)	   67.4	  (45.6-­‐80.8)	   0.48	  9am	  Cortisol	   265.0	  (203.50-­‐434.50)	   215.00	  (183.30-­‐292.80)	   0.10	  
Skeletal	  Muscle	  mRNA	  Expression	  11β-­‐HSD1	  (AU)	   0.01	  (0.00-­‐0.01)	   0.01	  (0.01-­‐0.02)	   0.11	  H6PDH	  (AU)	   0.09	  (0.03-­‐0.11)	   0.05	  (0.03-­‐0.11)	   1.00	  
Urine	  Steroid	  GC/MS	  Analysis	  (THF+5αTHF/THE)	  	   0.79	  (0.65-­‐0.92)	   0.89	  (0.77-­‐1.07)	   0.05	  (Cortols/Cortolones)	   0.41	  (0.34-­‐0.46)	   0.42	  (0.32-­‐0.54)	   0.64	  
Total	  F	  Metabolites	  
(μg/24h)	  
4955	  (4005-­‐6531)	   6817	  (4842-­‐8077)	   0.007	  F/E	   0.65	  (0.57-­‐0.82)	   0.60	  (0.51-­‐0.69)	   0.07	  THF/5αTHF	   1.53	  (1.17-­‐2.39)	   1.32	  (1.07-­‐1.72)	   0.11	  	  
Table	   6-­‐19:	   Subject	   characteristics	   in	   female	   ageing	   study	   participants	   as	   divided	   into	   2	  
groups	   depending	   on	   total	   fat	   mass	   (below	   and	   above	   median	   total	   fat	   mass	   measure	   of	  
20.87kg)(n=77,	   except	   in	   analyses	   involving	   gene	   expression	  when	   n=55).	   Characteristics	   include	  
general	   demographics,	   anthropometry,	   body	   composition,	   skeletal	   muscle	   gene	   expression	   and	  





6.5.23.	  Comparisons	  of	  Patient	  Characteristics,	  Skeletal	  Muscle	  Gene	  
Expression	   and	   Urine	   Steroid	   Metabolites	   according	   to	   Total	   Fat	  
Mass	  Levels	  in	  Male	  Subjects	  	  The	  male	  subjects	  followed	  a	  similar	  pattern	  with	  the	  higher	  fat	  mass	  group	  also	  having	   increased	   total	  F	  metabolites	   (10671μg/24h,	   IQR	  8866-­‐13317	  vs.	  7453,	  IQR	   5755-­‐10090),	   lower	   serum	   DHEAS	   and	   testosterone	   levels	   (illustrated	   in	  table	  6-­‐20).	  Similar	  analyses	  were	  performed	  using	  a	  group	  divided	  according	  to	  
	   212	  
median	  BMI	  with	  no	  differences	   in	  urine	   steroid	  markers	  of	  11β-­‐HSD1	  activity	  observed	  (supplementary	  tables	  S6.13	  and	  S6.14).	  	  	  
Male	  Subjects	   Subject	  Characteristics	  by	  Total	  Body	  Fat	  (DEXA	  analysis)	  
(Medians	  and	  IQRs)	  	   Below	  Median	  Fat	  
Mass	  (14.79	  kg)	  
Above	  Median	  Fat	  
Mass	  (14.79	  kg)	  
P-­‐value	  
Patient	  Characteristics	  
Age	  (years)	   38	  (27-­‐63)	   57	  (42-­‐65)	   0.02	  
Serum	  biochemistry	  IGF-­‐I	   20.6	  (16.1-­‐26.3)	   18.1	  (15.9-­‐22.9)	   0.23	  
DHEAS	   7.4	  (2.9-­‐9.5)	   4.7	  (2.8-­‐5.8)	   0.03	  
Testosterone	   17.4	  (13.3-­‐20.1)	   13.8	  (11.4-­‐17.4)	   0.04	  SHBG	   34.1	  (25.4-­‐44.5)	   32.8	  (27.0-­‐44.5)	   0.97	  9am	  Cortisol	   311	  (258-­‐410)	   276	  (219-­‐364)	   0.11	  
Skeletal	  Muscle	  mRNA	  Expression	  11β-­‐HSD1	  (AU)	   0.01	  (0.01-­‐0.02)	   0.01	  (0.01-­‐0.02)	   0.88	  H6PDH	  (AU)	   0.10	  (0.08-­‐0.11)	   0.09	  (0.06-­‐0.16)	   0.88	  
Urine	  Steroid	  GC/MS	  Analysis	  (THF+5αTHF/THE)	  	   0.95	  (0.81-­‐1.03)	   1.06	  (0.80-­‐1.22)	   0.18	  (Cortols/Cortolones)	   0.46	  (0.37-­‐0.53)	   0.38	  (0.33-­‐0.50)	   0.10	  
Total	  F	  Metabolites	  
(μg/24h)	  
7453	  (5755-­‐10090)	   10671	  (8866-­‐13317)	   0.003	  F/E	   0.69	  (0.60-­‐0.77)	   0.70	  (0.58-­‐0.79)	   0.97	  THF/5αTHF	   1.06	  (0.86-­‐1.35)	   1.04	  (0.67-­‐1.49)	   0.73	  	  
	  
Table	   6-­‐20:	   Subject	   characteristics	   in	   male	   ageing	   study	   participants	   as	   divided	   into	   2	  
groups	   depending	   on	   total	   fat	   mass	   (below	   and	   above	   median	   total	   fat	   mass	   measure	   of	  
20.87kg)(n=58,	   except	   in	   analyses	   involving	   gene	   expression	  when	   n=24).	   Characteristics	   include	  
general	   demographics,	   anthropometry,	   body	   composition,	   skeletal	   muscle	   gene	   expression	   and	  
urine	  steroid	  GC/MS	  data.	  P-­‐values	  shown	  are	  from	  Mann	  Whitney	  tests	  with	  statistically	  significant	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6.6.	  Discussion	  The	  work	  outlined	  in	  this	  chapter,	  represents	  the	  largest	  study	  assessing	  cortisol	  secretion	  and	  metabolism	  and	   local	   skeletal	  muscle	  11β-­‐HSD1	  gene	  expression	  across	   human	   ageing.	   A	   particular	   strength	   of	   the	   study	   is	   the	   favourable	  recruitment	   of	   healthy	   volunteers,	   which	   at	   135	   is	   much	   higher	   than	   other	  studies	   that	   have	   investigated	   tissue	   specific	   effects	   of	   11β-­‐HSD1	   in	   adipose	  (n=46),	   skin	   (n=40)	   and	   bone	   (n=18)(Andersson	   et	   al.,	   2009,	   Tiganescu	   et	   al.,	  2013,	  Cooper	  et	  al.,	  2002).	   In	  addition	  our	  recruitment	  has	   included	  both	  male	  and	   female	   subjects	   distributed	   across	   the	   age	   range	   allowing	   us	   to	   probe	  potential	  sexual	  dimorphism	  and	  changes	  across	  the	  human	  lifespan.	  Our	  cohort	  have	  been	  extensively	  phenotyped	  by	  undergoing	  assessment	  of	  anthropometric	  data,	   body	   composition	   analysis	   by	   DEXA,	   grip	   strength	   dynamometry,	   jump-­‐plate	  mechanography,	   serum	   biochemistry,	   vastus	   lateralis	   muscle	   biopsy	   and	  urine	  steroid	  analysis	  of	  24	  hour	  collections.	  Finally	  analysis	  of	  this	  cohort	  with	  a	  focused	  gene	  expression	  array	  of	  92	  target	  genes	  covering	  a	  range	  of	   functions	  validates	   and	   builds	   upon	   early	   exploratory	   studies	   that	   used	   a	   whole	  transcriptome	  approach	  in	  small	  numbers	  of	  subjects	  (Welle	  et	  al.,	  2003,	  Welle	  et	  al.,	   2004,	   Giresi	   et	   al.,	   2005).	   This	   work	   contributes	   to	   our	   knowledge	   of	   age-­‐associated	  changes	  in	  steroid	  metabolism	  and	  skeletal	  muscle	  gene	  expression	  in	  humans	   with	   potential	   consequences	   in	   generating	   therapeutic	   targets	   for	  related	  diseases.	  Furthermore	   it	  has	  allowed	  us	   to	  generate	  a	  valuable	  bank	  of	  tissues	   that	  will	   form	   the	   basis	   of	   further	   studies	   in	   this	   area.	   There	   are	   some	  general	   caveats	   that	   should	   be	   taken	   into	   account	   when	   interpreting	   the	   data	  relating	  to	  inherent	  limitations	  in	  the	  study	  design.	  The	  first	  among	  these	  is	  the	  cross-­‐sectional	  nature	  of	  the	  study,	  which	  is	  open	  to	  potential	  bias.	  For	  example	  
	   214	  
in	   aiming	   to	   recruit	   a	   ‘healthy’	   elderly	   cohort,	   by	   excluding	   those	  with	   obesity	  and	   other	  medical	   conditions	   in	   order	   to	   reduce	   interindividual	   variation,	   it	   is	  possible	  that	  this	  cohort	  is	  not	  a	  typical	  control.	  For	  example	  our	  cohort	  over	  70	  years,	   was	   community-­‐dwelling	   and	   largely	   independent,	   as	   well	   as	   being	  motivated	  to	  give	  their	  time	  to	  volunteer	  to	  enrol	  in	  a	  university-­‐based	  research	  study	  so	  those	  with	  frailty	  and	  poor	  functional	  status	  were	  unrepresented.	  	  	  Furthermore	  structured	  information	  on	  exercise	  capabilities	  was	  not	  collected	  at	  baseline.	   The	   data	   outlining	   baseline	   subject	   characteristics	   provide	   a	   useful	  summary	   when	   interpreting	   the	   gene	   expression	   and	   biochemical	   changes	  observed.	  It	  is	  clear	  from	  this	  data	  that	  expected	  age	  associated	  characteristics	  in	  serum	  biochemistry,	   including	  declines	  in	  hormones	  such	  as	  IGF-­‐I,	  testosterone	  and	  DHEA	  are	  represented	  across	  our	  cohort	  along	  with	  reductions	   in	  strength	  testing	  parameters.	  A	  reduction	  in	  lean	  mass	  was	  not	  observed	  across	  age	  in	  our	  cohort	  however,	  increases	  in	  body	  fat	  in	  middle	  age	  were	  observed	  in	  women,	  so	  any	   conclusions	   drawn	   should	   be	   related	   to	   dynapenia	   or	   inherent	   skeletal	  muscle	   ageing	   as	   opposed	   to	   sarcopenia.	   This	   study	   attempts	   to	   provide	   an	  insight	  into	  the	  changes	  in	  gene	  expression	  and	  steroid	  metabolism	  across	  age	  in	  a	  cohort	  without	  major	  co-­‐morbidity,	  so	  the	  results	  should	  not	  be	  extrapolated	  to	  apply	   to	   specific	   patient	   groups	   with	   conditions	   such	   as	   cancer,	   inflammatory	  disease	   or	   severe	   muscle	   wasting.	   A	   pragmatic	   approach	   was	   taken	   with	  recruitment	  of	  subjects	  with	  highly	  prevalent	  conditions	  however,	  and	  as	  a	  result	  some	  individuals	  with	  hypertension,	  hypercholesterolaemia	  and	  hypothyroidism	  on	   stable	   replacement	   were	   included.	   Three	   subjects	   with	   benign	   prostatic	  hypertrophy	   treated	  with	   finasteride	   or	   dutasteride	  were	   excluded	   from	   study	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analysis.	  Ethnicities	  of	  individuals	  were	  well	  matched	  between	  genders,	  however	  there	  was	  a	  less	  diverse	  ethnic	  mix	  in	  older	  individuals.	  It	  should	  be	  noted	  that	  no	   differences	   in	   11β-­‐HSD1	   skeletal	  muscle	   gene	   expression	   or	   global	   activity	  were	   observed	   between	   age	   and	   BMI	   matched	   Caucasians	   and	   South	   Asian	  participants.	  Overall	  size	  of	  the	  subject	  cohort	  and	  the	  detailed	  phenotypic	  data	  available	   should	   act	   to	   minimize	   the	   effects	   of	   the	   above	   factors.	   	   Finally,	   the	  sample	  size	  of	  men	  whose	  muscle	  biopsies	  were	  analysed	  was	  lower	  than	  that	  of	  women	  (n=24	  vs.	  n=55),	  so	  it	  is	  possible	  that	  observations	  in	  this	  group	  did	  not	  reach	  significance	  due	  to	  lack	  of	  statistical	  power.	  	  	  Our	   primary	   interest	  was	  whether	   11β-­‐HSD1	   gene	   expression	   and	   subsequent	  pre-­‐receptor	  GC	  metabolism	  play	  a	  role	   in	   the	  ageing	  process	   in	  humans.	  More	  specifically	  this	  study	  attempted	  to	  address	  whether	  changes	  in	  urinary	  steroid	  markers	   of	   global	   enzyme	   activity	   or	   skeletal	   muscle	   gene	   expression	   was	  altered	   with	   age.	   From	   this	   perspective	   the	   most	   striking	   finding	   was	   that	  expression	   of	   skeletal	   muscle	   11β-­‐HSD1	   was	   elevated	   in	   older	   compared	   to	  younger	  women,	  which	   is	  consistent	  with	  our	  central	  hypothesis.	  Furthermore,	  11β-­‐HSD1	  was	  one	  of	  only	  6	  genes	  whose	  expression	  changed	  significantly	  with	  age,	  of	  the	  92	  targets	  analysed.	  Although	  this	  is	  a	  novel	  finding	  in	  human	  skeletal	  muscle,	   it	   is	  consistent	  with	  previous	  data	  showing	  age-­‐dependent	   increases	   in	  11β-­‐HSD1	  gene	  expression	  in	  other	  human	  tissues	  including	  adipose	  tissue,	  skin,	  and	  bone	  (Andersson	  et	  al.,	  2009,	  Cooper	  et	  al.,	  2002,	  Tiganescu	  et	  al.,	  2013).	  In	  our	   study	   however,	   there	  was	   no	   such	   elevation	   in	   11β-­‐HSD1	   skeletal	  muscle	  expression	   in	  men,	   leading	   us	   to	   question	  whether	   sexual	   dimorphism	   in	   pre-­‐receptor	   glucocorticoid	   metabolism	   exists.	   There	   was,	   however	   evidence	   of	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increased	  skeletal	  muscle	  expression	  of	  H6PDH,	  which	  acts	  to	  provide	  co-­‐factor	  (NADPH)	  for	  11β-­‐HSD1	  oxo-­‐reductase	  activity	  (Lavery	  et	  al.,	  2006).	  Both	  of	  these	  observations	  are	  in	  keeping	  with	  a	  potential	  increase	  in	  11β-­‐HSD1	  activity	  with	  age	   in	  both	  genders,	  however	   further	  analyses	  would	  need	  to	  be	  carried	  out	   to	  confirm	  this.	  	  	  With	   respect	   to	   age-­‐associated	   changes	   in	   urinary	   steroid	   markers	   of	   cortisol	  metabolism,	  the	  only	  statistically	  significant	  difference	  observed	  was	  an	  increase	  in	   (THF+5aTHF)/THE	   ratio	   in	   the	   oldest	   female	   group,	   indicative	   of	   increased	  global	   11β-­‐HSD1	   activity.	   This	   conforms	   with	   the	   findings	   of	   Andersson	   et	   al	  (2009)	   who	   found	   evidence	   of	   both	   increased	   global	   and	   hepatic	   11β-­‐HSD1	  activity	   and	   subcutaneous	   adipose	   tissue	   gene	   expression	   in	   post-­‐menopausal	  women.	   However	   our	   findings	   regarding	   (THF+5aTHF)/THE	   should	   be	  interpreted	  with	  caution,	  as	  a	  progressive	  increase	  in	  the	  ratio	  was	  not	  seen	  over	  the	   full	   range	   of	   age	   groups.	   Furthermore	   related	   parameters	   including	  cortols/cortolones	  and	   total	  F	  metabolites	  were	  unaffected	  by	  age.	  Once	  again,	  there	   were	   no	   changes	   indicative	   of	   altered	   cortisol	   metabolism	   observed	   in	  men.	  On	  this	  background,	  if	  we	  accept	  the	  finding	  that	  skeletal	  muscle	  11β-­‐HSD1	  expression	   is	   increased	   with	   age	   in	   women,	   the	   potential	   regulators	   of	   this	  change	  and	  its	  pathophysiological	  consequences	  need	  to	  be	  established.	  To	  this	  end,	   we	   investigated	   associations	   between	   markers	   of	   11β-­‐HSD1	  expression/activity	  with	  phenotypic	  data.	  This	  analysis	  should	  be	  treated	  as	  an	  exploratory	   exercise,	   and	   is	   not	   designed	   to	   confirm	   causality.	   There	   is	   the	  question	   of	  whether	   this	   change	   is	   driven	   by	   a	   post-­‐menopausal	   factor	   rather	  than	   by	   the	   ageing	   process	   in	   a	   broader	   sense,	   and	   this	   study	   is	   limited	   in	   its	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ability	  to	  answer	  this.	  The	  data	  regarding	  a	  potential	  link	  between	  11β-­‐HSD1	  and	  menopausal	  status	  is	  of	  particular	  interest	  as	  up	  to	  the	  fifth	  decade	  men	  have	  an	  increased	   cardiovascular	   risk	   compared	   to	   women.	   Following	   the	   menopause	  women	   exhibit	   a	   sharp	   increase	   in	   cardiovascular	   risk,	   underpinned	   by	   the	  development	  of	  an	  adverse	  lipid	  and	  body	  composition	  profile	  (Barrett-­‐Connor,	  1997,	   Colombel	   and	   Charbonnel,	   1997,	   Collins,	   2008,	   Yamatani	   et	   al.,	   2013).	  Although	   oestrogen	   levels	   decline	   after	   the	  menopause,	   unfortunately	   a	   recent	  meta-­‐analysis	   revealed	   conventional	   hormone	   replacement	   therapy	   to	   be	  ineffective	  in	  reducing	  this	  risk	  in	  such	  women	  (Main	  et	  al.,	  2013).	  Furthermore,	  prevalence	  of	   osteoporosis	   and	   sarcopenia	   are	   also	   closely	   associated	  with	   the	  menopause	  (Joseph	  et	  al.,	  2005).	  Whether	  tissue	  specific	  increases	  in	  11β-­‐HSD1	  contribute	  to	  altered	  cardiovascular	  disease	  risk	  and	  other	  co-­‐morbidities	   is	  an	  important	   question	   and	   further	   studies	   of	   the	   impact	   of	   selective	   11β-­‐HSD1	  inhibitors	  in	  this	  cohort	  should	  be	  carried	  out	  to	  address	  this.	  	  	  	  Several	  previous	  studies	  have	  attempted	  to	  identify	  potential	  regulators	  of	  11β-­‐HSD1	  including	  glucocorticoids,	  growth	  factors,	  and	  pro-­‐inflammatory	  cytokines	  (Tomlinson	  et	  al.,	  2004).	  A	  review	  of	  our	  correlations	  between	  markers	  of	  11β-­‐HSD1	  skeletal	  muscle	  expression/global	  activity	  and	  other	  phenotypic	  variables	  highlights	   some	   potential	   regulators.	   Levels	   of	   serum	   gonadotrophins	   (LH	   and	  FSH),	   which	   are	   increased	   following	   the	   menopause,	   are	   positively	   correlated	  with	   skeletal	   muscle	   11β-­‐HSD1	   expression.	   Oestrogens	   are	   obvious	   candidate	  regulators	  of	  11β-­‐HSD1	  in	  skeletal	  muscle,	  although	  previous	  studies	  have	  only	  investigated	   their	   effects	   in	   adipose	   tissue.	   Experiments	   performed	   on	  ovarectomised	   rats	   showed	   that	   oestradiol	   suppressed	   11β-­‐HSD1	   activity	   and	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expression	   in	   liver	   and	   visceral	   adipose	   tissue,	   whilst	   it	   had	   no	   effect	   in	  subcutaneous	  tissue,	  with	  the	  authors	  suggesting	  that	  this	  may	  partly	  explain	  the	  differences	   in	   fat	   deposition	   observed	   post-­‐menopausally	   (Andersson	   et	   al.,	  2010).	  A	  recent	  study	  of	  post-­‐menopausal	  women	  reported	  a	  positive	  correlation	  between	   oestrogen	   receptor-­‐beta	   and	   11β-­‐HSD1-­‐gene	   expression	   in	   adipose	  tissue	   (McInnes	   et	   al.,	   2012).	   Furthermore,	   Yamatani	   et	   al	   (2013),	   found	   that	  both	   cortisol/cortisone	   ratios	   and	   11β-­‐HSD1	   gene	   expression	   levels	   were	  increased	   post-­‐menopausally	   in	   visceral	   but	   not	   subcutaneous	   adipose	   tissue.	  This	  study	  also	  reported	  a	  positive	  correlation	  between	  oestrone/oestradiol	  and	  cortisol/cortisone	  ratios	  in	  visceral	  fat.	  In	  our	  study	  we	  also	  observed	  a	  positive	  correlation	   between	  measures	   of	   body	   fat	   and	   11β-­‐HSD1	   gene	   expression	   and	  total	  F	  metabolites.	  It	  is	  possible	  that	  increases	  in	  body	  fat	  mass	  could	  be	  driving	  the	  post-­‐menopausal	  increase	  in	  11β-­‐HSD1	  gene	  expression.	  Previous	  reports	  of	  the	   relationship	   between	   fat	   and	   11β-­‐HSD1	   activity/expression	   have	   been	  mixed.	   Engeli	   et	   al	   (2004)	   found	   that	   subcutaneous	   adipose	   tissue	   11β-­‐HSD1	  expression	   correlated	   positively	   with	   waist	   circumference	   and	   HOMA-­‐IR	   in	   a	  study	   of	   70	   post-­‐menopausal	  women.	   Desbriere	   et	   al	   (2006)	  were	   the	   first	   to	  show	   an	   increase	   in	   11β-­‐HSD1	   expression	   in	   visceral	   adipose	   tissue	   samples	  from	   obese	   subjects.	   Koska	   et	   al	   (2006)	   showed	   that	   11β-­‐HSD1	   expression	   in	  subcutaneous	  tissue	  correlated	  positively	  with	  both	  BMI	  and	  measures	  of	  insulin	  resistance.	   Paulsen	   et	   al	   (2007)	   observed	  higher	  11β-­‐HSD1	  expression	   in	   both	  fat	  depots	  in	  obese	  compared	  to	  lean	  subjects.	  In	  addition	  they	  reported	  higher	  11β-­‐HSD1	   expression	   in	   lean	   men	   compared	   to	   lean	   women.	   Studies	   from	  Andersson	  et	  al	  (2009),	  Svendsen	  et	  al	  (2009)	  and	  Munoz	  et	  al	  (2009)	  supported	  the	   above	   findings.	   11β-­‐HSD1	   expression	   in	   subcutaneous	   tissue	   appears	   to	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decrease	  with	  significant	  weight	  loss	  following	  bariatric	  surgery	  (Simonyte	  et	  al.,	  2010,	   Leyvraz	   et	   al.,	   2012).	   However	   these	   relationships	   have	   not	   been	  reproducible	   in	  every	  study	  (Toogood	  et	  al.,	  2000b,	  Tomlinson	  et	  al.,	  2002b).	   It	  has	  been	  postulated	  that	  reduced	  11β-­‐HSD1	  activity	  is	  a	  protective	  adaptation	  to	  the	   “adverse	   metabolic	   consequences	   of	   obesity”	   (Tomlinson	   et	   al.,	   2004b).	  Furthermore	  weight	  loss	  was	  associated	  with	  increased	  11β-­‐HSD1	  expression	  in	  adipose	   tissue	   and	   activity	   indicated	   by	   serum	   cortisol/cortisone	   ratios	  (Tomlinson	   et	   al.,	   2004a).	   It	   has	   also	   been	   suggested	   that	   clearance	   of	   cortisol	  metabolites	   by	   5-­‐alpha	   reductase	   activity	   is	   important	   in	   protecting	   from	   the	  adverse	   metabolic	   consequences	   of	   obesity.	   In	   support	   of	   this	   Baudrand	   et	   al	  (2011)	   observed	   increased	   5-­‐alpha	   and	   5-­‐beta-­‐reductase	   hepatic	   gene	  expression	   in	   samples	   taken	   from	   morbidly	   obese	   patients	   during	   bariatric	  surgery.	   Alberti	   et	   al	   (2007)	   found	   that	   visceral	   adipose	   11β-­‐HSD1	   expression	  was	   unchanged	   in	   those	   with	   metabolic	   syndrome	   features,	   whereas	   in	  subcutaneous	  adipose	   it	  was	   increased.	  Michalaki	   et	   al	   (2012)	   found	   that	  11β-­‐HSD1	  expression	  in	  subcutaneous	  tissue	  was	  unchanged	  in	  an	  obese	  group	  with	  features	  of	  metabolic	  syndrome,	  whereas	  visceral	   fat	  expression	  was	   increased	  in	   this	   group.	   It	   is	   important	   to	   note	   however	   that	   our	   results	   are	   taken	   from	  healthy	   subjects	   with	   non-­‐obese	   BMIs,	   so	   the	   dynamics	   of	   any	   relationship	  between	   11β-­‐HSD1	   activity	   and	   fat	  mass	  may	   be	   different	   in	   obese	   cohorts	   or	  those	  with	  overt	  metabolic	  disease.	  	  	  There	  are	  marked	  differences	   in	  body	   composition	  between	  genders	  with	  men	  having	   increased	   lean	  mass,	   and	   reduced	   fat	  mass	   compared	   to	  women	   in	   our	  cohort.	  We	   report	   evidence	   of	   sexual	   dimorphism	   in	   cortisol	  metabolism,	  with	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higher	   total	   F	   metabolites,	   (THF+5αTHF)/THE	   ratios	   and	   lower	   THF/5αTHF	  ratios	  in	  men	  compared	  to	  women,	  indicative	  of	  higher	  global	  11β-­‐HSD1	  and	  5α-­‐reductase	  activities.	  These	   findings	  provide	  circumstantial	  support	   for	  negative	  regulation	   of	   11β-­‐HSD1	   by	   a	   pre-­‐menopausal	   female	   factor,	   with	   oestrogen	  appearing	   to	   be	   likely	   candidate.	   However	   the	   findings	   regarding	   the	   sexual	  dimorphism	   of	   11β-­‐HSD1	   activity	   are	   consistent	   with	   a	   previous	   study	   of	   22	  elderly	  subjects	  (Toogood	  et	  al.,	  2000b),	  so	  it	  may	  be	  that	  there	  is	  a	  legacy	  effect	  of	   pre-­‐menopausal	   oestrogens	   that	   lasts	   across	   the	   lifespan.	   Interestingly	   we	  found	   that	   testosterone	   and	   DHEAS	   were	   negatively	   correlated	   with	   urine	  steroid	  markers	  of	  11β-­‐HSD1	  activity	   in	  men	   indicating	   that	   secretion	  of	   these	  hormones	   in	   men	   cannot	   explain	   the	   observed	   sexual	   dimorphism.	   Adrenal	  androgens	   are	   known	   to	   have	   anti-­‐GC	   effects,	   and	   there	   is	   evidence	   that	   they	  inhibit	  11β-­‐HSD1	  oxo-­‐reductase	  activity	  in	  differentiated	  human	  adipocytes	  and	  skeletal	  myoblasts	  (Whorwood	  et	  al.,	  2001,	  Apostolova	  et	  al.,	  2005,	  McNelis	  et	  al.,	  2013).	  	  
	  If	   sex	   steroids	   do	   not	   regulate	   the	   age-­‐associated	   increase	   in	   11β-­‐HSD1	  expression	   in	   skeletal	   muscle,	   IGF-­‐I	   via	   the	   ‘somatopause’	   is	   a	   credible	  alternative.	   Indeed	   we	   observed	   a	   significant	   negative	   correlation	   between	  serum	  IGF-­‐I	  levels	  and	  11β-­‐HSD1	  gene	  expression	  and	  this	  finding	  is	  backed	  up	  by	   evidence	   from	   a	   number	   of	   in	   vitro	   cell	   culture	   and	   clinical	   studies,	   which	  were	  reviewed	  in	  depth	  by	  Tomlinson	  et	  al	  (2004).	  Of	  particular	  relevance	  here	  is	  the	  observation	  that	  treating	  primary	  human	  myoblasts	  with	  IGF-­‐I	  and	  serum	  downregulates	   11β-­‐HSD1	   expression	   (Whorwood	   et	   al	   (2001).	  Of	   interest	   also	  are	  results	  from	  patient	  groups,	  which	  reported	  effects	  of	  GH	  status	  on	  measures	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of	   global	   11β-­‐HSD1	   activity.	   Acromegalic	   patients	   have	   reduced	  cortisol/cortisone	  metabolite	  ratios	  in	  active	  disease,	  and	  these	  ratios	  normalize	  with	   effective	   biochemical	   control	   of	   GH	   hypersecretion.	   Patients	   with	  hypopituitarism	   and	   GH-­‐deficiency	   on	   hydrocortisone	   have	   increased	  cortisol/cortisone	   metabolite	   ratios,	   which	   are	   normalized	   with	   effective	   GH-­‐replacement	   (Moore	   et	   al.,	   1999,	   Toogood	   et	   al.,	   2000a,	   Stewart	   et	   al.,	   2001,	  Frajese	  et	  al.,	  2004).	  	  	  There	  are	  also	  some	  candidate	  regulators	  of	  11β-­‐HSD1	  that	  we	  were	  unable	   to	  assess	  in	  the	  study.	  Potential	  candidates	  include	  impaired	  insulin	  signaling,	  and	  systemic	   inflammation.	  Prevalence	  of	   insulin	  resistance	   increases	  with	  age,	  and	  in	   a	   preliminary	   experiment	   we	   showed	   that	   insulin	   suppresses	   11β-­‐HSD1	  expression	   in	  murine	   skeletal	  myotubes.	   Levels	   of	   pro-­‐inflammatory	   cytokines	  increase	  with	  age,	  and	  a	  number	  of	  cell	  culture	  experiments	   including	  our	  own	  have	  demonstrated	  that	  these	  can	  increase	  11β-­‐HSD1	  expression	  (Tomlinson	  et	  al.,	  2001,	  Ahasan	  et	  al.,	  2012).	  	  	  Correlations	   between	   markers	   of	   11β-­‐HSD1	   skeletal	   muscle	   expression	   and	  global	  activity	  are	  also	  useful	   in	  highlighting	  potential	  pathological	  effects,	  with	  negative	   correlations	   observed	   between	   gene	   expression	   and	   bone	   mineral	  density,	   grip	   strength	   and	   total	   cholesterol.	   In	   men,	   the	   results	   were	  contradictory,	  with	   skeletal	  muscle	   11β-­‐HSD1	   expression	   positively	   correlated	  with	   grip	   strength,	   and	   a	   trend	   towards	   negative	   correlation	   with	   jump-­‐plate	  measures	  of	  maximum	  power	  and	  velocity.	  Although	  11β-­‐HSD1	  has	  been	  shown	  to	   be	   expressed	   and	   functionally	   active	   within	   skeletal	   muscle,	   and	   some	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investigations	   of	   its	   effects	   on	   genes	   involved	   in	   insulin	   resistance	   and	  proteolysis,	  no	  previous	  study	  has	  investigated	  its	  associations	  with	  age	  or	  other	  factors	  in	  humans	  (Jang	  et	  al.,	  2006,	  Jang	  et	  al.,	  2007,	  Jang	  et	  al.,	  2009,	  Morgan	  et	  al.,	  2009,	  Salehzadeh	  et	  al.,	  2009,	  Dovio	  et	  al.,	  2010,	  Biedasek	  et	  al.,	  2011).	  The	  observations	  above	  are	  consistent	  with	  a	  role	  in	  osteoporosis,	  muscle	  weakness	  and	   dyslipidaemia,	   but	   it	   should	   be	   stressed	   that	   the	   analyses	   are	   only	  hypothesis	  generating	  and	  further	  in	  depth	  studies	  would	  be	  required	  to	  assess	  whether	  this	  is	  the	  case.	  Furthermore,	  we	  can	  only	  speculate	  as	  to	  the	  causality	  of	  the	  observed	  relationships	  between	  11β-­‐HSD1	  and	  variables	  such	  as	  fat,	  bone	  and	  lean	  mass.	  	  	  Moving	  on	  to	  our	  skeletal	  muscle	  gene	  expression	  data,	  particular	  considerations	  here	  are	  that	  the	  92	  target	  genes	  have	  been	  pre-­‐selected	  by	  us	  to	  cover	  a	  range	  of	  biological	   functions	  including	  energy	  metabolism,	  hormonal	  signaling,	  response	  to	   cell	   stress,	  DNA	   repair,	   cell	   cycle	   regulation,	   inflammation,	   nuclear	   function,	  protein	   synthesis,	   muscle	   contractile	   function,	   proteolysis,	   and	   apoptosis,	   so	   a	  degree	   of	   bias	   is	   inherent	   in	   the	   design.	   A	   benefit	   of	   this	   approach	   is	   that	   it	  enables	  us	   to	   assess	   the	  effects	  on	   specific	   candidate	  pathways	   that	  have	  been	  highlighted	  in	  previous	  studies,	  as	  opposed	  to	  a	  transcriptomic	  approach,	  which	  may	   be	   useful	   for	   generating	   new	   hypotheses.	   There	   is	   a	   complexity	   in	  interpreting	   our	   gene	   expression	   data	   however,	   in	   that	   any	   changes	   may	   be	  contributory	   to	   adverse	   ageing	  phenotype,	   or	   compensatory	   and	  protective,	   or	  even	  epiphenomena	  that	  are	  neutral.	  Where	  possible	  knowledge	  of	  the	  previous	  literature	  on	  candidate	  gene	  functions	  has	  been	  used	  to	  propose	  possible	  roles	  in	  our	  cohort.	  Furthermore	  some	  genes	  may	  in	  fact	  be	  regulated	  at	  the	  translational	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or	  post-­‐translational	  levels	  meaning	  that	  mRNA	  data	  is	  of	  limited	  use.	  	  	  In	   women,	   of	   the	   92	   target	   genes	   analysed,	   statistically	   significant	   changes	   in	  expression	   were	   observed	   in	   6	   (11β-­‐HSD1,	   hypoxia	   inducible	   factor	   1,	   alpha	  subunit	   (HIF-­‐1α),	   growth	   arrest	   and	   DNA-­‐damage-­‐inducible	   alpha	   (GADD45a),	  the	   proteasomal	   subunit	   alpha	   2	   (PSMA2)	   and	   26S	   subunit,	   non-­‐ATPase	   4	  (PSMD4),	  and	  skeletal	  muscle	  myosin	  heavy	  chain	  4	  (MYH4)).	  In	  men	  significant	  changes	   were	   observed	   in	   8	   genes	   (hexose-­‐6-­‐phosphate-­‐dehydrogenase	  (H6PDH),	  heat	  shock	  protein	  90kDa	  beta	  1	  (HSP90B1),	  growth	  arrest	  and	  DNA-­‐damage-­‐inducible	   alpha	   (GADD45a),	   cyclin-­‐dependent	   kinase	   inhibitor	   1A	  (CDKN1A),	   sirtuin	   3	   (SIRT3),	   SMAD	   family	   member	   3	   (SMAD3),	   v-­‐rel	  reticuloendotheliosis	   viral	   oncogene	   homolog	   A	   (relA)	   and	   proteasomal	   26S	  subunit,	   non-­‐ATPase	  4	   (PSMD4)).	  Aside	   from	   the	   changes	   in	   genes	   involved	   in	  pre-­‐receptor	   GC	   metabolism,	   a	   striking	   feature	   here	   is	   the	   representation	   of	  genes	   encoding	   proteins	   that	   are	   involved	   in	   the	   response	   to	   cell	   stress,	   with	  functions	   in	   cell	   cycle	   regulation,	   DNA	   repair,	   or	   immune	   signalling	   (including	  GADD45a,	   HIF-­‐1α,	   CDKN1A,	   SIRT3	   and	   relA).	   Interestingly,	   some	   well-­‐characterised	   atrophy	   genes	   (MAFbx/Atrogin1,	  MuRF1	   and	  myostatin)	   did	   not	  change	   in	   our	   cohort.	   Of	   note	   these	   genes	   were	   well	   represented	   in	   our	   own	  mouse	  studies	  of	  ageing	  (genes	  differentially	  regulated	  MAFbx/Atrogin1,	  MuRF1,	  GADD45a,	   PSMD11,	   MSTN,	   Calv	   3,	   NCAM1,	   CHARNB)	   and	   GC	   excess	   (genes	  differentially	   regulated	   MAFbx/Atrogin1,	   MuRF1,	   GADD45a,	   MSTN,	   FOXO1,	  Eif4bp,	   CHARNB,	   NCAM1),	   outlined	   in	   chapter	   5.	   We	   can	   speculate	   as	   to	   the	  possible	   explanations	   for	   this	   which	   include,	   that	   an	   alternative	   pathway	  involving	  cell	  stress	  response	  is	  a	  prominent	  pathway	  in	  human	  skeletal	  muscle	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ageing,	  or	  that	  compensatory	  mechanisms	  preventing	  UPS	  activation	  are	  at	  play	  during	  ‘healthy	  ageing’,	  as	  opposed	  to	  studies	  looking	  at	  acute	  muscle	  atrophy,	  or	  that	  our	  aged	  cohort	  do	  not	  have	  a	  severe	  enough	  muscle	  phenotype	  for	  the	  UPS	  to	  be	   activated.	  GADD45a	   appears	   to	  have	   a	   robust	   relationship	  with	  both	   age	  and	  GC	  signalling.	  In	  our	  experiments	  involving	  mice	  with	  exogenous	  GC	  excess	  outlined	  in	  chapter	  5,	  skeletal	  muscle	  GADD45a	  gene	  expression	  was	   increased	  vs.	  control	  mice.	  Furthermore,	  this	  change	  was	  attenuated	  in	  11β-­‐HSD1	  KO	  mice	  administered	  with	  11DHC.	  Gene	  expression	  was	  also	  increased	  in	  aged	  WT	  mice,	  and	   this	   change	  was	  partially	  attenuated	   in	  aged	  11β-­‐HSD1	  KO	  mice.	  This	  age-­‐related	   increase	   in	   skeletal	  muscle	   expression	   is	   also	   apparent	   in	  humans,	   and	  we	  could	  hypothesise,	  that	  in	  women	  local	  tissue	  GC	  amplification	  via	  11β-­‐HSD1	  could	  contribute	   to	   this.	  Along	  with	  assessing	   the	  effects	  on	  muscle	   function,	   it	  would	  be	   interesting	   to	   investigate	   the	  effects	  of	   selective	  11β-­‐HSD1	   inhibition	  on	   skeletal	   muscle	   GADD45a	   expression	   in	   humans.	   The	   gene	   is	   involved	   in	  response	  to	  cell	  stress,	  by	  promoting	  DNA	  repair	  or	  determining	  senescence	  by	  regulating	   the	   cell	   cycle	   or	   death	   by	   activating	   apoptosis	   (Saha	   et	   al.,	   2010,	  Salvador	   et	   al.,	   2013).	   It	   can	   be	   activated	   by	   p53	   dependent	   and	   independent	  mechanisms	  involving	  FOXO	  transcription	  factors	  (Smith	  et	  al.,	  1994,	  Furukawa-­‐Hibi	   et	   al.,	   2002,	   Chiba	   et	   al.,	   2009).	   Importantly	   both	   of	   these	   pathways	   are	  regulated	   by	   GCs.	   Several	   studies	   have	   shown	   that	   GADD45a	   is	   involved	   in	  muscle	   atrophy	   of	   different	   aetiologies	   including	   human	   and	   mouse	   skeletal	  muscle	   ageing	   (Welle	   et	   al.,	   2003,	   Welle	   et	   al.,	   2004,	   Edwards	   et	   al.,	   2007,	  Swindell,	   2009),	   acute	   quadriplegic	   myopathy	   (Di	   Giovanni	   et	   al.,	   2004)	   and	  critical	   illness	   in	   pigs	   (Banduseela	   et	   al.,	   2009).	   Recent	   studies	   have	  demonstrated	   that	   GADD45a	   plays	   a	   critical	   role	   in	   regulating	   pathways	   of	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muscle	  atrophy	  due	  to	  denervation	  and	  fasting	  (Bongers	  et	  al.,	  2013,	  Ebert	  et	  al.,	  2010).	  In	  addition	  it	  has	  been	  shown	  to	  increase	  transcription	  of	  some	  genes	  that	  changed	   significant	   with	   age	   in	   our	   study,	   including	   CDKN1a	   and	   HSP90B1	  (Ebert	   et	   al.,	   2012).	   Also	   of	   relevance	   to	   our	   findings	   is	   the	   observation	   that	  GADD45a	  induces	  type	  II	  muscle	   fibre	  atrophy	  by	  a	  mechanism	  independent	  of	  MAFbx/Atrogin1	  and	  MuRF1,	  which	   supports	   the	   idea	  of	   a	  distinct	  pathway	  of	  skeletal	  muscle	  ageing	  in	  humans.	  	  Interestingly	  cross-­‐talk	  between	  p53	  and	  GC	  signalling	  is	  well	  documented,	  with	  evidence	  of	  a	  loop	  whereby	  GCs	  are	  capable	  of	   activating	   p53,	  whilst	   p53	   is	   able	   to	   bind	   and	   inhibit	   the	  GR	   (Sengupta	   and	  Wasylyk,	   2004,	   Zhang	   et	   al.,	   2006,	   Poulsen	   et	   al.,	   2013).	   The	   relationship	  between	   p53	   and	   GADD45a	   is	   also	   a	   two-­‐way	   affair	   whereby	   GADD45a	  stimulates	   p53	   via	   p38	  MAPK	   signalling	   and	   p53	   is	   able	   to	   regulate	   GADD45a	  (Salvador	  et	  al.,	  2013).	  Furthermore	  GCs	  induce	  senescence	  in	  both	  tendon	  cells	  and	   osteoblasts	   via	   a	   p53	   dependent	   mechanism	   (Poulsen	   et	   al.,	   2013).	   It	   is	  possible	   that	   this	  pathway	   is	   involved	   in	   skeletal	  muscle	   atrophy	   secondary	   to	  GCs	  and	  ageing,	  and	  that	  selective	  11β-­‐HSD1	  would	  result	  in	  antagonism	  of	  this	  signalling.	  It	   is	   interesting	  to	  speculate	  that	  age-­‐associated	  muscle	  atrophy	  may	  be	   the	   price	   to	   pay	   for	   the	   tumour	   suppressing	   function	   of	   p53,	   resulting	   in	  adverse	   effects	   by	   inducing	   apoptosis	   or	   cell	   senescence	   (Hasty	   and	   Christy,	  2013).	  	  	  CDKN1A	  was	  upregulated	  with	  age	  and	  like	  GADD45a	  it	  also	  functions	  as	  a	  cell	  cycle	   regulator,	   involved	   in	  DNA	   repair	   and	   apoptosis	   (Giovannini	   et	   al.,	   2004,	  Swindell,	   2009).	   Swindell	   et	   al	   (2009)	   also	   noted	   that	   its	   expression	   was	  increased	  with	  age	  in	  an	  array	  study	  of	  mouse	  muscle.	  A	  meta-­‐analysis	  of	  muscle	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atrophy	  gene	  profiles	   confirmed	   that	   this	   gene	  was	   increased.	   It	   interacts	  with	  the	   TGF-­‐beta	   pathway	   and	   other	   proteins	   such	   as	   SMAD3,	   which	   was	   also	  increased	  in	  our	  study	  (Calura	  et	  al.,	  2008).	  HIF-­‐1α	  was	  also	  increased	  with	  age	  in	  our	  study.	  HIF-­‐1	   is	  a	   transcription	   factor	  and	  acts	  as	  a	   “master	  regulator”	  of	  the	  cell	  response	  to	  hypoxia.	  Interestingly	  it	  also	  has	  links	  with	  pre-­‐receptor	  GC	  metabolism	  and	  p53	  signalling	  (Goda	  et	  al.,	  2003).	  HIF-­‐1	  has	  been	  shown	  to	  have	  an	  antagonistic	  relationship	  with	  11β-­‐HSD1,	  as	  it	  negatively	  regulates	  11β-­‐HSD1	  expression	   in	  adipose	   tissue	   in	   cultures	  and	   transgenic	  mice	   (Lee	  et	   al.,	   2013).	  We	  observed	  increases	  in	  both	  HIF-­‐1α	  and	  11β-­‐HSD1	  in	  combination	  with	  age	  in	  skeletal	  muscle,	   and	   it	   is	   interesting	   to	   note	   that	   expression	   of	   both	   genes	   are	  regulated	   by	   components	   of	  NF-­‐κB	   signalling	   and	  we	   could	   speculate	   that	   this	  may	   be	   the	   underlying	   mechanism	   (Gorlach	   and	   Bonello,	   2008,	   Ahasan	   et	   al.,	  2012).	  SIRT3	  was	  increased	  in	  muscle	  biopsies	  from	  men	  in	  our	  study.	  It	  is	  one	  of	  the	   sirtuins,	  which	   are	  NAD+	  dependent	   acetylase,	   that	   regulate	   growth	   arrest	  and	   apoptosis	   in	   response	   to	   cell	   stress.	   It	   acts	   as	   a	   metabolic	   sensor	   and	   is	  upregulated	   during	   fasting	   and	   exercise	   and	   downregulated	   during	   nutrient	  excess	   (Jing	   et	   al.,	   2011,	   Green	   and	   Hirschey,	   2013).	   Effects	   on	   lifespan	   and	  ageing	   have	   been	   extensively	   studied	   in	   invertebrate	   and	   rodent	   studies.	  Interestingly	  it	  is	  associated	  with	  slow	  twitch	  type	  I	  fibres,	  which	  may	  explain	  its	  increase	  with	  age	   in	  our	  study	  where	   there	  was	  evidence	  of	   loss	  of	   type	   II	   fast	  twitch	  fibres.	  	  	  
	  HSP90B1	  was	  increased	  with	  age	  in	  our	  study.	  Heat	  shock	  proteins	  are	  nuclear	  chaperones	   that	   respond	   to	   endoplasmic	   reticulum	   stress	   as	   a	   protective	  mechanism	  (Murshid	  et	  al.,	  2013).	  They	  have	  been	  shown	  to	  modulate	  apoptosis	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and	   inhibit	   NF-­‐κB	   and	   FOXO	   transcription	   factor	   activities	   in	   animal	   models	  (McArdle	  et	  al.,	  2004,	  Chung	  and	  Ng,	  2006,	  Senf	  et	  al.,	  2008).	  There	  is	  evidence	  that	   GCs	   antagonize	   the	   protective	   effects	   of	   heat	   shock	   proteins	   in	   skeletal	  muscle	  via	  a	  microRNA1	  dependent	  mechanism,	  contributing	  to	  muscle	  atrophy	  (Kukreti	  et	  al.,	  2013).	  	  Age-­‐associated	  increases	  have	  been	  observed	  in	  a	  murine	  array	   study	   (Swindell,	   2009).	  Some	   age-­‐associated	   gene	   expression	   changes	   in	  our	  study	  that	  were	  expected	  include	  upregulation	  of	  relA,	  proteosomal	  subunits	  (PSMA2	  and	  PSMD4)	  and	  SMAD3.	  RelA	  is	  also	  known	  as	  p65,	  and	  is	  a	  component	  of	   the	   NF-­‐κB	   pathway,	   which	   is	   well	   known	   to	   be	   involved	   in	   skeletal	  muscle	  atrophy	   (Yamaki	   et	   al.,	   2012,	   Jackman	   et	   al.,	   2013).	   TNF-­‐α/IL-­‐1β	   caused	  increased	   expression	   of	   11β-­‐HSD1	   in	   mesenchymal	   stromal	   cells	   via	   a	   relA	  dependent	   mechanism	   (Ahasan	   et	   al.,	   2012).	   Increased	   expression	   of	  proteasomal	  subunits	  with	  age	  is	  consistent	  with	  the	  expected	  increase	  in	  muscle	  proteolysis	   (Combaret	   et	   al.,	   2009).	   GC	   induced	   regulation	   of	   proteosomal	  subunits	  has	  been	  observed	  previously	   in	  animal	  experiments	  (Combaret	  et	  al.,	  2004).	  SMAD3	  is	  part	  of	  the	  TGF-­‐β	  signalling	  pathway,	  and	  is	  also	  downstream	  of	  myostatin	   following	   activation	   of	   the	   activin	   IIB	   receptor	   (Zhu	   et	   al.,	   2004).	  Although	  upregulation	  is	  consistent	  with	  increased	  myostatin	  signalling,	  there	  is	  also	   evidence	   that	   SMADs	   are	   also	   regulated	   at	   the	   post-­‐translational	   level	  (Dalbo	  et	  al.,	  2011).	  	  	  
Summary	  and	  Conclusions	  To	  summarise	  our	  gene	  expression	  data,	  we	  have	  observed	  age-­‐related	  changes	  in	   genes	   encoding	   proteins	   with	   important	   functions	   in	   pre-­‐receptor	   GC	  metabolism	  (11β-­‐HSD1	  and	  H6PDH)	  in	  addition	  to	  those	   involved	  in	  cell	  stress	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response,	   involving	   regulatory	   functions	   in	   cell	   cycle,	   and	   apoptosis	   (including	  GADD45a,	   HIF-­‐1α,	   CDKN1A,	   HSP90B1	   and	   SIRT3)	   and	   those	   involved	   in	  proteolysis	   (PSMA2	   and	   PSMD4).	   Changes	   in	   classical	   ‘atrogenes’	   were	   under-­‐represented	  and	   this	  may	   indicate	   that	  an	  alternative	   signalling	  pathway	  has	  a	  more	   prominent	   role	   in	   human	   skeletal	   muscle	   ageing.	   There	   is	   cross-­‐talk	  between	  GC	  signalling	  and	  the	  pathways	  that	  the	  other	  genes	  are	  involved	  with,	  so	   that	   further	   investigation	   of	   the	   effects	   of	   modulation	   of	   this	   signalling	   in	  ageing	   is	   warranted.	   It	   is	   possible	   that	   the	   observed	   age-­‐related	   increase	   in	  skeletal	  muscle	  11β-­‐HSD1	  expression	  may	  be	  driven	  by	   the	  menopause,	   rather	  than	   by	   a	   broader	   factor	   involved	   with	   ageing.	   Consistent	   with	   this	   is	   the	  increased	   global	   activity	   of	   11β-­‐HSD1	   observed	   in	  men.	  However	   there	   is	   also	  evidence	  of	  other	  potential	  regulatory	   factors,	  with	  correlations	  noted	  between	  markers	   of	   11β-­‐HSD1	   expression/activity	   and	   factors	   including	   IGF-­‐I,	   DHEAS,	  testosterone,	   and	   fat	   mass.	   Furthermore	   our	   analyses	   highlight	   correlations	  between	   11β-­‐HSD1	   expression/activity	   and	   factors	   including	   bone	   mass,	   grip	  strength	   and	   total	   cholesterol	   that	   warrant	   further	   investigations	   to	   ascertain	  their	   pathophysiological	   significance.	   Going	   forward,	   an	   exciting	   area	   with	  translational	   potential	   is	   the	   assessment	   of	   the	   effectiveness	   of	   selective	  inhibition	   of	   11β-­‐HSD1	   on	   the	   adverse	   consequences	   of	   the	   menopause,	   with	  regards	  metabolic	   and	   body	   composition	   profile,	  which	   is	   pertinent	   in	   view	  of	  the	  controversies	  surrounding	   the	  use	  of	   long-­‐term	  HRT.	  Finally	   this	  study	  has	  highlighted	  potential	  targets	  for	  further	  investigation	  at	  a	  basic	  science	  level	  with	  respect	   to	   the	   interactions	   between	  GR	   signaling	   and	   cell	   cycle	   regulators	   that	  may	  represent	  important	  mediators	  of	  skeletal	  muscle	  ageing	  and	  atrophy.	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Chapter	  7	  –	  Final	  Conclusions	  and	  	  
Future	  Directions	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7.1.	   Final	  Conclusions	  
	  We	  have	  used	  a	   range	  of	  models	   to	   investigate	   the	  effects	  of	  GC	  exposure	  over	  the	   lifespan	   and	   its	   regulation	   at	   the	   pre-­‐receptor	   level.	   These	   include	   a	  retrospective	   single	   centre	   study	   of	   Cushing’s	   disease	   (CD)	   outcomes	   and	  mortality,	   in-­‐vitro	   studies	   of	   the	   effects	   of	   selective	   inhibition	   of	   11β-­‐HSD1	   on	  expression	   of	   muscle	   atrophy	   genes,	   in-­‐vivo	   mouse	   studies	   examining	   the	  functional	  effects	  of	  11β-­‐HSD1	  on	  muscle	  phenotype	  with	  age	  and	  GC-­‐excess,	  and	  a	   large	   human	   study	   examining	   global	   11β-­‐HSD1	   activity	   and	   skeletal	   muscle	  gene	  expression	  with	  age.	  	  
	  
Long-­‐term	  outcomes	  in	  patients	  with	  Cushing’s	  disease	  treated	  with	  
transsphenoidal	  surgery	  
	  Our	   study	   of	   outcomes	   in	   Cushing’s	   disease	   post-­‐transsphenoidal	   surgery	  highlighted	   the	   long-­‐term	   effects	   of	   excess	   GC	   exposure,	   on	   body	   composition	  (obesity,	   osteoporosis,	   myopathy),	   and	   adverse	   metabolic	   parameters	   (insulin	  resistance,	   hypertension,	   dyslipidaemia).	   Disease	   remission	   resulted	   in	  resolution	   of	   clinical	   features,	   with	   rapid	   and	   sustained	   improvements	   in	   BMI	  and	  BP	  over	   follow	  up.	   	   There	  was	   a	   3-­‐fold	   excess	  mortality	   in	   the	   group	   as	   a	  whole	  (SMR	  3.17,	  95%	  CI	  1.70-­‐5.43),	  whilst	  for	  recurrent/persistent	  disease	  the	  SMR	  was	  4.12	  (95%	  CI	  1.12-­‐10.54)	  and	  for	  patients	  cured	  by	  first	  surgery	  it	  was	  2.47	  (95%	  CI	  0.90-­‐5.77).	  Other	  studies	  have	  provided	  evidence	  of	  a	  legacy	  effect	  during	  remission	  of	  Cushing’s	  with	  persistence	  of	  cardiovascular	  risk	  factors	  and	  body	   composition	   changes	   over	   long-­‐term	   follow	   up	   (Colao	   et	   al.,	   1999,	  Barahona	  et	   al.,	   2009).	   It	  was	   striking	   that	   female	  gender	  was	   linked	   to	  excess	  mortality	  in	  our	  study	  (RR	  =	  4.5),	  and	  in	  light	  of	  our	  findings	  outlined	  in	  Chapter	  6,	  and	  those	  of	  Barahona	  et	  al	  (2009)	  and	  Andersson	  et	  al	  (2009)	  it	  is	  interesting	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to	  speculate	  that	  sexual	  dimorphism	  in	  11β-­‐HSD1	  expression	  may	  contribute	  to	  this.	   Currently	   we	   are	   collaborating	   with	   other	   centres	   (including	   Stoke-­‐on-­‐Trent)	   to	   combine	   our	   data	   and	   extend	   the	   duration	   of	   follow	   up	   in	   order	   to	  assess	  whether	   any	   excess	  mortality	   risk	   persists	   following	   disease	   remission,	  and	  identify	  prognostic	  factors.	  	  	  
Characterisation	   of	   the	   effects	   of	   pre-­‐receptor	   glucocorticoid	   regulation	   on	  
muscle	  atrophy	  gene	  expression	  in	  skeletal	  myotubes	  	  The	  central	  contribution	  of	  this	  chapter	  was	  to	  provide	  evidence	  of	  regulation	  of	  the	  key	  ubiquitin	  proteasome	  system	  mediator,	  MAFbx/Atrogin1	  by	  11β-­‐HSD1,	  as	   evidenced	   by	   experiments	   using	   a	   selective	   11β-­‐HSD1	   inhibitor.	   This	   is	   of	  translational	  importance,	  as	  it	  opens	  up	  a	  new	  potential	  therapeutic	  application	  in	  muscle	  atrophy	  for	  selective	  inhibitors	  of	  11β-­‐HSD1,	  that	  have	  been	  developed	  by	  industry	  for	  the	  treatment	  of	  components	  of	  the	  metabolic	  syndrome.	  In-­‐vivo	  studies	  were	  required	  in	  order	  to	  assess	  the	  role	  of	  11β-­‐HSD1	  with	  ageing.	  	  	  
The	  impact	  of	  global	  11β-­‐HSD1	  knockout	  on	  muscle	  phenotype	  and	  gene	  
expression	  in	  aged	  and	  glucocorticoid	  treated	  mice	  	  This	  study	  was	  the	  first	  in-­‐vivo	  assessment	  of	  the	  impact	  of	  11β-­‐HSD1	  on	  skeletal	  muscle	   function	  with	  age	  and	  GC-­‐excess.	  We	   identified	  a	   set	  of	   skeletal	  muscle	  gene	  expression	  changes	  common	  to	  GC	  excess	  and	  ageing	  that	  parallel	  changes	  in	   muscle	   function.	   Absence	   of	   11β-­‐HSD1	   attenuates	   these	   changes	   and	   was	  associated	   with	   preserved	   muscle	   strength.	   We	   performed	   a	   gene	   expression	  array	   of	   88	   target	   genes	   in	   a	   mouse	   ageing	   study.	   Of	   these,	   3	   genes	   (MuRF1,	  MSTN,	  GADD45a)	  increased	  with	  age	  in	  WT	  mice,	  changes	  that	  were	  attenuated	  in	   11β-­‐HSD1	   KO	   mice,	   which	   appeared	   to	   underpin	   the	   preserved	   muscle	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strength.	  Interestingly	  4	  genes,	  which	  have	  not	  been	  previously	  investigated	  with	  respect	   to	   pre-­‐receptor	   GC	   regulation	   (PSMD11,	   eif4bp,	   CHARNB,	   NCAM1)	  increase	   with	   age	   although	   effects	   of	   11β-­‐HSD1	   KO	   did	   not	   reach	   statistical	  significance.	   Furthermore,	   GADD45a,	   eif4bp,	   CHARNB,	   NCAM1,	   MuRF1	   and	  myostatin,	  were	   found	   to	  be	  GC	   inducible,	   supportive	  of	   an	   important	   effect	  of	  chronic	  GC	   exposure	   in	   skeletal	  muscle	   ageing.	  Absence	   of	   11β-­‐HSD1	  was	   also	  associated	  with	  markers	  of	  HPA-­‐axis	  activation,	  and	  improved	  glucose	  tolerance.	  	  	  
	  Global	  activity	  and	  local	  skeletal	  muscle	  expression	  of	  11β-­‐HSD1	  across	  
human	  ageing	  
	  This	   chapter	   represents	   the	   largest	   study	   assessing	   cortisol	   secretion	   and	  metabolism	  and	  local	  skeletal	  muscle	  11β-­‐HSD1	  gene	  expression	  across	  human	  ageing.	  We	  recruited	  135	  healthy	  subjects	  of	  both	  genders	  aged	  between	  20-­‐80	  years	  providing	  us	  with	  insights	  into	  sexual	  dimorphism	  and	  changes	  across	  the	  human	   lifespan.	   The	   cohort	   was	   extensively	   phenotyped	   by	   anthropometric	  assessment,	   body	   composition	   analysis	   by	   DEXA,	   grip	   strength	   dynamometry,	  jump-­‐plate	  mechanography,	  serum	  biochemistry,	  vastus	   lateralis	  muscle	  biopsy	  and	  urine	  steroid	  analysis	  of	  24-­‐hour	  collections.	  A	  muscle	  gene	  expression	  array	  of	  92	  target	  genes	  covering	  a	  range	  of	  functions	  was	  also	  completed.	  	  	  The	  most	   striking	   finding	  was	   that	   skeletal	  muscle	   11β-­‐HSD1	   gene	   expression	  was	  increased	  in	  older	  compared	  to	  younger	  women,	  consistent	  with	  our	  central	  hypothesis.	  Furthermore,	  of	  the	  92	  targets	  analysed,	  11β-­‐HSD1	  was	  one	  of	  only	  6	  genes	  whose	  expression	  changed	  significantly	  with	  age.	  This	   is	   consistent	  with	  previous	  data	  showing	  age-­‐dependent	  increases	  in	  11β-­‐HSD1	  gene	  expression	  in	  other	  human	  tissues	  including	  adipose	  tissue,	  skin,	  and	  bone	  (Cooper	  et	  al.,	  2002,	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Andersson	   et	   al.,	   2009,	   Tiganescu	   et	   al.,	   2013).	   However,	   there	   was	   no	   such	  increase	  in	  11β-­‐HSD1	  skeletal	  muscle	  expression	  in	  men,	  leading	  us	  to	  question	  whether	   sexual	   dimorphism	   in	   pre-­‐receptor	   glucocorticoid	   metabolism	   exists.	  There	   was	   evidence	   of	   increased	   skeletal	   muscle	   expression	   of	   H6PDH	   and	  assessment	   of	   11β-­‐HSD1	   activity	   is	   now	   required	   in	   order	   to	   confirm	   local	  functional	  effects.	  	  	  With	   respect	   to	   age-­‐associated	   changes	   in	   urinary	   steroid	   markers	   of	   cortisol	  metabolism,	  the	  only	  statistically	  significant	  difference	  observed	  was	  an	  increase	  in	   (THF+5aTHF)/THE	   ratio	   in	   the	   oldest	   female	   group,	   indicative	   of	   increased	  global	  11β-­‐HSD1	  activity.	  This	  is	  consistent	  with	  the	  findings	  of	  Andersson	  et	  al	  (2009)	   who	   found	   evidence	   of	   both	   increased	   global	   and	   hepatic	   11β-­‐HSD1	  activity	   and	   subcutaneous	   adipose	   tissue	   gene	   expression	   in	   post-­‐menopausal	  women.	   However	   our	   findings	   regarding	   (THF+5aTHF)/THE,	   should	   be	  interpreted	  with	  caution,	  as	  a	  progressive	  increase	  in	  the	  ratio	  was	  not	  seen	  over	  the	  full	  range	  of	  age	  groups.	  	  	  We	  observed	  evidence	  of	  sexual	  dimorphism	  in	  cortisol	  metabolism,	  with	  higher	  global	  11β-­‐HSD1	  and	  5α-­‐reductase	  activities	   in	  women.	  These	   findings	  provide	  circumstantial	  support	  for	  negative	  regulation	  of	  11β-­‐HSD1	  by	  a	  pre-­‐menopausal	  female	  factor	  such	  as	  oestrogen,	  which	  has	  been	  reported	  to	  inhibit	  11β-­‐HSD1.	  	  	  The	  analysis	  of	  correlations	  identified	  other	  potential	  regulatory	  factors	  of	  11β-­‐HSD1	   expression/activity	   including	   IGF-­‐I,	   DHEAS,	   testosterone,	   and	   fat	   mass.	  Furthermore	   our	   analyses	   highlight	   correlations	   between	   11β-­‐HSD1	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expression/activity	  and	  pathological	   factors	   including	  bone	  mass,	  grip	  strength	  and	  total	  cholesterol.	  	  
	  Skeletal	   muscle	   gene	   expression	   array	   revealed	   that	   targets	   involved	   in	   cell	  stress	  response,	  cell	  cycle,	  and	  apoptosis	  (including	  GADD45a,	  HIF-­‐1α,	  CDKN1A,	  HSP90B1	   and	   SIRT3)	   were	   well	   represented	   along	   with	   those	   involved	   in	  proteolysis	   (PSMA2	   and	   PSMD4).	   Changes	   in	   classical	   ‘atrogenes’	   were	   under-­‐represented	  and	   this	  may	   indicate	   that	  an	  alternative	   signalling	  pathway	  has	  a	  more	  prominent	  role	  in	  human	  skeletal	  muscle	  ageing.	  	  
	  
7.2.	   Future	  Directions	  
	  
Muscle	  atrophy	  and	  Pre-­‐Receptor	  GC-­‐metabolism	  The	   in-­‐vivo	   studies	   of	   ageing	   and	   GC-­‐excess	   demonstrate	   that	   11β-­‐HSD1	  regulates	   expression	   of	   muscle	   atrophy	   genes	   and	   modulates	   function.	   Target	  genes	  that	  were	  increased	  are	  involved	  in	  growth	  regulation,	  proteolysis	  and	  cell	  stress.	   Furthermore	  we	  have	   shown	   that	   skeletal	  muscle	  11β-­‐HSD1	  expression	  increases	  with	  age	   in	  women,	   and	  have	  highlighted	  potential	   regulators	  of	   this	  change.	   These	   findings	   set	   the	   scene	   for	   translational	   studies	   investigating	   the	  role	  of	  11β-­‐HSD1	  in	  muscle	  atrophy.	  Potential	  areas	   for	   investigation	  are	   listed	  below:	  
Ageing	  and	  Sarcopenia:	  	  i) In-­‐vitro	   studies	   of	   the	   regulation	   of	   11β-­‐HSD1,	   and	   its	   relationship	  with	   cell	   cycle	   regulators	   including	   GADD45a,	   in	   human	   primary	  cultures.	  Optimisation	  of	  functional	  proteolysis	  assays	  for	  use	  in	  these	  studies.	  	  
	   235	  
ii) In-­‐vivo	   mouse	   studies	   of	   transgenic	   animals	   with	   muscle	   specific	  knockoutof	   11β-­‐HSD1	   and	   GR.	   Optimisation	   of	   an	   array	   of	   strength	  testing	   techniques	   for	  use	   in	   these	   studies,	   to	   test	   endurance,	   speed,	  and	  ex-­‐vivo	  strength.	  	  iii) Analysis	  of	  existing	  human	  ageing	  study	  samples	  to	  investigate	  the	  relationship	   between	   factors	   such	   as	   oestrogens,	   insulin,	   pro-­‐inflammatory	   cytokines	   and	   vitamin	   D	   with	   11β-­‐HSD1	   and	   muscle	  function.	  Analysis	  of	  serum	  samples	  from	  these	  subjects	  to	  determine	  prednisolone	  generation	  following	  oral	  administration	  of	  prednisone,	  as	   a	   marker	   of	   hepatic	   first-­‐pass	   metabolism.	   In	   addition,	   more	  detailed	   analyses	   of	   the	   relationship	   of	   11β-­‐HSD1	   and	   body	  composition	   will	   be	   performed,	   with	   a	   particular	   focus	   on	   visceral	  obesity.	   Tissue	   banked	   samples	   and	   associated	   phenotypic	   data	  represent	  a	  significant	  resource	   for	  use	   in	  potential	   future	  studies	  of	  sarcopenia	   using	   novel	   targets	   or	   additional	   technologies	   including	  transcriptomics,	  proteomics,	  metabolomics	  and	  microRNA	  analysis.	  	  iv) Proof-­‐of-­‐concept	  studies	  to	  assess	  the	  effect	  of	  selective	  inhibition	  of	  11β-­‐HSD1	   on	   muscle	   protein	   turnover	   and	   muscle	   atrophy	   gene	  expression	  in	  healthy	  volunteers.	  v) Interventional	  clinical	   studies	  of	   selective	  11β-­‐HSD1	   in	   sarcopenic	  patients	   from	   community	   or	   nursing	   home	   cohorts.	   Outcome	  measures	   would	   include	   physical	   performance	   battery	   scores,	   grip	  strength,	   jump-­‐plate	  mechanography	   and	   body	   composition	   analysis	  measures.	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Related	  Areas	  for	  Investigation:	  i) The	  menopause:	  this	  is	  clinically	  important	  due	  to	  the	  adverse	  body	  composition	   and	   metabolic	   profile	   that	   develops	   post-­‐menopausally	  and	   the	   limitations	   of	   current	   conventional	   hormone	   replacement	  therapy	   (HRT)(Burger	   et	   al.,	   2012).	   These	   studies	   could	   include	   in-­‐vitro	  (regulation	  of	  11β-­‐HSD1	  by	  oestrogens),	  in-­‐vivo	  (ovarectomised	  mice)	  and	  human	  clinical	  studies	  in	  a	  post-­‐menopausal	  cohort.	  	  ii) Medical	  therapies	  for	  Cushing’s:	  our	  studies	  of	  GC-­‐excess	   illustrate	  that	  11β-­‐HSD1	  KO	  mice	  are	  protected	  from	  key	  side	  effects,	  including	  muscle	   atrophy,	   reduced	   strength	   and	   impaired	   glucose	   tolerance.	  These	   results	   suggest	   that	   the	   therapeutic	   potential	   of	   selective	  inhibition	  of	  11β-­‐HSD1	  as	  a	  medical	  treatment	  for	  Cushing’s	  syndrome	  and	  a	  adjunctive	  therapy	  to	  prevent	  adverse	  effects	  of	  exogenous	  GCs,	  warrants	   further	   attention.	   Interventional	   clinical	   studies	   should	   be	  considered,	   with	   end-­‐points	   involving	   reduction	   of	   clinical	   signs	   of	  hypercortisolism	  (BMI,	  body	  composition	  parameters,	  blood	  pressure	  and	  insulin	  resistance),	  with	  the	  absence	  of	  serum/urine	  cortisol	  as	  a	  useful	  biomarker.	  	  	  	  iii) Critical	   illness	   and	  myopathy:	   	   Muscle	   atrophy	   and	   weakness	   are	  highly	  prevalent	  in	  patients	  admitted	  to	  critical	  care,	  where	  they	  may	  impact	   rehabilitation	   and	   result	   in	   long-­‐term	   functional	   limitations	  (Herridge	   et	   al.,	   2011,	   Puthucheary	   et	   al.,	   2013).	   	   Critical	   illness	   is	  frequently	   underpinned	  by	   conditions,	  which	   are	   known	   to	   result	   in	  muscle	   atrophy	   via	   GC-­‐dependent	   mechanisms	   including	   metabolic	  acidosis	   (May	  et	   al.,	   1986)	   and	   sepsis	   (Tiao	  et	   al.,	   1996,	   Smith	  et	   al.,	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2010).	   Furthermore	   a	   recent	   study	   revealed	   that	   critical	   illness	   is	  characterized	   by	   raised	   circulating	   cortisol	   levels	   and	   reduced	  clearance	   via	   suppression	   of	   metabolising	   enzymes	   (Boonen	   et	   al.,	  2013).	  An	   initial	  observational	  study	   involving	  assessment	  of	  muscle	  expression	   of	   11β-­‐HSD1	   in	   critical	   illness,	   should	   be	   considered.	   A	  future	  interventional	  study	  could	  investigate	  the	  impact	  of	  11β-­‐HSD1	  inhibition	   in	  patients	  admitted	   to	  critical	  care,	  on	  outcome	  measures	  including	   muscle	   protein	   synthesis,	   proteolysis,	   atrophy	   gene	  expression,	   muscle	   mass,	   length	   of	   stay	   and	   mortality.	   A	   novel	  intervention	  for	  this	  condition	  has	  the	  potential	  to	  make	  considerable	  impact,	  in	  view	  of	  its	  prevalence,	  economic	  costs	  and	  lack	  of	  currently	  available	  treatment.	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Supplementary	  table	  S6.2:	  Ethnicities	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  male	  ageing	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  group	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Female	  Subjects	   Subject	  Characteristics	  by	  Ethnicity	  
(Medians	  and	  IQRs)	  
	  	   South	  Asian	   Caucasian	   P-­‐value	  
Patient	  Characteristics	  
	  Age	  (years)	   25	  (22-­‐34)	   25	  (22-­‐35)	   1.00	  BMI	  (kg/m2)	   23.6	  (20.6-­‐26.8)	   22.2	  (21.3-­‐24.3)	   1.00	  Fat	  Mass	  (kg)	   20.2	  (14.2-­‐27.6)	   17.2	  (15.7-­‐19.1)	   0.49	  
Lean	  Mass	  (kg)	   36.1	  (33.0-­‐40.6)	   42.7	  (40.9-­‐46.9)	   0.02	  
Serum	  biochemistry	   	  IGF-­‐I	   24.5	  (18.4-­‐28.6)	   25.8	  (20.4-­‐33.7)	   0.70	  DHEAS	   5.0	  (3.5-­‐7.9)	   3.3	  (2.7-­‐4.5)	   0.11	  Testosterone	   1.0	  (0.5-­‐1.2)	   0.7	  (0.5-­‐0.8)	   0.17	  
SHBG	   36.2	  (21.3-­‐59.8)	   70.1	  (45.6-­‐154.1)	   0.01	  9am	  Cortisol	   344	  (166-­‐592)	   331	  (194-­‐633)	   0.72	  
Skeletal	  Muscle	  mRNA	  	  
Expression	  11β-­‐HSD1	  (AU)	   0.01	  (0.00-­‐0.03)	   0.01	  (0.00-­‐0.01)	   0.41	  
H6PDH	  (AU)	   0.03	  (0.02-­‐0.06)	   0.09	  (0.06-­‐0.10)	   0.03	  
Urine	  Steroid	  GC/MS	  	  
Analysis	  (THF+5αTHF/THE)	  	   0.91	  (0.71-­‐1.16)	   0.92	  (0.64-­‐1.22)	   1.00	  (Cortols/Cortolones)	   0.38	  (0.37-­‐0.51)	   0.41	  (0.33-­‐0.57)	   0.80	  Total	  F	  Metabolites	  (μg/24h)	   5820	  (4763-­‐7225)	   4021	  (3089-­‐7930)	   0.30	  F/E	   0.58	  (0.51-­‐0.70)	   0.87	  (0.55-­‐0.95)	   0.30	  THF/5αTHF	   1.08	  (0.78-­‐1.47)	   1.60	  (1.09-­‐2.98)	   0.14	  	  
	  
Supplementary	   table	   S6.3:	   Subject	   characteristics	   in	   age-­‐matched	   female	   study	   participants	   as	  
divided	  by	  ethnicity	  (South	  Asian	  vs.	  Caucasian,	  n=10	  in	  each	  group,	  all	  subjects	  in	  20-­‐40	  year	  age	  
groups).	  Characteristics	   include	  general	  demographics,	  anthropometry,	  body	  composition,	  skeletal	  
muscle	  gene	  expression	  and	  urine	  steroid	  GC/MS	  data.	  P-­‐values	  shown	  are	  from	  Mann	  Whitney	  tests	  
with	   statistically	   significant	   results	   highlighted	   in	   bold.	   (THF+5αTHF/THE)	   =	   (tetra-­‐
hydrocortisol+5α-­‐tetrahydrocortisol)/tetrahydrocortisone.	   F=	   cortisol,	   F/E	   =	   cortisol/cortisone,	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Male	  Subjects	   Subject	  Characteristics	  by	  Ethnicity	  
(Medians	  and	  IQRs)	  
	  	   Asian	   Caucasian	   P-­‐value	  
Patient	  Characteristics	  
	  
	  Age	  (years)	   36	  (27-­‐50)	   38	  (30-­‐50)	   0.81	  BMI	  (kg/m2)	   25.1	  (22.2-­‐26.4)	   23.5	  (21.6-­‐28.5)	   1.00	  Fat	  Mass	  (kg)	   14.9	  (11.1-­‐18.5)	   16.0	  (13.6-­‐20.1)	   0.55	  Lean	  Mass	  (kg)	   53.5	  (47.3-­‐58.3)	   59.8	  (52.3-­‐65.8)	   0.16	  
Serum	  biochemistry	   	  IGF-­‐I	   21.7	  (17.4-­‐25.2)	   17.3	  (15.9-­‐21.3)	   0.14	  DHEAS	   6.7	  (3.7-­‐8.5)	   7.4	  (4.5-­‐8.3)	   1.00	  Testosterone	   12.8	  (11.3-­‐19.7)	   14.6	  (13.3-­‐17.8)	   0.96	  
Skeletal	  Muscle	  mRNA	  	  
Expression	  11β-­‐HSD1	  (AU)	   N/A	   N/A	   N/A	  H6PDH	  (AU)	   N/A	   N/A	   N/A	  
Urine	  Steroid	  GC/MS	  	  
Analysis	  (THF+5αTHF/THE)	  	   0.88	  (0.75-­‐1.13)	   0.97	  (0.62-­‐1.32)	   0.90	  (Cortols/Cortolones)	   0.45	  (0.33-­‐0.54)	   0.42	  (0.28-­‐0.56)	   0.76	  Total	  F	  Metabolites	  (μg/24h)	   8028	  (5947-­‐11432)	   13159	  (8089-­‐1676)	   0.17	  F/E	   0.70	  (0.58-­‐0.73)	   0.79	  (0.69-­‐0.88)	   0.03	  THF/5αTHF	   0.93	  (0.62-­‐1.17)	   0.93	  (0.60-­‐1.18)	   1.00	  
	  
Supplementary	   table	   S6.4:	   Subject	   characteristics	   in	   age-­‐matched	   male	   study	   participants	   as	  
divided	   by	   ethnicity	   (Asian	   vs.	   Caucasian,	   n=8	   in	   each	   group).	   Characteristics	   include	   general	  
demographics,	  anthropometry,	  body	  composition,	  skeletal	  muscle	  gene	  expression	  and	  urine	  steroid	  
GC/MS	   data.	   P-­‐values	   shown	   are	   from	   Mann	   Whitney	   tests	   with	   statistically	   significant	   results	  
highlighted	   in	   bold.	   (THF+5αTHF/THE)	   =	   (tetra-­‐hydrocortisol+5α-­‐
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Age	  Group	  (years)	   20-­‐30	   30-­‐40	   40-­‐50	   50-­‐60	   60-­‐70	   >70	   	  
N	   15	   12	   15	   12	   16	   7	   P-­‐value	  
ANDROS	  
1374	  	  (1003-­‐1613)	   1163	  	  (978-­‐1766)	   1380	  	  (912-­‐1729)	   707	  	  (416-­‐903)	   243***	  	  (172-­‐346)	   377**	  	  (270-­‐491)	   <0.0001	  
ETIO	  
1420	  	  (1241-­‐1721)	   1133	  	  (773-­‐1826)	   1199	  	  (986-­‐1552)	   974	  	  (657-­‐1124)	   331***	  (257-­‐572)	   453**	  	  (380-­‐536)	   <0.0001	  
DHEA	  
516	  	  (180-­‐1095)	   334	  (117-­‐1299)	   276	  	  (124-­‐528)	   204	  	  (109-­‐248)	   27***	  	  (17-­‐54)	   20**	  	  (13-­‐24)	   <0.0001	  
16a	  OH	  DHEA	  
572	  	  (353-­‐1039)	   360	  	  (155-­‐675)	   447	  	  (297-­‐674)	   179	  	  (123-­‐319)	   55***	  	  (39-­‐132)	   110*	  	  (35-­‐144)	   <0.0001	  
5-­‐PT	  
168	  	  (121-­‐249)	   170	  	  (136-­‐247)	   143	  	  (112-­‐208)	   104	  	  (64-­‐121)	   61	  **	  (40-­‐69)	   55	  	  (36-­‐62)	   0.0002	  
5-­‐PD	  
126	  	  (93-­‐188)	   123	  	  (89-­‐191)	   160	  	  (111-­‐210)	   56	  	  (48-­‐153)	   58	  	  (35-­‐76)	   44	  	  (31-­‐75)	   0.0007	  
Pregnadienol	  
77	  	  (58-­‐158)	   51	  	  (33-­‐103)	   43	  	  (24-­‐63)	   27	  	  (17-­‐49)	   16***	  	  (11-­‐24)	   21*	  	  (10-­‐36)	   <0.0001	  
THA	  
84	  	  (49-­‐145)	   65	  	  (57-­‐76)	   81	  	  (62-­‐111)	   113	  	  (50-­‐124)	   62	  	  (53-­‐104)	   69	  	  (56-­‐78)	   0.6117	  
5a-­‐THA	  
68	  	  (48-­‐80)	   69	  	  (54-­‐78)	   79	  	  (54-­‐96)	   64	  	  (41-­‐82)	   60	  	  (52-­‐81)	   72	  	  (63-­‐93)	   0.8466	  
THB	  
82	  	  (46-­‐137)	   77	  	  (65-­‐87)	   96	  	  (83-­‐107)	   84	  	  (52-­‐126)	   78	  	  (56-­‐141)	   66	  	  (51-­‐84)	   0.8216	  
5a-­‐THB	  
174	  	  (73-­‐304)	   140	  	  (128-­‐208)	   195	  	  (140-­‐246)	   189	  	  (140-­‐246)	   134	  	  (103-­‐150)	   184	  	  (136-­‐232)	   0.5547	  
TH-­‐DOC	  
16	  	  (13-­‐21)	   16	  	  (12-­‐19)	   25	  	  (14-­‐42)	   9	  	  (6-­‐11)	   6	  	  (6-­‐11)	   8*	  	  (4-­‐9)	   <0.0001	  
5α-­‐TH-­‐DOC	  
5	  	  (4-­‐6)	   3	  	  (3-­‐5)	   3	  	  (3-­‐6)	   3	  	  (3-­‐4)	   3	  	  (2-­‐6)	   5	  	  (4-­‐5)	   0.288	  
PD	  
252	  	  (152-­‐307)	   219	  	  (141-­‐364)	   495	  	  (226-­‐661)	   114	  	  (95-­‐151)	   115	  	  (97-­‐137)	   78	  	  (68-­‐142)	   <0.0001	  
3a5a	  17HP	  
6	  	  (3-­‐9)	   9	  	  (7-­‐13)	   10	  	  (6-­‐28)	   4	  	  (4-­‐6)	   4	  	  (1-­‐6)	   4	  	  (2-­‐4)	   0.0001	  
17-­‐HP	  
64	  	  (43-­‐89)	   62	  	  (52-­‐140)	   90	  	  (68-­‐278)	   36	  	  (27-­‐45)	   29*	  	  (21-­‐38)	   24	  	  (17-­‐30)	   <0.0001	  
PT	  
335	  	  (256-­‐427)	   410	  	  (247-­‐671)	   462	  	  (373-­‐688)	   236	  	  (212-­‐280)	   156*	  (113-­‐232)	   172	  	  (119-­‐327)	   <0.0001	  
PT'ONE	  
6	  	  (3-­‐8)	   6	  	  (5-­‐10)	   6	  	  (5-­‐12)	   7	  	  (6-­‐27)	   9	  	  (6-­‐16)	   10	  	  (7-­‐10)	   0.2513	  
THS	  
55	  	  (30-­‐65)	   52	  	  (45-­‐58)	   66	  	  (52-­‐77)	   48	  	  (43-­‐63)	   56	  	  (40-­‐71)	   44	  	  (30-­‐69)	   0.5859	  
Cortisol	  
53	  	  (37-­‐74)	   56	  	  (31-­‐64)	   46	  	  (37-­‐52)	   36	  	  (33-­‐49)	   39	  	  (34-­‐49)	   42	  	  (39-­‐55)	   0.3649	  
6b-­‐OH-­‐Cortisol	  
120	  	  (97-­‐192)	   119	  	  (91-­‐165)	   111	  	  (85-­‐130)	   97	  	  (70-­‐130)	   94	  	  (78-­‐122)	   119	  	  (90-­‐121)	   0.5413	  
THF	  
808	  	  (527-­‐1237)	   1014	  	  (899-­‐1208)	   1340	  	  (1129-­‐1503)	   821	  	  (723-­‐1182)	   885	  	  (785-­‐1291)	   1192	  	  (933-­‐1374)	   0.3011	  
5a-­‐THF	  
515	  	  (332-­‐964)	   762	  	  (553-­‐949)	   1011	  	  (572-­‐1157)	   553	  	  (342-­‐1078)	   438	  	  (377-­‐605)	   1025	  	  (732-­‐1321)	   0.1578	  
a-­‐cortol	  
183	  	  (123-­‐293)	   208	  	  (187-­‐221)	   266	  	  (199-­‐292)	   184	  	  (159-­‐225)	   180	  	  (161-­‐243)	   243	  	  (188-­‐297)	   0.4623	  
b-­‐cortol	  
264	  	  (226-­‐472)	   301	  	  (204-­‐411)	   315	  	  (278-­‐475)	   262	  	  (205-­‐424)	   310	  	  (226-­‐450)	   487	  	  (278-­‐681)	   0.6408	  
11b-­‐OH-­‐ANDRO	  
379	  	  (183-­‐498)	   428	  	  (324-­‐540)	   437	  	  (295-­‐582)	   324	  	  (221-­‐497)	   247	  (200-­‐322)	   375	  	  (299-­‐434)	   0.0843	  
11b-­‐OH-­‐ETIO	  
186	  	  (98-­‐233)	   296	  	  (136-­‐362)	   297	  	  (149-­‐386)	   297	  	  (92-­‐415)	   238	  	  (118-­‐287)	   531	  	  (409-­‐686)	   0.1545	  
Cortisone	  
73	  	  (61-­‐98)	   77	  	  (52-­‐94)	   74	  	  (67-­‐87)	   66	  	  (53-­‐76)	   62	  	  (53-­‐78)	   62	  	  (60-­‐82)	   0.5617	  
THE	  
1902	  (1373-­‐2461)	   1727	  	  (1615-­‐2164)	   2309	  	  (1932-­‐2440)	   1682	  	  (1430-­‐2846)	   1902	  	  (1663-­‐2906)	   2273	  	  (2066-­‐2666)	   0.6406	  
a-­‐cortolone	  
819	  	  (507-­‐973)	   719	  	  (651-­‐1006)	   899	  	  (682-­‐1232)	   651	  	  (581-­‐1247)	   826	  	  (751-­‐1088)	   932	  	  (718-­‐1090)	   0.8175	  
b-­‐cortolone	  
350	  	  (249-­‐531)	   344	  	  (274-­‐545)	   426	  	  (351-­‐529)	   362	  	  (226-­‐514)	   444	  	  (370-­‐542)	   578	  	  (440-­‐629)	   0.6408	  
11-­‐OXO-­‐Et	  
237	  	  (154-­‐273)	   258	  	  (150-­‐488)	   275	  	  (222-­‐412)	   264	  	  (157-­‐400)	   348	  	  (186-­‐483)	   438	  	  (303-­‐553)	   0.5165	  
18	  OH	  THA	  
73	  	  (63-­‐95)	   61	  	  (53-­‐82)	   54	  	  (41-­‐63)	   36	  	  (33-­‐54)	   39*	  (24-­‐47)	   35	  	  (32-­‐40)	   0.0082	  
Total	  F	  metab	  
5413	  (3432-­‐7250)	   5565	  	  (4298-­‐6687)	   6562	  	  (5261-­‐7792)	   4665	  	  (4117-­‐7929)	   4846	  	  (4573-­‐6637)	   7151	  	  (6096-­‐7424)	   0.3813	  
	  
Supplementary	  Table	  S6.5:	  Urine	  Steroid	  Analysis	  by	  GC/MS	  in	  female	  subjects	  (n=77).	  Overall	  p-­‐
values	   from	  Kruskal-­‐Wallis	  analysis	   shown.	  Differences	   from	  20-­‐30	  year	  age-­‐group	  highlighted	   in	  
red	  in	  bold	  type	  *p<0.05,	  **p<0.01	  and	  ***p<0.001.	  Data	  are	  expressed	  as	  medians	  and	  IQRs	  (Units	  =	  
μg/24	  hours).	  
	   287	  
	  
Urine	  Steroid	  Ratios	  (GC/MS):	  Female	  Ageing	  Study	  Subjects	  
(Medians	  and	  IQRs)	  
	   	  
	  


















































0.42	  (0.37-­‐0.51)	  	   0.41	  	  (0.37-­‐0.48)	  	   0.42	  	  (0.36-­‐0.54)	  	   0.46	  	  (0.30-­‐0.50)	  	   0.36	  	  (0.31-­‐0.44)	  	   0.42	  	  (0.37-­‐0.53)	  	   0.62	  	  
(F+E)/(THF+5aTHF+THE)	  
	  








7.47	  (5.55-­‐8.76)	  	   5.70	  	  (3.78-­‐6.54)	  	   4.11	  	  (2.86-­‐5.08)	  	   5.22	  	  (4.39-­‐6.45)	  	  
3.26***	  
(2.72-­‐



























































































1.16	  (0.63-­‐1.57)	  	   0.97	  	  (0.78-­‐1.32)	  	   0.95	  	  (0.81-­‐1.25)	  	   1.37	  	  (0.98-­‐1.44)	  	   1.47	  	  (1.27-­‐1.73)	  	   1.12	  	  (1.06-­‐1.28)	  	   0.09	  	  
	  
Supplementary	  Table	   S6.6:	   Urine	   Steroid	  Ratios	   as	   analysed	   by	  GC/MS	   for	   female	   ageing	   study	  
participants	   (n=77).	   Overall	   p-­‐value	   as	   determined	   by	   Kruskal-­‐Wallis	   testing	   is	   shown	   in	   table.	  
Statistically	  significant	  differences	  from	  the	  20-­‐30	  year	  age-­‐group	  as	  derived	  from	  Dunn’s	  multiple	  
comparison	   test	   are	   highlighted	   red	   in	   bold	   type	   *p<0.05,	   **p<0.01	   and	   ***p<0.001.	   Data	   are	  
expressed	  as	  medians	  and	  interquartile	  ranges	  (IQRs).	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Age	  Group	  
(years):	   20-­‐30	   30-­‐40	   40-­‐50	   50-­‐60	   60-­‐70	   >70	   	  




4295	  	  (2066-­‐6909)	   2070	  	  (1566-­‐3181)	   2158	  	  (1670-­‐3038)	   1635	  	  (1508-­‐2034)	   1258*	  (1063-­‐1747)	   730***	  (582-­‐982)	   0.0007	  
ETIO	  
2247	  	  (1872-­‐3545)	   1693	  	  (1316-­‐3086)	   2201	  	  (1307-­‐2493)	   1841	  	  (1218-­‐2217)	   1709	  	  (1043-­‐2197)	   719*	  	  (637-­‐1336)	   0.05	  
DHEA	  
1170	  	  (783-­‐5377)	   2284	  	  (1353-­‐3375)	   638	  	  (167-­‐1444)	   54	  	  (23-­‐311)	   116	  	  (74-­‐281)	   55**	  	  (36-­‐64)	   <0.0001	  
16a	  OH	  DHEA	  
745	  	  (624-­‐1145)	   786	  	  (646-­‐1321)	   837	  	  (267-­‐1031)	   116	  	  (56-­‐324)	   183	  	  (158-­‐340)	   130*	  (71-­‐133)	   0.0007	  
5-­‐PT	  
524	  	  (307-­‐819)	   473	  	  (300-­‐491)	   193	  	  (189-­‐417)	   125	  	  (88-­‐200)	   152**	  	  (96-­‐204)	   144**	  	  (66-­‐148)	   <0.0001	  
5-­‐PD	  
210	  	  (132-­‐672)	   502	  	  (244-­‐591)	   224	  	  (154-­‐411)	   171	  	  (110-­‐288)	   167	  	  (136-­‐260)	   66	  	  (54-­‐208)	   0.06	  
Pregnadienol	  
186	  	  (108-­‐414)	   207	  	  (127-­‐445)	   122	  	  (58-­‐158)	   62	  	  (44-­‐100)	   73	  	  (69-­‐121)	   30*	  	  (22-­‐74)	   0.001	  
THA	  
123	  	  (91-­‐167)	   132	  	  (55-­‐176)	   70	  	  (56-­‐154)	   90	  	  (67-­‐123)	   99	  	  (66-­‐184)	   93	  	  (89-­‐132)	   0.79	  
5a-­‐THA	  
115	  	  (88-­‐174)	   95	  	  (85-­‐134)	   102	  	  (52-­‐134)	   104	  	  (75-­‐158)	   100	  	  (77-­‐112)	   94	  	  (88-­‐98)	   0.79	  
THB	  
116	  	  (110-­‐159)	   112	  	  (64-­‐161)	   83	  	  (57-­‐98)	   91	  	  (44-­‐163)	   124	  	  (73-­‐190)	   98	  	  (86-­‐161)	   0.75	  
5a-­‐THB	  
283	  	  (231-­‐470)	   244	  	  (220-­‐430)	   226	  	  (118-­‐389)	   264	  	  (135-­‐478)	   179	  	  (120-­‐263)	   202	  	  (180-­‐293)	   0.45	  
TH-­‐DOC	  
21	  	  (15-­‐46)	   12	  	  (10-­‐21)	   11	  	  (8-­‐15)	   11	  	  (8-­‐19)	   13	  	  (11-­‐13)	   11	  	  (6-­‐15)	   0.07	  
5α-­‐TH-­‐DOC	  
8	  	  (4-­‐9)	   4	  	  (3-­‐5)	   4	  	  (4-­‐6)	   5	  	  (3-­‐5)	   4	  	  (4-­‐7)	   4	  	  (3-­‐5)	   0.45	  
PD	  
227	  	  (206-­‐354)	   213	  	  (183-­‐257)	   152	  	  (138-­‐219)	   111	  	  (84-­‐145)	   159	  	  (148-­‐216)	   123	  	  (103-­‐249)	   0.06	  
3a5a	  17HP	  
24	  	  (21-­‐77)	   20	  	  (13-­‐25)	   10	  	  (8-­‐27)	   15	  	  (11-­‐22)	   13	  	  (9-­‐19)	   12*	  	  (8-­‐13)	   0.03	  
17-­‐HP	  
239	  	  (208-­‐412)	   140	  	  (108-­‐233)	   160	  	  (68-­‐229)	   119	  	  (59-­‐210)	   136	  	  (87-­‐248)	   97	  	  (92-­‐142)	   0.07	  
PT	  
874	  	  (671-­‐1341)	   745	  	  (505-­‐844)	   698	  	  (541-­‐779)	   679	  	  (505-­‐792)	   473	  	  (439-­‐671)	   399**	  (310-­‐438)	   0.01	  
PT'ONE	  
13	  	  (8-­‐18)	   12	  	  (11-­‐16)	   25	  	  (8-­‐30)	   12	  	  (11-­‐13)	   14	  	  (12-­‐16)	   11	  	  (8-­‐13)	   0.59	  
THS	  
76	  	  (37-­‐129)	   48	  	  (43-­‐72)	   42	  	  (35-­‐49)	   77	  	  (59-­‐93)	   70	  	  (56-­‐80)	   64	  	  (49-­‐98)	   0.42	  
Cortisol	  
70	  	  (42-­‐90)	   49	  	  (44-­‐92)	   47	  	  (45-­‐56)	   56	  	  (47-­‐63)	   72	  	  (57-­‐86)	   64	  	  (53-­‐75)	   0.91	  
6b-­‐OH-­‐
Cortisol	  
181	  	  (84-­‐223)	   104	  	  (93-­‐131)	   106	  	  (96-­‐174)	   108	  	  (91-­‐121)	   126	  	  (70-­‐175)	   129	  	  (65-­‐154)	   0.55	  
THF	  
1795	  	  (1055-­‐2490)	   1504	  	  (889-­‐1834)	   1583	  	  (1031-­‐1773)	   1638	  	  (1213-­‐1944)	   1771	  	  (1370-­‐2255)	   1761	  	  (1379-­‐2005)	   0.86	  
5a-­‐THF	  
1529	  	  (1033-­‐2672)	   1519	  	  (713-­‐1961)	   1185	  	  (712-­‐2346)	   2134	  	  (1731-­‐2354)	   1353	  	  (910-­‐1684)	   1410	  	  (873-­‐1557)	   0.74	  
a-­‐cortol	  
305	  	  (229-­‐472)	   357	  	  (209-­‐394)	   292	  	  (178-­‐429)	   354	  	  (320-­‐372)	   293	  	  (240-­‐346)	   277	  	  (240-­‐398)	   1.00	  
b-­‐cortol	  
548	  	  (456-­‐613)	   617	  	  (333-­‐683)	   583	  	  (409-­‐1023)	   531	  	  (495-­‐562)	   475	  	  (449-­‐584)	   369	  	  (306-­‐586)	   0.56	  
11b-­‐OH-­‐
ANDRO	  
587	  	  (438-­‐1207)	   788	  	  (395-­‐911)	   707	  	  (372-­‐823)	   637	  	  (571-­‐663)	   505	  	  (412-­‐599)	   306	  	  (275-­‐507)	   0.45	  
11b-­‐OH-­‐ETIO	  
249	  	  (120-­‐395)	   378	  	  (178-­‐417)	   224	  	  (124-­‐350)	   573	  	  (454-­‐665)	   330	  	  (178-­‐419)	   352	  	  (326-­‐381)	   0.49	  
Cortisone	  
112	  	  (60-­‐141)	   86	  	  (70-­‐116)	   74	  	  (68-­‐76)	   81	  	  (66-­‐93)	   102	  	  (95-­‐129)	   85	  	  (77-­‐100)	   0.52	  
THE	  
3457	  	  (2449-­‐6442)	   2754	  	  (2397-­‐5083)	   2621	  	  (2326-­‐4628)	   3594	  	  (3037-­‐3729)	   3445	  	  (2798-­‐4260)	   2762	  	  (2411-­‐3492)	   0.89	  
a-­‐cortolone	  
1312	  	  (919-­‐1626)	   1067	  	  (698-­‐1917)	   1232	  	  (844-­‐1617)	   1260	  	  (1146-­‐1437)	   1224	  	  (952-­‐1422)	   1233	  	  (959-­‐1467)	   0.95	  
b-­‐cortolone	  
740	  	  (534-­‐1012)	   621	  	  (455-­‐1043)	   875	  	  (557-­‐987)	   797	  	  (631-­‐937)	   726	  	  (594-­‐881)	   631	  	  (553-­‐685)	   0.76	  
11-­‐OXO-­‐Et	  
318	  	  (192-­‐467)	   365	  	  (280-­‐694)	   510	  	  (220-­‐670)	   559	  	  (466-­‐673)	   458	  	  (375-­‐556)	   346	  	  (330-­‐372)	   0.76	  
18	  OH	  THA	  
79	  	  (46-­‐107)	   53	  	  (36-­‐86)	   44	  	  (37-­‐79)	   75	  	  (59-­‐94)	   61	  	  (33-­‐72)	   39	  	  (38-­‐47)	   0.39	  
Total	  F	  
metabolites	  
10979	  (6571-­‐15828)	   8904	  	  (5878-­‐13317)	   8118	  	  (7151-­‐10803)	   10192	  	  (9008-­‐10914)	   9611	  	  (8061-­‐12223)	   8216	  	  (7551-­‐9873)	   0.88	  
Supplementary	   Table	   S6.7:	   Urine	   Steroid	   Analysis	   by	   GC/MS	   in	  male	   ageing	   study	   participants	  
(n=58).	  Overall	   p-­‐values	   from	  Kruskal-­‐Wallis	   testing	  are	   show.	   Statistically	   significant	  differences	  
from	   the	  20-­‐30	  year	  age-­‐group	  highlighted	   in	   red	   in	  bold	   type	   *p<0.05,	   **p<0.01	  and	   ***p<0.001.	  
Data	  are	  expressed	  as	  medians	  and	  interquartile	  ranges	  (Units	  =	  μg/24	  hours).	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0.66	  (0.43-­‐0.77)	  	   0.87	  	  (0.52-­‐1.10)	  	   0.90	  	  (0.61-­‐1.15)	  	   0.80	  	  (0.63-­‐1.01)	  	   0.98	  	  (0.76-­‐1.56)	  	   0.93	  	  (0.81-­‐1.21)	  	   0.22	  	  
	  
Supplementary	   Table	   S6.8:	   Urine	   Steroid	   Ratios	   as	   analysed	   by	   GC/MS	   for	   male	   ageing	   study	  
subjects	   (n=58).	   Overall	   p-­‐value	   as	   determined	   by	   Kruskal-­‐Wallis	   testing	   is	   shown	   in	   table.	  
Comparisons	  between	  groups	  made	  using	  Dunn’s	  post-­‐test	  correction.	  Comparisons	  with	  20-­‐30	  year	  
age	   group	   are	   highlighted	   in	   red	   in	   bold	   type	   *p<0.05,	   **p<0.01	   and	   ***p<0.001.	   Medians	   and	  
interquartile	  ranges	  shown	  (IQRs).	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Human	  Skeletal	  Muscle	  Gene	  Expression:	  Part	  1/3	  











Gene	   N=23	   N=22	   	  	  
IRS-­‐1	   14.75	  (14.43-­‐15.66)	   14.75	  (14.24-­‐15.31)	   0.91	  
Akt1	   20.38	  (19.59-­‐21.97)	   21.14	  (19.07-­‐22.63)	   0.61	  
GSK-­‐3β	   11.43	  (11.07-­‐12.93)	   11.58	  (10.95-­‐13.85)	   0.97	  
DDIT3	   12.40	  (11.95-­‐14.18)	   12.81	  (11.47-­‐14.36)	   0.98	  
11β-­‐HSD1	   16.81	  (16.47-­‐17.55)	   15.90	  (15.21-­‐16.39)	   0.0007	  
11β-­‐HSD2	   19.62	  (18.50-­‐20.65)	   18.86	  (18.37-­‐19.61)	   0.15	  
H6PDH	   13.66	  (13.14-­‐14.90)	   14.19	  (12.80-­‐14.77)	   0.99	  
HSP90AA	   8.76	  (8.24-­‐9.98)	   8.90	  (8.30-­‐9.53)	   0.97	  
HSP90B1	   12.01	  (11.77-­‐12.91)	   11.93	  (11.75-­‐12.49)	   0.62	  
GH-­‐R	   12.63	  (12.30-­‐13.53)	   12.72	  (12.23-­‐13.62)	   0.95	  
GHS-­‐R	   18.71	  (17.92-­‐19.91)	   17.89	  (16.60-­‐18.86)	   0.03	  
IGF-­‐I	   14.92	  (14.50-­‐15.67)	   14.76	  (13.81-­‐15.65)	   0.37	  
HIF-­‐1a	   13.61	  (13.43-­‐14.54)	   13.21	  (12.65-­‐13.73)	   0.02	  
eif6	   17.60	  (17.24-­‐21.01)	   18.18	  (16.87-­‐18.90)	   0.33	  
eif2b1	   11.97	  (11.64-­‐13.13)	   12.04	  (11.53-­‐13.13)	   0.66	  
PDK4	   9.52	  (8.55-­‐11.88)	   10.08	  (8.53-­‐12.08)	   0.76	  
IGF-­‐IR	   12.49	  (12.23-­‐13.33)	   12.34	  (12.02-­‐12.91)	   0.26	  
GADD45a	   17.92	  (17.53-­‐18.26)	   17.14	  (16.45-­‐17.77)	   0.005	  
ACACA	   14.48	  (14.03-­‐14.91)	   14.19	  (13.69-­‐14.71)	   0.18	  
AR	   12.92	  (12.40-­‐13.87)	   13.02	  (12.47-­‐13.58)	   0.81	  
CD36	   8.09	  (7.84-­‐9.05)	   8.03	  (7.62-­‐8.73)	   0.35	  
CDKN1A	   17.96	  (16.87-­‐18.74)	   16.93	  (16.39-­‐18.28)	   0.10	  
CEBPB	   10.91	  (10.50-­‐12.90)	   11.37	  (10.06-­‐13.85)	   0.95	  
CRYAB	   5.39	  (5.04-­‐8.19)	   5.79	  (4.98-­‐8.25)	   0.95	  
CYCS	   8.77	  (8.03-­‐12.37)	   9.74	  (8.61-­‐12.82)	   0.14	  
GLUL	   6.49	  (5.83-­‐7.68)	   6.15	  (5.02-­‐8.48)	   0.42	  
HSL	   20.21	  (19.25-­‐20.68)	   19.33	  (18.62-­‐20.86)	   0.20	  
IRS-­‐2	   16.22	  (15.78-­‐17.13)	   16.09	  (15.62-­‐17.07)	   0.50	  
LPL	   11.02	  (10.52-­‐11.62)	   10.70	  (9.74-­‐11.35)	   0.30	  
MYCL1	   21.76	  (20.76-­‐22.34)	   20.62	  (19.93-­‐21.65)	   0.16	  
MYF5	   16.27	  (15.88-­‐16.90)	   16.35	  (15.64-­‐17.03)	   0.83	  	  
Supplementary	   table	   S6.9	   (part	   I	   of	   III):	   Human	   skeletal	  muscle	   (vastus	   lateralis	   biopsy)	   gene	  
expression	   in	   female	   subjects	   aged	   under	   50	   vs.	   those	   aged	   over	   50	   years,	   as	   analysed	   by	  
microfluidic	  array	  (n=55).	  Statistically	  significant	  differences	  between	  age	  groups	  are	  highlighted	  in	  
bold	   red	   type	   (11β-­‐HSD1,	   HIF-­‐1a	   and	   GADD45a).	   Median	   and	   inter-­‐quartile	   ranges	   for	   delta	   CT	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Human	  Skeletal	  Muscle	  Gene	  Expression:	  Part	  2/3	  











Gene	   N=23	   N=22	   	  	  
MyoD	   15.36	  (15.06-­‐15.93)	   15.11	  (14.56-­‐15.63)	   0.26	  
PPARD	   13.26	  (12.76-­‐14.91)	   13.08	  (12.28-­‐14.38)	   0.23	  
PPARG	   16.00	  (14.20-­‐17.04)	   14.47	  (12.23-­‐16.55)	   0.06	  
PPARGC1A	   10.62	  (10.17-­‐16.64)	   10.90	  (10.27-­‐17.32)	   0.36	  
PPIB	   14.44	  (14.20-­‐14.97)	   14.30	  (13.83-­‐14.91)	   0.59	  
PPP3R2	   18.04	  (16.75-­‐18.37)	   17.14	  (16.37-­‐18.06)	   0.08	  
PSMA2	   13.91	  (13.56-­‐14.87)	   13.09	  (12.60-­‐13.80)	   0.004	  
PSMC1	   9.10	  (8.68-­‐11.25)	   9.64	  (8.87-­‐10.74)	   0.85	  
PSMC2	   10.30	  (9.96-­‐12.99)	   10.77	  (10.11-­‐12.58)	   0.78	  
PSMC4	   13.20	  (12.85-­‐15.90)	   13.87	  (12.77-­‐15.18)	   0.87	  
PSMC5	   11.94	  (11.43-­‐13.39)	   12.19	  (11.45-­‐14.11)	   0.71	  
PSMC6	   10.69	  (10.30-­‐13.21)	   11.34	  (10.60-­‐12.91)	   0.67	  
PSMD1	   12.32	  (11.76-­‐13.58)	   12.28	  (11.69-­‐13.69)	   0.88	  
PSMD11	   10.63	  (10.24-­‐12.99)	   11.03	  (10.41-­‐13.57)	   0.62	  
PSMD12	   10.89	  (10.34-­‐13.26)	   11.48	  (10.58-­‐13.27)	   0.55	  
PSMD14	   11.53	  (10.72-­‐13.27)	   11.75	  (10.93-­‐12.56)	   1.00	  
PSMD2	   11.05	  (10.49-­‐13.52)	   11.95	  (10.73-­‐13.42)	   0.61	  
PSMD3	   17.33	  (16.81-­‐18.85)	   18.14	  (16.64-­‐19.80)	   0.62	  
PSMD4	   18.10	  (17.45-­‐18.59)	   17.07	  (16.12-­‐18.13)	   0.006	  
PSMD6	   11.14	  (10.65-­‐13.15)	   11.50	  (10.86-­‐12.74)	   0.61	  
PSMD7	   9.85	  (9.30-­‐12.38)	   10.40	  (9.56-­‐12.53)	   0.46	  
RPS6KB1	   11.94	  (11.43-­‐13.70)	   12.00	  (11.21-­‐13.77)	   0.95	  
RXRG	   10.70	  (10.00-­‐16.18)	   11.06	  (10.54-­‐14.63)	   0.32	  
SLC2A4	   10.87	  (10.40-­‐14.73)	   11.31	  (10.14-­‐14.67)	   0.91	  
SOCS3	   20.57	  (19.17-­‐21.69)	   19.54	  (18.72-­‐20.31)	   0.07	  
SOD1	   9.66	  (9.20-­‐11.28)	   9.51	  (9.06-­‐10.38)	   0.67	  
SREBF1	   12.58	  (11.96-­‐13.54)	   12.40	  (11.65-­‐12.90)	   0.28	  
TGFB1	   14.79	  (13.97-­‐15.37)	   14.48	  (13.77-­‐15.04)	   0.65	  
TNF-­‐α	   19.56	  (18.98-­‐20.41)	   18.92	  (18.42-­‐19.90)	   0.13	  
TRIM54	   11.86	  (11.56-­‐16.29)	   12.46	  (11.23-­‐19.30)	   0.99	  	  
Supplementary	   table	  S6.9	   (part	   II	  of	   III):	  Human	  skeletal	  muscle	   (vastus	   lateralis	  biopsy)	  gene	  
expression	   in	   female	   subjects	   aged	   under	   50	   vs.	   those	   aged	   over	   50	   years,	   as	   analysed	   by	  
microfluidic	  array	  (n=55).	  Statistically	  significant	  differences	  between	  age	  groups	  are	  highlighted	  in	  
bold	  red	  type	  (PSMA2	  and	  PSMD4).	  Median	  and	  inter-­‐quartile	  ranges	  (IQRs)	  for	  delta	  CT	  values	  are	  
shown.	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Human	  Skeletal	  Muscle	  Gene	  Expression:	  Part	  3/3	  











Gene	   N=23	   N=22	   	  	  
mTOR	   8.87	  (8.35-­‐11.20)	   9.11	  (8.63-­‐12.08)	   0.23	  
MAFbx/Atrogin1	   8.86	  (8.29-­‐13.46)	   9.48	  (8.19-­‐13.52)	   0.74	  
p300	   12.85	  (12.28-­‐14.02)	   13.17	  (12.41-­‐14.44)	   0.64	  
MuRF/TRIM63	   11.90	  (11.02-­‐16.96)	   11.71	  (10.80-­‐12.70)	   0.51	  
Calpain1	   13.26	  (12.84-­‐15.23)	   13.46	  (12.54-­‐14.75)	   0.89	  
Calpain2	   12.66	  (12.22-­‐13.52)	   12.32	  (12.09-­‐14.34)	   0.56	  
USP19	   10.73	  (10.23-­‐13.09)	   11.33	  (10.25-­‐12.99)	   0.61	  
ATF-­‐4	   9.11	  (8.55-­‐11.10)	   9.44	  (8.81-­‐10.77)	   0.53	  
Caspase3	   13.59	  (13.09-­‐15.24)	   13.96	  (13.50-­‐14.83)	   0.54	  
eif4BP	   10.51	  (9.87-­‐11.98)	   10.30	  (9.58-­‐11.33)	   0.17	  
FOXO1	   11.76	  (11.01-­‐12.27)	   11.36	  (10.68-­‐12.71)	   0.48	  
FOXO3a	   13.72	  (13.01-­‐15.21)	   13.57	  (13.09-­‐15.30)	   0.91	  
MYH1	   7.69	  (5.95-­‐14.50)	   9.52	  (5.74-­‐16.65)	   0.50	  
MYH2	   2.37	  (1.98-­‐11.99)	   3.64	  (1.95-­‐12.07)	   0.56	  
MYH4	   18.24	  (17.40-­‐18.85)	   17.28	  (16.69-­‐18.17)	   <0.05	  
Myogenin	   10.13	  (9.74-­‐10.59)	   10.21	  (9.61-­‐13.30)	   0.84	  
SIRT1	   13.65	  (13.19-­‐15.15)	   13.54	  (13.09-­‐13.89)	   0.45	  
SIRT3	   16.66	  (16.31-­‐18.50)	   17.23	  (16.22-­‐18.69)	   0.66	  
Myostatin	   12.44	  (11.32-­‐17.33)	   12.87	  (12.20-­‐15.23)	   0.54	  
SMAD2	   13.99	  (13.43-­‐14.91)	   14.18	  (13.54-­‐14.86)	   0.89	  
SMAD3	   11.21	  (10.82-­‐13.51)	   11.33	  (10.51-­‐13.87)	   0.95	  
SMAD4	   11.51	  (10.91-­‐13.33)	   11.96	  (10.98-­‐14.17)	   0.46	  
SMAD7	   16.83	  (15.88-­‐17.70)	   15.92	  (15.46-­‐17.58)	   0.25	  
ACVR2A	   14.19	  (13.63-­‐15.32)	   14.42	  (13.46-­‐15.10)	   0.94	  
ACVR2B	   15.38	  (14.89-­‐18.01)	   15.46	  (14.28-­‐17.16)	   0.36	  
relA	   17.86	  (16.65-­‐18.91)	   17.56	  (16.75-­‐19.04)	   0.91	  
relB	   22.18	  (21.64-­‐22.87)	   22.27	  (21.58-­‐22.90)	   0.96	  
IL-­‐6	   17.34	  (16.55-­‐18.06)	   16.89	  (14.11-­‐18.49)	   0.61	  
IL-­‐1β	   19.89	  (19.09-­‐21.58)	   20.99	  (20.06-­‐21.74)	   0.15	  
NF-­‐kappa	  B	   14.18	  (13.62-­‐15.38)	   14.20	  (13.72-­‐14.60)	   0.71	  
Insulin-­‐R	   12.68	  (12.40-­‐14.64)	   13.14	  (12.21-­‐14.58)	   0.96	  	  
Supplementary	  table	  S6.9	  (part	  III	  of	  III):	  Human	  skeletal	  muscle	  (vastus	  lateralis	  biopsy)	  gene	  
expression	   in	   female	   subjects	   aged	   under	   50	   vs.	   those	   aged	   over	   50	   years,	   as	   analysed	   by	  
microfluidic	  array	  (n=55).	  Statistically	  significant	  differences	  between	  age	  groups	  are	  highlighted	  in	  
bold	  red	  type	  (MYH4).	  Median	  and	  inter-­‐quartile	  ranges	  for	  delta	  CT	  values	  are	  shown.	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Human	  Skeletal	  Muscle	  Gene	  Expression:	  Part	  1/3	  











Gene	   N=17	   N=7	   	  	  
IRS-­‐1	   13.82	  (13.14-­‐14.39)	   13.91	  (13.53-­‐14.83)	   0.53	  
Akt1	   20.31	  (18.65-­‐22.37)	   20.32	  (18.78-­‐21.70)	   0.80	  
GSK-­‐3β	   11.30	  (11.16-­‐11.68)	   10.98	  (10.67-­‐11.46)	   0.13	  
DDIT	   12.65	  (11.96-­‐13.35)	   12.21	  (11.51-­‐12.95)	   0.23	  
11β-­‐HSD1	   16.35	  (15.87-­‐16.92)	   16.04	  (15.84-­‐16.43)	   0.48	  
11β-­‐HSD2	   18.68	  (18.17-­‐19.47)	   18.19	  (17.33-­‐20.75)	   0.90	  
H6PDH	   13.45	  (13.27-­‐13.92)	   12.82	  (12.59-­‐13.12)	   0.002	  
HSP90AA	   8.47	  (8.08-­‐8.91)	   8.51	  (8.37-­‐8.86)	   1.00	  
HSP90B1	   12.32	  (11.89-­‐12.65)	   11.91	  (11.55-­‐12.26)	   0.04	  
GH-­‐Receptor	   12.47	  (11.83-­‐12.95)	   12.21	  (12.10-­‐12.75)	   0.70	  
GHS-­‐Receptor	   19.09	  (18.39-­‐20.62)	   17.99	  (17.58-­‐20.07)	   0.15	  
IGF-­‐I	   15.34	  (14.96-­‐15.60)	   15.08	  (14.68-­‐15.27)	   0.25	  
HIF-­‐1a	   13.61	  (13.21-­‐13.99)	   13.30	  (12.69-­‐13.76)	   0.31	  
eif6	   17.55	  (16.46-­‐18.52)	   17.13	  (16.67-­‐18.18)	   0.61	  
eif2b1	   11.87	  (11.66-­‐12.12)	   11.67	  (11.19-­‐12.01)	   0.18	  
PDK4	   10.68	  (9.56-­‐11.76)	   11.35	  (9.88-­‐11.62)	   0.66	  
IGF-­‐I	  Receptor	   12.63	  (12.25-­‐12.85)	   12.24	  (12.00-­‐12.68)	   0.10	  
GADD45a	   17.43	  (16.70-­‐18.24)	   16.58	  (16.30-­‐16.79)	   0.04	  
ACACA	   14.83	  (14.58-­‐15.07)	   14.53	  (13.94-­‐14.93)	   0.18	  
AR	   13.07	  (12.85-­‐13.33)	   13.08	  (12.27-­‐13.26)	   0.66	  
CD36	   8.66	  (8.31-­‐9.00)	   8.60	  (8.09-­‐8.97)	   0.85	  
CDKN1A	   18.66	  (18.20-­‐19.58)	   17.99	  (16.11-­‐18.52)	   0.04	  
CEBPB	   10.88	  (10.37-­‐11.20)	   10.38	  (10.25-­‐11.43)	   0.41	  
CRYAB	   5.39	  (4.97-­‐5.59)	   5.17	  (4.47-­‐5.69)	   0.53	  
CYCS	   8.40	  (7.90-­‐8.84)	   8.51	  (7.88-­‐8.69)	   0.95	  
GLUL	   6.67	  (6.09-­‐7.24)	   5.89	  (5.21-­‐7.68)	   0.53	  
HSL	   19.93	  (19.15-­‐20.40)	   18.73	  (17.47-­‐19.61)	   0.10	  
IRS-­‐2	   16.27	  (15.78-­‐17.49)	   15.97	  (15.60-­‐17.24)	   0.28	  
LPL	   12.08	  (11.63-­‐12.59)	   11.99	  (10.90-­‐12.25)	   0.57	  
MYCL1	   21.03	  (20.11-­‐21.54)	   20.67	  (20.62-­‐22.82)	   0.32	  
MYF5	   16.21	  (15.84-­‐16.50)	   16.46	  (15.61-­‐16.64)	   0.66	  	  
	  
Supplementary	  table	  S6.10	  (part	  I	  of	   III):	  Human	  skeletal	  muscle	  (vastus	   lateralis	  biopsy)	  gene	  
expression	  in	  male	  subjects	  aged	  under	  50	  vs.	  those	  aged	  over	  50	  years,	  as	  analysed	  by	  microfluidic	  
array	   (n=24).	   Statistically	   significant	   differences	   between	   age	   groups	   are	   highlighted	   in	   bold	   red	  
type	  (H6PDH,	  HSP90B1,	  GADD45a	  and	  CDKN1A).	  Median	  and	  inter-­‐quartile	  ranges	  (IQRs)	  for	  delta	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Human	  Skeletal	  Muscle	  Gene	  Expression:	  Part	  2/3	  











Gene	   N=17	   N=7	   	  	  
MyoD	   14.71	  (13.92-­‐16.01)	   14.27	  (13.66-­‐15.56)	   0.31	  
PPARD	   12.98	  (12.61-­‐13.31)	   12.96	  (12.50-­‐13.02)	   0.37	  
PPARG	   16.38	  (16.10-­‐16.81)	   16.57	  (15.47-­‐17.01)	   0.80	  
PPARGC1A	   10.47	  (10.29-­‐10.73)	   10.60	  (9.94-­‐10.87)	   0.95	  
PPIB	   14.81	  (14.41-­‐15.24)	   14.46	  (13.91-­‐14.69)	   0.06	  
PPP3R2	   18.05	  (17.29-­‐18.82)	   17.80	  (16.37-­‐18.09)	   0.31	  
PSMA2	   13.81	  (13.49-­‐14.14)	   13.74	  (12.89-­‐14.02)	   0.31	  
PSMC1	   8.91	  (8.57-­‐9.35)	   8.87	  (8.42-­‐9.08)	   0.45	  
PSMC2	   10.28	  (9.96-­‐10.51)	   10.40	  (9.50-­‐10.48)	   0.90	  
PSMC4	   13.29	  (12.79-­‐13.45)	   12.85	  (12.46-­‐13.09)	   0.16	  
PSMC5	   11.50	  (11.15-­‐11.83)	   11.50	  (11.15-­‐11.70)	   0.75	  
PSMC6	   10.58	  (10.22-­‐10.98)	   10.69	  (10.13-­‐10.86)	   0.61	  
PSMD1	   12.03	  (11.81-­‐12.35)	   11.50	  (11.34-­‐12.12)	   0.23	  
PSMD11	   10.77	  (10.46-­‐10.89)	   10.40	  (10.17-­‐10.91)	   0.31	  
PSMD12	   10.62	  (10.15-­‐10.94)	   10.62	  (10.47-­‐10.96)	   0.90	  
PSMD14	   10.78	  (10.50-­‐11.11)	   11.17	  (11.06-­‐11.29)	   0.13	  
PSMD2	   10.75	  (10.37-­‐11.06)	   10.49	  (10.38-­‐10.72)	   0.25	  
PSMD3	   16.99	  (16.33-­‐17.49)	   16.66	  (15.53-­‐17.39)	   0.41	  
PSMD4	   17.76	  (17.40-­‐18.10)	   16.87	  (16.45-­‐17.66)	   0.04	  
PSMD6	   10.49	  (9.98-­‐10.93)	   10.73	  (10.50-­‐11.23)	   0.34	  
PSMD7	   9.48	  (9.24-­‐9.87)	   9.52	  (9.35-­‐9.72)	   0.95	  
RPS6KB1	   11.41	  (10.98-­‐11.87)	   11.37	  (10.67-­‐11.64)	   0.66	  
RXRG	   10.38	  (9.91-­‐10.65)	   10.46	  (9.90-­‐10.96)	   0.90	  
SLC2A4	   10.69	  (10.49-­‐11.03)	   10.56	  (10.04-­‐10.81)	   0.34	  
SOCSS3	   21.00	  (20.03-­‐22.11)	   20.40	  (19.76-­‐21.68)	   0.62	  
SOD1	   9.46	  (9.25-­‐9.60)	   9.51	  (9.13-­‐9.68)	   0.95	  
SREBF1	   12.49	  (12.17-­‐13.05)	   12.55	  (12.15-­‐12.74)	   0.66	  
TGFB1	   14.90	  (14.50-­‐15.50)	   14.54	  (13.91-­‐15.24)	   0.53	  
TNF-­‐α	   19.83	  (18.85-­‐21.47)	   19.39	  (18.79-­‐21.02)	   0.70	  
TRIM54	   11.73	  (10.95-­‐12.00)	   11.23	  (11.15-­‐11.96)	   0.53	  	  
Supplementary	  table	  S6.10	  (part	  II	  of	  III):	  Human	  skeletal	  muscle	  (vastus	  lateralis	  biopsy)	  gene	  
expression	  in	  male	  subjects	  aged	  under	  50	  vs.	  those	  aged	  over	  50	  years,	  as	  analysed	  by	  microfluidic	  
array	   (n=24).	   Statistically	   significant	   differences	   between	   age	   groups	   are	   highlighted	   in	   bold	   red	  
type	  (PSMD4).	  Median	  and	  inter-­‐quartile	  ranges	  for	  delta	  CT	  values	  are	  shown.	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Human	  Skeletal	  Muscle	  Gene	  Expression:	  Part	  3/3	  











Gene	   N=17	   N=7	   	  	  
mTOR	   8.71	  (8.51-­‐9.07)	   8.46	  (8.05-­‐8.70)	   0.13	  
MAFbx/Atrogin1	   8.14	  (7.92-­‐8.57)	   8.35	  (7.33-­‐8.72)	   1.00	  
p300	   12.86	  (12.54-­‐13.29)	   12.42	  (12.11-­‐12.98)	   0.11	  
MuRF1/TRIM63	   11.84	  (11.15-­‐12.66)	   11.44	  (11.21-­‐12.60)	   0.80	  
Calpain1	   12.86	  (12.69-­‐13.10)	   12.81	  (12.29-­‐12.84)	   0.14	  
Calpain2	   12.19	  (12.05-­‐12.85)	   12.20	  (11.64-­‐12.72)	   0.41	  
USP19	   10.43	  (10.25-­‐10.72)	   10.26	  (10.23-­‐10.64)	   0.34	  
ATF-­‐4	   8.92	  (8.62-­‐9.22)	   8.81	  (8.20-­‐9.02)	   0.61	  
Caspase3	   13.28	  (12.88-­‐13.49)	   13.30	  (13.16-­‐13.47)	   0.70	  
eiF4BP	   10.44	  (10.10-­‐10.77)	   10.78	  (10.33-­‐11.15)	   0.18	  
FOXO1	   12.07	  (11.60-­‐12.81)	   11.08	  (10.77-­‐13.09)	   0.10	  
FOXO3a	   14.22	  (13.74-­‐14.49)	   13.55	  (12.93-­‐14.58)	   0.11	  
MYH1	   5.96	  (4.85-­‐6.83)	   5.12	  (3.97-­‐6.65)	   0.37	  
MYH2	   1.93	  (1.49-­‐2.38)	   1.81	  (1.26-­‐2.08)	   0.23	  
MYH4	   16.01	  (15.33-­‐16.69)	   15.93	  (14.44-­‐16.43)	   0.52	  
Myogenin	   10.12	  (9.69-­‐10.70)	   10.12	  (9.61-­‐10.42)	   0.70	  
SIRT1	   13.83	  (13.39-­‐14.01)	   13.20	  (12.61-­‐13.65)	   0.08	  
SIRT3	   16.85	  (15.85-­‐17.07)	   16.09	  (15.66-­‐16.47)	   0.04	  
Myostatin	   11.92	  (11.01-­‐12.99)	   11.19	  (10.19-­‐12.44)	   0.18	  
SMAD2	   13.71	  (13.51-­‐14.08)	   13.65	  (13.14-­‐13.91)	   0.31	  
SMAD3	   10.85	  (10.55-­‐11.23)	   10.38	  (9.83-­‐10.62)	   0.01	  
SMAD4	   11.14	  (10.88-­‐11.60)	   10.87	  (10.72-­‐11.15)	   0.16	  
SMAD7	   16.37	  (15.53-­‐16.94)	   15.77	  (15.18-­‐16.70)	   0.31	  
ACVR2A	   14.12	  (13.69-­‐14.51)	   13.76	  (13.34-­‐14.13)	   0.18	  
ACVR2B	   15.54	  (14.84-­‐15.87)	   14.93	  (14.84-­‐15.24)	   0.11	  
relA	   16.93	  (16.54-­‐17.44)	   15.94	  (15.47-­‐16.67)	   0.009	  
relB	   21.89	  (20.57-­‐22.34)	   20.71	  (20.37-­‐21.34)	   0.14	  
IL-­‐6	   17.52	  (16.38-­‐18.17)	   17.47	  (15.76-­‐17.69)	   0.90	  
IL-­‐1β	   20.64	  (19.47-­‐21.48)	   21.71	  (19.64-­‐22.53)	   0.61	  
NF-­‐kappa	  B	   13.86	  (13.73-­‐14.42)	   13.79	  (13.39-­‐14.02)	   0.20	  
Insulin	  Receptor	   12.78	  (12.50-­‐13.06)	   12.62	  (12.43-­‐12.82)	   0.37	  	  	  
Supplementary	  table	  S6.10	  (part	  III	  of	  III):	  Human	  skeletal	  muscle	  (vastus	  lateralis	  biopsy)	  gene	  
expression	  in	  male	  subjects	  aged	  under	  50	  vs.	  those	  aged	  over	  50	  years,	  as	  analysed	  by	  microfluidic	  
array	   (n=24).	   Statistically	   significant	   differences	   between	   age	   groups	   are	   highlighted	   in	   bold	   red	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Female	  Subjects	   Subject	  Characteristics	  by	  Grip	  Strength	  
Dynamometry	  
(Medians	  and	  IQRs)	  	  
	  	   Below	  Median	  Grip	  
Strength	  (28kg)	  
Above	  Median	  Grip	  
Strength	  (28kg)	   P-­‐value	  
Patient	  Characteristics	  
	  Age	  (years)	   52	  (32-­‐65)	   46	  (28-­‐57)	   0.14	  BMI	  (kg/m2)	   24.2	  (22.1-­‐26.9)	   24.7	  (21.3-­‐27.1)	   0.98	  Fat	  Mass	  (kg)	   20.5	  (16.5-­‐24.4)	   21.3	  (17.1-­‐25.2)	   0.89	  
Lean	  Mass	  (kg)	   39.9	  (35.1-­‐42.2)	   42.6	  (40.4-­‐45.9)	   0.0007	  
Serum	  biochemistry	   	  IGF-­‐I	   15.6	  (12.5-­‐24.4)	   20.7	  (15.7-­‐23.9)	   0.27	  DHEAS	   2.6	  (1.5-­‐3.6)	   3.3	  (2.2-­‐4.6)	   0.11	  Testosterone	   0.6	  (0.4-­‐0.8)	   0.7	  (0.5-­‐1.0)	   0.14	  SHBG	   65.6	  (46.5-­‐95.1)	   59.7	  (36.4-­‐74.6)	   0.16	  9am	  Cortisol	   227	  (183-­‐344)	   236	  (196-­‐323)	   0.99	  
Skeletal	  Muscle	  mRNA	  	  
Expression	  11β-­‐HSD1	  (AU)	   0.01	  (0.01-­‐0.02)	   0.01	  (0.01-­‐0.01)	   0.34	  H6PDH	  (AU)	   0.05	  (0.02-­‐0.13)	   0.08	  (0.04-­‐0.11)	   0.40	  
Urine	  Steroid	  GC/MS	  	  
Analysis	  (THF+5αTHF/THE)	  	   0.82	  (0.67-­‐0.92)	   0.88	  (0.74-­‐1.12)	   0.06	  (Cortols/Cortolones)	   0.41	  (0.32-­‐0.51)	   0.43	  (0.36-­‐0.51)	   0.42	  Total	  F	  Metabolites	  (μg/24h)	   6317	  (4075-­‐7862)	   5844	  (4518-­‐6891)	   0.79	  F/E	   0.63	  (0.53-­‐0.78)	   0.61	  (0.51-­‐0.68)	   0.27	  THF/5αTHF	   1.51	  (1.17-­‐2.20)	   1.37	  (1.05-­‐1.79)	   0.28	  	  
Supplementary	  table	  S6.11:	  Subject	  characteristics	  in	  female	  ageing	  study	  participants	  as	  divided	  
into	   2	   groups	   depending	   on	   maximum	   grip	   strength	   (below	   and	   above	   median	   maximal	   grip	  
strength	   dynamometry	   measure	   of	   28.00kg)	   (n=77,	   except	   in	   analyses	   involving	   gene	   expression	  
when	   n=55).	   Characteristics	   include	   general	   demographics,	   anthropometry,	   body	   composition,	  
skeletal	   muscle	   gene	   expression	   and	   urine	   steroid	   GC/MS	   data.	   P-­‐values	   shown	   are	   from	   Mann	  
Whitney	  tests	  with	  statistically	  significant	  results	  highlighted	  in	  bold.	  (THF+5αTHF/THE)	  =	  (tetra-­‐
hydrocortisol+5α-­‐tetrahydrocortisol)/tetrahydrocortisone.	   F=	   cortisol,	   F/E	   =	   cortisol/cortisone,	  
THF/5αTHF	  =	  tetrahydrocortisol/5α-­‐tetrahydrocortisol.	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Male	  Subjects	   Subject	  Characteristics	  by	  Grip	  Strength	  
Dynamometry	  
(Medians	  and	  IQRs)	  
	  	   Below	  Median	  Grip	  
Strength	  (43kg)	  





Age	  (years)	   58	  (33-­‐73)	   44	  (27-­‐61)	   <0.05	  BMI	  (kg/m2)	   24.8	  (23.4-­‐26.5)	   26.0	  (23.6-­‐27.7)	   0.30	  Fat	  Mass	  (kg)	   16.1	  (13.5-­‐21.3)	   17.5	  (12.6-­‐20.8)	   0.78	  
Lean	  Mass	  (kg)	   53.2	  (49.1-­‐62.8)	   59.1	  (57.5-­‐68.1)	   0.006	  
Serum	  biochemistry	   	  IGF-­‐I	   18.2	  (15.6-­‐23.0)	   20.5	  (16.2-­‐26.6)	   0.19	  DHEAS	   4.4	  (2.5-­‐7.6)	   6.4	  (3.7-­‐8.1)	   0.12	  
Testosterone	   13.8	  (11.2-­‐17.3)	   17.4	  (12.6-­‐20.4)	   0.02	  SHBG	   37.6	  (27.6-­‐55.1)	   32.0	  (25.0-­‐39.1)	   0.18	  9am	  Cortisol	   281	  (221-­‐369)	   330	  (243-­‐380)	   0.52	  
Skeletal	  Muscle	  mRNA	  	  
Expression	  11β-­‐HSD1	  (AU)	   0.01	  (0.01-­‐0.01)	   0.01	  (0.01-­‐0.02)	   0.32	  H6PDH	  (AU)	   0.11	  (0.08-­‐0.12)	   0.09	  (0.08-­‐0.10)	   0.43	  
Urine	  Steroid	  GC/MS	  	  
Analysis	  (THF+5αTHF/THE)	  	   0.98	  (0.80-­‐1.22)	   0.95	  (0.77-­‐1.09)	   0.40	  (Cortols/Cortolones)	   0.47	  (0.34-­‐0.55)	   0.39	  (0.35-­‐0.48)	   0.29	  Total	  F	  Metabolites	  (μg/24h)	   9095	  (7341-­‐12268)	   9180	  (6515-­‐12474)	   0.83	  F/E	   0.70	  (0.57-­‐0.79)	   0.67	  (0.59-­‐0.77)	   0.78	  THF/5αTHF	   1.06	  (0.86-­‐1.21)	   1.08	  (0.79-­‐1.51)	   0.75	  	  
Supplementary	  table	  S6.12:	  Subject	  characteristics	   in	  male	  ageing	  study	  participants	  as	  divided	  
into	   2	   groups	   depending	   on	   maximum	   grip	   strength	   (below	   and	   above	   median	   maximal	   grip	  
strength	   dynamometry	   measure	   of	   43.00kg)	   (n=58,	   except	   in	   analyses	   involving	   gene	   expression	  
when	   n=24).	   Characteristics	   include	   general	   demographics,	   anthropometry,	   body	   composition,	  
skeletal	   muscle	   gene	   expression	   and	   urine	   steroid	   GC/MS	   data.	   P-­‐values	   shown	   are	   from	   Mann	  
Whitney	  tests	  with	  statistically	  significant	  results	  highlighted	  in	  bold.	  (THF+5αTHF/THE)	  =	  (tetra-­‐
hydrocortisol+5α-­‐tetrahydrocortisol)/tetrahydrocortisone.	   F=	   cortisol,	   F/E	   =	   cortisol/cortisone,	  
THF/5αTHF	  =	  tetrahydrocortisol/5α-­‐tetrahydrocortisol.	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Female	  Subjects	   Subject	  Characteristics	  by	  Body	  Mass	  Index	  
(Medians	  and	  IQRs)	  
	  	   Below	  Median	  BMI	  
(24.5kg/m2)	  





Age	  (years)	   35	  (25-­‐63)	   51	  (46-­‐62)	   0.01	  
Fat	  Mass	  (kg)	   16.9	  (14.5-­‐20.2)	   24.3	  (22.8-­‐27.4)	   <0.0001	  
Lean	  Mass	  (kg)	   39.0	  (34.6-­‐42.4)	   42.5	  (40.5-­‐45.4)	   0.001	  
Serum	  biochemistry	   	  
IGF-­‐I	   23.3	  (19.6-­‐26.8)	   14.4	  (11.7-­‐18.6)	   <0.0001	  
DHEAS	   3.3	  (2.5-­‐4.6)	   2.1	  (1.0-­‐3.3)	   0.0002	  
Testosterone	   0.7	  (0.6-­‐1.0)	   0.6	  (0.4-­‐0.8)	   0.01	  SHBG	   61.6	  (43.4-­‐74.6)	   67.8	  (45.6-­‐84.4)	   0.41	  9am	  Cortisol	   265	  (204-­‐435)	   218	  (184-­‐297)	   0.13	  
Skeletal	  Muscle	  mRNA	  	  
Expression	  11β-­‐HSD1	  (AU)	   0.01	  (0.00-­‐0.01)	   0.01	  (0.01-­‐0.03)	   0.37	  H6PDH	  (AU)	   0.10	  (0.03-­‐0.11)	   0.05	  (0.04-­‐0.12)	   0.48	  
Urine	  Steroid	  GC/MS	  	  
Analysis	  (THF+5αTHF/THE)	  	   0.81	  (0.67-­‐0.93)	   0.87	  (0.73-­‐1.06)	   0.23	  (Cortols/Cortolones)	   0.42	  (0.35-­‐0.50)	   0.42	  (0.32-­‐0.54)	   0.97	  Total	  F	  Metabolites	  (μg/24h)	   5060.00	  (4075.00-­‐7173.00)	   6562.00	  (4519.00-­‐7985.00)	   0.12	  
F/E	   0.65	  (0.58-­‐0.82)	   0.58	  (0.51-­‐0.68)	   0.03	  THF/5αTHF	   1.52	  (1.15-­‐2.37)	   1.43	  (1.08-­‐1.75)	   0.38	  	  	  
Supplementary	  table	  S6.13:	  Subject	  characteristics	  in	  female	  ageing	  study	  participants	  as	  divided	  
into	   2	   groups	   depending	   on	   BMI	   (below	   and	   above	  median	   BMI	  measure	   of	   24.46	   kg/m2)(n=77,	  
except	   in	   analyses	   involving	   gene	   expression	   when	   n=55).	   Characteristics	   include	   general	  
demographics,	  anthropometry,	  body	  composition,	  skeletal	  muscle	  gene	  expression	  and	  urine	  steroid	  
GC/MS	   data.	   P-­‐values	   shown	   are	   from	   Mann	   Whitney	   tests	   with	   statistically	   significant	   results	  
highlighted	   in	   bold.	   (THF+5αTHF/THE)	   =	   (tetra-­‐hydrocortisol+5α-­‐
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Male	  Subjects	   Subject	  Characteristics	  by	  Body	  Mass	  Index	  
(Medians	  and	  IQRs)	  
	  	   Below	  Median	  BMI	  
(20.1kg/m2)	  




	  Age	  (years)	   36	  (27-­‐68)	   50	  (41-­‐64)	   0.21	  Fat	  Mass	  (kg)	   13.6	  (11.7-­‐15.9)	   18.6	  (16.9-­‐23.7)	   <0.0001	  Lean	  Mass	  (kg)	   53.2	  (50.1-­‐58.7)	   62.7	  (57.7-­‐69.0)	   <0.0001	  
Serum	  biochemistry	   	  IGF-­‐I	   19.7	  (15.8-­‐22.8)	   19.4	  (16.0-­‐25.1)	   0.60	  DHEAS	   5.9	  (2.6-­‐9.2)	   5.0	  (3.2-­‐7.0)	   0.47	  Testosterone	   17.3	  (13.1-­‐19.8)	   14.0	  (11.9-­‐18.9)	   0.25	  SHBG	   33.3	  (23.0-­‐52.0)	   33.7	  (28.1-­‐42.0)	   0.81	  9am	  Cortisol	   311	  (265-­‐392)	   293	  (219-­‐368)	   0.29	  
Skeletal	  Muscle	  mRNA	  	  
Expression	  11β-­‐HSD1	  (AU)	   0.01	  (0.01-­‐0.02)	   0.01	  (0.01-­‐0.02)	   0.60	  H6PDH	  (AU)	   0.10	  (0.08-­‐0.11)	   0.10	  (0.07-­‐0.16)	   0.56	  
Urine	  Steroid	  GC/MS	  	  
Analysis	  (THF+5αTHF/THE)	  	   0.98	  (0.78-­‐1.03)	   0.97	  (0.78-­‐1.20)	   0.70	  (Cortols/Cortolones)	   0.47	  (0.36-­‐0.52)	   0.39	  (0.33-­‐0.51)	   0.22	  Total	  F	  Metabolites	  (μg/24h)	   8216	  (6038-­‐11079)	   9665	  (7446-­‐13032)	   0.19	  F/E	   0.71	  (0.61-­‐0.80)	   0.68	  (0.58-­‐0.77)	   0.45	  THF/5αTHF	   1.02	  (0.84-­‐1.36)	   1.07	  (0.73-­‐1.39)	   0.90	  
	  
Supplementary	  table	  S6.14:	  Subject	  characteristics	   in	  male	  ageing	  study	  participants	  as	  divided	  
into	   2	   groups	   depending	   on	   BMI	   (below	   and	   above	  median	   BMI	  measure	   of	   24.46	   kg/m2)(n=58,	  
except	   in	   analyses	   involving	   gene	   expression	   when	   n=24).	   Characteristics	   include	   general	  
demographics,	  anthropometry,	  body	  composition,	  skeletal	  muscle	  gene	  expression	  and	  urine	  steroid	  
GC/MS	   data.	   P-­‐values	   shown	   are	   from	   Mann	   Whitney	   tests	   with	   statistically	   significant	   results	  
highlighted	   in	   bold.	   (THF+5αTHF/THE)	   =	   (tetra-­‐hydrocortisol+5α	   tetrahydrocortisol)/	  
























Supplementary	  Figure	  S.5.1:	  Response	  to	  glucose	  tolerance	  test	  (GTT)	  and	  calculated	  area	  under	  
the	   curve	   (AUC)	   was	   measured	   in	   C57BL/6	   mice.	   Aged	   WT	   mice	   were	   less	   tolerant	   to	   glucose	  
challenge	  with	   increased	  AUC	   values	   compared	   to	   young	  WT	  mice.	   Aged	   11β-­‐HSD1	  KO	  mice	   had	  
improved	  glucose	  tolerance	  compared	  to	  the	  age-­‐matched	  WT	  group.	  Means	  and	  S.E.s	  shown	  (n=6-­‐8	  
per	  group).	  *P<0.05	  vs.	  young	  WT	  and	  §P<0.05	  vs.	  Old	  WT.	  	  
	  
	  




Supplementary	  Figure	  S.5.2:	  C57BL/6	  wildtype	  and	  11β-­‐HSD1	  knockout	  mice	  were	  treated	  with	  
CORT	  (100μg/mL,	  0.66%	  ethanol),	  11DHC	  (100μg/mL,	  0.66%	  ethanol)	  or	  vehicle	  (0.66%	  ethanol)	  
via	  drinking	  water	  for	  5	  weeks	  (n=7-­‐9).	  Assessment	  of	  fasting	  insulin	  (A),	  glucose	  tolerance	  in	  11β-­‐
HSD1	   KO	   mice	   and	   calculated	   area	   under	   curve	   (AUC)	   for	   glucose	   tolerance	   data	   (B).	   Glucose	  
tolerance	   in	   WT	   (C)	   and	   11β-­‐HSD1KO	   mice	   (D).	   Statistics	   analysed	   using	   two-­‐way	   ANOVA	  
(***p<0.001	  vs.	  WT	  vehicle;	  ∅∅p<0.01	  vs.	  WT	  CORT).	  11DHC	  =	  11-­‐dehydrocorticosterone,	  CORT	  =	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Supplementary	   figure	  S6.1:	   Correlations	   between	   serum	  androgen	   levels	   and	  markers	   of	   global	  
11β-­‐HSD1	  activity	  as	  measured	  by	  urine	  GC/MS	  analysis	  in	  men	  (n=58).	  In	  male	  participants	  in	  the	  
ageing	   study,	   a)	   testosterone	   and	   b)	   DHEAS	   were	   inversely	   correlated	   with	   urine	  
(THF+5αTHF)/THE	   ratios.	   In	   addition	   an	   inverse	   correlation	  was	   seen	   between	   testosterone	   and	  
urinary	  cortol/cortolone	  ratios	  in	  men.	  Full-­‐line	  =	  linear	  regression.	  r-­‐values	  represent	  correlation	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